



CURRICULUM VITAE

Kelly K. Hunt, MD, FACS, FSSO

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor & Chair, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Olla Stribling Distinguished Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
Department of Breast Surgical Oncology
1400 Pressler Street
Unit Number: 1434
Houston, TX 77030
Room Number: FCT7.5010
Phone: 713-792-7216
Fax: 713-794-5720

EDUCATION

Degree-Granting Education

Memphis State University, Memphis, TN, BSC, *summa cum laude*, 1982, Chemistry

The University of Tennessee Center for the Health Sciences, Memphis, TN, MD, 1986, with highest honors

Postgraduate Training

Resident, Surgery, Department of Surgery, University of California Los Angeles School of Medicine, Los Angeles, CA, 7/1986-6/1988

Sponsored by National Institutes of Health and the American Cancer Society, Surgical Oncology Research Fellowship at the John Wayne Cancer Institute, Division of Surgical Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA, 7/1988-6/1990

Assistant Resident in General Surgery, Department of Surgery, University of California Los Angeles School of Medicine, Los Angeles, CA, 7/1990-6/1991

Registrar in General and Vascular Surgery, University Hospital, Queen's Medical Centre, Nottingham, England, United Kingdom, 7/1991-12/1991

Assistant Resident in General Surgery, Surgery, Department of Surgery, University of California Los Angeles School of Medicine, Los Angeles, CA, 1/1992-6/1992

Chief Resident in General Surgery, University of California Los Angeles School of Medicine, Los Angeles, CA, 7/1992-6/1993

Fellow in Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1994-6/1996

CREDENTIALS

Board Certification

Diplomate of the National Board of Medical Examiners, 327819, 1987

Diplomate of the American Board of Surgery, 38999, 2/1994-6/2024, Recertification Date: 12/2013

Licensures

Active

Texas Medical Board, TX, J6135, 5/1994-5/2021

Florida Board of Medicine, FL, TPME1960, 7/2021-7/2099

Tennessee Board of Medical Examiners, TN, 68358, 3/2023-9/2024

Arizona Board of Medical Examiners, AZ, 69944, 3/2023-1/2025

Alabama Board of Medical Examiners, AL, 46208, 3/2023-12/2023

Louisiana State Board of Medical Examiners, LA, 335777, 3/2023-9/2023

Mississippi State Board of Medical Licensure, MS, 31522, 4/2023-6/2024

Georgia Composite Medical Board, GA, 95209, 4/2023-9/2024

Washington State Department of Health, WA, MD61428969, 4/2023-9/2023

Oklahoma State Board of Medical Licensure, OK, 41396, 4/2023-4/2024

Inactive

Medical Board of California, CA, G 61133, 8/1987

EXPERIENCE/SERVICE

Academic Appointments

Instructor, Division of Surgical Oncology, University of California Los Angeles School of Medicine, Los Angeles, CA, 7/1993-6/1994

Staff General Surgeon, Department of Surgery, Division of Surgery, Sepulveda Veterans Administration Hospital, Sepulveda, CA, 7/1993-6/1994

Junior Faculty Associate, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1994-6/1996

Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1996-8/2000

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2000-8/2004

Associate Professor, Division of Surgery, The University of Texas Health Science Center at Houston Medical School, Houston, TX, 9/2000

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2004-present

Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Chair Ad Interim, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-2016

Professor & Chair, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016-present

Administrative Appointments/Responsibilities

Medical Student Preceptorship Program, University of California Los Angeles School of Medicine, Los Angeles, CA, 1987-1988

Director, Surgical Oncology Grand Rounds, University of California Los Angeles School of Medicine, Los Angeles, CA, 1993-1994

Faculty Liaison to Advanced Care Practitioners, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-2004

Director, Breast Lymphatic Mapping Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997-2005

Director, Breast Educational Conference, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-2018

Associate Medical Director, Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-2012

Internal Advisory Council Member, The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2022-present

Other Appointments/Responsibilities

Member, Student Representative to the Basic Science Committee, University of Tennessee Center for Health Sciences, Memphis, TN, 1984-1986

Member, Quality Assurance Committee for Oncology Trials, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, 1993-1994

Member, Quality of Care Assessment Committee, University of California Los Angeles, Los Angeles, CA, 1993-1994

Member, Surgery Center Policy Committee, University of California Los Angeles, Los Angeles, CA, 1993-1994

Member, Society of University Surgeons, Committee on Social and Legislative Issues, N/A, 2002-2005

Chair, American College of Surgeons Oncology Group, Breast Organ Site Committee, N/A, 2003-2011

Member, American College of Surgeons Oncology Group, Executive Committee, N/A, 2003-2011

Member, American Society of Clinical Oncology, Scientific Program Committee, N/A, 2004-2005

Member, Breast Cancer Intergroup of North America (TBCI), Correlative Science Committee, N/A, 2004-2011

Member, Society of Surgical Oncology, Scientific Program Committee, N/A, 2005-2008

External Reviewer, CTEP Concept Review Committee, National Cancer Institute, N/A, 2005-2011

Member, Coalition of Cancer Cooperative Groups, Breast Cancer Scientific Leadership Council, N/A, 2006-2008

Member Advisory, The US-Middle East Partnership for Breast Cancer Awareness and Research, N/A, 2007-2008

Member, Advisory Committee, EMPOWER study, PI: Kevin C Oeffinger, MD, MSKCC, New York, NY, 2007-2010

Member, Technical Expert Panel, Diagnosis and Management of Ductal Carcinoma in Situ (DCIS), University of Minnesota, Minneapolis, MN, 2008-2009

Member, Breast Cancer Steering Committee, Cancer Therapy Evaluation Program, National Cancer Institute, N/A, 2008-2014

Member, American College of Surgeons, Committee for the Forum on Fundamental Surgical Problems, Chicago, IL, 2010-2013

Member, SSO Breast Disease Site Workgroup, N/A, 2011-2013

Vice Chair, Alliance for Clinical Trials in Oncology Breast Committee, N/A, 2011-2018

Member, Executive Committee, Alliance for Clinical Trials in Oncology Board of Directors, N/A, 2011-present

Examination Consultant, American Board of Surgery, N/A, 2011-present

Member, American Board of Surgery, N/A, 2011-present

Member, Alliance for Clinical Trials in Oncology Board of Directors, N/A, 2011-present

Member, Breast Cancer Survivorship Guidelines Development Committee, Baylor College of Medicine, N/A, 2012-2014

Chair, Alliance ACS Clinical Research Program Cancer Care Standards Development Committee, N/A, 2012-2014

Leader, Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, N/A, 2012-present

Member, American Society of Clinical Oncology Breast Cancer Guideline Advisory Committee, Chicago, IL, 2014-2018

Volunteer, American Society of Clinical Oncology, Alexandria, VA, 2014-2018

Program Leader, American College of Surgeons-Clinical Research Program, Chicago, IL, 2014-present

Member, Complex General Surgical Oncology Board, American Board of Surgery, Philadelphia, PA, 2015-2021

Member, Society of Surgical Oncology, Executive Council, Rosemont, IL, 2017

Member, American Society of Clinical Oncology (ASCO) Annual Meeting Program Committee, Chicago, IL, 2018-2020

Member, Society of Surgical Oncology, Education Council, Rosemont, IL, 2018-2020

Chair, Society of Surgical Oncology, Membership Committee, Rosemont, IL, 2019-2022

Secretary, Society of Surgical Oncology, Executive Council, Rosemont, IL, 2019-present

Representative for the Society of Surgical Oncology, American College of Surgeons Advisory Council for General Surgery, Chicago, IL, 11/2019-10/2022

Treasurer, American Radium Society, Executive Committee, Mount Royal, NJ, 2020-2022

Executive Council Liaison, Society of Surgical Oncology, Training - Breast Program Directors, Rosemont, IL, 3/2020-3/2021

Executive Council Liaison, Society of Surgical Oncology, FSSO Work Group, Rosemont, IL, 3/2020-3/2021

Vice Chair, ACS Cancer Surgery Standards Program (CSSP), Chicago, IL, 6/2020-10/2025

Secretary, Society of Surgical Oncology, SSO 2022 Advisory Committee, Rosemont, IL, 2021-2022

Member, The University of Tennessee College of Medicine Alumni Council, Memphis, TN, 4/2021-present

Chair, American Surgical Association Flance-Karl Award Committee, Beverly, MA, 4/2021

SSO President-Elect, Society of Surgical Oncology, Rosemont, IL, 2022-2023

President, American Radium Society, Executive Committee, Mount Royal, NJ, 2022-2023

Executive Council Liaison, Quality Committee, Society of Surgical Oncology, Rosemont, IL, 4/2022-3/2023

Executive Council Liaison, SSO Constitution and Bylaws Committee, Society of Surgical Oncology, Rosemont, IL, 4/2023-3/2024

Publications Committee, Society of Surgical Oncology, Rosemont, IL, 1/2024-3/2025

Executive Council Liaison to the Women in Surgery Work Group, Society of Surgical Oncology, Rosemont, IL, 4/2024-3/2025

Endowed Positions

Hamill Foundation Distinguished Professorship in Honor of Dr. Richard G. Martin, Sr., The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2009-2022

Olla Stribling Distinguished Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2022-present

Consultantships

The University of Texas MD Anderson Physicians' Network, Houston, TX, Faculty Host Advocate

Military or Other Governmental Service

N/A

Institutional Committee Activities

Gooch/Doggett Scholarship Selection Program, University of Tennessee Center for Health Sciences, Member, 1984-1986

Medical Student Executive Council, University of Tennessee Center for Health Sciences, Member, 1985-1986

Breast Cancer Tumor Bank Committee, Member, 1997-1999

Tumor Registry Steering Committee, Member, 1998-2000

Utilization Management Cancer Committee, Member, 1998-2000

Scientific Review Committee, Student and Trainee Resources: Clinical Fellows Research Award, Member, 1998-2000

Advanced Care Planning: GI Study Committee, Member, 1998-2000

Medical Records Subcommittee, Member, 1998-2004

Study Section Review Committee for Clinical, Translational, and Population-based Projects, Member, 1999-2000

Ambulatory Care Building Committee, Member, 2000-2002

Physicians Network Credentials Committee, Member, 2000

Plastic Surgery Center Steering Committee, Member, 2000

Study Section New Drug Discovery, Member, 2000

Steering Committee of the Cancer Prevention Center, Member, 2001-2003

Breast Cancer Research Group (BCRG) Committee, Member, 2001-2012

Women's Cancer Research Group Steering Committee (WCRG), Member, 2001-2012

Nellie B. Connally Breast Center Operations Committee, Member, 2001-2013

Faculty Achievement Award for Basic Science Subcommittee, Member, 2001

Search Committee for Senior Scientist, Breast Medical Oncology, Member, 2001

Clinical Council Subcommittee on Clinical Research Funding (SCRF), Member, 2001

Blue Ribbon Committee, Task Force on Clinical Research, Member, 2002-2003

Executive Committee of the Medical Staff, Member, 2003-2005

Clinical Research Impact Committee, Member, 2003-2005
Breast Cancer Serum/DNA Bank Oversight Committee, Member, 2003-2010
Faculty Achievement Award: Clinical Research Committee, Member, 2003
Breast Cancer Tumor Bank Committee, Chair, 2005-2012
Breast Reconstruction Research Committee, Member, 2005-2012
Radiation Oncology Chair Search Committee, Chair, 2006
Task Force on Growth Committee, Member, 2006
Advisory Committee for Recruitment of the EVP and CAO, Member, 6/2006-2007
Breast Cancer Tumor Bank Committee, Member, 2007-2012
Diagnostic Imaging Division Head Search Committee, Member, 2008-2010
Odyssey Committee, Office of Academic Affairs, Member, 2008-2011
Research Laboratory Space Subcommittee of the Research Council, Member, 2009-2010
Department of Pathology Chair Search Committee, Member, 2010-2011
Endowed Positions and Awards Committee (EPAC), Member, 2010-2013
Multidisciplinary Research Advisory Committee (MRAC), Member, 2010-2013
Paul Calabresi Scholar (Clinician-Investigator) Committee, Member, 2010-present
Diagnostic Radiology Chair Search Committee, Chair, 2011
Odyssey Committee, Office of Academic Affairs, Chair, 2011
Vice President of Education Search Committee, Member, 2012
Breast Medical Oncology Chair Search Committee, Member, 2012
Promotion and Tenure Committee, Member, 2012-2015
Vice Provost Advisory Council on Clinical Research, Member, 2012-2017
Alliance for Clinical Trials in Oncology, Institutional PI, 2012-present
Diagnostic Radiology Chair Search Committee, Chair, 2013-2014
Scientific Research Committee, Co-Chair, 2014-present
Electronic Protocol Accrual Auditing Committee, Member, 2014-present
Anesthesiology and Critical Care Division Head Search Committee, Co-Chair, 2015-2016
Vice Chair of Research of the Diagnostic Radiology Search Committee, Member, 8/2015
Division of Surgery Inclusion and Diversity Workgroup, Member, 2018-present
Operational Priority #6 Sub-Task Force, Member, 4/2018-9/2018
Product Evaluation Committee MD Anderson Periop VAT at University of Texas System, Member, 9/2018-present
Health Disparities Research Faculty Search Committee, Member, 4/2019-4/2020

HONORS AND AWARDS

Alpha Lambda Delta Honor Society, 1979
Dean's List, Memphis State University, 1979-1982
Memphis State University State Board Scholarship Recipient, Memphis State University, 1981
Chi Beta Phi Award for Excellence in Chemistry, 1982
Dean's List, University of Tennessee Center for Health Sciences College of Medicine, 1982-1984

Fellowship, St. Jude Children's Research Hospital, Memphis, TN, NIH, 1983

Alpha Omega Alpha Medical Honor Society, 1985

Distinguished Student Achievement Award, University of Tennessee Center for Health Sciences College of Medicine, 1986

Leadership Recognition Organization Recipient, The IMHOTEP Society, 1986

Surgical Resident of the Year, University of California Los Angeles School of Medicine, 1987-1988

American Cancer Society Clinical Fellowship Award, University of California Los Angeles School of Medicine Recipient, American Cancer Society, 1988-1990

Surgical Oncology Training Grant, University of California Los Angeles School of Medicine, NIH, 1988-1990

American Cancer Society Clinical Fellowship Award, University of California Los Angeles School of Medicine Recipient, American Cancer Society, 1993-1994

Surgical Oncology Fellowship, "Gene Therapy of Cancer," University of California Los Angeles School of Medicine, NIH, 1993-1994

American Cancer Society Clinical Fellow of the Year, The University of Texas MD Anderson Cancer Center Recipient, American Cancer Society, 1994-1995

The Best Doctors in America, Castle Connolly Medical Ltd., 2003-2005, 2005-2009, 2009-2010, 2011-2012, 2012-2013, 2014-2015, 2015-2016, 2016-2017, 2017-2018, 2018-2019

America's Top Doctors for Cancer, Castle Connolly Medical, 2005-2019

Finalist, Best Boss Award, The University of Texas MD Anderson Cancer Center, 2006-2007

Certificate for Exceptional Leadership and Support as a Mentor, The University of Texas MD Anderson Cancer Center, 2007-2008

Outstanding Teacher Award, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2007

America's Top Surgeons, Castle Connolly Medical, 2008-2019

Teacher of the Year Award, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2008

Outstanding Teacher Award, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2010

Who's Who Among Executives and Professionals, Who's Who Publication, 2010

Texas Business Women's Award, 2011

Outstanding Alumnus Award, The University of Tennessee College of Medicine Alumni Association, 2012

2013 Faculty Achievement Award in Clinical Research, The University of Texas MD Anderson Cancer Center, 2013

America's Top Physicians for Cancer, Castle Connolly Medical, 2013-2019

Southeastern Texas Top Doctors, 2013

Kathryn S. Stream, Ph.D. Award for Excellence in Women's Health, The Greater Houston Women's Chamber of Commerce, 2015

The Greater Houston Women's Hall of Fame Inductee, The Greater Houston Women's Chamber of Commerce, 2015

Medical Science researcher from MD Anderson elected as AAAS Fellows, American Association for the Advancement of Science (AAAS), 2017-2018

2018 Texas Super Doctors, Super Doctors, 2018

2018 Top Doctors in Texas, American Registry, 2018
2018 Top Performer, The University of Texas MD Anderson Cancer Center, 2018
Breast Surgical Faculty Excellence in Research Mentorship Award, University of Texas MD Anderson Cancer Center, Breast Surgical Oncology Department, 2018
2019 Texas Super Doctors, 2019
2019 Top 1 % Performer, Consumer Assessment of Healthcare Providers and Systems (CAHPS), The University of Texas MD Anderson Cancer Center, 2019
2019-2020 Best Doctors in America, Best Doctors, 2019-2020
Castle Connolly's Exceptional Women in Medicine, Castle Connolly Medical, 2019
2020 Texas Super Doctors, 2020
2020 Texas Top Doctors, The American Registry, 2020
America's Most Honored Doctors Top 1%, The American Registry, 2020
The John Mendelsohn Award for Faculty Leadership, The University of Texas MD Anderson Cancer Center, 2020
2021 Texas Super Doctors, 2021
2021 Top Doctors, Castle Connolly Medical, 2021
America's Most Honored Doctors Top 1%, The American Registry, 2021
2022 Exceptional Women in Medicine, Castle Connolly Top Doctors, 2022
2022 Texas Super Doctors, 2022
Best Female Scientists in the United States 2022 Ranking, Research.com, 2022
Castle Connolly 2022 Top Doctor of Texas, Castle Connolly Medical, 2022
Top Surgical Oncologist 2022, Top Doctors Surgical Oncologist, 2022
2023 Castle Connolly Exceptional Women in Medicine, Castle Connolly Medical, 2023
2023 Castle Connolly Top Doctor of Houston, 2023
2023 Texas Super Doctors, Super Doctors, LLC, 2023
2023 Top 1% Performer, Consumer Assessment of Healthcare Providers and Systems (CAHPS), The University of Texas MD Anderson Cancer Center, 2023
2023 Top Doctors, Castle Connolly Top Doctors, 2023
2024 Exceptional Women in Medicine, Castle Connolly Top Doctors, 2024

RESEARCH

Grants and Contracts

Funded

Breast Program Leader, 1.2 months, Cancer Center Support Grant Research Program in Breast Cancer, 5 P30 CA016672 36(PP-RP6), NIH/NCI, PI - Pisters/Hunt, 9/4/1998-6/30/2024 (\$44,426/year)

Co-Principal Investigator, 1.2 months, UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1, UG1 CA233329-01 (U10 CA180858), NIH/NCI, PI - Tsao/Hunt/Pinnix, 4/15/2014-2/28/2025 (\$1,427,201/year)

Co-Principal Investigator, 0.96 months, Training Program to Reduce Breast Cancer Disparities in Black and Hispanic Women, GTDR17498270, Susan G. Komen Breast Cancer Foundation, PI - McNeill/Hunt, 7/11/2017-1/10/2021 (\$404,235/year)

Co-Principal Investigator, 0.6 months, A prospective, Multi-Center Pivotal Study of the LUM Imaging System for Real-Time, In vivo Margin Assessment in Breast Conserving Surgery, 1R01CA212138-01, NIH/NCI, PI - Smith/Hunt, 9/18/2017-8/31/2021 (\$75,107/year)

Principal Investigator, Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects with Breast Cancer (CL0006), 2017-0658, Lumicell, Inc., 12/14/2017-12/13/2020, \$67,969

Mentor of PI, Mechanism of Action and Resistance to CDK4/6 Inhibitors in Breast Cancer, BC170615, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), PI - Nicole Kettner, 1/1/2018-1/1/2021, \$300,000

Principal Investigator, 3.6 months, Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy, RP180712, Cancer Prevention & Research Institute of Texas (CPRIT), 8/31/2018-8/30/2022 (\$1,464,296/year)

Principal Investigator, 0.12 months, Pivotal Study of the LUM Imaging System for Assisting Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Patients with Breast Cancer, 13035416, Lumicell, Inc., 2/1/2019-1/31/2026, \$142,719 (\$109,100/year)

Principal Investigator, 0.12 months, Novel Sequential Targeted Therapy for Soft Tissue Sarcomas, John Wayne Cancer Foundation, 5/1/2019-4/30/2021, \$20,823

Principal Investigator, 0.12 months, Volunteer Endowment for Patient Support: Clinical Trials - Patient Education Videos, MD Anderson Cancer Center, 5/1/2019-4/30/2021, \$7,470

Co-Investigator, 1%, Wide-field optical coherence tomography imaging of excised breast tissue for evaluation of the computer-aided detection tool ImgAssist™, 2019-01225, Perimeter Medicine, PI - Krishnamurthy, 2/4/2020-2/3/2022, \$132,511

Principal Investigator, 0.12 months, A Randomized Prospective Trial of Breast Cancer Locator Guided VS Wire Localized Partial Mastectomy for Breast Cancer, 2020-0343, Cairn Surgical, 8/31/2020-8/30/2027, \$226,685

Principal Investigator, 30%, The University of Texas MD Anderson Cancer Center SPORE in Breast Cancer, 2021-00059231-Yr1, MD Anderson Cancer Center, 12/1/2020-8/31/2021, \$300,000

Principal Investigator, A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer, 2020-1127, Eli Lilly and Company, 1/12/2021-present, \$164,424

Pending

Principal Investigator, A Phase 2a, single-dose, open-label study to evaluate diagnostic performance, safety, and timing of postdose imaging of ONM-100 in patients with solid tumors undergoing routine surgery, 2019-0641, OncoNano Medicine, Inc.

Other

N/A

Completed

Principal Investigator, Development of Department of Surgical Oncology Breast Cancer Database, O.H. Davenport Award, 1996-1997, \$10,000 (\$10,000/year)

Principal Investigator, Gene Therapy of Breast Cancer Using Recombinant Adenovirus Vectors, UT MD Anderson Breast Cancer Basic Science Research Program, 1997-1998, \$20,000 (\$20,000/year)

Principal Investigator, Induction of Apoptosis in Human Breast Cancer by Adenoviral-Mediated Gene Transfer of the Transcription Factor E2F-1, DAMD17-97-1-7162, US Army Medical Research & Materiel Command, 1997-2002, \$200,000 (\$50,000/year)

Co-Investigator, Involvement of Cell Cycle Regulators in Tumorigenesis, William G. McGowan Charitable Foundation Grant, PI - Mong Hong Lee, Ph.D., 1998-2000, \$65,000 (\$32,500/year)

Core Leader, 0.6 months, Cancer Center Support Grant Research Program in Breast Cancer, 5P30CA016672 36, NIH/NCI, PI - Pisters/Hunt, 9/4/1998-6/30/2019, \$44,426 (\$11,500/year)

Principal Investigator, MDA-7 Gene Therapy in Human Breast Carcinoma, Introgen Therapeutics Sponsored Research Agreement, 1999-10/31/2004, \$41,000 (\$8,200/year)

Principal Investigator, A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women with Clinical T1 or T2 N0 M0 Breast Cancer, American College of Surgeons Oncology Group, 1999-2005, \$204,175 (\$34,030/year)

Collaborator, An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers that are Modulated by Tamoxifen vs. Placebo in Women with an Increased Risk for Breast Cancer, N01-CN095139, National Institutes of Health, PI - David Euhus, M.D., 1999-2005, \$783,957 (\$13,066/year)

Principal Investigator, E2F-1 as a Potential Gene for Induction of Apoptosis in Human Breast Cancer, Shooting Down Cancer Award, 2000-2001, \$25,000 (\$25,000/year)

Principal Investigator, E2F-1 as a Potential Gene for Induction of Apoptosis in Human Breast Cancer, Shooting Down Cancer Award, 2001-2002, \$25,000 (\$25,000/year)

Mentor of PI, Novel Mechanism of interaction of statins with the proteasome: implications in breast cancer, K01 CA105066, NIH/NCI, PI - Ekem Efuet, 5/1/2001-4/30/2010, \$126,000

Co-Investigator, Ad-mda7 Plus Herceptin Against Breast Cancer, R43 CA97598, Introgen Therapeutics; NIH SBIR Program, PI - Abner Mhashilkar, PhD, 2002-2003, \$125,000 (\$12,500/year)

Collaborator, Cyclin E, A Powerful Predictor of Survival in Breast Cancer - A Prospective Study, DAMD17-02-1-0452-1, U.S. Army Department of Defense, PI - Khandan Keyomarsi, M.D., 2002-2005, \$300,000 (\$100,000/year)

Principal Investigator, Ad-mda7 Effectively Induces Cell Death in Breast Cancer Cells in vitro and in vivo: a Potential New Treatment for Breast Cancer, Bridge Funding - UT M.D. Anderson Cancer Center, 2003-2004, \$50,000 (\$25,000/year)

Collaborator, Radiation Dosimetry of Intratumoral Injection of Radionuclides Into Breast Cancer, DAMD17-03-1-045501, U.S. Army Department of Defense, PI - Franklin Wong, M.D., Ph.D., 6/9/2003-7/8/2008, \$300,000 (\$60,000/year)

Collaborator, Fluorescence Optical Imaging for Sentinel Lymph Node Mapping, R21 CA96305-01, National Institutes of Health, PI - Eva M. Sevick-Muraca, M.D., 7/1/2003-6/30/2004, \$159,590 (\$159,590/year)

Co-Investigator, Molecular Characterization of Leiomyosarcoma and GIST by Genomics, R01 CA098570 01A1, National Institutes of Health, PI - Wei Zhang, PhD, Raphael Pollock, MD, PhD, 7/1/2003-6/30/2008, \$950,000 (\$190,000/year)

Study Co-Chair, Outcomes by Ethnicity: Sentinel Lymph Node Status in Women with Breast Cancer, DAMD17-BC03-NURSE, U.S. Army Department of Defense, PI - Mary Alice Hassett, RN, 2004-2006, \$197,162 (\$98,581/year)

Collaborator, ARHI (NOEY2), An Imprinted Breast Cancer Suppressor Gene, R01 CA80957-4, National Institutes of Health, PI - Yinhua Yu, MD, 6/1/2004-5/31/2009, \$783,750 (\$156,750/year)

Mentor, M.D. Anderson Cancer Center, Amgen Oncology Institute Award, PI - Michelle Fanale, M.D., 7/2004-6/2005, \$10,000 (\$10,000/year)

Collaborator, Mechanism/Activity/Resistance/Gleevec/GI Stromal Tumors, 5K23CA109060-05, NIH/NCI, PI - Jonathan Trent, MD, PhD, 7/9/2004-6/30/2009, \$630,000 (\$126,000/year)

Sponsor, Utility of Transcription Factor E2F-1 in Therapy and Prognosis of Human Breast Cancer, National Institutes of Health Loan Repayment Grant, PI - Michelle Fanale, M.D., 10/2004-7/2006, \$63,000 (\$31,500/year)

Mentor of PI, Specific reversible cytostatic protection of normal cells against chemotherapeutics in breast cancer therapy, US Department of Defense, W23RYX-4322-N635, Department of Defense (DOD), PI - Benjamin Mull, 2/21/2005-3/20/2008, \$30,000

Principal Investigator, Targeting the Cell Cycle in Breast Cancer Treatment, BCTR0504200, The Susan G. Komen Breast Cancer Foundation, 5/1/2005-4/30/2008, \$249,819 (\$83,273/year)

Principal Investigator, E2F-1 and Telomeres: A Combined Strategy for Treatment and Prognosis of Breast Cancer, PDF0504074, Susan G. Komen Breast Cancer Foundation, 5/1/2005-4/30/2009, \$135,000 (\$33,750/year)

Mentor of PI, Mechanism of elafin down regulation in breast cancer cells, MDACC Odyssey Fellowship, PI - Tomoya Yokota, 6/1/2005-5/31/2008, \$67,000

Co-Investigator, 1.2 months, UTMDACC SPORE in Breast Cancer: Project 2, Cyclin E as a novel and powerful prognosticator for breast cancer, 1 P50 CA116199, NIH/NCI, PI - Gabriel N. Hortobagyi, MD, 9/23/2005-8/31/2010, \$4,588,260 (\$1,529,420/year)

Mentor of PI, Cell cycle regulation of ER alpha in breast cancer, US Department of Defense, W91ZSQ-5323-N746, Department of Defense (DOD), PI - Sonia Kamrani, MD, 3/1/2006-3/31/2009, \$30,000

Co-Investigator, The Breast Cancer Research Foundation Fund, The Breast Cancer Research Foundation, 10/1/2006-9/20/2007, \$225,000

Mentor, HER2 Regulation of Low Molecular Weight Cyclin E Isoforms in Breast Cancer, American Association for Cancer Research (AACR), PI - Elizabeth A. Mittendorf, MD, 7/1/2007-6/30/2009, \$70,000 (\$35,000/year)

Mentor of PI, Her2 regulation of low molecular weight cyclin E isoforms in breast cancer, American Association for Cancer Research-Genentech BioOncology Fellowship for Cancer Research on the Her Family Pathway, American Association for Cancer Research (AACR), PI - Elizabeth Mittendorf, 7/1/2007-6/30/2009, \$35,000

Co-Investigator, Support for protocol embedded imaging and correlative science endpoints in the ACOSOG Z1031 neoadjuvant endocrine therapy study, The Breast Cancer Research Foundation, 10/1/2007-9/20/2008, \$250,000

Collaborator, 0.6 months, HER2 and Cyclin E: Novel interaction and opportunities for therapy, PDF0707621, Susan G. Komen for the Cure, PI - Khandan Keyomarsi, PhD, 11/14/2007-11/13/2010, \$135,000 (\$45,000/year)

Mentor of PI, Susan G. Komen for the Cure, HER2 and Cyclin E: Novel interaction and opportunities for therapy, PDF0707621, Susan G. Komen Breast Cancer Foundation, PI - Anna Biernacka, 11/14/2007-11/13/2010, \$45,000

Mentor of PI, Mechanistic Regulation of Tumor Specific Forms of Cyclin E in Breast Cancer, 1F32CA1282960-01, NIH/NCI, PI - Nikki Delk, PhD, 6/1/2008-5/31/2011, \$56,000

Mentor, 1.2 months, Cyclin E: Implications for Targeted Therapy in HER2-Overexpressing Breast Cancer, 1K99CA133244, NIH/NCI, PI - Elizabeth A. Mittendorf, MD, 7/1/2008-6/30/2013, \$957,000 (\$191,400/year)

Principal Investigator, 0.12 months, Cyclin E Mediates Response to Chemotherapeutic Agents in Breast Cancer, KG080785, Susan G. Komen for the Cure, 9/1/2008-8/31/2011, \$180,000 (\$60,000/year)

Co-Investigator, Tailoring Chemotherapy Decisions in ER+ Breast Cancer, The Breast Cancer Research Foundation, 10/2/2008-9/30/2009, \$200,000

Mentor of PI, Cell cycle deregulation by LMW cyclin E and p53 disrupts mammary acinar morphogenesis, BC083129, Department of Defense (DOD), PI - MyLinh Duong, MD, 11/1/2008-10/31/2011, \$30,000

Principal Investigator, T Gerke Fund for Paget's Skin Cancer Research, T Gerke Fund for Paget's Skin Cancer Research, 2010-2012, \$48,084 (\$24,042/year)

Mentor of GSBS student and PI, Autophagy as a therapeutic target against triple negative breast cancer, 5TL1RR024147, NIH CCTS T32 Fellowship (UT Health Science Center Houston), PI - Natalie Jabbour, 4/1/2010-3/31/2013, \$28,500

Mentor of PI, Department of Defense Breast Cancer Research Program, BC093412, Department of Defense (DOD), PI - Kimberly Szymanski, 6/1/2010-5/31/2013, \$36,110

Principal Investigator, Rutherford Breast Cancer Research Fund, Rutherford, 6/28/2010-2011, \$100,000

Principal Investigator, 0.12 months, CDK2 is a Novel Target for Triple Negative Breast Cancer, Susan G. Komen for the Cure, 7/15/2010-7/14/2014, \$600,000 (\$150,000/year)

Co-Principal Investigator, 1.2 months, LMW-E, A Novel Indicator of Letrozole Resistance in Breast Cancer, Susan G. Komen for the Cure, PI - Keyomarsi, 7/15/2010-7/14/2014, \$600,000 (\$150,000/year)

Co-Investigator, Tailoring neoadjuvant endocrine therapy based on early on treatment Ki67 analysis, The Breast Cancer Research Foundation, 10/1/2010-9/30/2011, \$223,000

Principal Investigator, Breast Cancer Prevention and Research, Harley's Angels, 10/2/2010-2011, \$28,000

Principal Investigator, Breast Cancer Research Fund, The Hamill Foundation, 11/9/2010-2011, \$200,000

Principal Investigator, 0.12 months, American College of Surgeons Oncology Group ACOSOG Committee Chair, 5U01CA76001, Duke University, 12/1/2010-11/30/2011, \$96,000

Principal Investigator, Hamill Foundation Genome Sequencing Fund, The Hamill Foundation, 2011-2012, \$50,000

Principal Investigator, Hamill Foundation Pathology Test LMW-E, The Hamill Foundation, 2011-2012, \$100,000

Co-Investigator, The ALTERNATE Trial: A biomarker directed approach in the management of postmenopausal women with clinical stage II or III estrogen receptor positive breast cancer, The Breast Cancer Research Foundation, 10/1/2011-9/30/2012, \$240,000

Principal Investigator, Breast Cancer Prevention and Research, Harley's Angels, 10/3/2011-2018, \$120,000 (\$30,000/year)

Principal Investigator, 0.12 months, Alliance Committee Chair, 710CA076001, Brigham & Women's Hospital, 12/1/2011-11/30/2015, \$64,000 (\$16,000/year)

Co-Investigator, 0.6 months, Genomic Studies in Leiomyosarcoma, Sister Institution Network Fund (SINF), PI - Zhang, 5/1/2012-4/30/2014, \$100,000 (\$50,000/year)

Mentor of PI, DOD Breast Cancer Postdoctoral Fellowship Award, Establishing cyclin E/CDK2 as a novel therapeutic target in inflammatory breast cancer, BC112270, Department of Defense (DOD), PI - Angela Alexander, 9/20/2012-2/28/2017, \$297,796

Co-Investigator, 0.24 months, Innovative Strategies for Breast Cancer Immunotherapy, BC113114, Department of Defense (DOD), PI - Feng Wang-Johanning, 9/30/2012-9/29/2016, \$3,067,309 (\$766,827/year)

Co-Investigator, Novel Strategies for Detecting Resistance in Estrogen Receptor Positive Breast Cancer, The Breast Cancer Research Foundation, 10/1/2012-9/20/2013, \$240,000

Mentor of PI, Low Molecular weight cyclin E mediates resistance to aromatase inhibitors in post-menopausal breast cancer patients, Julia Jones Matthews Scholar Award, PI - Iman Doostan, 11/1/2012-2/28/2017, \$29,600

Mentor of PI, Center for Clinical and Translational Science, Elucidating the role of estrogen receptor-alpha binding proteins during antiestrogen resistance in breast cancer, Center for Clinical And Translational Science, PI - Amanda Hanks, 12/1/2012-11/30/2015, \$29,000

Mentor of PI, Mechanisms by which LMW-E induces an enrichment of cancer stemness in mammary epithelial cells, Johnson Foundation Postdoctoral CSCDB, PI - Sira Macalou, 3/1/2013-2/28/2015, \$44,340

Co-Principal Investigator, 1.2 months, UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP), 1 U10 CA180858-01, NIH/NCI, 4/15/2014-2/28/2019, \$3,774,050 (\$754,810/year)

Mentor of PI, Knockin of the Prognostic Breast Cancer Marker LMW-E Into Somatic Human Cells and Mice, Odyssey Post-doctoral Fellowship, PI - Kwang Huei Low, 7/19/2014-12/8/2016, \$61,692

Co-Investigator, 0.12 months, Population-based assessment of patient outcomes in older breast cancer survivors, American Society of Clinical Oncology (ASCO), PI - Smith B, 9/19/2014-9/18/2016, \$100,000 (\$50,000/year)

Mentor of PI, Targeting the cell cycle in Sporadic & BRCA mutant triple negative breast cancer, PDF14302675, Susan G. Komen Breast Cancer Foundation, PI - Jason Carey, 9/23/2014-9/22/2017, \$180,000 (\$60,000/year)

Co-Investigator, Innovative Strategies for Breast Cancer Immunotherapy, W81XWH-12-1-0223 (BC113114), Department of Defense Breast Cancer Research Program Impact Award, 10/2/2014-2/28/2018 (\$3,067,309/year)

Principal Investigator, A Pivotal, Prospective, Open-Label, Multicenter Comparison Study Of SentiMag®/Sienna®+ And The Standard Of Care For Lymph Node Detection In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure, 2014-0914, Endomagnetics Limited, 1/26/2015-1/25/2018, \$131,906

Mentor of PI, UT GSBS Scholarship, T.C. Hsu Memorial Scholarship, PI - Smruthi Vijayaraghavan, 1/1/2016-7/31/2017, \$17,000

Subaward Principal Investigator, Prospective, Multi-Center Pivotal Study of the LUM Imaging System, 1R44CA211013-01, Lumicell, Inc., PI - Lee, 7/4/2016-6/30/2018 (\$1,033,123/year)

Principal Investigator, A Prospective, Open Label, Post Marketing Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion., 2016-0459, Endomagnetics Limited, 12/5/2016-12/4/2019, \$238,006

Principal Investigator, A novel therapeutic strategy targeting the sarcoma cell cycle, John Wayne Cancer Foundation, 1/1/2017-12/31/2017, \$33,333 (\$33,333/year)

Principal Investigator, 0.12 months, Novel sequential targeted therapy for soft tissue sarcomas, John Wayne Cancer Foundation, 5/1/2019-10/30/2020 (\$20,823/year)

Principal Investigator, Breast Cancer Prevention & Treatment Fund, Harley's Angels, 2012, \$35,092

Not Funded

N/A

Protocols

Funded

Collaborator, A Randomized Study of Oral Ondansetron Versus Placebo to Reduce Nausea and Vomiting after Outpatient Surgery for Breast Cancer, ID95-081, PI - S. Eva Singletary, MD, 1995-1998, Burroughs Wellcome Dow; GlaxoSmithKline

Principal Investigator, A Pilot Study of the Therapeutic Efficacy of Large Core Stereotactic Breast Biopsy (ABBI) for the Local Treatment of Nonpalpable Breast Cancer, IDP97-222, 1997-2000, US Surgical Corporation

Collaborator, A Phase II Evaluation of Targretin (LDG1069) Capsules in Patients with Liposarcoma, ID97-207, PI - Robert Benjamin, MD, 1997-2001, Ligand

Collaborator, A Phase I/II Trial to Evaluate Brachytherapy as the Sole Method of Radiation Therapy for Stage I and II Breast Carcinoma, RTOG95-17, PI - Eric Strom, MD, 1997-2002, RTOG

Collaborator, Phase I Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intraperitoneally in Patients with Peritoneal Carcinomatosis or Sarcomatosis, DM97-213, PI - Claire Verschraegen, MD, 1997-2002, Aronex

Collaborator, Phase II Open Label, Single Center Trial of Primary Chemotherapy w/ Taxotere and Doxorubicin+Filgrastim, Surgery Postop Chemotherapy w/ Cyclophosphamide, Methotrexate, & 5-FU, Radiotherapy & Tamoxifen in Patients w/ Locally Advanced Breast Cancer, ID97-099, PI - Vicente Valero, MD, 1997-2010, Rhone Poulenc

Collaborator, Prospective Study of Menstrual Cycle Maintenance and Quality of Life after Breast Cancer, BS97-274, PI - Raphael Pollock, MD, 1997-2010, Department of Defense

Collaborator, Evaluation of Lumpectomy, Tamoxifen and Irradiation of the Breast Compared with Lumpectomy Plus Tamoxifen in Women 70 Yrs. of Age or Older Who Have Carcinoma of the Breast that is Less Than or Equal to 2 cm and Clinically Node Negative, RTOG-9702, PI - Eric Strom, MD, 1997-2012, RTOG

Collaborator, Radiosensitivity and Biological Aging of Normal Skin Fibroblasts as Predictors of Normal Tissue Treatment Toxicity, ID98-212, PI - Thomas Buchholz, MD, 1998-2005, NIH

Collaborator, Trial of Amifostine (Wr-2721) During Chemoradiation for Anal Cancer, ID98-274, PI - Nora Janjan, MD, 1998-2006, Medimmune

Collaborator, Evaluation of Paclitaxel Weekly Versus Every 3 Weeks (Q3W) as Adjuvant or Neoadjuvant Therapy for Operable Breast Cancer, ID98-240, PI - Aman Buzdar, MD, 1998-2010, Bristol-Myers Squibb

Collaborator, Early Detection of Occult Micrometastases by Lymph Node Mapping and RT-PCR in Patients with Invasive Breast Cancer: A Multi-Center Trial, ID97-336, PI - Merrick I. Ross, MD, 1998-present, Department of Defense, University of South Florida

Principal Investigator, A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Clinical T1 or T2 N0 M0 Breast Cancer (Z0010), ID99-336, 1999-2015, The American College of Surgeons Oncology Group

Principal Investigator, A Randomized Trial of Axillary Node Dissection in Clinical T1-2, N0, M0 Breast Cancer who have a Positive Sentinel Node (Z0011), ID99-336, 1999-2015, American College of Surgeons Oncology Group

Collaborator, The Impact of Quality of Life in Early Stage Breast Cancer: Clinical Implications for Breast Conservation Treatment and Radiotherapy, RO98-358, PI - George Perkins, MD, 1999-present, NIH

Collaborator, Identification of Intraductal Breast Pathology in High Risk Women: A Multicenter Study, ID99-413, PI - Henry Kuerer, MD, PhD, 2000-2002, ProDuct Health

Collaborator, Randomized, Double-Blind Study Comparing Arimidex with Nolvadex as Neoadjuvant & Adjuvant Treatment in Postmenopausal Women with Large Operable (T2(3>cm), T3, N0-2, M0) or Potentially-Operable, Locally Advanced (T4B, N0-2, M0), ER+ and/or PR+ Breast Cancer, DM00-261, PI - Aman Buzdar, MD, 2000-2006, AstraZeneca

Principal Investigator, Modulators Of The Cell Cycle As Prognostic Factors For Breast Cancer, LAB00-222, 2000-present, \$400,000, Susan G. Komen Foundation; NCI

Co-Principal Investigator, Phase III Trial of Tamoxifen Alone Vs Tamoxifen Plus RT for Good Risk Duct Carcinoma-In-Situ (DCIS) of the Female Breast, RTOG98-04, PI - Eric Strom, MD, 2000-present, Radiation Therapy Oncology Group Trial

Collaborator, A Phase I/II Study of Preop Radiotherapy with/without Sugem 5416 (NSC #696819 A TK Inhibitor Anti-Angiogenesis Compound) in the Management of Low to Intermediate Grade Soft Tissue Sarcoma of the Trunk or Extremity, RTOG S0120, PI - Matthew Ballo, MD, 2001-2002, RTOG

Collaborator, A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients with Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery, ID00-264, PI - Saroj Vadhan-Raj, MD, 2001-2004, Ortho

Collaborator, Phase II, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination with Local Administration of AD5CMV-P53 (RPR/INGN 201) in Locally Advanced Breast Cancer (LABC), ID00-008, PI - Massimo Cristofanilli, MD, 2001-2005, RPR Gencell

Collaborator, Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women with One to Three Positive Axillary Nodes, RTOG99-15, PI - Eric Strom, MD, 2001-2006, RTOG

Collaborator, Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer, ID99-146, PI - Aman Buzdar, M.D., 2001-2011, Genentech; MDACC

Collaborator, A Phase I Study of Preoperative Concomitant Gemcitabine and External-Beam Radiation Therapy and Surgical Resection for Patients with Extremity and Trunk Soft Tissue Sarcomas, ID01-532, PI - Peter W. Pisters, MD, 2001-2015, Eli Lilly

Collaborator, Sentinel Lymph Node Mapping Using Fluorescent Contrast Agents and Near-Infrared (NIR) Optical Imaging, ID01-512, PI - Gary Whitman, MD, 2002-2005, NIH

Principal Investigator, An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers that are Modulated by Tamoxifen vs. Placebo in Women with an Increased Risk for Breast Cancer, ID01-312, 2002-2008, National Cancer Institute

Collaborator, Phase II Study of Multimodality Therapy for Primary and Recurrent Retroperitoneal Sarcomas, RTOG S0124, PI - Peter Pisters, MD, 2002-2010, Radiation Therapy Oncology Group Study

Collaborator, Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Axillary Node Dissection in Patients with Breast Cancer, GS01-562, PI - Barry Feig, MD, 2002-2010, Cohesion Technologies

Collaborator, A Phase II Study Of Adjuvant STI571 (Gleevec) Therapy In Patients Following Completely Resected High-Risk Primary Gastrointestinal Stromal Tumor (GIST), ID02-116, PI - Shreyaskumar Patel, MD, 2002-2015, American College of Surgeons Oncology Group

Collaborator, A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST), ID02-491, PI - Shreyaskumar Patel, MD, 2002-2019, American College of Surgeons Oncology Group

Collaborator, A Randomized, Placebo-Controlled Study of Exploratory Pharmacogenomics and Pharmacodynamic Effects of Oral CCI-779 Administered to Women with Operable Breast Cancer Prior to Surgery, ID02-512, PI - Funda Meric-Bernstam, MD, 2003-2004, Wyeth Pharmaceuticals

Collaborator, A Prospective Study of the Prognostic Significance of Microsatellite Instability in Patients with Early Age-of-Onset Colorectal Cancer, American College of Surgeons Oncology Group Trial, ACOSOG Z0190, PI - Miguel Rodriguez-Bigas, MD, 2003-2005, American College of Surgeons Oncology Group

Collaborator, A Phase 1/2 Study of Gcl-2 Antisense Oligonucleotide (Genasense) in Combination with Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer, DM02-700, PI - Francisco Esteva, MD, PhD, 2003-2008, NCI

Collaborator, A Prospective, Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib Mesylate (Gleevec, Formerly STI-571) in Patients with Primary, Recurrent, or Metastatic Resectable, Kit-Expressing, Gastrointestinal Stromal Tumor (GIST), ID03-0023, PI - Jonathan Trent, MD, 2003-2011, Novartis

Collaborator, Mammosite RTS as the Sole Radiation Therapy Technique for Ductal Carcinoma in Situ, 2003-0420, PI - Henry Kuerer, MD, PhD, Eric Strom, MD, 2003-2013, Proxima Therapeutics

Collaborator, Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy, NSABP Multicenter Trial, NSABP B-35, PI - Henry Kuerer, MD, PhD, Vicente Valero, MD, 2003-2018, \$250,000, NSABP

Collaborator, A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS), ACOSOG Z9031, PI - Peter W. Pisters, MD, 2004-2006, American College of Surgeons Oncology Group

Collaborator, A Presurgical Study to Evaluate Molecular Alterations that Occur in Human Breast Cancer Tissue and Normal Skin after Short Term Exposure to ZD1839 (Iressa) and to Correlate these Alterations with Pharmacokinetic Parameters, BCIRG 103, PI - Vicente Valero, MD, 2004-2006, Breast Cancer International Research Group

Principal Investigator, Pivotal Study: GeneSearch Breast Lymph Node (BLN) Assay for Intraoperative Molecular Testing, 2004-0337, 2004-2007, GeneSearch

Collaborator, A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) (ACRIN 6665), RTOG 0132, PI - Robert Benjamin, MD, 2004-2013, RTOG

Principal Investigator, Outcomes by Ethnicity: Sentinel Lymph Node Status in Women with Breast Cancer, LAB03-1033, 2004-2013, Department of Defense

Collaborator, A Model of COX-2 Mediated Bone Metastasis in Human Breast Cancer, LAB04-0657, PI - Anthony Lucci, MD, 2004-present, Department of Defense

Collaborator, Breast Cancer Disease and Outcomes Database, 2004-0541, PI - Carlos Barcenas, MD, 2004-present, Nellie Connally Research Fund

Collaborator, A Neoadjuvant Phase II Trial of ZD1839 (IRESSA) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study, 2004-0400, PI - Francisco Esteva, MD, PhD, 2005-2006, Baylor

Collaborator, A Pilot Phase II Study of Pre-Operative Radiation Therapy & Thalidomide for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative Maf/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall, RTOG-0330, PI - Ashleigh Guadagnolo, MD, MPH, 2005-2007, RTOG

Collaborator, ARHI (NOEY2), an Imprinted Breast Cancer Suppressor Gene, LAB05-0499, PI - Robert Bast, MD, 2005-2011, NCI

Collaborator, Delayed-Immediate Breast Reconstruction, 2004-0955, PI - Steven Kronowitz, MD, 2005-2015, Susan G. Komen for the Cure

Collaborator, Breast Cancer Risk Assessment and Genetic Polymorphisms, LAB04-0412, PI - Abenaa Brewster, MD, 2005-2016, Inter Genetics

Principal Investigator, Characterization of Human Endogenous Retrovirus Env Proteins as Ovarian and Breast Tumor Vaccines, LAB04-0083, 2005-2022, Department of Defense; SRI International

Collaborator, A Phase II Study of Neoadjuvant Chemotherapy with Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane), NSABPFB-AX-003, PI - Aman Buzdar, MD, 2006-2009, NSABP

Principal Investigator, A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5mg), or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer, ACOSOG Z1031, 2006-present, \$114,356, American College of Surgeons Oncology Group

Principal Investigator, Cyclin E as a Prognostic Marker and Predictor of Clinical Response to Neoadjuvant Chemotherapy and Adjuvant Hormonal Therapy in Patients with Stage II-III Breast Cancer, LAB05-0969, 2006-present, Breast Cancer SPORE; NIH

Collaborator, Establishing Cell Lines and Examining Tumor and Serum Biological Markers from Human Sarcoma, LAB06-0581, PI - Keila Torres, MD, 2006-present, Exelixis; NCI

Collaborator, Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans, 2005-0618, PI - Jonathan Trent, MD, 2007-2010, Novartis; SARC

Collaborator, A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer, ACOSOG Z1041, PI - Funda Meric-Bernstam, MD, 2007-2018, American College of Surgeons Oncology Group

Collaborator, Bone Marrow Analysis in Early-Stage Breast Cancer, NSABP BP-59, PI - Anthony Lucci, MD, 2007-2018 (\$210,000/year), NSABP

Collaborator, A Phase II Randomized Study of Intraductal Carboplatin in Women with Ductal Carcinoma in Situ, 2008-0397, PI - Henry Kuerer, MD, PhD, 2009, Wendy Hill Medical, Inc.

Principal Investigator, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis, ACOSOG Z1071, 2009-present, \$165,000, ACOSOG

Collaborator, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy, NSABPB43, PI - Henry Kuerer, MD, PhD, 2009-present, \$105,000, NSABP

Collaborator, Multicenter NCI Division of Cancer Prevention, Neoadjuvant Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer, 2008-0086, PI - Powell Brown, MD, 2009-present, National Cancer Institute

Collaborator, A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients with Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy, 2010-0053, PI - Steven J. Kronowitz, MD, 2010-2015, NCI

Collaborator, A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma, ACOSOG Z1072, PI - Rosa Hwang, MD, 2010-2016, \$122,500, ACOSOG

Collaborator, Phase Ib Trial of Combination Immunotherapy with HER2/neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients, 2009-0892, PI - Elizabeth Mittendorf, MD, PhD, 2010-2017, \$273,544, Brooke Army Medical Center; Henry Jackson Foundation

Co-Principal Investigator, Expression of Cyclin E and Low Molecular Weight Cyclin E as Predictors of Response to Aromatase Inhibition with Letrozole, Anastrozole and Exemestane, LAB10-0383, PI - Stacy Moulder, MD, 2010-2018, Susan G. Komen for the Cure

Collaborator, A Phase I with Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination with Seliciclib for the Treatment of Patients with Metastatic Triple Negative Breast Cancer, 2011-0013, PI - Stacy Moulder, MD, 2011-2012, NIH

Collaborator, A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer, 2010-0098, 2011-present, Translational Breast Cancer Research

Principal Investigator, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer, ECOG E2108, 2011-present, ECOG

Co-Principal Investigator, Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative primary Invasive Breast Cancer (Clinical Stage I to III), 2011-0007, PI - Stacy Moulder, MD, 2011-present, Kellogg Foundation

Collaborator, Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer, 2010-0559, PI - Benjamin Smith, MD, 2011-present, ASCO; Northwestern University

Co-Principal Investigator, A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer, CALGB70305, PI - Sarah DeSnyder, MD, 2012-2017, Alliance for Clinical Trials in Oncology

Co-Principal Investigator, A Phase I Study with Dose Expansion of Dinaciclib (SCH 727965) in Combination with Epirubicin in Patients with Metastatic Triple Negative Breast Cancer, 2012-0229, PI - Stacy Moulder, MD, 2012-2018, NCI

Collaborator, Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS), CALGB 40903, PI - Isabelle Bedrosian, MD, 2012-2018, CALGB

Principal Investigator, Z11102 - Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC), ACOSOG Z11102, 2012-present, Alliance for Clinical Trials in Oncology

Collaborator, Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2- Expressing Breast Cancer Patients to Prevent Recurrence, 2013-0436, PI - Isabelle Bedrosian, MD, 2013-2018, Cancer Insight, LLC

Co-Principal Investigator, Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients, 2013-0139, PI - Isabelle Bedrosian, MD, 2013-2018, Galena Biopharma Inc.

Collaborator, A Randomized Pre-Surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole on Primary Breast Cancer, 2013-0534, PI - Funda Meric-Bernstam, MD, 2013-2019, Novartis

Collaborator, Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer, AllianceA011104, PI - Isabelle Bedrosian, MD, 2013-present, Alliance for Clinical Trials in Oncology

Collaborator, Impact of the Oncotype DX® DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma in Situ, 2013-0849, PI - Henry Kuerer, MD, PhD, 2014-2016, Genomic Health

Collaborator, A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients with Clinically Node Negative Breast Cancer, 2013-1021, PI - Merrick Ross, MD, 2014-2018, Vestin, Inc.

Collaborator, A Phase 1, Open-Label, Multiple Ascending Dose Study Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered LV305 in Patients with

Unresectable or Metastatic Cancer, 2013-0823, PI - Neeta Somaiah, MD, 2014-2019, Immune Design Corp.

Principal Investigator, A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy, Alliance_A011202, 2014-present, Alliance for Clinical Trials in Oncology

Collaborator, A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measurement in the Prevention of Lymphedema Following Locoregional Treatment for Breast Cancer, 2014-0911, PI - Sarah DeSnyder, MD, 2014-present, ImpediMed

Collaborator, ALTERNATE Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study, Alliance-A011106, PI - Abigail Caudle, MD, 2014-present, Alliance for Clinical Trials in Oncology

Co-Principal Investigator, Breast Implant-Associated Anaplastic Large Cell Lymphoma: An Evaluation of Pathogenic Mechanisms and Molecular Targets, PA14-0321, PI - Mark Clemens, MD, 2014-present, Foundation Medicine, Inc.

Collaborator, Identification of Predictors of Response in Patients with Sarcoma Treated with Pazopanib, PA14-0217, PI - Vinod Ravi, MD, 2014-present, GlaxoSmithKline

Collaborator, Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging with Guided Biopsy in Breast Cancer Patients, 2014-0611, PI - Basak Dogan, MD, 2015-2016, General Electric Healthcare

Principal Investigator, A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/Sienna+ And The Standard Of Care For Lymph Node Detection In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure, 2014-0914, 2015-2018, Endomagnetics, Inc.

Collaborator, An Integrated Approach to the Proteomic and Genomic Analysis of Breast Cancer, PA14-0887, PI - Isabelle Bedrosian, MD, 2015-2019, IncellDx, Inc.

Collaborator, A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1, 2014-0952, PI - Neeta Somaiah, MD, 2015-present, Immune Design Corp.

Co-Principal Investigator, ARTEMIS: A Robust TNBC Evaluation framework to Improve Survival., 2014-0185, PI - Stacy Moulder, MD, 2015-present, CPRIT

Collaborator, Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women with Invasive Breast Cancer using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study, 2014-0812, PI - Gaiane M Rauch, MD, 2015-present, Diagnostic Imaging Clinical Research Committee Grant

Collaborator, Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-Risk HER2+ Breast Cancer Patients, 2014-0443, PI - Isabelle Bedrosian, MD, 2015-present, Department of Defense; Cancer Insight, LLC

Collaborator, Population-Based Assessment of Patient Outcomes in Older Breast Cancer Survivors, 2014-0668, PI - Benjamin Smith, MD, 2015-present, American Society for Radiation Oncology; Survivorship IRG

Principal Investigator, A Prospective, Open Label, Post Marketing Study of Magseed and SentiMag in Patients Undergoing Surgical Excision of a Breast Lesion, 2016-0459, 2016-present, Endomagnetics, Inc.

Collaborator, Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with DCIS of the Breast, 2016-0164, PI - Isabelle Bedrosian, MD, 2016-present, NCI; Galena Biopharma, Inc.

Collaborator, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer, AllianceA011401, PI - Sarah DeSnyder, MD, 2016-present, \$73,680, Alliance for Clinical Trials in Oncology

Collaborator, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, AllianceA011502, PI - Isabelle Bedrosian, MD, 2017-present, Alliance for Clinical Trials in Oncology

Collaborator, Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial, AllianceAFT-25, PI - Joanna Lee, MD, 2017-present, Alliance Foundation Trials, LLC

Collaborator, PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer, 2016-0022, PI - Vicente Valero, MD, 2017-present, Alliance Foundation Trials, LLC

Collaborator, Phase II Study of Neoadjuvant Checkpoint Blockade in Patients with Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma, Protocol 2017-0143, PI - Christina Roland, MD, 2017-present, ACOS; MDACC

Collaborator, Shortening Adjuvant Photon Irradiation to Reduce Edema(SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer, 2016-0142, PI - Karen Hoffman, MD, 2017-present, NCI

Principal Investigator, Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects with Breast Cancer (CL0006), 2017-0658, 2018-present, Lumicell

Co-Principal Investigator, Phase I/II Safety and Efficacy Study of Autophagy Inhibition with Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib plus Letrozole for Estrogen Receptor-Positive and HER2-negative Breast Cancer, 2017-0071, PI - Debasish Tripathy, MD, 2018-present, NCI; MDACC

Principal Investigator, Retrospective Chart Review of SentimagIC Clinical Study Subjects, PA17-1074, 2018-present, Endomagnetics, Inc.

Principal Investigator, TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer - (CCTG MA.39), 2019-1023, 2019-2026, Canadian Cancer Trials Group (CCTG) LAPS Grant

Collaborator, A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating ZW25 in Patients with low risk HER2/neu Positive (HER2+) Breast Cancer (BC), 2019-0523, PI - Rashmi Murthy, MD, 2019-present

Principal Investigator, A Phase 2a, single-dose, open-label study to evaluate diagnostic performance, safety, and timing of postdose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer, in patients with solid tumors undergoing routine surgery, 2019-0641, 2019-present, Onco-Nano

Collaborator, ALLIANCE-A221702: ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse, Alliance-A221702, PI - Sarah DeSnyder, MD, 2019-present, Alliance

Collaborator, Biomarkers of Resistance to Hormonal Therapy in Hormone Receptor (HR) Positive Breast Cancer, PA19-0047, PI - Debasish Tripathy, MD, 2019-present, CPRIT

Collaborator, Magseed Enabled Long-Term Localization of Axillary Lymph Nodes (MAGELLAN): A Prospective Open Label Study of the Use of Magseed Markers and Sentimag to Localize Axillary Lymph Nodes with Biopsy-Proven Metastases in Breast Cancer Patients,

2018-0974, PI - Abigail Caudle, MD, 2019-present, \$98,487 (\$77,990/year), Endomagnetics, Inc.

Principal Investigator, Pivotal Study of the LUM Imaging System for Assisting Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Patients with Breast Cancer, 2017-0667, 2019-present, Lumicell

Principal Investigator, EMBER-2: A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer, 2020-1127, 2020-present, Eli Lilly and Company

Principal Investigator, Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Patients with Breast Cancer Receiving Neoadjuvant Therapy, 2020-1100, 2020-present, Massachusetts General Hospital R01 Grant

Co-Principal Investigator, Wide-field optical coherence tomography imaging of excised breast tissue for evaluation of the computer-aided detection tool ImgAssist, 2019-1225, PI - Savitri Krishnamurthy, MD, 2020-present, Cancer Prevention Research Institute of Texas

Investigator, Development of an application-based digital navigator for perioperative breast surgery patients, 2021-1211, PI - Piotrowski, 2022-present, The University of Texas MD Anderson Cancer Center

Unfunded

Collaborator, Standardized Anesthetic Regimen and Postoperative Management of Patients Undergoing Outpatient Surgery for Breast Cancer - A Current Practice Protocol, CPPGS95-001, PI - S. Eva Singletary MD, 1995-1996, The University of Texas MD Anderson Cancer Center

Principal Investigator, Abnormalities of Tumor Suppressor Genes in Human Breast Cancer, LAB96-292, 1996-2007, The University of Texas MD Anderson Cancer Center

Collaborator, A Phase I Study of Preoperative Concurrent Chemoradiation for High Risk Extremity and Trunk Soft Tissue Sarcomas, ID97-335, PI - Peter Pisters, MD, 1998-2011, The University of Texas MD Anderson Cancer Center

Principal Investigator, A Pilot Study of Intraperitoneal Hyperthermic Chemotherapy for the Treatment of Sarcomatosis and Peritoneal Mesothelioma, IDP98-176, 1998-2011, The University of Texas MD Anderson Cancer Center

Collaborator, National Cancer Institute Division of Cancer Treatment and Diagnosis Model Informed Consent Pilot Project, DM99-124, PI - Aman Buzdar, MD, 1999-2001, The University of Texas MD Anderson Cancer Center

Collaborator, Molecular Stratification of Gastrointestinal Stromal Tumors and Leiomyosarcoma, LAB99-323, PI - Wei Zhang, MD, 1999-2016, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, A Prospective Study to Compare the Cytology and Biomarker Expression of Cells Obtained by Nipple Aspiration and Four Quadrant Fine Needle Aspiration of Concurrent and Contralateral Breast in Women with Unilateral Breast Cancer, LAB00-359, PI - Savitri Krishnamurthy, MD, 2000-2003, The University of Texas MD Anderson Cancer Center

Collaborator, The Immune Response in Breast Cancer Sentinel Nodes, LAB00-288, PI - Nancy Poindexter, PhD, 2000-2003, The University of Texas MD Anderson Cancer Center

Collaborator, Immune Response in Breast Cancer Sentinel Lymph Nodes, LAB00-353, PI - Nancy Poindexter, PhD, 2000-2004, The University of Texas MD Anderson Cancer Center

Collaborator, Pilot Study to Evaluate the Use of Adriamycin in Isolated Limb Perfusion for Patients with Unresectable Extremity Sarcoma, GS00-143, PI - Barry Feig, MD, 2000-2005, The University of Texas MD Anderson Cancer Center

Collaborator, Personalized Immunotherapy - A Laboratory Study of Various Preparation of Heat Shock Protein Peptides Complex (Hsppc) from Autologous Soft Tissue Sarcoma, LAB00-287, PI - Robert Benjamin, MD, 2000-2006, The University of Texas MD Anderson Cancer Center

Collaborator, Pilot Study of Lymphatic Mapping for Colon Cancer-Multicenter Study, ID00-041, PI - Barry Feig, MD, 2000-2007, The University of Texas MD Anderson Cancer Center

Collaborator, A Prospective Investigation to Determine the Ability to Obtain, Cytologically Characterize, and Biochemically Analyze Nipple Aspirate Fluid in Women with Carcinoma of the Breast, LAB00-312, PI - Henry Kuerer, MD, PhD, 2000-present, The University of Texas MD Anderson Cancer Center

Collaborator, Retrospective Review of Peritoneal Mesothelioma, RCR01-663, PI - Claire Verschraegen, MD, 2001-2002, The University of Texas MD Anderson Cancer Center

Principal Investigator, Impact of Postmastectomy Breast Reconstruction on Patients' Body Image, Sexual Function and Quality of Life, GS00-245, 2001-2003, The University of Texas MD Anderson Cancer Center

Collaborator, Retrospective Chart Review to Analyze the Role of Surgery and Outcome of Women with Chest Wall Recurrence Following Mastectomy for Breast Carcinoma, RCR01-653, PI - Henry Kuerer, MD, PhD, 2001-2003, The University of Texas MD Anderson Cancer Center

Collaborator, Development of an Allergen Specific Test to Predict Allergic Reactions to Isosulfan Blue Dye During Lymphatic Mapping and Sentinel Lymph Node Biopsy, LAB01-499, PI - Henry Kuerer, MD, PhD, 2001-2005, The University of Texas MD Anderson Cancer Center

Collaborator, In-Vitro Ultrasound Diagnosis of Metastatic Axillary Lymphadenopathy, LAB00-422, PI - Deepak Bedi, MD, 2001-2005, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review to Develop a Database Library for Patients with Breast Sarcoma, RCR01-647, 2001-2006, The University of Texas MD Anderson Cancer Center

Collaborator, A Preliminary Study to Explore Subareolar Injection as the Site for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients with Breast Cancer, ID01-538, PI - Gildy Babiera, MD, 2001-2008, The University of Texas MD Anderson Cancer Center

Principal Investigator, A Feasibility Pilot Study of Intraperitoneal Hyperthermic Chemoperfusion With Cisplatin Combined With Intraperitoneal Mitoxantrone for the Treatment of Patients With Sarcomatosis, ID00-419, 2001-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Phase II Trial of Preoperative Chemotherapy, Preoperative Chemoradiotherapy, and Resection with Intraoperative Radiotherapy Boost for Patients with Intermediate and High-Grade Retroperitoneal or Pelvic Sarcomas, ID01-202, PI - Peter Pisters, MD, 2001-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Inverse Correlation Between iNOS and mda-7 Expression in Breast Cancer: Potential Prognostic Markers, LAB01-272, PI - Aysegul Sahin, MD, 2001-2014, The University of Texas MD Anderson Cancer Center

Collaborator, A Chart Review Study to Develop a Database Library for Patients with Sarcoma, RCR01-110, PI - Keila Torres, MD, 2001-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, A Prospective Chart Review Study to Develop a Database Library for Patients with Breast Cancer, RCR01-182, 2001-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Chart Review Study to Develop a Database Library for Patients with Breast Lymphatic Mapping, RCR01-309, 2001-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review Study to Develop a Database Library for Breast Conserving Therapy Patients, RCR01-297, 2001-present, The University of Texas MD Anderson Cancer Center

Collaborator, Role of Surgery and Outcome of Women Requiring Laparotomy for Bowel Obstruction Due to Metastatic Lobular Carcinoma of the Breast, RCR02-649, PI - Henry Kuerer, MD, PhD, 2002-2003, The University of Texas MD Anderson Cancer Center

Collaborator, Chart Review Study to Develop a Treatment Plan for the Management of Breast Cancer Metastases to the Dermis, RCR02-653, PI - Gildy Babiera, MD, 2002-2004, The University of Texas MD Anderson Cancer Center

Collaborator, Clinical and Pathologic Features of Breast Carcinoma in Women Presenting with Nipple Discharge, RCR02-650, PI - Gildy Babiera, MD, 2002-2004, The University of Texas MD Anderson Cancer Center

Collaborator, Techniques in Reducing Re-Excision Rates for DCIS Treated with Breast Conserving Therapy, RCR02-610, PI - Henry Kuerer, MD, PhD, 2002-2004, The University of Texas MD Anderson Cancer Center

Collaborator, Dendritic Cells in Breast Cancer Sentinel Lymph Nodes, LAB02-472, PI - Nancy Poindexter, PhD, 2002-2005, The University of Texas MD Anderson Cancer Center

Collaborator, Efficacy of Contralateral Prophylactic Mastectomy in Breast Cancer Prevention, RCR02-659, PI - Funda Meric-Bernstam, MD, 2002-2005, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, HIN-200 Gene Expression in Breast Cancer Progression, LAB02-363, PI - Duen-Hwa Yan, PhD, 2002-2005, The University of Texas MD Anderson Cancer Center

Collaborator, Incidence of Allergic Reactions During Breast Cancer Lymphatic Mapping Following Preoperative Prophylaxis: Initial Results of a Prospective Clinical Practice, RCR02-574, PI - Henry Kuerer, MD, PhD, 2002-2005, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, High-Resolution Rf Thermoacoustic Tomography, LAB02-315, PI - Bruno Fornage, MD, 2002-2006, The University of Texas MD Anderson Cancer Center

Collaborator, Current National Use of Tamoxifen Following Breast Surgery for Ductal Carcinoma in Situ, RCR02-462, PI - Henry Kuerer, MD, PhD, 2002-2007, The University of Texas MD Anderson Cancer Center

Collaborator, Immune Function of Dendritic Cells in Breast Cancer Patients, LAB02-619, PI - Nancy Poindexter, PhD, 2002-2007, The University of Texas MD Anderson Cancer Center

Collaborator, Phase II Study of Capecitabine in Combination with Pre-Operative Pelvic Radiotherapy Using the Concomitant Boost Technique in Rectal Cancer, ID02-009, PI - Nora Janjan, MD, 2002-2007, The University of Texas MD Anderson Cancer Center

Collaborator, Role of Combined Prophylactic Mastectomy with or without Reconstruction and Salpingo-Oophorectomy in the Management of the High Risk Patients, RCR02-654, PI - Funda Meric-Bernstam, MD, 2002-2009, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients with Operable Breast Cancer, ID01-580, PI - Aman Buzdar, MD, 2002-2011, The University of Texas MD Anderson Cancer Center

Collaborator, Markers of Distant Metastasis in Breast Cancer, LAB02-647, PI - Funda Meric-Bernstam, MD, 2002-2011, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Markers Predictive of Local Recurrence After Breast-Conserving Therapy, LAB02-043, PI - Funda Meric-Bernstam, MD, 2002-2014, The University of Texas MD Anderson Cancer Center

Collaborator, Collection and Banking of Blood, Body Fluids and Tissue Samples from Patients with Gastrointestinal Malignancies: An Endoscopic, Surgical and Banking Protocol, LAB01-543, PI - Jaffer Ajani, MD, 2002-present, The University of Texas MD Anderson Cancer Center

Collaborator, Needle Localization for Excisional Biopsy of Breast Lesions: Comparison of Full-Field Digital versus Screen-Film Mammographic Guidance on Procedure Time, RCR03-0333, PI - Gary Whitman, MD, 2003-2004, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review Study to Examine the Outcome of Patients Having Breast Conserving Therapy after Chemotherapy, RCR03-0325, 2003-2004, The University of Texas MD Anderson Cancer Center

Collaborator, Determination of Extent of Residual Tumor Following Neoadjuvant Chemotherapy for Operable Breast Cancer, RCR03-0051, PI - S. Eva Singletary, MD, 2003-2006, The University of Texas MD Anderson Cancer Center

Collaborator, Surgical Treatment of Breast Cancer in Patients with BRCA1 and BRCA2 Mutations, RCR03-0291, PI - Funda Meric-Bernstam, MD, 2003-2006, The University of Texas MD Anderson Cancer Center

Principal Investigator, Clinical Outcome of Patients Undergoing Breast Conserving Therapy, RCR03-0338, 2003-2007, The University of Texas MD Anderson Cancer Center

Collaborator, Radiation Dosimetry of Intra-tumoral Injection of Radionuclides in Human Breast Cancer, ID03-0070, PI - Edmund Kim, MD, 2003-2007, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review for Breast Lymphatic Mapping: Detailed Histologic Assessment of Negative Sentinel Lymph Nodes, RCR03-0324, 2003-2007, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Surgical Management of Regional Recurrences After Breast Cancer Therapy, RCR03-0521, PI - Funda Meric-Bernstam, MD, 2003-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Surgical Margins in Ductal Carcinoma In Situ, RCR03-0121, PI - Gildy Babiera, MD, 2003-2012, The University of Texas MD Anderson Cancer Center

Collaborator, Phase I Study of Post-Operative Concurrent Chemoradiation for Extremity and Trunk Soft Tissue Sarcoma, ID02-336, PI - Jeffrey Lee, MD, 2003-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Clinical and Pathologic Factors Associated with Patients Receiving Breast Conservation Therapy or Mastectomy at The University of Texas M. D. Anderson Cancer Center, RCR03-0905, PI - Gildy Babiera, MD, 2004-2006, The University of Texas MD Anderson Cancer Center

Principal Investigator, Paget's disease of the Breast, RCR04-0297, 2004-2006, The University of Texas MD Anderson Cancer Center

Collaborator, The Incidence, Prophylaxis and Treatment of Deep Venous Thrombosis in Patients Undergoing Breast Cancer Surgery, RCR03-1003, PI - Henry Kuerer, MD, PhD, 2004-2006, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Incidence of Axillary Nodal Metastasis from Occult Breast Cancer in Patients, RCR04-0814, PI - Isabelle Bedrosian, MD, 2004-2007, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Feasibility Trial to Assess the Quality of Protein Extracts for Low Molecular Weight Cyclin E from Paraffin-Embedded Breast Cancer Specimens, LAB04-0258,

PI - Khandan Keyomarsi, PhD, 2004-2008, The University of Texas MD Anderson Cancer Center

Collaborator, Surgically Resected Gastrointestinal Stromal Tumors, Recurrence Rates and Prognostic Survival Factors, RCR04-0425, PI - Barry Feig, MD, 2004-2011, The University of Texas MD Anderson Cancer Center

Collaborator, Breast Reconstruction in the Elderly Patient, RCR03-1070, PI - Charles Butler, MD, 2004-2014, The University of Texas MD Anderson Cancer Center

Collaborator, Biomarker and Gene Expression in Relation to the Clinical Course of Patients with Ductal Carcinoma in Situ Treated with Breast Conservation Therapy, LAB04-0388, PI - Henry Kuerer, MD, PhD, 2004-present, The University of Texas MD Anderson Cancer Center

Collaborator, Prospective Follow-up of Women Who are at Increased Risk of Developing Breast Cancer, LAB03-0479, PI - Banu Arun, MD, 2004-present, The University of Texas MD Anderson Cancer Center

Collaborator, Outcome of Breast Cancer Patients with Positive Sentinel Nodes Who do not Undergo Complete Axillary Dissection, RCR05-0738, PI - Rosa Hwang, MD, 2005-2006, The University of Texas MD Anderson Cancer Center

Collaborator, Proton (1H) Magnetic Resonance Spectroscopy for the Diagnosis of Axillary Nodal Metastases, LAB04-0308, PI - Wei Yang, MD, Jingfei Ma, PhD, 2005-2006, The University of Texas MD Anderson Cancer Center

Collaborator, Reliability of Ultrasound and FNA in Identifying Axillary Lymph Node Metastases in Patients with Lobular Carcinoma of the Breast, RCR05-0689, PI - Isabelle Bedrosian, MD, 2005-2007, The University of Texas MD Anderson Cancer Center

Principal Investigator, Evaluation of Pathologic Response Rate as a Factor in the Breast Cancer Staging System, RCR05-0850, 2005-2008, The University of Texas MD Anderson Cancer Center

Collaborator, The Validity of RAS Oncogene Expression in Diagnosis and Prognosis of Gastrointestinal Stromal Tumors, LAB05-0081, PI - Barry W. Feig, MD, 2005-2008, The University of Texas MD Anderson Cancer Center

Collaborator, CpG Island Methylator Phenotype (CIMP) in Breast Cancer: A Novel Biomarker for Prognosis and Treatment, LAB05-0500, PI - Robert Bast, MD, 2005-2009, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Intra-operative Assessment of Sentinel Lymph Nodes in Invasive Breast Carcinoma Using Frozen Section and Rapid Cytokeratin Immunostain, LAB04-0967, PI - Savitri Krishnamurthy, MD, 2005-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Neoadjuvant Herceptin for Ductal Carcinoma in Situ of the Breast, 2004-0701, PI - Henry Kuerer, MD, PhD, 2005-2010, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Radiation-Induced Changes of the Normal Breast in Patients Who Develop Breast Cancer After Prior Radiation Treatment of Hodgkin's Disease, LAB05-0353, PI - Thomas Buchholz, MD, 2005-2010, The University of Texas MD Anderson Cancer Center

Collaborator, Outcome of Lymphadenectomy on Patients with Nodal Metastasis from Soft Tissue Sarcoma of the Extremities, RCR05-0282, PI - Barry Feig, MD, 2005-2011, The University of Texas MD Anderson Cancer Center

Collaborator, Bilateral Breast Cancer: Clinicopathological Features and Reasons for Treatment, RCR05-0006, PI - Gildy Babiera, MD, 2005-2012, The University of Texas MD Anderson Cancer Center

Collaborator, NCCN Breast Cancer Outcomes Project Database at MDACC, 2004-0772, PI - Richard Theriault, DO, 2005-2013, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, The Economic Impact of Excisional Biopsy over Percutaneous Biopsy to Diagnose Breast Cancer: Results from a Large Prospective Database, RCR05-0593, PI - Anthony Lucci, MD, 2005-2018, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Evaluation of Cone Beam Breast CT Imaging for Diagnosis and Management of Breast Cancers, LAB05-0588, PI - Gary Whitman, MD, 2005-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Role of Primary Tumor Characteristics in Predicting Positive Sentinel Lymph Nodes in Ductal Carcinoma in Situ or Microinvasive Breast Cancer, RCR06-0734, 2006-2008, The University of Texas MD Anderson Cancer Center

Collaborator, Prospective Randomized Clinical Trial to Evaluate the Use of Paravertebral Blocks in Breast Surgery, 2005-1020, PI - Frederick Ames, MD, 2006-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Mammography and Sonography of Mucocoele-Like Tumors of the Breast, RCR05-0891, PI - Wei Yang, MD, 2006-2011, The University of Texas MD Anderson Cancer Center

Collaborator, Breast Cancer Multidisciplinary Care Database, RCR05-0803, PI - Carlos Barcenas, MD, 2006-2018, The University of Texas MD Anderson Cancer Center

Principal Investigator, Investigation of the Significance of Micrometastases and Isolated Tumor Cells Identified in Sentinel Lymph Nodes of Patients with Invasive Breast Cancer, RCR06-0176, 2006-present, The University of Texas MD Anderson Cancer Center

Collaborator, An Increased Rate of Ipsilateral Breast Tumor Recurrence (IBTR) after Neoadjuvant Chemotherapy and Breast Conservative Surgery in Patients with a Pathological Complete Response and the Omission of a Radiopaque Tumor Marker, RCR06-0774, PI - Julia Oh, MD, 2007, The University of Texas MD Anderson Cancer Center

Collaborator, Imaging Features of Invasive Micropapillary Breast Cancers, DR07-0514, PI - Wei Yang, MD, 2007-2010, The University of Texas MD Anderson Cancer Center

Principal Investigator, Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy, RCR07-0005, 2007-2010, The University of Texas MD Anderson Cancer Center

Collaborator, Molecular Testing of Axillary Sentinel Lymph Nodes in Breast Cancer, LAB06-1056, PI - Savitri Krishnamurthy, MD, 2007-2011, The University of Texas MD Anderson Cancer Center

Collaborator, A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy, 2007-0194, PI - Gildy Babiera, MD, 2007-2013, The University of Texas MD Anderson Cancer Center

Collaborator, Genotype/Phenotype Correlation for BRCA-Associated Breast and Ovarian Cancer, DR07-0755, PI - Funda Meric-Bernstam, MD, 2007-2014, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Response to Neoadjuvant Chemotherapy in Breast Cancer as a Function of Proliferative Indices and Graded Hormone Receptor Expression, RCR07-0085, 2007-2015, The University of Texas MD Anderson Cancer Center

Principal Investigator, Sentinel Lymph Node Dissection in Patients with Multicentric Invasive Breast Cancer, DR07-0359, 2007-2016, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review Study to Develop a Database Library for Breast Conservation Therapy Patients Treated at The University of Texas M. D. Anderson Cancer Center from 2000-2005, RCR07-0142, 2007-2017, The University of Texas MD Anderson Cancer Center

Collaborator, A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Escalating Doses of Cisplatin for Children with Peritoneal Carcinomatosis or Advanced

Peritoneal and Retroperitoneal Disease, 2005-0917, PI - Andrea Hayes-Jordan, MD, 2007-2019, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Prospective Collection of Needle Biopsies from Primary and Recurrent Breast Cancer for Molecular Analysis, LAB07-0200, PI - Funda Meric-Bernstam, MD, 2007-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Retrospective Chart Review Study to Develop a Database Library for Breast Cancer Patients Treated at The University of Texas M. D. Anderson Cancer Center, RCR06-0891, 2007-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Systematic Profiling of a Subset of Sarcomas, LAB07-0695, 2007-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Predictors of Contralateral Breast Cancer in Patients with Unilateral Breast Cancer, DR07-0720, 2008-2009, The University of Texas MD Anderson Cancer Center

Collaborator, Axillary Reverse Mapping for Invasive Carcinoma of the Breast, 2007-0951, PI - Funda Meric-Bernstam, MD, 2008-2010, The University of Texas MD Anderson Cancer Center

Collaborator, Clinicopathologic Evaluation of Pleomorphic Ductal Carcinoma, LAB08-0566, PI - Michael Gilcrease, MD, 2008-2010, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Determinants of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer, DR08-0736, PI - Funda Meric-Bernstam, MD, 2008-2010, The University of Texas MD Anderson Cancer Center

Principal Investigator, Does Sentinel Lymph Node Dissection Improve Staging and Treatment in Elderly Patients with Breast Cancer?, DR08-0377, 2008-2010, The University of Texas MD Anderson Cancer Center

Principal Investigator, Ipsilateral Breast Tumor Relapse (IBTR) After Breast Conservation Therapy (BCT), DR08-0346, 2008-2010, The University of Texas MD Anderson Cancer Center

Principal Investigator, Local-Regional and Distant Recurrence Rates in Skin-Sparing Mastectomies Compared with Non-Skin-Sparing Mastectomies, DR08-0456, 2008-2010, The University of Texas MD Anderson Cancer Center

Collaborator, Integrin-Induced EGFR Clustering in Breast Cancer: Correlation with Clinical Outcome, LAB07-0856, PI - Michael Gilcrease, MD, 2008-2012, The University of Texas MD Anderson Cancer Center

Collaborator, The Significance of IMC Nodal Drainage on Preoperative Lymphoscintigraphy, DR07-0911, PI - Funda Meric-Bernstam, MD, 2008-2012, The University of Texas MD Anderson Cancer Center

Collaborator, Comprehensive Examination of Axillary Lymph Nodes in Breast Cancer, LAB08-0230, PI - Savitri Krishnamurthy, MD, 2008-2013, The University of Texas MD Anderson Cancer Center

Collaborator, Breast Cancer in Women 75 Years and Older: The Role of Digital Mammographic Screening, DR08-0563, PI - Gildy Babiera, MD, 2008-2014, The University of Texas MD Anderson Cancer Center

Principal Investigator, The Impact of Internal Mammary Drainage and Sentinel Node, DR08-0429, 2008-2014, The University of Texas MD Anderson Cancer Center

Collaborator, MRI for Preoperative Staging of Patients with Invasive Lobular Carcinoma of the Breast, 2007-0736, PI - Isabelle Bedrosian, MD, 2008-2015, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Tumor Size on Imaging and Surgical Pathology and the Impact of Time to Surgery, DR07-0953, PI - Funda Meric-Bernstam, MD, 2008-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Elastography of Axillary Lymph Nodes: Can this Real-Time Technique Reliably Distinguish Benign from Malignant Axillary Nodes in Women with Breast Cancer?, DR08-0524, PI - Wei Tse Yang, MD, 2008-2016, The University of Texas MD Anderson Cancer Center

Collaborator, A Pilot Study for the Optical Imaging of Breast Cancer in Breast Tissue and Lymph Nodes, LAB07-0700, PI - Wei Tse Yang, MD, 2008-2017, The University of Texas MD Anderson Cancer Center

Collaborator, Clinical Outcome of Breast Cancer Patients After Neoadjuvant Chemotherapy and Mastectomy VS Segmental Mastectomy, DR08-0659, PI - Karen Hoffman, MD, 2008-present, The University of Texas MD Anderson Cancer Center

Collaborator, Clinicopathologic Evaluation of Metaplastic Carcinoma Subtypes, LAB07-0855, PI - Michael Gilcrease, MD, 2008-present, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Recent Local Recurrence Rates and Mortality in Patients Receiving Mastectomy without Radiation, DR08-0701, PI - Henry Kuerer, MD, PhD, 2008-present, The University of Texas MD Anderson Cancer Center

Collaborator, Incidence of Documented Eradication of Breast Cancer in Axillary Lymph Node Metastases in Patients Overexpressing Human Epidermal Growth Factor Receptor-2 Treated with Neoadjuvant Chemotherapy Regimens Including Trastuzumab, DR08-0812, PI - Henry Kuerer, MD, PhD, 2009-2010, The University of Texas MD Anderson Cancer Center

Collaborator, Retrospective Review of Patients with Stage III Breast Cancer who Underwent a Skin Preserving Approach to Delayed Breast Reconstruction, DR07-0354, PI - Steven Kronowitz, MD, 2009-2014, The University of Texas MD Anderson Cancer Center

Collaborator, The Evaluation of Mammographic Tumoral Calcifications During Neoadjuvant Chemotherapy, DR09-0036, PI - Wei Yang, MD, 2009-2015, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Molecular Testing of Sentinel Lymph Nodes in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy, LAB10-125, PI - Savitri Krishnamurthy, MD, 2010-2011, The University of Texas MD Anderson Cancer Center

Principal Investigator, Risk of Ipsilateral Breast Events in Patients with Ductal Carcinoma in Situ after Local Excision, DR10-0573, 2010-2011, The University of Texas MD Anderson Cancer Center

Collaborator, Imaging Features of Primary Sarcoma of the Breast, DR10-0757, PI - Wei Tse Yang, MD, 2010-2012, The University of Texas MD Anderson Cancer Center

Collaborator, Outcome Analysis of 9-gauge MRI-Guided Vacuum Assisted Breast Biopsies, DR10-0779, PI - Wei Tse Yang, MD, 2010-2013, The University of Texas MD Anderson Cancer Center

Principal Investigator, Secondary Primary Malignancies in Breast Cancer Patients Undergoing Breast Conservation Therapy, DR10-0604, 2010-2014, The University of Texas MD Anderson Cancer Center

Principal Investigator, Sentinel Lymph Node Dissection and the Impact of Adjuvant and Neoadjuvant Chemotherapy, DR10-0738, 2010-2016, The University of Texas MD Anderson Cancer Center

Principal Investigator, Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated with Surgery as the First Intervention, DR11-1098, 2011-2012, The University of Texas MD Anderson Cancer Center

Principal Investigator, Results of ACOSOG Z0011 Algorithm Applied to a Contemporary Patient Population, PA11-1085, 2011-2012, The University of Texas MD Anderson Cancer Center

Collaborator, Synchronous Bilateral Breast Cancer: Mammography, Sonography, and Histopathologic Correlation, DR10-0875, PI - Beatriz Adrada, MD, 2011-2014, The University of Texas MD Anderson Cancer Center

Principal Investigator, Are Mastectomy Rates Really Increasing? Experiences from a Single Institution and a population-based database, PA11-0978, 2011-2018, The University of Texas MD Anderson Cancer Center

Collaborator, Multi-Center Analysis of Boost vs. No Boost for Ductal Carcinoma in Situ, PA11-0749, PI - Karen Hoffman, MD, 2011-present, The University of Texas MD Anderson Cancer Center

Collaborator, Retrospective Data Review of Clinical Management and Outcomes Among Sarcoma Patients, PA11-0775, PI - Keila Torres, MD, 2011-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Is Sentinel Lymph Node Biopsy Accurate After Neoadjuvant Chemotherapy in Patients who Present with Node Positive Breast Cancer?, PA11-1072, 2012, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Recent Experience and Outcome of Sternectomy and Chest-Wall Resection for Breast Cancer, PA12-0871, PI - Henry Kuerer, MD, PhD, 2012-2013, The University of Texas MD Anderson Cancer Center

Principal Investigator, Estrogen Receptor Positivity Criteria: 10% or 1%?, PA12-0150, 2012-2014, The University of Texas MD Anderson Cancer Center

Collaborator, Local-Regional Treatment Outcome of Patients with T1,2 Breast Cancer with 1-3 Positive Lymph Nodes Treated with Mastectomy, PA12-0670, PI - Thomas Buchholz, MD, 2012-2014, The University of Texas MD Anderson Cancer Center

Collaborator, Feasibility of Selective Image Guided Resection of Cytologically Documented Axillary Lymph Node Metastases, 2012-0163, PI - Henry Kuerer, MD, PhD, 2012-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Role of Sonography and Sonographically Guided Fine-Needle Aspiration of Ipsilateral Internal Mammary Lymph Nodes in the Staging of Breast Cancer Patients, PA12-0918, PI - Basak Dogan, MD, 2012-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Assessment of Ultrasound-Based Staging in Patients with Non-Metastatic, Triple Negative Breast Cancer, PA12-0014, PI - Simona Shaitelman, MD, 2012-2016, The University of Texas MD Anderson Cancer Center

Collaborator, A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy, 2010-0986, PI - Rosa Hwang, MD, 2012-2017, The University of Texas MD Anderson Cancer Center

Principal Investigator, Evaluation of Intraoperative Margin Analysis for Breast Cancer Patients Undergoing Breast Conserving Surgery, PA12-0655, 2012-2017, The University of Texas MD Anderson Cancer Center

Principal Investigator, Evaluation of Surgical Treatment Outcomes in Patients with Gastrointestinal Stromal Tumors, PA12-0299, 2012-2017, The University of Texas MD Anderson Cancer Center

Collaborator, Comprehensive Treatment of Inflammatory Breast Cancer at MD Anderson Cancer Center Over 10 Years., PA12-0785, PI - Edward Chang, MD, 2012-present, The University of Texas MD Anderson Cancer Center

Collaborator, Epidemiological Risk Factors Associated with Breast Cancer Risks, PA12-0862, PI - Hua Zhao, PhD, 2012-present, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Prospective Registry of Breast Cancer Patients with Axillary Nodal Metastases Identified During Ultrasound Staging at MD Anderson Cancer Center, PA11-1087, PI - Henry Kuerer, MD, PhD, 2012-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Re-Excision Following Breast Conservation Surgery, PA12-0309, 2012-present, The University of Texas MD Anderson Cancer Center

Collaborator, Clinical Relevance of Additional MDACC Mammography and Ultrasound Work Up for ACR Category 6 Breast Cancer Patients, PA13-0675, PI - Rosalind Candelaria, MD, 2013-2014, The University of Texas MD Anderson Cancer Center

Collaborator, Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer, 2011-1075, PI - Simona Shaitelman, MD, 2013-2015, The University of Texas MD Anderson Cancer Center

Principal Investigator, The Utility of Sentinel Lymph Node Dissection in Patients with Ductal Carcinoma in Situ, PA13-0825, 2013-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Correlating Fine Needle Aspiration to Surgical Excision to Assess for Eradication of Nodal Metastases After Chemotherapy in Breast Cancer, 2013-0877, PI - Abigail Caudle, MD, 2013-2018, The University of Texas MD Anderson Cancer Center

Principal Investigator, Analysis of Breast Cancer Data with Misclassified Outcome and Informative Terminal Event, PA12-0957, 2013-present, The University of Texas MD Anderson Cancer Center

Collaborator, Receipt of Post-Mastectomy Radiotherapy and Clinical Correlation After Total Mastectomy, Positive Sentinel Lymph Node Biopsy and Completion Axillary Lymph Node Dissection, PA12-1083, PI - Michael Stauder, MD, 2013-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, BRCA1/2 Status and Low Molecular Weight Cyclin-E (LMW-E) Expression in Triple Negative Breast Cancer as a Function of Race and Survival, PA13-0995, 2014-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Locoregional Recurrence after Lipofilling for Breast Reconstruction, PA14-0201, PI - Steven Kronowitz, MD, 2014-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Preoperative I-125 Radioactive Seed Localization (I-125 RSL) of Breast Lesions: Impact of Lesion Selection on Surgical Margins, PA14-0228, PI - Mark Dryden, MD, 2014-2015, The University of Texas MD Anderson Cancer Center

Collaborator, Aggressive-Variant Breast Implant Associated Anaplastic Large Cell Lymphoma: Characteristics, Disease Progression, and Treatment, PA14-0723, PI - Mark Clemens, MD, 2014-2016, The University of Texas MD Anderson Cancer Center

Collaborator, Ultrasound Evaluation and Guided Needle Biopsy of Regional Nodal Basins in Breast Cancer Patients, PA14-0167, PI - Basak Dogan, MD, 2014-2016, The University of Texas MD Anderson Cancer Center

Collaborator, Sonographic Features of Axillary Lymph Node Metastasis in Patients with Invasive Lobular Cancer, PA14-0355, PI - Beatriz Adrada, MD, 2014-2017, The University of Texas MD Anderson Cancer Center

Principal Investigator, Evaluation of Biologic Markers in Determining Prognosis in Breast Cancer Patients, PA14-0710, 2014-present, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Genomic Changes in Breast Cancer Metastasis, PA14-0421, PI - Sarah DeSnyder, MD, 2014-present, The University of Texas MD Anderson Cancer Center

Collaborator, Retrospective Analysis of the MD Anderson Experience with Radioactive Iodine Seed Localization Compared to Wire Localization in Breast Cancer Surgery, PA14-0143, PI - Dallah Black, MD, 2014-present, The University of Texas MD Anderson Cancer Center

Collaborator, Ultrasound (US) Imaging Lexicon of Axillary Lymph Nodes in Patients with Breast Cancer, PA14-0227, PI - Wei Yang, MD, 2014-present, The University of Texas MD Anderson Cancer Center

Collaborator, Breast Specimen Imaging Immediately following Mastectomy, PA15-0541, PI - Gregory Reece, MD, 2015-present, The University of Texas MD Anderson Cancer Center

Collaborator, Epidemiology of Breast Implant Associated Anaplastic Large Cell Lymphoma, PA15-0815, PI - Mark Clemens, MD, 2015-present, The University of Texas MD Anderson Cancer Center

Collaborator, Imaging of Primary Angiosarcoma of the Breast, PA15-0930, PI - Miral Patel, MD, 2015-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Outcomes After Breast Conserving Therapy with N1 Disease in the Z0011 Era, PA15-0849, 2015-present, The University of Texas MD Anderson Cancer Center

Collaborator, Pilot Study for Identification of Breast Cancer Patients for Potential Avoidance of Surgery: Accuracy of Image Guided Percutaneous Sampling Compared with Surgery to Evaluate Eradication of Breast Cancer after Preoperative Chemotherapy, 2014-1039, PI - Henry Kuerer, MD, PhD, 2015-present, The University of Texas MD Anderson Cancer Center

Collaborator, Practice Patterns and Clinical Outcomes of Surgery for Breast Cancer Patients, PA15-0289, PI - Rosa Hwang, MD, 2015-present, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Long-Term Outcome of Node Positive Breast Cancer Patients Treated with Preoperative Chemotherapy Followed by Sentinel Node Biopsy and No Completion Axillary Dissection, PA16-0640, PI - Sarah DeSnyder, MD, 2016-2018, The University of Texas MD Anderson Cancer Center

Collaborator, Primary Liposarcoma of the Breast: Imaging Findings, PA16-0763, PI - Lumarie Santiago, MD, 2016-2018, The University of Texas MD Anderson Cancer Center

Principal Investigator, Risk -Factors of Local Recurrence in Early-Stage Breast Cancer with Breast-Conserving Therapy in Different Tumor Subtypes, PA16-0938, 2016-2018, The University of Texas MD Anderson Cancer Center

Collaborator, A Retrospective Cohort Study of Clinical and Pathology Assessment, Molecular Characteristics and Clinical Outcome for DCIS Treated at MD Anderson, PA16-0612, PI - Savitri Krishnamurthy, MD, 2016-present, The University of Texas MD Anderson Cancer Center

Collaborator, Designing Potential Selection Criteria for Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Systemic Therapy, PA15-1070, PI - Henry Kuerer, MD, PhD, 2016-present, The University of Texas MD Anderson Cancer Center

Collaborator, Prospective Trial to Collect Germline Genetic Material to Assist in Evaluation of Molecular Characterization of Breast Cancer, PA15-1050, PI - Stacy Moulder, MD, 2016-present, The University of Texas MD Anderson Cancer Center

Collaborator, Refining the Anatomy and Biomechanics of the Breast Fascial System, PA16-0364, PI - Gregory Reece, MD, 2016-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, The Effect of Consensus 2014 Margin Guidelines on Re-Excision: A Multi-Institution Retrospective Study, PA16-0608, 2016-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, A Comparative Analysis of Surgical Management and Prognosis in Patients with Early Stage Breast Cancer by Approximated Subtype, PA16-1110, 2017-2018, The University of Texas MD Anderson Cancer Center

Co-Principal Investigator, Evaluating Contemporary Characteristics and Outcomes of Patients who Undergo Nipple Sparing Mastectomy, PA17-0321, PI - Alastair Thompson, MD, 2017-2018, The University of Texas MD Anderson Cancer Center

Collaborator, A Prospective, Open Label Study of the Use of Magseed and Sentimag to Localize Axillary Lymph Nodes with Biopsy-Proven Metastases in Breast Cancer Patients, 2016-0806, PI - Abigail Caudle, MD, 2017-present, The University of Texas MD Anderson Cancer Center

Collaborator, Designing a Decision Aid to Help Women Make Decisions with Their Doctors About Axillary Lymph Node Dissection with/without Post-Mastectomy Radiation Therapy: User-Centered Design Using Focus Groups and Cognitive Interviews, Protocol PA17-0368, PI - Isabelle Bedrosian, MD, 2017-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Local Regional Recurrence Rates following Sentinel Lymph Node Dissection in Breast Cancer, PA17-0740, 2017-present, The University of Texas MD Anderson Cancer Center

Collaborator, Multicenter Trial for Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy, 2016-0046, PI - Henry Kuerer, MD, PhD, 2017-present, The University of Texas MD Anderson Cancer Center

Collaborator, Incidence, Management and Clinical Outcomes of Chyle Leak Following Axillary Lymphadenectomy for Breast Cancer, PA18-0936, PI - Mediget Teshome, MD, 2018-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Magseed Magnetic Marker Localization: Retrospective Data Review of Cohort from a Prospective Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion that Requires Preoperative Radiographic Localization, PA18-1029, 2018-present, The University of Texas MD Anderson Cancer Center

Collaborator, The Role of Biomarkers in Differentiating Indolent Versus Aggressive Ductal Carcinoma in Situ (DCIS), PA17-0963, PI - Aysegul Sahin, MD, 2018-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, Use of Lymphoscintigraphy in Breast Cancer Patients and Influence on Treatment, PA18-0346, 2018-present, The University of Texas MD Anderson Cancer Center

Principal Investigator, A Phase 2a, single-dose, open-label study to evaluate diagnostic performance, safety, and timing of postdose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer, in patients with solid tumors undergoing routine surgery, 2019-0641, 2019-present, The University of Texas MD Anderson Cancer Center

Collaborator, Breast Implant Associated -Anaplastic Large Cell Lymphoma (BIA-ALCL): A Systematic Review Study, PA19-0775, PI - Clemens M, 2019-present, The University of Texas MD Anderson Cancer Center

Collaborator, Impact of the COVID-19 Pandemic on Breast Surgical Oncology Fellows and Fellowships, 2020-0525, PI - Mediget Teshome, MD, 2020-present, The University of Texas MD Anderson Cancer Center

Patents and Technology Licenses

Patents

MDACC, Hunt KK, Suh YJ, Swisher SG, Pataer A, Ramesh R, Shanker M. Compositions and Methods Involving MDA-7 for the Treatment of Cancer, United States, 11/349,727, 2/8/2006, Filed

MDACC, Keyomarsi K, Delk N, Hunt KK, Wingate H, Mittendorf EA. Low Molecular Weight Cyclin E (LMW-E) as a Biomarker for Personalization of Cancer Therapies, United States, 13/355,380, 9/8/2011, Filed

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Breast Cancer Study Section, U.S. Army Department of Defense, DOD, Scientific Reviewer, 1999-2004

Susan G. Komen for the Cure, Other, Scientific Reviewer, 2000-2005

SBIR Study Section, NIH, Member, 2002-2004

Lytmos Group LLC, Florida Department of Health, Member, 2008-2013

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Kopald KH, Layfield LJ, Mohrmann R, Foshag LJ, Giuliano AE. Clarifying the role of fine-needle aspiration cytologic evaluation and frozen section examination in the operative management of thyroid cancer. *Arch Surg* 124(10):1201-4; discussion 1204-5, 10/1989. PMID: 2802984.
2. Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL. Prognostic significance of pregnancy in stage I melanoma. *Arch Surg* 124(10):1227-30; discussion 1230-1, 10/1989. PMID: 2802988.
3. Selch MT, Kopald KH, Ferreiro GA, Mirra JM, Parker RG, Eilber FR. Limb salvage therapy for soft tissue sarcomas of the foot. *Int J Radiat Oncol Biol Phys* 19(1):41-8, 7/1990. PMID: 2380094.
4. Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. *J Surg Oncol* 44(3):146-50, 7/1990. PMID: 2370798.
5. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. *Arch Surg* 125(10):1298-301; discussion 1301-2, 10/1990. PMID: 2171453.
6. Kopald KH, Hiatt JR, Irving C, Giuliano AE. The pathology of nonpalpable breast cancer. *Am Surg* 56(12):782-7, 12/1990. PMID: 2268107.
7. Layfield LJ, Mohrmann RL, Kopald KH, Giuliano AE. Use of aspiration cytology and frozen section examination for management of benign and malignant thyroid nodules. *Cancer* 68(1):130-4, 7/1991. PMID: 2049733.
8. Hunt KK, Shibata M, Gupta RK, Morton DL. Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen. *Cancer Immunol Immunother* 34(6):377-82, 1992. PMID: 1563014.
9. Singh KP, Shau H, Gupta RK, Kopald K, Ray PK. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes. *Immunopharmacol Immunotoxicol* 14(1-2):73-103, 1992. PMID: 1597662.
10. Alvarez C, Hunt K, Ashley SW, Reber HA. Emphysematous cholecystitis after ERCP. *Dig Dis Sci* 39(8):17, 19-23, 8/1994. PMID: 8050324.
11. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. *Ann Surg Oncol* 1(5):436-50, 9/1994. PMID: 7850546.
12. Swisher SG, Cates JA, Hunt KK, Robert ME, Bennion RS, Thompson JE, Roslyn JJ, Reber HA. Pancreatitis associated with adult choledochal cysts. *Pancreas* 9(5):633-7, 9/1994. PMID: 7809018.
13. Swisher SG, Hunt KK, Schmit PJ, Hiyama DT, Bennion RS, Thompson JE. Management of pancreatitis complicating pregnancy. *Am Surg* 60(10):759-62, 10/1994. PMID: 7944038.
14. Badie B, Hunt K, Economou JS, Black KL. Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model. *Neurosurgery* 35(5):910-6, 11/1994. PMID: 7838341.

15. Swisher SG, Schmit PJ, Hunt KK, Hiyama DT, Bennion RS, Swisher EM, Thompson JE. Biliary disease during pregnancy. *Am J Surg* 168(6):576-9; discussion 580-1, 12/1994. PMID: 7977999.
16. Swisher SG, Hunt KK, Holmes EC, Zinner MJ, McFadden DW. Changes in the surgical management of esophageal cancer from 1970 to 1993. *Am J Surg* 169(6):609-14, 6/1995. PMID: 7771626.
17. Swisher SG, Holmes EC, Hunt KK, Gornbein JA, Zinner MJ, McFadden DW. Perioperative blood transfusions and decreased long-term survival in esophageal cancer. *J Thorac Cardiovasc Surg* 112(2):341-8, 8/1996. PMID: 8751501.
18. Swisher SG, Holmes EC, Hunt KK, Doty JE, Zinner MJ, McFadden DW. The role of neoadjuvant therapy in surgically resectable esophageal cancer. *Arch Surg* 131(8):819-24; discussion 824-5, 8/1996. PMID: 8712904.
19. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Beldegrun A, Glaspy J, Economou JS. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. *Cancer Gene Ther* 3:11-7, 1996.
20. Toloza EM, Hunt K, Miller AR, McBride W, Lau R, Swisher S, Rhoades K, Arthur J, Choi J, Chen L, Chang P, Chen A, Glaspy J, Economou JS. Transduction of murine and human tumors using recombinant adenovirus vectors. *Ann Surg Oncol* 4:70-9, 1/1997.
21. Hunt KK, Baldwin BJ, Strom EA, Ames FC, McNeese MD, Kroll SS, Singletary SE. Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. *Ann Surg Oncol* 4(5):377-84, 7/1997. PMID: 9259963.
22. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. *Cancer Res* 57(21):4722-6, 11/1997. PMID: 9354430.
23. Ricardo AE, Feig BW, Ellis LM, Hunt KK, Curley SA, MacFadyen BV, Jr, Mansfield PF. Gallbladder cancer and trocar site recurrences. *Am J Surg* 174(6):619-22; discussion 622-3, 12/1997. PMID: 9409585.
24. Bouvet M, Ollila DW, Hunt KK, Babiera GV, Spitz FR, Giuliano AE, Strom EA, Ames FC, Ross MI, Singletary SE. Role of conservation therapy for invasive lobular carcinoma of the breast. *Ann Surg Oncol* 4(8):650-4, 12/1997. PMID: 9416413.
25. Mansfield PF, Hunt KK. Classification, staging, and management of non-Hodgkin's lymphomas. *Cancer Treat Res* 90:203-11, 1997. PMID: 9367084.
26. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. *Cancer J Sci Am* 4(4):230-6, 7/1998. PMID: 9689981.
27. Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, Ames FC, Schusterman MA, Singletary SE. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. *Ann Surg Oncol* 5(6):529-38, 9/1998. PMID: 9754762.
28. Newman LA, Kuerer HM, Hunt KK, Kroll SS, Ames FC, Ross MI, Feig BW, Singletary SE. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. *Ann Surg Oncol* 5(7):620-6, 10/1998. PMID: 9831111.
29. McMasters KM, Giuliano AE, Ross MI, Reintgen DS, Hunt KK, Byrd DR, Klimberg VS, Whitworth PW, Tafra LC, Edwards MJ. Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. *N Engl J Med* 339(14):990-5, 10/1998. PMID: 9753717.
30. Hunt KK, Fleming JB, Abramian A, Zhang L, Evans DB, Chiao PJ. Overexpression of the tumor suppressor gene Smad4/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells. *Cancer Res* 58(24):5656-61, 12/1998. PMID: 9865717.
31. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. *Am J Surg* 176(6):502-9, 12/1998. PMID: 9926779.
32. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor

- downstaging with induction chemotherapy for locally advanced breast cancer. *Ann Surg Oncol* 5(8):673-80, 12/1998. PMID: 9869512.
33. Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FC, Buchholz TA, Strom EA, McNeese MD, Hunt KK. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. *Ann Surg Oncol* 6(1):102-8, 1/1999. PMID: 10030422.
 34. Delpassand ES, Singletary E, Ross MI, Ames FC, Hunt KK, Podoloff DA. Non-invasive staging of axilla in patients with breast cancer using Tc99m sestamibi and different nuclear medicine techniques - A pilot project. *Clin Nucl Med* 24(3), 1/1999.
 35. Pearlstone DB, Pisters PW, Bold RJ, Feig BW, Hunt KK, Yasko AW, Patel S, Pollack A, Benjamin RS, Pollock RE. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. *Cancer* 85(1):85-92, 1/1999. PMID: 9921978.
 36. Pearlstone DB, Janjan NA, Feig BW, Yasko AW, Hunt KK, Pollock RE, Lawyer A, Horton J, Pisters PW. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. *Cancer J Sci Am* 5(1):26-33, 1/1999. PMID: 10188058.
 37. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 17(2):460-9, 2/1999. PMID: 10080586.
 38. Newman LA, Kuerer HM, Hunt KK, Singh G, Ames FC, Feig BW, Ross MI, Taylor S, Singletary SE. Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. *Ann Surg Oncol* 6(3):241-8, Apr-May, 4/1999. PMID: 10340882.
 39. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD, Buzdar AU, Singletary SE, Hortobagyi GN. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. *Cancer J Sci Am* 5(3):159-64, May-Jun, 5/1999. PMID: 10367172.
 40. Chiao PJ, Hunt KK, Grau AM, Abramian A, Fleming J, Zhang W, Breslin T, Abbruzzese JL, Evans DB. Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. *Ann N Y Acad Sci* 880:31-7, 6/1999. PMID: 10415848.
 41. Steck K, Hunt K, Tucker S, Singletary S, El-Naggar AK. Flow cytometric analysis of Ki-67 in invasive ductal carcinoma of the breast: correlation with tumor and patient characteristics. *Oncol Rep* 6(4):835-8, Jul-Aug, 7/1999. PMID: 10373666.
 42. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. *Ann Surg* 230(1):72-8, 7/1999. PMID: PMC1420847.
 43. Feig BW, Lu X, Hunt KK, Shan Q, Yu D, Pollock R, Chiao P. Inhibition of the transcription factor nuclear factor-kappa B by adenoviral-mediated expression of I kappa B alpha M results in tumor cell death. *Surgery* 126(2):399-405, 8/1999. PMID: 10455913.
 44. Newman LA, Kuerer HM, Harper T, Hunt KK, Laronga C, Breslin T, Singletary SE. Special considerations in breast cancer risk and survival. *J Surg Oncol* 71(4):250-60, 8/1999. PMID: 10440767.
 45. Fleming JB, Berman RS, Cheng SC, Chen NP, Hunt KK, Feig BW, Respondek PM, Yasko AW, Pollack A, Patel SR, Burgess MA, Papadopoulos NE, Plager C, Zagars G, Benjamin RS, Pollock RE, Pisters PW. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. *J Clin Oncol* 17(9):2772-80, 9/1999. PMID: 10561352.
 46. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Theriault R, Fry N, Kroll SS, Robb GL, Singletary SE. Feasibility of immediate breast reconstruction for locally advanced breast cancer. *Ann Surg Oncol* 6(7):671-5, Oct-Nov, 10/1999. PMID: 10560853.
 47. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *J Clin Oncol* 17(11):3412-7, 11/1999. PMID: 10550135.

48. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. *Ann Surg Oncol* 6(8):762-7, 12/1999. PMID: 10622504.
49. Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. *Cancer Res* 60(4):788-92, 2/2000. PMID: 10706081.
50. Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. *J Am Coll Surg* 190(3):350-63, 3/2000. PMID: 10703863.
51. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. *Cancer* 88(6):1417-24, 3/2000. PMID: 10717625.
52. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC, Jr, Yu Y. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. *Int J Cancer* 86(5):690-4, 6/2000. PMID: 10797292.
53. Vlastos G, Fornage BD, Mirza NQ, Bedi D, Lenert JT, Winchester DJ, Tolley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Buzdar AU, Singletary SE. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. *Am J Surg* 179(6):446-52, 6/2000. PMID: 11004328.
54. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: Effectiveness of dose escalation in decreasing recurrence. *Int J Radiat Oncol Biol Phys* 47(5):1191-1200, 7/2000. PMID: 10889372.
55. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. *Ann Surg Oncol* 7(6):435-40, 7/2000. PMID: 10894139.
56. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. *Breast J* 6(4):242-246, 7/2000. PMID: 11348372.
57. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. *Am J Surg Pathol* 24(9):1266-72, 9/2000. PMID: 10976701.
58. Newman LA, Kuerer HM, Hunt KK, Vlastos G, Ames FC, Ross MI, Singletary SE. Prophylactic mastectomy. *J Am Coll Surg* 191(3):322-30, 9/2000.
59. Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. *Ann Surg Oncol* 7(9):656-64, 10/2000. PMID: 11034242.
60. Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. *J Clin Oncol* 18(19):3378-83, 10/2000. PMID: 11013278.
61. Newman LA, Hunt KK, Buchholz T, Kuerer HM, Vlastos G, Mirza N, Ames FC, Ross MI, Singletary SE. Presentation, management and outcome of axillary recurrence from breast cancer. *Am J Surg* 180(4):252-6, 10/2000. PMID: 11113430.
62. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, Hunt KK. Primary treatment of cystosarcoma phyllodes of the breast. *Cancer* 89(7):1502-11, 10/2000. PMID: 11013364.
63. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. *J Clin Oncol* 18(20):3480-6, 10/2000. PMID: 11032588.
64. Freedman LM, Buchholz TA, Thames HD, Strom EA, McNeese MD, Hortobagyi GN, Singletary SE, Heaton KM, Hunt KK. Local-regional control in breast cancer patients with a

- possible genetic predisposition. *Int J Radiat Oncol Biol Phys* 48(4):951-7, 11/2000. PMID: 11072150.
65. Portera CA, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. *Cancer* 91(3):585-91, 2/2001. PMID: 11169942.
 66. Newman LA, Kuerer HM, McNeese MD, Hunt KK, Gurtner GC, Vlastos GS, Robb G, Singletary SE. Reduction mammoplasty improves breast conservation therapy in patients with macromastia. *Am J Surg* 181(3):215-20, 3/2001. PMID: 11376574.
 67. Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, Ames FC, Buzdar AU, Singletary SE. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. *Am J Surg* 181(4):313-8, 4/2001. PMID: 11438265.
 68. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. *J Clin Oncol* 19(8):2240-6, 4/2001. PMID: 11304777.
 69. Kuerer HM, Hunt KK, Singletary SE, Ames FC. Unusual aspects of breast cancer: case 3. Blue hives during lymphatic mapping for breast cancer. *J Clin Oncol* 19(9):2573-4, 5/2001. PMID: 11331339.
 70. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. *Ann Surg Oncol* 8(5):425-31, 6/2001. PMID: 11407517.
 71. Fleming JB, Cantor SB, Varma DG, Holst D, Feig BW, Hunt KK, Patel SR, Benjamin RS, Pollock RE, Pisters PW. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. *Cancer* 92(4):863-8, 8/2001. PMID: 11550159.
 72. Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, Ross MI, Buchholz TA, Hortobagyi GN, Singletary SE. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. *Cancer* 92(5):1092-100, 9/2001. PMID: 11571720.
 73. Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. *Cancer* 92(6):1550-5, 9/2001. PMID: 11745234.
 74. Baker TP, Lenert JT, Parker J, Kemp B, Kushwaha A, Evans G, Hunt KK. Lactating adenoma: a diagnosis of exclusion. *Breast J* 7(5):354-7, Sep-Oct, 9/2001. PMID: 11906446.
 75. Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, Feig BW, Ross MI, Kuerer HM. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. *Am J Surg* 182(4):393-8, 10/2001. PMID: 11720678.
 76. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. *Cancer* 92(7):1775-82, 10/2001. PMID: 11745249.
 77. Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, McNeese MD, Perkins GH, Hunt KK. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. *Int J Radiat Oncol Biol Phys* 51(3):671-8, 11/2001. PMID: 11597808.
 78. Feig BW, Curley S, Lucci A, Hunt KK, Vauthey JN, Mansfield PF, Cleary K, Hamilton S, Ellis V, Brame M, Berger DH. A caution regarding lymphatic mapping in patients with colon cancer. *Am J Surg* 182(6):707-12, 12/2001. PMID: 11839343.
 79. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. *Am J Surg* 182(6):601-8, 12/2001. PMID: 11839324.

80. Solorzano CC, Ross MI, Delpassand E, Mirza N, Akins JS, Kuerer HM, Meric F, Ames FC, Newman L, Feig B, Singletary SE, Hunt KK. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. *Ann Surg Oncol* 8(10):821-7, 12/2001. PMID: 11776497.
81. Porter GA, Cantor SB, Ahmad SA, Lenert JT, Ballo MT, Hunt KK, Feig BW, Patel SR, Benjamin RS, Pollock RE, Pisters PW. Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. *Cancer* 94(1):197-204, 1/2002. PMID: 11815977.
82. Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW. Extrasosseous osteosarcoma: response to treatment and long-term outcome. *J Clin Oncol* 20(2):521-7, 1/2002. PMID: 11786582.
83. Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM. Multidisciplinary management of breast cancer concurrent with pregnancy. *J Am Coll Surg* 194(1):54-64, 1/2002. PMID: 11800340.
84. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. *J Clin Oncol* 20(1):17-23, 1/2002. PMID: 11773149.
85. Meric F, Bernstam EV, Mirza NQ, Hunt KK, Ames FC, Ross MI, Kuerer HM, Pollock RE, Musen MA, Singletary SE. Breast cancer on the World Wide Web: cross sectional survey of quality of information and popularity of websites. *BMJ* 324(7337):577-81, 3/2002. PMID: 11878995.
86. Singletary SE, Fornage BD, Sneige N, Ross MI, Simmons R, Giuliano A, Hansen N, Kuerer HM, Newman LA, Ames FC, Babiera G, Meric F, Hunt KK, Edeiken B, Mirza AN. Radiofrequency ablation of early-stage invasive breast tumors: an overview. *Cancer J* 8(2):177-80, Mar-Apr, 3/2002. PMID: 11999950.
87. Yared MA, Middleton LP, Smith TL, Kim HW, Ross MI, Hunt KK, Sahin AA. Recommendations for sentinel lymph node processing in breast cancer. *Am J Surg Pathol* 26(3):377-82, 3/2002. PMID: 11859211.
88. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. *Ann Surg Oncol* 9(3):228-34, 4/2002. PMID: 11923128.
89. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H, Stewart AL, Balachandran S, Roth JA, Hunt KK, Swisher SG. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). *Cancer Res* 62(8):2239-43, 4/2002. PMID: 11956076.
90. Mirza NQ, Vlastos G, Meric F, Buchholz TA, Esnaola N, Singletary SE, Kuerer HM, Newman LA, Ames FC, Ross MI, Feig BW, Pollock RE, McNeese M, Strom E, Hunt KK. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. *Ann Surg Oncol* 9(3):256-65, 4/2002. PMID: 11923132.
91. Shmulevich I, Hunt K, El-Naggar A, Taylor E, Ramdas L, Labordé P, Hess KR, Pollock R, Zhang W. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. *Cancer* 94(7):2069-75, 4/2002. PMID: 11932911.
92. Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. *J Interferon Cytokine Res* 22(5):583-92, 5/2002. PMID: 12060497.
93. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. *Clin Cancer Res* 8(5):1073-9, 5/2002. PMID: 12006521.

94. Kronowitz SJ, Chang DW, Robb GL, Hunt KK, Ames FC, Ross MI, Singletary SE, Symmans WF, Kroll SS, Kuerer HM. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. *Plast Reconstr Surg* 109(6):1888-96, 5/2002. PMID: 11994589.
95. Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW, Pisters PW, Patel S, Pollock RE, Benjamin RS, Papadopoulos NE, Plager C, Murphy A, Griffin JR, Burgess MA, Hunt KK. Tumor volume as a prognostic factor for sarcomatosis. *Cancer* 94(9):2441-6, 5/2002. PMID: 12015769.
96. Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. *Ann Surg Oncol* 9(6):543-9, 7/2002. PMID: 12095969.
97. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. *Int J Radiat Oncol Biol Phys* 53(4):880-8, 7/2002. PMID: 12095553.
98. Lee A, Krishnamurthy S, Sahin A, Symmans WF, Hunt K, Sneige N. Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients. *Cancer* 96(4):225-31, 8/2002. PMID: 12209664.
99. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. *Int J Radiat Oncol Biol Phys* 53(5):1225-33, 8/2002. PMID: 12128124.
100. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. *Cancer* 95(5):1120-6, 9/2002. PMID: 12209699.
101. Vorburger SA, Pataer A, Yoshida K, Barber GN, Xia W, Chiao P, Ellis LM, Hung MC, Swisher SG, Hunt KK. Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. *Oncogene* 21(41):6278-88, 9/2002. PMID: 12214268.
102. Krishnamurthy S, Sneige N, Bedi DG, Edieken BS, Fornage BD, Kuerer HM, Singletary SE, Hunt KK. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. *Cancer* 95(5):982-8, 9/2002. PMID: 12209680.
103. Solorzano CC, Middleton LP, Hunt KK, Mirza N, Meric F, Kuerer HM, Ross MI, Ames FC, Feig BW, Pollock RE, Singletary SE, Babiera G. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. *Am J Surg* 184(4):364-8, 10/2002. PMID: 12383904.
104. Jhingran A, Kim JS, Buchholz TA, Katz A, Strom EA, Hunt KK, Sneige N, McNeese MD. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience. *Int J Radiat Oncol Biol Phys* 54(3):804-9, 11/2002. PMID: 12377332.
105. Vlastos G, Mirza NQ, Meric F, Hunt KK, Mirza AN, Newman LA, Ames FC, Kuerer HM, Ross MI, Feig B, Babiera G, Buchholz TA, Hortobagyi GN, Singletary SE. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. *Ann Surg Oncol* 9(9):912-9, 11/2002. PMID: 12417515.
106. Krishnamurthy S, Sneige N, Ordóñez NG, Hunt KK, Kuerer HM. Characterization of foam cells in nipple aspirate fluid. *Diagn Cytopathol* 27(5):261-4; discussion 265, 11/2002. PMID: 12411988.
107. Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. *Cancer* 95(10):2059-67, 11/2002. PMID: 12412158.
108. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the

- hTERT promoter in breast cancer cells. *Oncogene* 21(52):8020-8, 11/2002. PMID: 12439752.
109. Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. *Cancer* 95(11):2276-82, 12/2002. PMID: 12436432.
 110. Albo D, Ames FC, Hunt KK, Ross MI, Singletary SE, Kuerer HM. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. *Breast Cancer Res Treat* 77(1):9-14, 1/2003. PMID: 12602900.
 111. Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. *Clin Cancer Res* 9(2):601-5, 2/2003. PMID: 12576424.
 112. Butler CE, Hunt KK, Singletary SE. Management of breast carcinoma identified intraoperatively during reduction mammoplasty. *Ann Plast Surg* 50(2):193-7, 2/2003. PMID: 12567059.
 113. Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. *Cancer* 97(4):926-33, 2/2003. PMID: 12569592.
 114. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. *Am J Surg Pathol* 27(3):385-9, 3/2003. PMID: 12604895.
 115. Yan DH, Abramian A, Li Z, Ding Y, Wen Y, Liu TJ, Hunt K. P202, an Interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells. *Biochem Biophys Res Commun* 303(1):219-22, 3/2003. PMID: 12646190.
 116. Cabioglu N, Hunt KK, Singletary SE, Stephens TW, Marcy S, Meric F, Ross MI, Babiera GV, Ames FC, Kuerer HM. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. *J Am Coll Surg* 196(3):354-64, 3/2003. PMID: 12648684.
 117. Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, Kuerer HM, Singletary SE, Babiera G, Meric F, Akins JS, Neely J, Ross MI. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. *Ann Surg Oncol* 10(3):248-54, 4/2003. PMID: 12679309.
 118. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM. Nipple aspirate fluid cytology in breast carcinoma. *Cancer* 99(2):97-104, 4/2003. PMID: 12704689.
 119. Vorburger SA, Pataer A, Yoshida K, Liu Y, Lu X, Swisher SG, Hunt KK. The mitochondrial apoptosis-inducing factor plays a role in E2F-1-induced apoptosis in human colon cancer cells. *Ann Surg Oncol* 10(3):314-22, 4/2003. PMID: 12679318.
 120. Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral melanoma differentiation-associated gene 7 induces apoptosis in lung cancer cells through mitochondrial permeability transition-independent cytochrome c release. *J Thorac Cardiovasc Surg* 125(6):1328-35, 6/2003. PMID: 12830052.
 121. Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. *Ann Surg Oncol* 10(6):628-34, 7/2003. PMID: 12839847.
 122. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. *Mol Ther* 8(2):207-19, 8/2003. PMID: 12907143.
 123. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I trial of preoperative concurrent

- doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. *J Clin Oncol* 21(16):3092-7, 8/2003. PMID: 12915599.
124. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, Singletary SE, Theriault RL, Hortobagyi GN, Hunt KK, Buchholz TA. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. *J Clin Oncol* 21(17):3244-8, 9/2003. PMID: 12947058.
 125. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. *Cancer* 98(6):1150-60, 9/2003. PMID: 12973838.
 126. Chagpar A, Kuerer HM, Hunt KK, Strom EA, Buchholz TA. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. *Int J Radiat Oncol Biol Phys* 57(1):128-35, 9/2003. PMID: 12909225.
 127. Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. *Am J Surg* 186(4):371-7, 10/2003. PMID: 14553853.
 128. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. *Int J Radiat Oncol Biol Phys* 57(2):336-44, 10/2003. PMID: 12957243.
 129. Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. *Ann Surg Oncol* 10(9):1025-30, 11/2003. PMID: 14597440.
 130. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? *Am J Surg* 186(6):665-9, 12/2003. PMID: 14672776.
 131. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. *Cancer Invest* 21(5):682-9, 2003. PMID: 14628425.
 132. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane C, Janjan N, Skibber JM. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. *J Gastrointest Surg* 8(1):56-62; discussion 62-3, 1/2004. PMID: 14746836.
 133. Raut CP, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, Marshall GD, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. *J Clin Oncol* 22(3):567-8, 2/2004. PMID: 14752082.
 134. Pawlik TM, Perry A, Strom EA, Babiera GV, Buchholz TA, Singletary E, Perkins GH, Ross MI, Schechter NR, Meric-Bernstam F, Ames FC, Hunt KK, Kuerer HM. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. *Cancer* 100(3):490-8, 2/2004. PMID: 14745864.
 135. Chagpar A, Langstein HN, Kronowitz SJ, Singletary SE, Ross MI, Buchholz TA, Hunt KK, Kuerer HM. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. *Am J Surg* 187(2):164-9, 2/2004. PMID: 14769300.
 136. Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, Ames FC, Theriault RL, Kuerer HM. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. *Cancer* 100(5):942-9, 3/2004. PMID: 14983489.
 137. Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, Pollock R, Zhang W. Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate. *Histol Histopathol* 19(2):565-74, 4/2004. PMID: 15024716.

138. Ballo MT, Zagars GK, Cormier JN, Hunt KK, Feig BW, Patel SR, Pisters PW. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 58(5):1461-7, 4/2004. PMID: 15050324.
139. Yang WT, Whitman GJ, Johnson MM, Bolanos-Clark M, Kushwaha AC, Hunt KK, Dempsey PJ. Needle localization for excisional biopsy of breast lesions: comparison of effect of use of full-field digital versus screen-film mammographic guidance on procedure time. *Radiology* 231(1):277-81, 4/2004. PMID: 15068954.
140. Patten LC, Berger DH, Rodriguez-Bigas M, Mansfield P, Delpassand E, Cleary KR, Fagan SP, Curley SA, Hunt KK, Feig BW. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping. *Cancer* 100(10):2104-9, 5/2004. PMID: 15139051.
141. Kronowitz SJ, Hunt KK, Kuerer HM, Babiera G, McNeese MD, Buchholz TA, Strom EA, Robb GL. Delayed-immediate breast reconstruction. *Plast Reconstr Surg* 113(6):1617-28, 5/2004. PMID: 15114121.
142. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poindexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. *Int Immunopharmacol* 4(5):649-67, 5/2004. PMID: 15120650.
143. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. *Int J Radiat Oncol Biol Phys* 59(1):138-45, 5/2004. PMID: 15093909.
144. Ding Y, Wang L, Su LK, Frey JA, Shao R, Hunt KK, Yan DH. Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer. *Oncogene* 23(26):4556-66, 6/2004. PMID: 15122330.
145. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. *J Clin Oncol* 22(12):2303-12, 6/2004. PMID: 15197191.
146. Chagpar A, Eveleigh M, Fritsche HA, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. *Cancer* 100(12):2549-54, 6/2004. PMID: 15197795.
147. Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. *Int J Radiat Oncol Biol Phys* 59(4):1074-9, 7/2004. PMID: 15234041.
148. Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejjic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HM. Adverse events associated with the intraoperative injection of isosulfan blue. *J Clin Anesth* 16(5):332-41, 8/2004. PMID: 15374553.
149. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. *Surgery* 136(2):437-42, 8/2004. PMID: 15300212.
150. Cabioglu N, Krishnamurthy S, Kuerer HM, Hunt KK, Singletary SE, Meric-Bernstam F, Ross MI, Feig BW, Ames FC, Babiera GV. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. *Cancer* 101(3):508-17, 8/2004. PMID: 15274063.
151. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. *Int J Radiat Oncol Biol Phys* 59(5):1337-42, 8/2004. PMID: 15275718.

152. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. *J Clin Oncol* 22(16):3375-80, 8/2004. PMID: 15310783.
153. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. *Cancer Res* 64(17):5913-9, 9/2004. PMID: 15342366.
154. Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. *Ann Surg Oncol* 11(9):854-60, 9/2004. e-Pub 8/2004. PMID: 15313733.
155. Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames FC, Babiera GV. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. *Cancer* 101(6):1330-7, 9/2004. PMID: 15316905.
156. Newman LA, Hurd T, Leitch M, Kuerer HM, Diehl K, Lucci A, Giuliano A, Hunt KK, Putnam W, Wells SA. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. *J Am Coll Surg* 199(4):644-51, 10/2004. PMID: 15454152.
157. Krishnamurthy S, Zhao L, Hayes K, Glassman AB, Cristofanilli M, Singletary SE, Hunt KK, Kuerer HM, Sneige N. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. *Cancer* 102(5):322-7, 10/2004. PMID: 15376199.
158. Xing Y, Cormier JN, Kuerer HM, Hunt KK. Sentinel lymph node biopsy following neoadjuvant chemotherapy: review of the literature and recommendations for use in patient management. *Asian J Surg* 27(4):262-7, 10/2004. PMID: 15564176.
159. Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. *Cancer* 101(7):1514-23, 10/2004. PMID: 15378473.
160. Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, Krishnamurthy S, Marcy S, Hung MC, Hunt KK. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. *Surgery* 136(5):1061-9, 11/2004. PMID: 15523402.
161. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. *Cancer* 101(9):1977-86, 11/2004. PMID: 15389473.
162. Berman RS, Feig BW, Hunt KK, Mansfield PF, Pollock RE. Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancy. *Ann Surg* 240(5):852-7, 11/2004. PMID: PMC1356492.
163. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. *J Clin Oncol* 22(23):4691-9, 12/2004. PMID: 15570071.
164. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. *Breast Cancer Res* 6(4):R408-15, 2004. e-Pub 6/2004. PMID: PMC468660.
165. Vorburger SA, Pataer A, Swisher SG, Hunt KK. Genetically targeted cancer therapy: tumor destruction by PKR activation. *Am J Pharmacogenomics* 4(3):189-98, 2004. PMID: 15174900.

166. Babiera GV, Delpassand ES, Breslin TM, Ross MI, Ames FC, Singletary SE, Kuerer HM, Feig BW, Meric-Bernstam F, Hunt KK. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. *Clin Nucl Med* 30(1):11-5, 1/2005. PMID: 15604959.
167. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. *Breast Cancer Res Treat* 89(2):149-57, 1/2005. PMID: 15692757.
168. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. *Cancer* 103(4):689-95, 2/2005. PMID: 15641036.
169. Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. *Cancer* 103(8):1581-6, 4/2005. PMID: 15747375.
170. Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, Kuerer HM, Feig BW, Meric-Bernstam F, Babiera GV, Singletary SE, Akins JS, Mirza NQ, Hunt KK. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. *Cancer* 103(7):1323-9, 4/2005. PMID: 15726547.
171. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. *J Am Coll Surg* 200(4):516-26, 4/2005. PMID: 15804465.
172. Pataer A, Vorburger SA, Chada S, Balachandran S, Barber GN, Roth JA, Hunt KK, Swisher SG. Melanoma differentiation-associated gene-7 protein physically associates with the double-stranded RNA-activated protein kinase PKR. *Mol Ther* 11(5):717-23, 5/2005. PMID: 15851010.
173. Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW, Kuerer HM, Meric-Bernstam F, Babiera G, Ames FC, Singletary SE, Hunt KK. Paget's disease of the breast: there is a role for breast-conserving therapy. *Ann Surg Oncol* 12(5):391-7, 5/2005. e-Pub 3/2005. PMID: 15915373.
174. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). *Ann Surg* 241(5):810-7; discussion 817-20, 5/2005. PMID: 1581357136.
175. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. *Int J Radiat Oncol Biol Phys* 62(2):351-7, 6/2005. PMID: 15890574.
176. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23(16):3676-85, 6/2005. e-Pub 2/2005. PMID: 15738535.
177. Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single-institution experience. *Cancer* 104(1):20-9, 7/2005. PMID: 15912514.

178. Raut CP, Hunt KK, Akins JS, Daley MD, Ross MI, Singletary SE, Marshall GD, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. *Cancer* 104(4):692-9, 8/2005. PMID: 15981283.
179. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. *Cancer* 104(3):479-90, 8/2005. PMID: 15968686.
180. von Holzen U, Bocangel D, Pataer A, Vorburger SA, Liu Y, Lu X, Hunt KK, Swisher SG. Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-alpha gene therapy in esophageal cancer. *Surgery* 138(2):261-8, 8/2005. PMID: 16153435.
181. Nguyen KH, Hachem P, Khor LY, Salem N, Hunt KK, Calkins PR, Pollack A. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. *Int J Radiat Oncol Biol Phys* 63(1):238-46, 9/2005. PMID: 16153435.
182. Suh YJ, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A, Hunt KK. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. *Surgery* 138(3):422-30, 9/2005. PMID: 16213894.
183. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Puzstai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. *J Clin Oncol* 23(25):5983-92, 9/2005. e-Pub 8/2005. PMID: 16087943.
184. Al-Refaie W, Kuerer HM, Khuwaja A, Perry A, Hunt KK, Feig B, Ames F, Ross M, Singletary SE, Meric-Bernstam F, Babiera GV. Determinants of mastectomy in breast conservation therapy candidates. *Am J Surg* 190(4):602-5, 10/2005. PMID: 16164931.
185. Schechter NR, Strom EA, Perkins GH, Arzu I, McNeese MD, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Babiera G, Hunt KK, Hortobagyi GN, Buchholz TA. Immediate breast reconstruction can impact postmastectomy irradiation. *Am J Clin Oncol* 28(5):485-94, 10/2005. PMID: 16199989.
186. Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE, Hunt KK, Giuliano AE. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. *Am J Surg* 190(4):539-42, 10/2005. PMID: 16164916.
187. Khakpour N, Hunt KK, Kuerer HM, Yi M, Meric-Bernstam F, Ross MI, Lucci A. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. *Am J Surg* 190(4):598-601, 10/2005. PMID: 16164930.
188. Posther KE, McCall LM, Blumencranz PW, Burak WE, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE, Hunt KK, Giuliano AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. *Ann Surg* 242(4):593-9; discussion 599-602, 10/2005. PMID: 161402354.
189. Ku G, Fornage BD, Jin X, Xu M, Hunt KK, Wang LV. Thermoacoustic and photoacoustic tomography of thick biological tissues toward breast imaging. *Technol Cancer Res Treat* 4(5):559-66, 10/2005. PMID: 16173826.
190. Vorburger SA, Hetrakul N, Xia W, Wilson-Heiner M, Mirza N, Pollock RE, Feig B, Swisher SG, Hunt KK. Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo. *Mol Cancer Ther* 4(11):1710-6, 11/2005. PMID: 16275992.
191. Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. *Am J Surg Pathol* 29(11):1456-63, 11/2005. PMID: 16224212.
192. Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Pisters PW, Ballo MT, Chen L, Trent J, Burgess M, Patel S, Pollock RE, Cormier JN. Angiosarcoma of the breast. *Cancer* 104(12):2682-8, 12/2005. PMID: 16288486.

193. Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM, Cimmino VM, Chang AE, Lucas PC, Newman LA. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. *Ann Surg Oncol* 13(1):36-44, 1/2006. e-Pub 1/2006. PMID: 16378156.
194. Kronowitz SJ, Feledy JA, Hunt KK, Kuerer HM, Youssef A, Koutz CA, Robb GL. Determining the optimal approach to breast reconstruction after partial mastectomy. *Plast Reconstr Surg* 117(1):1-11; discussion 12-4, 1/2006. PMID: 16404237.
195. Lu Z, Luo RZ, Peng H, Huang M, Nishimoto A, Hunt KK, Helin K, Liao WS, Yu Y. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. *Oncogene* 25(2):230-9, 1/2006. PMID: 16158053.
196. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. *Cancer* 106(1):42-50, 1/2006. PMID: 16333852.
197. Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, Ames FC, Ross MI, Dejesus Y, Kuerer HM. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. *Ann Surg* 243(1):96-101, 1/2006. PMID: PMC1449977.
198. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. *Ann Surg* 243(2):257-64, 2/2006. PMID: PMC1448900.
199. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane CH, Janjan N, Skibber JM. Outcome after curative resection for locally recurrent rectal cancer. *Dis Colon Rectum* 49(2):175-82, 2/2006. PMID: 16392024.
200. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. *BMC Cancer* 6:68, 3/2006. e-Pub 3/2006. PMID: PMC1431555.
201. Lambert LA, Ayers GD, Hwang RF, Hunt KK, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Ames FC, Feig B, Lucci A, Krishnamurthy S, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. *Ann Surg Oncol* 13(3):310-20, 3/2006. e-Pub 2/2006. PMID: 16463073.
202. Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, Ballo MT, Catton CN, Jones JJ, O'Sullivan B, Pollock RE, Swallow CJ. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol* 13(4):508-17, 4/2006. e-Pub 2/2006. PMID: 16491338.
203. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. *Ann Surg Oncol* 13(4):491-500, 4/2006. e-Pub 3/2006. PMID: 16514477.
204. Nykter M, Hunt KK, Pollock RE, El-Naggar AK, Taylor E, Shmulevich I, Yli-Harja O, Zhang W. Unsupervised analysis uncovers changes in histopathologic diagnosis in supervised genomic studies. *Technol Cancer Res Treat* 5(2):177-82, 4/2006. PMID: 16551137.
205. Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, Vorburger SA, Pataer A, Swisher SG, Ramesh R, Kawase K, Meyn RE, Hunt KK. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. *Cancer Gene Ther* 13(5):490-502, 5/2006. PMID: 16282987.

206. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. *Br J Surg* 93(5):539-46, 5/2006. PMID: 16329089.
207. Khakpour N, Zager JS, Yen T, Stephens T, Kuerer HM, Singletary ES, Ross MI, Hunt KK, Babiera GV. The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. *Breast J* 12(3):212-5, May-Jun, 5/2006. PMID: 16684318.
208. Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. *Ann Surg Oncol* 13(6):776-82, 6/2006. e-Pub 4/2006. PMID: 16614878.
209. Kawase K, Gayed IW, Hunt KK, Kuerer HM, Akins J, Yi M, Grimes L, Babiera GV, Ross MI, Feig BW, Ames FC, Singletary SE, Buchholz TA, Symmans WF, Meric-Bernstam F. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. *J Am Coll Surg* 203(1):64-72, 7/2006. e-Pub 5/2006. PMID: 16798488.
210. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. *Cancer Gene Ther* 13(8):806-14, 8/2006. e-Pub 4/2006. PMID: 16628227.
211. Boughey JC, Ross MI, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Hunt KK. Sentinel lymph node surgery in locally recurrent breast cancer. *Clin Breast Cancer* 7(3):248-53, 8/2006. PMID: 16942642.
212. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. *Ann Surg* 244(3):464-70, 9/2006. PMID: PMC1856540.
213. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PW. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. *Ann Surg Oncol* 13(9):1209-15, 9/2006. e-Pub 9/2006. PMID: 16952046.
214. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. *Cancer* 107(6):1248-1254, 9/2006. PMID: 16862596.
215. Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. *Am J Surg* 192(4):541-4, 10/2006. PMID: 16978971.
216. Bocangel D, Zheng M, Mhashilkar A, Liu Y, Ramesh R, Hunt KK, Chada S. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells. *Cancer Gene Ther* 13(10):958-68, 10/2006. e-Pub 6/2006. PMID: 16783343.
217. Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, Giordano SH, Babiera GV, Ames FC, Hunt KK. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. *J Am Coll Surg* 203(4):475-80, 10/2006. e-Pub 8/2006. PMID: 17000390.
218. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. *Int J Radiat Oncol Biol Phys* 66(2):352-7, 10/2006. e-Pub 8/2006. PMID: 16887286.
219. Rouzier R, Pusztai L, Garbay JR, Delalogue S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. *Cancer* 107(7):1459-66, 10/2006. PMID: 16948128.

220. Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. *Cancer* 107(8):1898-908, 10/2006. PMID: 16986125.
221. Kronowitz SJ, Kuerer HM, Hunt KK, Ross MI, Massey PR, Ensor JE, Robb GL. Impact of sentinel lymph node biopsy on the evolution of breast reconstruction. *Plast Reconstr Surg* 118(5):1089-99, 10/2006. PMID: 17016172.
222. Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. *Am J Surg* 192(4):552-5, 10/2006. PMID: 16978974.
223. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetskova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. *Cancer* 107(8):1760-8, 10/2006. PMID: 16977650.
224. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. *Cancer* 107(7):1440-7, 10/2006. PMID: 16955504.
225. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. *Ann Surg Oncol* 13(11):1443-9, 11/2006. e-Pub 9/2006. PMID: 17028770.
226. Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, Ross MI, Cormier JN. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? *Cancer* 107(10):2328-36, 11/2006. PMID: 17039501.
227. Oh JL, Dryden MJ, Woodward WA, Yu TK, Tereffe W, Strom EA, Perkins GH, Middleton L, Hunt KK, Giordano SH, Oswald MJ, Domain D, Buchholz TA. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. *J Clin Oncol* 24(31):4971-5, 11/2006. PMID: 17075114.
228. Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women ≤ 55 years. *Carcinogenesis* 27(11):2209-16, 11/2006. e-Pub 5/2006. PMID: 16714331.
229. Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl-amino-17-demethoxy analogue. *Cancer Gene Ther* 14(1):12-8, 1/2007. e-Pub 10/2006. PMID: 17024233.
230. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. *Clin Cancer Res* 13(1):228-33, 1/2007. PMID: 17200359.
231. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. *Int J Radiat Oncol Biol Phys* 67(1):158-63, 1/2007. e-Pub 11/2006. PMID: 17084545.
232. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. *Ann Surg Oncol* 14(1):14-24, 1/2007. PMID: 17072676.
233. Price ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, Hunt KK, Pollock RE, Hood L, Shmulevich I, Zhang W. Highly accurate two-gene classifier for differentiating gastrointestinal

- stromal tumors and leiomyosarcomas. *Proc Natl Acad Sci U S A* 104(9):3414-9, 2/2007. e-Pub 2/2007. PMID: PMC1805517.
234. Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. *Cancer Immunol Immunother* 56(2):205-15, 2/2007. e-Pub 5/2006. PMID: 16710719.
 235. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. *Int J Radiat Oncol Biol Phys* 67(2):490-6, 2/2007. PMID: 17236970.
 236. Yang WT, Hennessy BT, Dryden MJ, Valero V, Hunt KK, Krishnamurthy S. Mammary angiosarcomas: imaging findings in 24 patients. *Radiology* 242(3):725-34, 3/2007. PMID: 17325063.
 237. Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. *Cancer* 109(7):1255-63, 4/2007. PMID: 17330229.
 238. Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. *Ann Surg Oncol* 14(4):1458-71, 4/2007. e-Pub 1/2007. PMID: 17260108.
 239. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. *Int J Radiat Oncol Biol Phys* 68(4):1004-9, 7/2007. e-Pub 4/2007. PMID: PMC4329732.
 240. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Primary angiosarcomas of the breast. *Cancer* 110(1):173-8, 7/2007. PMID: PMC4329779.
 241. Hayes-Jordan A, Anderson P, Curley S, Herzog C, Lally KP, Green HL, Hunt K, Mansfield P. Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. *J Pediatr Surg* 42(8):E29-32, 8/2007. PMID: 17706484.
 242. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. *Cancer* 110(4):723-30, 8/2007. PMID: 17587208.
 243. Williams SA, Ehlers RA, Hunt KK, Yi M, Kuerer HM, Singletary SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. *Cancer* 110(4):731-7, 8/2007. PMID: 17582626.
 244. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE, American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. *J Clin Oncol* 25(24):3657-63, 8/2007. e-Pub 5/2007. PMID: 17485711.
 245. Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. *Ann Surg Oncol* 14(8):2309-18, 8/2007. e-Pub 5/2007. PMID: 17541691.
 246. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. *Am J Surg* 194(4):527-31, 10/2007. PMID: 17826073.
 247. Pisters PW, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, Feig BW, Hunt KK, Lin PP, Zagars G, Wei C, Ballo MT. Long-term results of prospective trial of surgery

- alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. *Ann Surg* 246(4):675-81; discussion 681-2, 10/2007. PMID: 17893504.
248. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. *Clin Cancer Res* 13(20):6032-9, 10/2007. PMID: 17947465.
 249. Boughey JC, Middleton LP, Harker L, Garrett B, Fornage B, Hunt KK, Babiera GV, Dempsey P, Bedrosian I. Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. *Am J Surg* 194(4):450-5, 10/2007. PMID: 17826054.
 250. Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. *Cancer* 110(11):2542-50, 12/2007. PMID: 17932905.
 251. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. *Cancer Res* 67(23):11272-83, 12/2007. PMID: 18056453.
 252. Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, Valero V, Hunt KK, Gilcrease MZ. Imaging differences in metaplastic and invasive ductal carcinomas of the breast. *AJR Am J Roentgenol* 189(6):1288-93, 12/2007. PMID: 18029860.
 253. Oh JL, Nguyen G, Whitman GJ, Hunt KK, Yu TK, Woodward WA, Tereffe W, Strom EA, Perkins GH, Buchholz TA. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. *Cancer* 110(11):2420-7, 12/2007. PMID: PMC4329780.
 254. Kronowitz SJ, Hunt KK, Kuerer HM, Strom EA, Buchholz TA, Ensor JE, Koutz CA, Robb GL. Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. *Plast Reconstr Surg* 120(7):1755-68, 12/2007. PMID: 18090737.
 255. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. *Breast Cancer Res* 9(4):R57, 2007. PMID: PMC2206733.
 256. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. *J Clin Oncol* 26(2):246-52, 1/2008. e-Pub 12/2007. PMID: 18056680.
 257. Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Development of Ad-mda7/IL-24-resistant lung cancer cell lines. *Cancer Biol Ther* 7(1):103-8, 1/2008. e-Pub 10/2007. PMID: PMC3442784.
 258. Lim SJ, Feig BW, Wang H, Hunt KK, Rodriguez-Bigas MA, Skibber JM, Ellis V, Cleary K, Chang GJ. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. *Ann Surg Oncol* 15(1):46-51, 1/2008. e-Pub 11/2007. PMID: 17985187.
 259. Al-Refaie WB, Andtbacka RH, Ensor J, Pisters PW, Ellis TL, Shrout A, Hunt KK, Cormier JN, Pollock RE, Feig BW. Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. *Cancer* 112(8):1821-6, 4/2008. PMID: 18306370.
 260. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. *J Clin Oncol* 26(15):2482-8, 5/2008. e-Pub 4/2008. PMID: 18427152.
 261. Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, Yi M, Waljee JF, Ross MI, Hunt KK. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. *Cancer* 112(12):2646-54, 6/2008. PMID: PMC4365777.
 262. Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV. Timing of surgical intervention for the intact primary in stage

- IV breast cancer patients. *Ann Surg Oncol* 15(6):1696-702, 6/2008. e-Pub 3/2008. PMID: 18357493.
263. Chen LL, Holden JA, Choi H, Zhu J, Wu EF, Jones KA, Ward JH, Andtbacka RH, Randall RL, Scaife CL, Hunt KK, Prieto VG, Raymond AK, Zhang W, Trent JC, Benjamin RS, Frazier ML. Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. *Mod Pathol* 21(7):826-36, 7/2008. e-Pub 5/2008. PMID: 18488000.
 264. Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged \leq 55 years. *Breast Cancer Res Treat* 110(2):357-66, 7/2008. e-Pub 9/2007. PMCID: PMC3030478.
 265. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? *Cancer* 113(1):30-37, 7/2008. PMCID: PMC4365472.
 266. Wang-Johanning F, Radvanyi L, Rycak K, Plummer JB, Yan P, Sastry KJ, Piyathilake CJ, Hunt KK, Johanning GL. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. *Cancer Res* 68(14):5869-77, 7/2008. PMCID: PMC5802396.
 267. Olson JA, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE, American College of Surgeons Oncology Group Trials Z0010 and Z0011. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. *J Clin Oncol* 26(21):3530-5, 7/2008. PMID: 18640934.
 268. Buchholz TA, Woodward WA, Duan Z, Fang S, Oh JL, Tereffe W, Strom EA, Perkins GH, Yu TK, Hunt KK, Meric-Bernstam F, Hortobagyi GN, Giordano SH. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. *Int J Radiat Oncol Biol Phys* 71(4):1022-7, 7/2008. e-Pub 1/2008. PMCID: PMC5001849.
 269. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. *Am J Surg* 196(1):81-7, 7/2008. e-Pub 4/2008. PMCID: PMC4336928.
 270. Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK, Swisher SG. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. *Mol Cancer Ther* 7(8):2528-35, 8/2008. PMCID: PMC2597048.
 271. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. *Cancer Res* 68(16):6477-81, 8/2008. PMCID: PMC4441792.
 272. Bedi DG, Krishnamurthy R, Krishnamurthy S, Edeiken BS, Le-Petross H, Fornage BD, Bassett RL, Hunt KK. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. *AJR Am J Roentgenol* 191(3):646-52, 9/2008. PMID: 18716089.
 273. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. *Cancer Res* 68(19):7966-74, 10/2008. PMCID: PMC2561224.
 274. Roh V, Laemmle A, Von Holzen U, Stroka D, Dufour JF, Hunt KK, Candinas D, Vorburger SA. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. *Cancer Gene Ther* 15(10):636-44, 10/2008. e-Pub 6/2008. PMID: 18535617.
 275. Yang J, Du X, Lazar AJ, Pollock R, Hunt K, Chen K, Hao X, Trent J, Zhang W. Genetic aberrations of gastrointestinal stromal tumors. *Cancer* 113(7):1532-1543, 10/2008. PMCID: PMC2651090.
 276. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional

- treatment outcomes after multimodality management of inflammatory breast cancer. *Int J Radiat Oncol Biol Phys* 72(2):474-84, 10/2008. e-Pub 4/2008. PMID: 19047898. PMCID: PMC3041513.
277. Kronowitz SJ, Kuerer HM, Buchholz TA, Valero V, Hunt KK. A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. *Plast Reconstr Surg* 122(6):1631-47, 12/2008. PMID: 19050516.
278. Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. *Ann Surg Oncol* 15(12):3369-77, 12/2008. e-Pub 9/2008. PMID: 19050516. PMCID: PMC4331098.
279. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. *Clin Cancer Res* 14(23):7909-16, 12/2008. PMID: 19050516. PMCID: PMC4375958.
280. Yang J, Du X, Chen K, Ylipää A, Lazar AJ, Trent J, Lev D, Pollock R, Hao X, Hunt K, Zhang W. Genetic aberrations in soft tissue leiomyosarcoma. *Cancer Lett* 275(1):1-8, 3/2009. e-Pub 7/2008. PMID: 19050516. PMCID: PMC2674272.
281. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. *Cancer* 115(5):962-971, 3/2009. PMID: 19050516. PMCID: PMC4365476.
282. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. *Cancer* 115(7):1555-62, 4/2009. e-Pub 2/2009. PMID: 19050516. PMCID: PMC5790117.
283. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A randomized, Phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Ann Surg Oncol* 16(4):910-919, 4/2009. e-Pub 10/2008. PMID: 19050516. PMCID: PMC5647649.
284. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. *Cancer Res* 69(7):2817-2825, 4/2009. e-Pub 3/2009. PMID: 19050516. PMCID: PMC2669888.
285. Lahat G, Lazar A, Wang X, Wang WL, Zhu QS, Hunt KK, Pollock RE, Lev D. Increased vascular endothelial growth factor-c expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. *Clin Cancer Res* 15(8):2637-2646, 4/2009. e-Pub 4/2009. PMID: 19351758.
286. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. *Cell Cycle* 8(7):1062-1068, 4/2009. e-Pub 4/2009. PMID: 19050516. PMCID: PMC2692060.
287. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing Carcinoma of the Breast: An Aggressive Subtype of Metaplastic Carcinoma. *Am J Surg Pathol* 33(4):534-41, 4/2009. e-Pub 11/2008. PMID: 19047898.
288. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. *PLoS Med* 6(5):e1000068, 5/2009. e-Pub 5/2009. PMID: 19050516. PMCID: PMC2673042.
289. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. *Breast Cancer Res Treat* 115(3):651-9, 6/2009. e-Pub 12/2008. PMID: 19050516. PMCID: PMC6130890.

290. Sahin AA, Guray M, Hunt KK. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. *Arch Pathol Lab Med* 133(6):869-78, 6/2009. PMID: 19492879.
291. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. *Ann Surg Oncol* 16(6):1606-1611, 6/2009. e-Pub 3/2009. PMID: PMC4338983.
292. Blazer DG, Lazar AJ, Xing Y, Askew RL, Feig BW, Pisters PW, Pollock RE, Lev D, Hunt KK, Cormier JN. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. *Cancer* 115(13):2971-9, 7/2009. PMID: 19402173.
293. Lahat G, Dhuka AR, Lahat S, Lazar AJ, Lewis VO, Lin PP, Feig B, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Lev D. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. *Ann Surg Oncol* 16(9):2579-2586, 9/2009. e-Pub 6/2009. PMID: 19557478.
294. Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved postoperative pain control using thoracic paravertebral block for breast operations. *Breast J* 15(5):483-8, Sep-Oct, 9/2009. e-Pub 7/2009. PMID: 19624418.
295. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. *Am J Surg* 198(3):387-391, 9/2009. e-Pub 4/2009. PMID: PMC4355914.
296. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, Ravi V, Lazar AJ, Lev D. Outcome of locally recurrent and metastatic angiosarcoma. *Ann Surg Oncol* 16(9):2502-2509, 9/2009. e-Pub 6/2009. PMID: 19551444.
297. Smith GL, Xu Y, Shih YC, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the united states. *J Am Coll Surg* 209(4):425-433, 10/2009. e-Pub 8/2009. PMID: 19801315.
298. Wagner M, Roh V, Strehlen M, Laemmler A, Stroka D, Egger B, Trochsler M, Hunt KK, Candinas D, Vorburger SA. Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1. *J Gastrointest Surg* 13(10):1781-90, 10/2009. e-Pub 6/2009. PMID: 19565301.
299. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. *Ann Surg* 250(4):558-66, 10/2009. PMID: 19730235.
300. Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. *Breast J* 15(6):645-8, Nov-Dec, 11/2009. e-Pub 9/2009. PMID: PMC5790109.
301. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. *Am J Surg* 198(5):720-725, 11/2009. e-Pub 5/2009. PMID: PMC5842353.
302. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. *Clin Cancer Res* 15(23):7381-8, 12/2009. e-Pub 11/2009. PMID: PMC2788123.
303. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. *Oncology* 77(2):75-81, 2009. e-Pub 7/2009. PMID: PMC2790774.
304. Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-individual comparison of lymphatic drainage patterns using

- subareolar and peritumoral isotope injection for breast cancer. *Ann Surg Oncol* 17(1):220-7, 1/2010. e-Pub 8/2009. PMID: PMC4351872.
305. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. *Breast Cancer Res Treat* 119(2):379-90, 1/2010. PMID: PMC2810126.
 306. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. *Clin Breast Cancer* 10(1):52-8, 2/2010. PMID: 20133259.
 307. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. *Clin Cancer Res* 16(4):1179-90, 2/2010. e-Pub 2/2010. PMID: PMC2822889.
 308. Anaya DA, Lahat G, Wang X, Xiao L, Pisters PW, Cormier JN, Hunt KK, Feig BW, Lev DC, Pollock RE. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. *Ann Oncol* 21(2):397-402, 2/2010. e-Pub 7/2009. PMID: 19622598.
 309. Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. *Cell Cycle* 9(6):1-9, 3/2010. e-Pub 3/2010. PMID: 20237430.
 310. Yang D, Ylipaa A, Yang J, Hunt K, Pollock R, Trent J, Yli-Harja O, Shmulevich I, Nykter M, Zhang W. An integrated study of aberrant gene copy number and gene expression in GIST and LMS. *Technol Cancer Res Treat* 9(2):171-8, 4/2010. PMID: 20218739.
 311. Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL, Gilcrease MZ. Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. *Am J Surg Pathol* 34(4):486-93, 4/2010. e-Pub 2/2010. PMID: 20154588.
 312. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 28(11):1821-8, 4/2010. e-Pub 3/2010. PMID: PMC2860366.
 313. Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. *Breast Cancer Res Treat* 120(2):273-84, 4/2010. e-Pub 12/2009. PMID: 20024613.
 314. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. *Cancer* 116(11):2543-8, 6/2010. PMID: PMC4406355.
 315. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ, Lev D. Angiosarcoma: clinical and molecular insights. *Ann Surg* 251(6):1098-106, 6/2010. PMID: 20485141.
 316. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. *Cancer* 116(12):2884-9, 6/2010. PMID: PMC4361091.
 317. Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. *Cancer* 116(12):2878-83, 6/2010. PMID: PMC4394640.
 318. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin e. overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. *Cancer Res* 70(12):5074-84, 6/2010. e-Pub 6/2010. PMID: PMC2888821.

319. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. *Oncogene* 29(27):1-12, 7/2010. e-Pub 5/2010. PMID: PMC2900397.
320. Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK. Adherence to the national quality forum (NQF) breast cancer measures within cancer clinical trials: a review from acosog Z0010. *Ann Surg Oncol* 17(8):1989-94, 8/2010. e-Pub 3/2010. PMID: PMC2950006.
321. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. *Int J Radiat Oncol Biol Phys* 77(5):1296-302, 8/2010. e-Pub 5/2010. PMID: 20472353.
322. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. *Cancer Prev Res (Phila)* 3(8):1026-34, 8/2010. e-Pub 7/2010. PMID: PMC4340054.
323. Rosbach KJ, Shin D, Muldoon TJ, Quraishi MA, Middleton LP, Hunt KK, Meric-Bernstam F, Yu TK, Richards-Kortum RR, Yang W. High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. *Biomed Opt Express* 1(3):911-922, 9/2010. e-Pub 9/2010. PMID: PMC3018063.
324. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. *Ann Surg* 252(3):426-32; discussion 432-3, 9/2010. PMID: PMC5593421.
325. Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. *Cancer* 116(17):4000-6, 9/2010. PMID: PMC4329781.
326. Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. *Cancer Res* 70(18):7125-36, 9/2010. e-Pub 9/2010. PMID: PMC2940941.
327. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer? *Ann Surg Oncol* 17:280-5, 10/2010. e-Pub 9/2010. PMID: PMC4341979.
328. Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. *Cancer* 116(19):4463-4473, 10/2010. PMID: 20572042.
329. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. *Ann Surg Oncol* 17(Suppl 3):343-51, 10/2010. e-Pub 9/2010. PMID: PMC4324560.
330. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. *Cancer* 116(21):4933-43, 11/2010. PMID: 20665494.
331. Yang J, Eddy JA, Pan Y, Hategan A, Tabus I, Wang Y, Cogdell D, Price ND, Pollock RE, Lazar AJ, Hunt KK, Trent JC, Zhang W. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. *Mol Cell Proteomics* 9(11):2405-13, 11/2010. e-Pub 7/2010. PMID: PMC2984227.
332. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. *Ann Surg Oncol* 17(11):2899-908, 11/2010. e-Pub 5/2010. PMID: PMC4324592.

333. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. *Ann Surg Oncol* 17(12):3252-8, 12/2010. e-Pub 6/2010. PMID: PMC4551449.
334. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. *Clin Breast Cancer* 10(6):477-82, 12/2010. PMID: 21147692.
335. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. *Cancer* 117(1):39-47, 1/2011. e-Pub 8/2010. PMID: PMC2997136.
336. Ylipää A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, Nykter M, Pollock RE, Trent J, Zhang W. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. *Cancer* 117(2):380-9, 1/2011. e-Pub 9/2010. PMID: PMC3008331.
337. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 305(6):569-75, 2/2011. PMID: PMC5389857.
338. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. *Ann Surg* 253(3):572-9, 3/2011. PMID: PMC4331097.
339. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. *Cancer* 117(5):916-24, 3/2011. e-Pub 10/2010. PMID: PMC4371507.
340. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. *Ann Surg Oncol* 18(4):932-8, 4/2011. e-Pub 11/2010. PMID: PMC4347926.
341. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, Strom EA, Hunt KK, Tucker SL, Buchholz TA. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. *Cancer* 117(8):1595-601, 4/2011. e-Pub 11/2010. PMID: 21472707.
342. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* 305(18):1873-81, 5/2011. PMID: 21558518.
343. Bloom ES, Kirsner S, Mason BE, Nelson CL, Hunt KK, Baumann DP, Gifford KA. Accelerated partial breast irradiation using the strut-adjusted volume implant single-entry hybrid catheter in brachytherapy for breast cancer in the setting of breast augmentation. *Brachytherapy* 10(3):178-83, May-Jun, 5/2011. e-Pub 8/2010. PMID: 20719576.
344. Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related? *J Clin Oncol* 29(13):e369-71, 5/2011. e-Pub 2/2011. PMID: 21321294.
345. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. *Plast Reconstr Surg* 127(5):1763-72, 5/2011. PMID: 21532405.
346. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel

- staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. *J Clin Oncol* 29(15):1956-62, 5/2011. e-Pub 4/2011. PMID: PMC3107758.
347. Kronowitz SJ, Lam C, Terefe W, Hunt KK, Kuerer HM, Valero V, Lance S, Robb GL, Feng L, Buchholz TA. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. *Plast Reconstr Surg* 127(6):2154-66, 6/2011. PMID: 21311392.
 348. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline pam50-based intrinsic subtype--acosog Z1031. *J Clin Oncol* 29(17):2342-9, 6/2011. e-Pub 5/2011. PMID: PMC3107749.
 349. Langsner RJ, Middleton LP, Sun J, Meric-Bernstam F, Hunt KK, Drezek RA, Yu TK. Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue. *Biomed Opt Express* 2(6):1514-23, 6/2011. e-Pub 5/2011. PMID: PMC3114220.
 350. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. *JAMA* 306(4):385-393, 7/2011. PMID: PMC5389856.
 351. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. *Ann Surg* 254(1):119-24, 7/2011. PMID: PMC4345121.
 352. Wray CJ, Benjamin RS, Hunt KK, Cormier JN, Ross MI, Feig BW. Isolated limb perfusion for unresectable extremity sarcoma: Results of 2 single-institution phase 2 trials. *Cancer* 117(14):3235-41, 7/2011. e-Pub 1/2011. PMID: 21246524.
 353. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. *Cancer Gene Ther* 18(7):510-9, 7/2011. e-Pub 5/2011. PMID: PMC3875403.
 354. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. *Breast Cancer Res Treat* 128(2):421-7, 7/2011. e-Pub 5/2011. PMID: 21553292.
 355. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetskova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. *Hum Pathol* 42(8):1169-77, 8/2011. e-Pub 2/2011. PMID: 21334720.
 356. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer. *Breast J* 17(5):462-9, Sep-Oct, 9/2011. e-Pub 7/2011. PMID: 21726347.
 357. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the american college of surgeons oncology group (ACOSOG) Z0011 study: a practice-changing trial. *Ann Surg Oncol* 18(9):2407-12, 9/2011. e-Pub 2/2011. PMID: PMC4332388.
 358. Van Leeuwen BL, Rosenkranz KM, Feng LL, Bedrosian I, Hartmann K, Hunt KK, Kuerer HM, Ross M, Singletary SE, Babiera GV, Department of Surgical Oncology, MD Anderson Cancer Center. The effect of under-treatment of breast cancer in women 80 years of age and older. *Crit Rev Oncol Hematol* 79(3):315-20, 9/2011. e-Pub 7/2010. PMID: 20655242.

359. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. *Ann Surg Oncol* 18(10):2873-8, 10/2011. e-Pub 4/2011. PMID: 21476105.
360. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. *Ann Surg Oncol* 18(11):3164-73, 10/2011. e-Pub 9/2011. PMID: PMC4337779.
361. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, Woodward WA, Gonzalez-Angulo AM, Hunt KK, Buchholz TA, Yu TK. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. *Int J Radiat Oncol Biol Phys* 81(3):782-7, 11/2011. e-Pub 8/2011. PMID: 21885207.
362. Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. *Cancer Prev Res (Phila)* 4(11):1852-62, 11/2011. e-Pub 7/2011. PMID: PMC3208724.
363. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current american joint committee on cancer staging system. *J Clin Oncol* 29(35):4654-61, 12/2011. e-Pub 11/2011. PMID: PMC3236648.
364. Bilimoria KY, Wayne JD, Merkow RP, Abbott DE, Cormier JN, Feig BW, Hunt KK, Pisters PW, Pollock R, Bentrem DJ. Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. *Ann Surg Oncol* 19(1):184-91, 1/2012. e-Pub 7/2011. PMID: 21725688.
365. Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. *Ann Surg* 255(1):109-15, 1/2012. PMID: PMC4760742.
366. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. *Breast Cancer Res Treat* 131(1):41-8, 1/2012. e-Pub 2/2011. PMID: PMC3867807.
367. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. *J Clin Oncol* 30(6):600-7, 2/2012. e-Pub 1/2012. PMID: PMC3295558.
368. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, Glynn SA, Dorsey TH, Hunt KK, Ambs S, Johanning GL. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. *J Natl Cancer Inst* 104(3):189-210, 2/2012. e-Pub 1/2012. PMID: PMC3274512.
369. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the md anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. *Ann Surg Oncol* 19(3):901-7, 3/2012. e-Pub 8/2011. PMID: PMC6086605.
370. Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, Broglio K, Buchholz TA, Hunt KK, Sahin AA. Occult axillary lymph node metastasis do not have prognostic significance in early stage breast cancer. *Cancer* 118(6):1507-14, 3/2012. e-Pub 8/2011. PMID: 22009292.
371. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial

- evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. *J Clin Oncol* 30(9):930-5, 3/2012. e-Pub 2/2012. PMID: 22331946.
372. Smith TB, Gilcrease MZ, Santiago L, Hunt KK, Yang WT. Imaging features of primary breast sarcoma. *AJR Am J Roentgenol* 198(4):W386-93, 4/2012. PMID: 22451578.
373. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. *Ann Surg Oncol* 19(4):1137-44, 4/2012. e-Pub 10/2011. PMCID: PMC3854933.
374. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. *Breast Cancer Res Treat* 132(2):575-88, 4/2012. e-Pub 6/2011. PMCID: PMC3855283.
375. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. *Breast Cancer Res* 14(3):R82, 5/2012. e-Pub 5/2012. PMCID: PMC3446345.
376. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. *Breast Cancer Res* 14(3):R83, 5/2012. e-Pub 5/2012. PMCID: PMC3446346.
377. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. *Surgery* 151(5):710-6, 5/2012. e-Pub 1/2012. PMCID: PMC3628698.
378. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. *Breast Cancer Res Treat* 133(3):1131-41, 6/2012. e-Pub 3/2012. PMCID: PMC3855009.
379. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature* 486(7403):353-360, 6/2012. e-Pub 6/2012. PMCID: PMC3383766.
380. Yi M, Liu P, Li X, Mittendorf EA, He J, Ren Y, Nayeemuddin K, Hunt KK. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. *Cancer* 118(17):4117-25, 9/2012. e-Pub 1/2012. PMID: 22460701.
381. Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D. Dual targeting of mTOR and Aurora-A kinase for the treatment of uterine leiomyosarcoma. *Clin Cancer Res* 18(17):4633-45, 9/2012. e-Pub 7/2012. PMCID: PMC3432751.
382. Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. *Ann Surg* 256(3):428-436, 9/2012. PMCID: PMC5345746.
383. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American college of surgeons

- oncology group (ACOSOG) Z0011: impact on surgeon practice patterns. *Ann Surg Oncol* 19(10):3144-3151, 10/2012. e-Pub 7/2012. PMID: PMC4403637.
384. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the american society of breast surgeons. *Ann Surg Oncol* 19(10):3152-3158, 10/2012. e-Pub 7/2012. PMID: 22820938.
 385. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. *Cancer* 118(20):4936-43, 10/2012. e-Pub 4/2012. PMID: PMC3888990.
 386. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. *Ann Surg Oncol* 19(10):3177-3184, 10/2012. e-Pub 7/2012. PMID: 22772869.
 387. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with dcis. *Ann Surg Oncol* 19(12):3777-3784, 11/2012. e-Pub 5/2012. PMID: PMC3854959.
 388. Henteleff HJ, Hunt KK, Quan ML, Evidence-Based Reviews in Surgery Group. Comparative effectiveness of magnetic resonance imaging in breast cancer. *J Am Coll Surg* 215(6):894-896, 12/2012. PMID: 23164142.
 389. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. *Cancer* 118(24):6287-96, 12/2012. e-Pub 5/2012. PMID: PMC3913471.
 390. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. *PLoS Genet* 8(3):e1002538, 2012. e-Pub 3/2012. PMID: PMC3315462.
 391. Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. *Breast Cancer Res* 15(1):R3, 1/2013. e-Pub 1/2013. PMID: PMC3672770.
 392. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetskova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. *Histopathology* 62(2):267-74, 1/2013. e-Pub 9/2012. PMID: PMC3881372.
 393. Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the American College of Surgeons Oncology Group Z0011 criteria applied to a contemporary patient population. *J Am Coll Surg* 216(1):105-13, 1/2013. e-Pub 11/2012. PMID: PMC4331643.
 394. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. *Cancer J* 19(1):10-7, Jan-Feb, 1/2013. PMID: PMC3568679.
 395. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. *Ann Surg* 257(2):173-179, 2/2013. PMID: PMC6058313.
 396. Yi M, Xu J, Liu P, Chang GJ, Du XL, Hu CY, Song Y, He J, Ren Y, Wei Y, Yang J, Hunt KK, Li X. Comparative analysis of lifestyle factors, screening test use, and clinicopathologic features in association with survival among Asian Americans with colorectal cancer. *Br J Cancer* 108(7):1508-14, 4/2013. e-Pub 3/2013. PMID: PMC3629437.
 397. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and

- radiotherapy for breast cancer. *Ann Surg Oncol* 20(4):1267-74, 4/2013. e-Pub 12/2012. PMID: PMC5036516.
398. Yi M, Cormier JN, Xing Y, Giordano SH, Chai C, Meric-Bernstam F, Vlastos G, Kuerer HM, Mirza NQ, Buchholz TA, Hunt KK. Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. *Ann Surg Oncol* 20(5):1514-21, 5/2013. e-Pub 12/2012. PMID: PMC3886684.
399. Luo S, Yi M, Huang X, Hunt KK. A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. *Stat Med* 32(13):2320-34, 6/2013. e-Pub 9/2012. PMID: PMC3897718.
400. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. *Ann Surg Oncol* 20(6):1893-9, 6/2013. e-Pub 1/2013. PMID: PMC4353581.
401. Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, Lazar AJ, Hunt KK, Anderson ML, Creighton CJ, Lev D, Pollock RE. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. *Ann Surg Oncol* 20(7):2364-72, 7/2013. e-Pub 1/2013. PMID: PMC3913478.
402. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. *Ann Oncol* 24(8):1999-2004, 8/2013. e-Pub 4/2013. PMID: PMC3718505.
403. Liu P, Li X, Mittendorf EA, Li J, Du XL, He J, Ren Y, Yang J, Hunt KK, Yi M. Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer. *Br J Cancer* 109(5):1302-9, 9/2013. e-Pub 8/2013. PMID: PMC3778276.
404. Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin e/cdk2 substrate that enriches breast cancer stem-like cells. *Cancer Res* 73(17):5556-68, 9/2013. e-Pub 8/2013. PMID: PMC3773499.
405. Gould DJ, Hunt KK, Liu J, Kuerer HM, Crosby MA, Babiera G, Kronowitz SJ. Impact of surgical techniques, biomaterials, and patient variables on rate of nipple necrosis after nipple-sparing mastectomy. *Plast Reconstr Surg* 132(3):330e-8e, 9/2013. PMID: PMC3935717.
406. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local-regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. *Ann Surg Oncol* 20(11):3430-7, 10/2013. e-Pub 5/2013. PMID: 23720073.
407. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. *JAMA* 310(14):1455-61, 10/2013. PMID: PMC4075763.
408. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. *Carcinogenesis* 34(10):2244-52, 10/2013. e-Pub 5/2013. PMID: PMC3786379.
409. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomized, controlled, phase 3 trial. *Lancet Oncol* 14(13):1317-25, 12/2013. e-Pub 11/2013. PMID: PMC4176878.
410. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-

- Bernstam F, Hunt KK, Kuerer HM. Incidence and consequence of close margins in patients with ductal carcinoma in situ treated with mastectomy: is further therapy warranted? *Ann Surg Oncol* 20(13):4103-12, 12/2013. e-Pub 8/2013. PMID: PMC4337951.
411. Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. *Ann Surg Oncol* 21(1):60-5, 1/2014. e-Pub 9/2013. PMID: 24046126.
412. Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE, Giordano SH, Hunt KK, Smith BD. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. *Int J Radiat Oncol Biol Phys* 88(2):274-84, 2/2014. e-Pub 11/2013. PMID: PMC3947195.
413. Yang J, Du X, Wang G, Sun Y, Chen K, Zhu X, Lazar AJ, Hunt KK, Pollock RE, Zhang W. Mesenchymal to epithelial transition in sarcomas. *Eur J Cancer* 50(3):593-601, 2/2014. e-Pub 11/2013. PMID: 24291235.
414. MacDermid DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GH, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman KE. Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. *Pract Radiat Oncol* 4(2):116-22, Mar-Apr, 3/2014. e-Pub 7/2013. PMID: 24890352.
415. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. *Cancer* 120(9):1319-28, 5/2014. e-Pub 2/2014. PMID: PMC4278570.
416. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. *Ann Oncol* 25(5):1004-11, 5/2014. e-Pub 2/2014. PMID: PMC3999801.
417. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. *Int J Radiat Oncol Biol Phys* 89(2):392-8, 6/2014. e-Pub 4/2014. PMID: 24721590.
418. Luo S, Su X, DeSantis SM, Huang X, Yi M, Hunt KK. Joint model for a diagnostic test without a gold standard in the presence of a dependent terminal event. *Stat Med* 33(15):2554-66, 7/2014. e-Pub 1/2014. PMID: PMC4209250.
419. Eberth JM, Xu Y, Smith GL, Shen Y, Jiang J, Buchholz TA, Hunt KK, Black DM, Giordano SH, Whitman GJ, Yang W, Shen C, Elting L, Smith BD. Surgeon influence on use of needle biopsy in patients with breast cancer: a national Medicare study. *J Clin Oncol* 32(21):2206-16, 7/2014. e-Pub 6/2014. PMID: PMC4164811.
420. Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. *Ann Surg Oncol* 21(8):2499-505, 8/2014. e-Pub 3/2014. PMID: PMC4524653.
421. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the american college of surgeons oncology group Z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? *Ann Surg Oncol* 21(8):2468-73, 8/2014. e-Pub 5/2014. PMID: 24841348.
422. Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Munsell MF, Chemaly RF, Graviss LS, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. *Ann Surg Oncol* 21(8):2512-6, 8/2014. e-Pub 4/2014. PMID: 24736987.

423. Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA. Predicting the extent of nodal disease in early-stage breast cancer. *Ann Surg Oncol* 21(11):3440-7, 10/2014. e-Pub 5/2014. PMID: 24859939.
424. Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. *Ann Surg* 260(4):608-16, 10/2014. PMCID: PMC4159769.
425. Ren Y, Black DM, Mittendorf EA, Liu P, Li X, Du XL, He J, Yang J, Hunt KK, Yi M. Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. *PLoS One* 9(10):e110281, 2014. e-Pub 10/2014. PMCID: PMC4204865.
426. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. *Breast Cancer Res* 16(6):3417, 2014. e-Pub 12/2014. PMCID: PMC4326485.
427. Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, Wu Y. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. *PLoS One* 9(2):e89778, 2014. e-Pub 2/2014. PMCID: PMC3934955.
428. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. *Ann Surg Oncol* 22(1):90-5, 1/2015. e-Pub 9/2014. PMID: 25249256.
429. Chang EI, Ito R, Zhang H, Nguyen AT, Skoracki RJ, Hanasono MM, Crosby MA, Ueno NT, Hunt KK. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. *Plast Reconstr Surg* 135(2):262e-9e, 2/2015. PMID: 25626809.
430. Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. *Br J Cancer* 112(4):630-5, 2/2015. e-Pub 1/2015. PMCID: PMC4333494.
431. Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. *JAMA Surg* 150(2):137-43, 2/2015. e-Pub 12/2014. PMCID: PMC4508192.
432. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK, Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). *Ann Surg* 261(3):547-52, 3/2015. PMCID: PMC4324533.
433. Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. *Ann Surg Oncol* 22(4):1068-72, 4/2015. e-Pub 10/2014. PMCID: PMC4520392.
434. Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the stage IB designation of the american joint committee on cancer staging system in breast cancer. *J Clin Oncol* 33(10):1119-27, 4/2015. e-Pub 12/2014. PMCID: PMC4372850.
435. Caruso JA, Akli S, Pigeon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. *Oncogene* 34(27):3556-67, 7/2015. e-Pub 9/2014. PMCID: PMC4362782.
436. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. *Histopathology* 67(2):245-54, 8/2015. e-Pub 2/2015. PMID: 25564996.

437. Brudvik KW, Patel SH, Roland CL, Conrad C, Torres KE, Hunt KK, Cormier JN, Feig BW, Aloia TA, Vauthey JN. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. *J Gastrointest Surg* 19(8):1476-83, 8/2015. e-Pub 5/2015. PMID: PMC4506212.
438. Bishop AJ, Zagars GK, Torres KE, Hunt KK, Cormier JN, Feig BW, Guadagnolo BA. Combined modality management of retroperitoneal sarcomas: a single-institution series of 121 patients. *Int J Radiat Oncol Biol Phys* 93(1):158-65, 9/2015. e-Pub 5/2015. PMID: PMC4928583.
439. Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing eligibility criteria for molecularly driven trials. *J Clin Oncol* 33(25):2815-20, 9/2015. e-Pub 7/2015. PMID: 26195710.
440. Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of ultrasonography of regional nodal basins in staging triple-negative breast cancer and implications for local-regional treatment. *Int J Radiat Oncol Biol Phys* 93(1):102-10, 9/2015. e-Pub 5/2015. PMID: 26279028.
441. Smith GL, Huo J, Giordano SH, Hunt KK, Buchholz TA, Smith BD. Utilization and outcomes of breast brachytherapy in younger women. *Int J Radiat Oncol Biol Phys* 93(1):91-101, 9/2015. e-Pub 5/2015. PMID: PMC4542059.
442. Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. *JAMA Oncol* 1(7):931-41, 10/2015. PMID: PMC4635441.
443. DeSnyder SM, Hunt KK, Smith BD, Moran MS, Klimberg S, Lucci A. Assessment of practice patterns following publication of the SSO-ASTRO consensus guideline on margins for breast-conserving therapy in stage I and II invasive breast cancer. *Ann Surg Oncol* 22(10):3250-6, 10/2015. e-Pub 7/2015. PMID: PMC4696114.
444. Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Le-Petross HT. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the american college of surgeons oncology group Z1071 trial (alliance). *J Clin Oncol* 33(30):3386-3393, 10/2015. e-Pub 2/2015. PMID: PMC4606058.
445. Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. *Cancer* 121(20):3659-67, 10/2015. e-Pub 7/2015. PMID: PMC4777348.
446. Dogan BE, Dryden MJ, Wei W, Fornage BD, Buchholz TA, Smith B, Hunt K, Krishnamurthy S, Yang WT. Sonography and sonographically guided needle biopsy of internal mammary nodes in staging of patients with breast cancer. *AJR Am J Roentgenol* 205(4):905-911, 10/2015. PMID: 26397343.
447. Zhou F, Krishnamurthy J, Wei Y, Li M, Hunt K, Johanning GL, Cooper LJ, Wang-Johanning F. Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. *Oncoimmunology* 4(11):e1047582, 11/2015. e-Pub 5/2015. PMID: PMC4589998.
448. Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Sanna GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. *Ann Surg Oncol* 22(12):3913-20, 11/2015. e-Pub 3/2015. PMID: PMC4561200.
449. Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, Bedrosian I, Caudle AS, Babiera GV, Krishnamurthy S, Kuerer HM, Hunt KK. Is sentinel lymph node dissection

- warranted for patients with a diagnosis of ductal carcinoma in situ? *Ann Surg Oncol* 13(13):4270-9, 12/2015. e-Pub 4/2015. PMID: PMC5271669.
450. Luo S, Su X, Yi M, Hunt KK. Simultaneous inference of a misclassified outcome and competing risks failure time data. *J Appl Stat* 42(5):1080-1090, 2015. PMID: PMC4372162.
 451. Bedrosian I, Xing Y, Abdel Rahman S, Allen L, Le-Petross H, Whitman GJ, Meric-Bernstam F, Hunt KK, Babiera GV, Cormier JN. A cost analysis of preoperative breast MRI use for patients with invasive lobular cancer. *Ann Surg Oncol* 23(1):23-9, 1/2016. e-Pub 7/2015. PMID: 26156655.
 452. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete surgical excision is essential for the management of breast implant-associated anaplastic large cell lymphoma. *J Clin Oncol* 34(2):160-8, 1/2016. e-Pub 11/2015. PMID: PMC4872006.
 453. Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast cancer. *Clin Cancer Res* 22(1):26-33, 1/2016. e-Pub 8/2015. PMID: 26286912.
 454. Haffty BG, McCall LM, Ballman KV, McLaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC. Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance). *Int J Radiat Oncol Biol Phys* 94(3):493-502, 3/2016. e-Pub 11/2015. PMID: PMC4752720.
 455. Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sanna GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE. Clinical observations and molecular variables of primary vascular leiomyosarcoma. *JAMA Surg* 151(4):347-54, 4/2016. PMID: PMC4941943.
 456. Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin e associates with the lipogenic enzyme atp-citrate lyase to enable malignant growth of breast cancer cells. *Cancer Res* 76(8):2406-18, 4/2016. e-Pub 2/2016. PMID: PMC4873469.
 457. Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). *Ann Surg* 263(4):802-7, 4/2016. e-Pub 11/2015. PMID: PMC4777661.
 458. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. *J Clin Oncol* 34(10):1072-8, 4/2016. e-Pub 1/2016. PMID: PMC4933133.
 459. Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. *Mol Cancer Ther* 15(4):593-607, 4/2016. e-Pub 1/2016. PMID: PMC4873336.
 460. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. *JAMA Oncol* 2(4):508-16, 4/2016. PMID: PMC4845895.
 461. Dryden MJ, Dogan BE, Fox P, Wang C, Black DM, Hunt K, Yang WT. Imaging Factors That Influence Surgical Margins After Preoperative I125 Radioactive Seed Localization of Breast Lesions: Comparison With Wire Localization. *AJR Am J Roentgenol* 206(5):1112-8, 5/2016. e-Pub 3/2016. PMID: PMC4852474.

462. Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKC α promotes ovarian tumor progression through deregulation of cyclin E. *Oncogene* 35(19):2428-40, 5/2016. e-Pub 8/2015. PMID: PMC4856585.
463. Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a magnetic tracer for sentinel lymph node detection in early-stage breast cancer patients: a meta-analysis. *Ann Surg Oncol* 23(5):1508-14, 5/2016. e-Pub 2/2016. PMID: 26893221.
464. JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. *Cell Cycle* 15(12):1-12, 6/2016. e-Pub 4/2016. PMID: PMC4934046.
465. Roland CL, May CD, Watson KL, Al Sanna GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo BA, Feig B, Hunt KK, Cormier JN, Lazar AJ, Torres KE. Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma. *Ann Surg Oncol* 23(7):2220-8, 7/2016. e-Pub 2/2016. PMID: PMC4937623.
466. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic cyclin e and phospho-cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer. *Am J Pathol* 186(7):1900-12, 7/2016. e-Pub 5/2016. PMID: PMC4929404.
467. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. *JAMA Oncol* 2(7):929-36, 7/2016. e-Pub 3/2016. PMID: PMC5757376.
468. Simmons RM, Ballman KV, Cox C, Carp N, Sabol J, Hwang RF, Attai D, Sabel M, Nathanson D, Kenler A, Gold L, Kaufman C, Han L, Bleznak A, Stanley Smith J, Holmes D, Fornage B, Le-Petross C, Hoda S, McCall L, Hunt KK, ACOSOG investigators. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (alliance) Z1072. *Ann Surg Oncol* 23(8):2438-45, 8/2016. e-Pub 5/2016. PMID: PMC5433250.
469. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, Colditz GA, DeSchryver K, Wilson RK, Mardis ER, Ellis MJ. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. *Nat Commun* 7:12498, 8/2016. e-Pub 8/2016. PMID: PMC4980485.
470. Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters R, Tripathy D, Hunt KK, Buchholz TA, Feeley TW, Kuerer HM. Value-based breast cancer care: a multidisciplinary approach for defining patient-centered outcomes. *Ann Surg Oncol* 23(8):2385-90, 8/2016. e-Pub 3/2016. PMID: 26979306.
471. Chagpar AB, Hughes T, Hunt K, Aguirre J, Babiera G. Variation in Follow-up of Asymptomatic Breast Cancer Patients: Can We Choose More Wisely? *Am Surg* 82(8):e188-90, 8/2016. PMID: 27657562.
472. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (alliance) ACOSOG Z0011 randomized trial. *Ann Surg* 264(3):413-20, 9/2016. PMID: PMC5070540.
473. Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. *Ann Surg Oncol* 23(11):3501-3509, 10/2016. e-Pub 5/2016. PMID: 27216742.
474. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. *Ann Surg Oncol* 23(10):3190-8, 10/2016. e-Pub 7/2016. PMID: 27406093.
475. Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez-MacGregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post

- Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. *Int J Radiat Oncol Biol Phys* 96(3):637-44, 11/2016. e-Pub 7/2016. PMID: 27681760.
476. Chagpar AB, Babiera GV, Aguirre J, Hunt KK, Hughes T. Variation in practice of the diagnostic workup of asymptomatic patients diagnosed with invasive breast cancer. *Front Oncol* 6:56, 2016. e-Pub 3/2016. PMID: PMC4786549.
 477. Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL inhibition suppresses the dna damage response and sensitizes cells to parp inhibition in multiple cancers. *Mol Cancer Res* 15(1):45-58, 1/2017. e-Pub 9/2016. PMID: PMC5215967.
 478. Smith BD, Jiang J, Shih YC, Giordano SH, Huo J, Jagsi R, Momoh AO, Caudle AS, Hunt KK, Shaitelman SF, Buchholz TA, Shirvani SM. Cost and Complications of Local Therapies for Early-Stage Breast Cancer. *J Natl Cancer Inst* 109(1), 1/2017. e-Pub 9/2016. PMID: PMC6075189.
 479. Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, Cormier JN, Hunt KK, Feig BW, Ashleigh Guadagnolo B, Bishop AJ, Wang WL, Slopis JM, McCutcheon IE, Lazar AJ, Torres KE. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. *J Neurosurg* 126(1):1-11, 1/2017. e-Pub 4/2016. PMID: PMC5045773.
 480. Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. *Oncotarget* 8(9):14897-14911, 2/2017. PMID: PMC5362453.
 481. Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT. Incremental cancer detection of locoregional restaging with diagnostic mammography combined with whole-breast and regional nodal ultrasound in women with newly diagnosed breast cancer. *Acad Radiol* 24(2):191-199, 2/2017. e-Pub 12/2016. PMID: PMC5237415.
 482. Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, Kulkarni SA, McCready DR, Mamounas EP, Wilke LG, Van Zee KJ, Morrow M. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. *Ann Surg Oncol* 24(2):375-397, 2/2017. e-Pub 12/2016. PMID: 27933411.
 483. Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study. *Ann Surg Oncol* 24(2):418-424, 2/2017. e-Pub 9/2016. PMID: PMC5437722.
 484. Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK, Mittendorf EA. Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. *Ann Surg* 265(3):574-580, 3/2017. PMID: 27735826.
 485. FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. *Ann Surg Oncol* 24(3):652-659, 3/2017. e-Pub 10/2016. PMID: PMC5977973.
 486. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). *J Clin Oncol* 35(10):1061-1069, 4/2017. e-Pub 1/2017. PMID: PMC5455353.
 487. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant

- Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. *J Clin Oncol* 35(10):1049-1060, 4/2017. e-Pub 1/2017. PMID: PMC5455352.
488. Reddy JP, Lei X, Huang SC, Nicklaus KM, Fingeret MC, Shaitelman SF, Hunt KK, Buchholz TA, Merchant F, Markey MK, Smith BD. Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. *Int J Radiat Oncol Biol Phys* 97(5):894-902, 4/2017. e-Pub 12/2016. PMID: PMC5685181.
489. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. *Ann Oncol* 28(5):1070-1077, 5/2017. PMID: PMC5790063.
490. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. *Nat Commun* 8:15916, 6/2017. e-Pub 6/2017. PMID: PMC5490269.
491. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic cyclin e predicts recurrence in patients with breast cancer. *Clin Cancer Res* 23(12):2991-3002, 6/2017. e-Pub 11/2016. PMID: PMC5441976.
492. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. *JAMA Surg* 152(7):665-670, 7/2017. e-Pub 4/2017. PMID: PMC5547923.
493. Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, Hoffman K, Hunt K, Wong J, Halasz LM, Freedman G, Prosnitz R, Yassa M, Nguyen DHA, Hijal T, Haffty BG, Wai ES, Truong PT. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. *JAMA Oncol* 3(8):1060-1068, 8/2017. PMID: PMC5824216.
494. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. *Mol Cancer Ther* 16(9):1751-1764, 9/2017. e-Pub 6/2017. PMID: PMC5975955.
495. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. *JAMA* 318(10):918-926, 9/2017. PMID: PMC5672806.
496. Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, Hunt KK, Cormier JN, Feig BW. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. *J Surg Oncol* 116(3):313-319, 9/2017. e-Pub 5/2017. PMID: PMC5937256.
497. Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. *Cancer Discov* 7(10):1168-1183, 10/2017. e-Pub 8/2017. PMID: PMC5733075.
498. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. *Ann Oncol* 28(10):2420-2428, 10/2017. PMID: PMC5834134.
499. Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). *Ann Surg* 266(4):667-676, 10/2017. PMID: PMC5755619.

500. Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. *Ann Surg Oncol* 24(10):2925-2934, 10/2017. e-Pub 8/2017. PMID: PMC5759951.
501. Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. *Ann Surg Oncol* 24(12):3502-3509, 11/2017. e-Pub 7/2017. PMID: PMC5880531.
502. Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. *Oncologist* 22(11):1292-1300, 11/2017. e-Pub 6/2017. PMID: PMC5679819.
503. Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. *Clin Cancer Res* 23(23):7288-7300, 12/2017. e-Pub 9/2017. PMID: PMC5768442.
504. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. *J Cancer* 8(14):2653-2662, 2017. e-Pub 8/2017. PMID: PMC5604195.
505. Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. *Eur J Surg Oncol* 44(1):170-177, 1/2018. e-Pub 11/2017. PMID: PMC5747371.
506. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. *Breast J* 24(1):28-34, 1/2018. e-Pub 6/2017. PMID: PMC5729065.
507. Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. *Cancer Res* 78(3):742-757, 2/2018. e-Pub 11/2017. PMID: PMC5811386.
508. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. *JAMA Oncol* 4(2):203-209, 2/2018. PMID: PMC5838705.
509. Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, Boughey JC. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). *AJR Am J Roentgenol* 210(3):1-8, 3/2018. e-Pub 1/2018. PMID: PMC5884109.
510. Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, Lofts J, Amin MB, Ming Chai S, Morine A, Di Napoli A, Dogan A, Parkash V, Bhagat G, Tritz D, Quesada AE, Pina-Oviedo S, Hu Q, Garcia-Gomez FJ, Jose Borrero J, Horna P, Thakral B, Narbaitz M, Hughes RC, Yang LJ, Fromm JR, Wu D, Zhang D, Sohani AR, Hunt J, Vadlamani IU, Morgan EA, Ferry JA, Szigeti R, C Tardio J, Granados R, Dertinger S, Offner FA, Pircher A, Hosry J, Young KH, Miranda RN. Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. *Am J Surg Pathol* 42(3):293-305, 3/2018. PMID: 29194092.
511. Swanick CW, Lei X, Xu Y, Shen Y, Goodwin NA, Smith GL, Giordano SH, Hunt KK, Jagsi R, Shaitelman SF, Peterson SK, Smith BD. Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study. *Int J Radiat Oncol Biol Phys* 100(4):882-890, 3/2018. e-Pub 12/2017. PMID: PMC5842799.
512. Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following

- neoadjuvant tyrosine kinase inhibitor therapy. *J Surg Oncol* 117(5):879-885, 4/2018. e-Pub 2/2018. PMID: PMC5992050.
513. Ikoma N, Roland CL, Cormier JN, Chiang YJ, Torres KE, Hunt KK, You YN, Feig BW. Nongastrointestinal Stromal Tumor Spindle Cell Sarcomas of the Colon or Rectum. *Am Surg* 84(4):570-575, 4/2018. PMID: 29712608.
 514. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. *Ann Surg* 267(5):946-951, 5/2018. e-Pub 5/2017. PMID: PMC6051523.
 515. Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities. *Ann Surg Oncol* 25(5):1126-1132, 5/2018. e-Pub 2/2018. PMID: PMC6135610.
 516. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. *J Surg Oncol* 117(6):1188-1194, 5/2018. e-Pub 12/2017. PMID: 29228466.
 517. Loghavi S, Medeiros LJ, Javadi S, Lin P, Khoury JD, Nastoupil L, Hunt KK, Clemens MW, Miranda RN. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. *Aesthet Surg J* 38(7), 6/2018. PMID: 29635424.
 518. Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. *Cancer* 124(14):2923-2930, 7/2018. e-Pub 5/2018. PMID: 29723396.
 519. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. *Clin Breast Cancer* 18(4):276-281, 8/2018. e-Pub 10/2017. PMID: PMC5899057.
 520. Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. *Cell Rep* 24(6):1434-1444.e7, 8/2018. PMID: PMC6171747.
 521. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. *Ann Surg Oncol* 25(8):2193-2200, 8/2018. e-Pub 3/2018. PMID: PMC6030482.
 522. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. *BMC Cancer* 18(1):913, 9/2018. e-Pub 9/2018. PMID: PMC6154892.
 523. Parker PA, Peterson SK, Shen Y, Bedrosian I, Black DM, Thompson AM, Nelson JC, DeSnyder SM, Cook RL, Hunt KK, Volk RJ, Cantor SB, Dong W, Brewster AM. Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. *J Clin Oncol* 36(25):2630-2638, 9/2018. e-Pub 7/2018. PMID: PMC6118404.
 524. DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-

- Conserving Surgery With Whole-Breast Irradiation. *Ann Surg Oncol* 25(10):2965-2974, 10/2018. e-Pub 7/2018. PMID: 29987598.
525. Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. *Cancer Res* 78(19):5481-5491, 10/2018. e-Pub 9/2018. PMID: PMC6168358.
 526. Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. *Ann Surg Oncol* 25(10):2932-2938, 10/2018. e-Pub 6/2018. PMID: PMC6123252.
 527. Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. *Ann Surg Oncol* 25(10):2858-2866, 10/2018. e-Pub 7/2018. PMID: PMC6192830.
 528. Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. *J Clin Oncol* 36(35):3495-3503. e-Pub 10/2018. PMID: PMC6286164.
 529. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. *Clin Cancer Res* 24(24):6594-6610, 12/2018. e-Pub 9/2018. PMID: PMC6317865.
 530. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. *Breast Cancer Res* 20(150):150, 12/2018. e-Pub 12/2018. PMID: PMC6290546.
 531. Keung EZ, Chiang YJ, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. *Cancer* 124(23):4495-4503, 12/2018. e-Pub 10/2018. PMID: PMC6289614.
 532. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. *Oncoimmunology* 7(2):e1385689, 2018. e-Pub 10/2017. PMID: PMC5749668.
 533. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. *JAMA Oncol* 5(1):45-50, 1/2019. e-Pub 9/2018. PMID: PMC6331049.
 534. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2mm: Contemporary Outcomes With Breast Conservation. *Ann Surg* 269(1):150-157, 1/2019. e-Pub 7/2017. PMID: PMC6051916.
 535. Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. An Evaluation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) Staging System for Retroperitoneal Sarcomas Using the National Cancer Data Base (NCDB): Does Size Matter? *Am J Clin Oncol* 42(2):160-165, 2/2019. PMID: PMC6345601.
 536. Tevis SE, Hunt KK, Miranda RN, Lange C, Butler CE, Clemens MW. Differences in Human Leukocyte Antigen Expression Between Breast Implant-Associated ALCL Patients and the General Population. *Aesthet Surg J*. e-Pub 2/2019. PMID: 30715139.
 537. Caudle AS, Kuerer HM, Krishnamurthy S, Shin K, Hobbs BP, Ma J, Mittendorf EA, Washington AC, DeSnyder SM, Black DM, Hunt KK, Yang WT. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in

- breast cancer: A prospective registry study. *Cancer* 125(3):365-373, 2/2019. e-Pub 10/2018. PMID: PMC6340747.
538. Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. *Support Care Cancer* 27(2):495-503, 2/2019. e-Pub 7/2018. PMID: PMC6342501.
539. Lamarin GA, Butler CE, Deva AK, Miranda RN, Hunt KK, Connell T, Lipa JE, Clemens MW. Breast Reconstruction Following Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plast Reconstr Surg* 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):51S-58S, 3/2019. PMID: 30817556.
540. Tevis SE, Bassett R, Bedrosian I, Barcnas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. *Ann Surg Oncol* 26(3):815-820, 3/2019. e-Pub 12/2018. PMID: 30556120.
541. Tevis SE, Hunt KK, Clemens MW. Stepwise En Bloc Resection of Breast Implant-Associated Anaplastic Large Cell Lymphoma with Oncologic Considerations. *Aesthetic Surgery Journal Open Forum* 1(1), 3/2019.
542. Advani PG, Lei X, Swanick CW, Xu Y, Shen Y, Goodwin NA, Smith GL, Giordano SH, Hunt KK, Jagsi R, Smith BD. Local Therapy Decisional Regret in Older Women With Breast Cancer: A Population-Based study. *Int J Radiat Oncol Biol Phys* 104(2):383-391, 6/2019. e-Pub 2/2019. PMID: PMC6624842.
543. Park KU, Kyriash K, Terrell J, Yi M, Caudle AS, Hunt KK, Kuerer HM, Bedrosian I, Thompson A, DeSnyder SM, other members of Department of Breast Surgical Oncology Study Group. Surgeon perception versus reality: Opioid use after breast cancer surgery. *J Surg Oncol* 119(7):909-915, 6/2019. e-Pub 2/2019. PMID: 30737785.
544. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. *Clin Cancer Res* 25(13):3996-4013, 7/2019. e-Pub 3/2019. PMID: PMC6606366.
545. Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. *Breast Cancer Res Treat* 176(2):435-444, 7/2019. e-Pub 4/2019. PMID: 31025270.
546. Armer JM, Ballman KV, McCall L, Ostby PL, Zagar E, Kuerer HM, Hunt KK, Boughey JC. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. *JAMA Surg*. e-Pub 7/2019. PMID: PMC6647005.
547. Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, Beitsch PD, Blair SL, Kivilaid K, Harmer QJ, Hunt KK. SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. *Ann Surg Oncol*. e-Pub 7/2019. PMID: 31297674.
548. Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. *Mod Pathol*. e-Pub 8/2019. PMID: 31383966.
549. Zhao B, Tsai C, Hunt KK, Blair SL. Adherence to Surgical and Oncologic Standards Improves Survival in Breast Cancer Patients. *J Surg Oncol* 120(2):148-159, 8/2019. e-Pub 6/2019. PMID: 31172534.

550. Haffty BG, McCall LM, Ballman KV, Buchholz TA, Hunt KK, Boughey JC. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. *Int J Radiat Oncol Biol Phys* 105(1):174-182, 9/2019. e-Pub 5/2019. PMID: PMC6699883.
551. Simons JM, van Pelt MLMA, Marinelli AWKS, Straver ME, Zeillemaker AM, Pereira Arias-Bouda LM, van Nijnatten TJA, Koppert LB, Hunt KK, Smidt ML, Luiten EJT, van der Pol CC. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. *Br J Surg* 106(12):1632-1639, 11/2019. e-Pub 10/2019. PMID: PMC6856822.
552. Al-Refaie WB, Decker PA, Ballman KV, Pisters PWT, Posner MC, Hunt KK, Meyers B, Weinberg AD, Nelson H, Newman L, Tan A, Le-Rademacher JG, Hurria A, Jatoi A. Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). *Ann Surg Oncol* 26(13):4213-4221, 12/2019. e-Pub 10/2019. PMID: PMC6868343.
553. Smith BD, Lei X, Diao K, Xu Y, Shen Y, Smith GL, Giordano SH, DeSnyder SM, Hunt KK, Teshome M, Jagsi R, Shaitelman SF, Peterson SK, Swanick CW. Effect of Surgeon Factors on Long-Term Patient-Reported Outcomes After Breast Conserving Therapy in Older Breast Cancer Survivors. *Ann Surg Oncol*. e-Pub 1/2020. PMID: 31916092.
554. Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. *Br J Cancer*. e-Pub 1/2020. PMID: 31942030.
555. Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. *Ann Surg Oncol* 27(2):359-366, 2/2020. e-Pub 10/2019. PMID: 31667721.
556. Johnston SJ, Syed BM, Parks RM, Monteiro CJ, Caruso JA, Green AR, Ellis IO, Hunt KK, Karakas C, Keyomarsi K, Cheung KL. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. *Cancers (Basel)* 12(3), 3/2020. e-Pub 3/2020. PMID: PMC7140020.
557. Asare EA, Davis CH, Chiang YJ, Sabir S, Rajkot NF, Phillips PR, Roland CL, Torres KE, Hunt KK, Feig BW. Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. *J Surg Oncol* 121(3):474-479, 3/2020. e-Pub 12/2019. PMID: 31846095.
558. Park KU, Kyrish K, Yi M, Bedrosian I, Caudle AS, Kuerer HM, Hunt KK, Miggins MV, DeSnyder SM. Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. *Ann Surg Oncol* 27(3):730-735, 3/2020. e-Pub 12/2019. PMID: 31820211.
559. Park KU, Mamounas EP, Katz MHG, Unzeitig G, Carpizo D, You YN, Francescatti A, Hunt KK, Boughey JC. Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles. *Ann Surg Oncol*. e-Pub 4/2020. PMID: 32318946.
560. Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. *Ann Surg Oncol*. e-Pub 5/2020. PMID: 32409969.
561. Roland CL, Grubbs EG, Katz MHG, Teshome M, Hunt KK, Tzeng CW. Clinical Trials - Designing, Implementing, and Collaborating. *J Surg Oncol* 122(1):25-28, 7/2020. e-Pub 3/2020. PMID: PMC7598771.
562. Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez-MacGregor M. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. *Ann Surg Oncol* 27(7):2229-2237, 7/2020. e-Pub 1/2020. PMID: 31916091.
563. Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Torres KE, Hunt KK, Feig BW, Cormier JN, Roland CL, Katz MHG, Lee JE, Tzeng CD. Postoperative pancreatic fistula after

- distal pancreatectomy for non-pancreas retroperitoneal tumor resection. *Am J Surg* 220(1):140-146, 7/2020. e-Pub 11/2019. PMID: 31843190.
564. Chapman BV, Lei X, Patil P, Tripathi S, Nicklaus KM, Grossberg AJ, Shaitelman SF, Thompson AM, Hunt KK, Buchholz TA, Merchant F, Markey MK, Smith BD, Reddy JP. Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *Adv Radiat Oncol* 5(5):824-833, Sep-Oct, 9/2020. e-Pub 5/2020. PMCID: PMC7557136.
565. Rosenkranz KM, Ballman K, McCall L, McCarthy C, Kubicky CD, Cuttino L, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. Cosmetic outcomes following breast conservation surgery and radiation for multiple ipsilateral breast cancer: Data from the Alliance Z11102 Study. *Ann Surg Oncol* 27(12):4650-4661, 11/2020. e-Pub 7/2020. PMCID: PMC7554157.
566. Singh P, Scoggins ME, Sahin AA, Hwang RF, Kuerer HM, Caudle AS, Mittendorf EA, Thompson AM, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. *Ann Surg* 1(2), 12/2020.
567. DeCoster RC, Lynch EB, Bonaroti AR, Miranda RN, Hunt KK, Clemens MW. Breast Implant-Associated Anaplastic Large Cell Lymphoma: Defining Future Research Priorities. *Clin Plast Surg* 48(1):33-43, 1/2021. PMID: 33220903.
568. Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. *Ann Surg Oncol*. e-Pub 1/2021. PMID: 33417121.
569. Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. *JAMA Netw Open* 4(3):e210945, 3/2021. e-Pub 3/2021. PMCID: PMC7974640.
570. Sheu TG, Hunt KK, Middleton LP. MYC and NOTCH1 positive post-radiation cutaneous angiosarcoma of the breast. *Breast J* 27(00):1-4, 3/2021. e-Pub 2/2021. PMID: 33527629.
571. Freedman RA, Minami CA, Winer EP, Morrow M, Smith AK, Walter LC, Sedrak MS, Gagnon H, Perilla-Glen A, Wildiers H, Wildes TM, Lichtman SM, Loh KP, Brain EGC, Ganschow PS, Hunt KK, Mayer DK, Ruddy KJ, Jagsi R, Lin NU, Canin B, LeStage BK, Revette AC, Schonberg MA, Keating NL. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. *JAMA Oncol* 7(4):609-615, 4/2021. e-Pub 1/2021. PMID: 33507222.
572. Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. *Cancers (Basel)* 13(7), 4/2021. e-Pub 4/2021. PMCID: PMC8036262.
573. Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi K. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. *Oncogenesis* 10(5):40, 5/2021. e-Pub 5/2021. PMCID: PMC8121779.
574. Evans MG, Medeiros LJ, Marques-Piubelli ML, Wang HY, Ortiz-Hidalgo C, Pina-Oviedo S, Morine A, Clemens MW, Hunt KK, Iyer S, Hu Q, Recavarren C, Demichelis R, Romero M, Sohani AR, Misialek M, Amin MB, Bueso-Ramos CE, Carballo-Zarate AA, Lee HJ, Ok CY, Xu J, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. *Mod Pathol*. e-Pub 6/2021. PMID: 34155351.

575. Weiss A, Cooley V, Al-Hilli Z, Ballman K, Poorvu N, Haffty B, Hunt KK, Nelson H, Blair SL, Boughey J. Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers. *Breast J* 27(6):537-542, 6/2021. e-Pub 3/2021. PMID: 33720478.
576. Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RN. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. *Mod Pathol*. e-Pub 7/2021. PMID: 34226673.
577. Kilgore LJ, Murphy BL, Postlewait LM, Liang DH, Bedrosian I, Lucci A, Kuerer HM, Hunt KK, Teshome M. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. *J Surg Oncol*. e-Pub 7/2021. PMID: PMC8426719.
578. Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. *Ann Surg* 274(2):e150-e159, 8/2021. e-Pub 8/2019. PMID: PMC7031042.
579. Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, Torres KE. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. *Acta Neuropathol* 142(3):565-590, 9/2021. e-Pub 7/2021. PMID: 34283254.
580. Kantor O, Chang C, Yao K, Boughey J, Roland C, Francescatti AB, Blair S, Dickson Witmer D, Hunt KK, Nelson H, Weiss A, Oseni T. Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers. *Ann Surg Oncol* 28(9):4995-5004, 9/2021. e-Pub 1/2021. PMID: 33423122.
581. Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. *Ann Surg Oncol* 28(10):5477-5485, 10/2021. e-Pub 7/2021. PMID: 34247335.
582. Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. *Int J Radiat Oncol Biol Phys* 111(2):360-370, 10/2021. e-Pub 5/2021. PMID: 33992718.
583. Adesoye T, Babayemi O, Postlewait LM, DeSnyder SM, Sun SX, Woodward WA, Ueno NT, Hunt KK, Lucci A, Teshome M. Inflammatory Breast Cancer at the Extremes of Age. *Ann Surg Oncol* 28(10):5626-5634, 10/2021. e-Pub 7/2021. PMID: 34292426.
584. Nissen AP, Vreeland TJ, Teshome M, Archer MA, Francescatti AB, Katz MHG, Hunt KK, Zheng L, Mullett TW. American College of Surgeons Commission on Cancer Standard for Curative Intent Pulmonary Resection. *Ann Thorac Surg* 113(1):5-8, 1/2022. e-Pub 6/2021. PMID: 34119494.
585. Tevis SE, Hunt KK, Miranda RN, Lange C, Pinnix CC, Iyer S, Butler CE, Clemens MW. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Prospective Series of 52 Patients. *Ann Surg* 275(1):e245-e249, 1/2022. e-Pub 6/2020. PMID: 32568749.
586. Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. *Ann Surg Oncol*. e-Pub 2/2022. PMID: 35224688.
587. Cuttino LW, McCall L, Kubicky C, Ballman KV, Le-Petross H, Hunt KK, Haffty B, Rosenkranz KM, Boughey JC. The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. *Int J Radiat Oncol Biol Phys* 112(3):636-642, 3/2022. e-Pub 10/2021. PMID: PMC8928138.

588. Hwang ES, Beitsch P, Blumencranz P, Carr D, Chagpar A, Clark L, Dekhne N, Dodge D, Dyess DL, Gold L, Grobmyer S, Hunt K, Karp S, Lesnikoski BA, Wapnir I, Smith BL, INSITE study team. Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicarianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. *JAMA Surg*. e-Pub 5/2022. PMID: 35544130.
589. Adams AM, Vreeland TJ, Teshome M, Francescatti AB, Zheng L, Hunt KK, Katz MHG, Messick CA. American College of Surgeons Commission on Cancer Standard 5.7 for Total Mesorectal Excision for Mid-to-Low Rectal Cancer. *J Am Coll Surg* 234(6):1249-1253, 6/2022. e-Pub 3/2022. PMID: 35703824.
590. Liang DH, Black D, Yi M, Luo CK, Singh P, Sahin A, Scoggins ME, Moseley TW, Hunt KK. Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions. *Ann Surg Oncol* 29(6):3822-3828, 6/2022. e-Pub 3/2022. PMID: 35233742.
591. Douglas SR, Lizarraga IM, Boughey JC, Weiss A, Hunt KK, Dickson-Witmer D, Subhedar PD, Park KU, Zhao B, Blair SL. National Cancer Database trends in surgical resection of the breast primary for stage IV breast cancer. *Surg Oncol* 42:101778, 6/2022. e-Pub 5/2022. PMID: 35609361.
592. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study. *Int J Cancer* 150(12):2025-2037, 6/2022. e-Pub 3/2022. PMID: 35233742.
593. Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. *Int J Cancer* 150(12):2012-2024, 6/2022. e-Pub 2/2022. PMID: 35128664.
594. Suman VJ, Du L, Hoskin T, Anurag M, Ma C, Bedrosian I, Hunt KK, Ellis MJ, Symmans WF. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). *Clin Cancer Res* 28(15):3287-3295, 8/2022. PMID: 35233742.
595. Boughey JC, Blair SL, Subhedar PD, Edge SB, White JR, Hunt KK. The EA2108 Clinical Trial and Real-World Data: A Cautionary Tale in Stage IV Breast Cancer. *Ann Surg Oncol* 29(8):4663-4666, 8/2022. e-Pub 5/2022. PMID: 35578060.
596. Lillemoe HA, Miranda RN, Nastoupil LJ, Clemens MW, Hunt KK. Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines. *Ann Surg Oncol* 29(9):5722-5729, 9/2022. e-Pub 5/2022. PMID: 35597841.
597. Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. *Ann Surg Oncol* 29(11):7092-7100, 10/2022. e-Pub 4/2022. PMID: 35501583.
598. Katz MHG, Francescatti AB, Hunt KK, Cancer Surgery Standards Program of the American College of Surgeons. Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3-5.8. *Ann Surg Oncol* 29(11):6549-6558, 10/2022. e-Pub 2/2022. PMID: 35187620.
599. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STs): a single-centre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 23(12):1547-1557, 12/2022. e-Pub 11/2022. PMID: 36343656.
600. Li M, Tsavachidis S, Wang F, Bui T, Nguyen TDT, Luo L, Multani AS, Bondy ML, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. *Oncogene* 41(50):5331-5346, 12/2022. e-Pub 11/2022. PMID: 359742291.

601. Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. ASO Visual Abstract: Re-Excision After Unplanned Excision of Soft Tissue Sarcoma Is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. *Ann Surg Oncol* 30(1):492, 1/2023. PMID: 36245056.
602. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. *Sci Rep* 13(1):1171, 1/2023. e-Pub 1/2023. PMID: PMC9859781.
603. Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. *Ann Surg Oncol* 30(1):480-489, 1/2023. e-Pub 9/2022. PMID: 36085392.
604. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. *Cancers (Basel)* 15(4), 2/2023. e-Pub 2/2023. PMID: PMC9953797.
605. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. *Ann Surg Oncol* 30(2):926-940, 2/2023. e-Pub 9/2022. PMID: 36115928.
606. Murphy BL, Yi M, Gutierrez Barrera AM, Tripathy D, Hunt KK, Arun BK. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. *Ann Surg Oncol* 30(3):1663-1668, 3/2023. e-Pub 9/2022. PMID: 36094691.
607. Smith-Graziani DJ, Parker PA, Peterson SK, Bedrosian I, Shen Y, Black DM, DeSnyder SM, Hunt KK, Dong W, Brewster AM. Prospective Study of Pain Outcomes Associated with Breast Surgery in Women with Nonhereditary Breast Cancer. *Ann Surg* 277(3):e617-e623, 3/2023. e-Pub 4/2021. PMID: 33938495.
608. Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Houghton PJ, Mawlawi O, Lazar AJ, Hunt KK, Keyomarsi K. Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. *Cancer Res* 83(6):939-955, 3/2023. e-Pub 1/2023. PMID: PMC10023441.
609. Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson JA. ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer. *Ann Surg Oncol* 30(4):2119-2120, 4/2023. PMID: 36745260.
610. Smith BL, Hunt KK, Carr D, Blumencranz PW, Hwang ES, Gadd MA, Stone K, Dyess DL, Dodge D, Valente S, Dekhne N, Clark P, Lee MC, Samiian L, Lesnikoski BA, Clark L, Smith KP, Chang M, Harris DK, Schlossberg B, Ferrer J, Wapnir IL. Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery. *NEJM Evidence*, 4/2023.
611. Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson J. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. *Ann Surg Oncol* 30(4):2111-2118, 4/2023. e-Pub 1/2023. PMID: 36653664.
612. Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S,

- Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. *Cancer Res.* e-Pub 6/2023. PMID: 37384539.
613. Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). *J Clin Oncol* 41(17):JCO2202553, 6/2023. e-Pub 3/2023. PMID: PMC10256355.
614. Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice Pattern Variability in the Management of Regional Lymph Node Metastasis in Extremity and Trunk Soft Tissue Sarcoma: A Survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. *Ann Surg Oncol* 30(6):3668-3676, 6/2023. e-Pub 2/2023. PMID: 36723723.
615. Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. *Ann Surg Oncol.* e-Pub 7/2023. PMID: 37458948.
616. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. *J Magn Reson Imaging.* e-Pub 1/2024. PMID: 38294179.
617. Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. *JAMA Oncol.* e-Pub 1/2024. PMID: PMC10797521.
618. Krishnamurthy S, Rempel D, Berkeley A, Rabindran B, Salgia P, Ban K, Wu Y, Ding Q, Hunt KK. Evaluation of a wide-field optical coherence tomography imaging platform with an artificial intelligence tool to detect alterations in breast tissue. *Human Pathology.* Submitted.
619. Smith B, Hunt KK, Carr D, Blumencranz P, Hwang S, Gadd M, Stone K, Dyess D, Dodge D, Valente S, Dekhne N, Clark P, Lee MC, Samiian L, Lesnikoski BA, Clark L, Smith KP, Chang M, Schlossberg B, Ferrer J, Wapnir I. Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery. *NEJM Evidence.* Submitted.

Invited Articles

1. Hunt KK, Feig B, Ames F. Ambulatory surgery for breast cancer. *Cancer Bulletin* 47(4):292-7, 1995.
2. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. *Surg Clin North Am* 76(2):393-410, 4/1996. PMID: 8610271.
3. Hunt KK, Ross MI. Changing trends in the diagnosis and treatment of early breast cancer. *Cancer Treat Res*:171-201, 1997.
4. Hunt KK, Ross MI. The Cox et al article reviewed. *Lymphatic Mapping in the Treatment of Breast Cancer.* *Oncology* 12(9):1294-8, 1998.
5. Hunt KK, Feig BW. Preclinical experimental therapeutic approaches in soft tissue sarcoma. *Semin Surg Oncol* 17(1):78-82, Jul-Aug, 7/1999. PMID: 10402641.
6. Newman LA, Kuerer HM, Hunt KK, Vlastos G, Ames FC, Ross MI, Singletary SE. Educational review: role of the surgeon in hereditary breast cancer. *Ann Surg Oncol* 8(4):368-78, 5/2001. PMID: 11352312.
7. Buchholz TA, Crane C, Hunt KK. 1st annual oncology update: advances and controversies. Steamboat Springs, Colorado, USA, 13-17 February 2001. *Expert Rev Anticancer Ther* 1(1):6-8, 6/2001. PMID: 12113134.

8. Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. *J Am Coll Surg* 194(4):488-501, 4/2002. PMID: 11949754.
9. Hunt KK, Vorburger SA. Tech Sight. Gene therapy. Hurdles and hopes for cancer treatment. *Science* 297(5580):415-6, 7/2002. PMID: 12130788.
10. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. *Mol Cancer Ther* 1(11):971-9, 9/2002. PMID: 12481419.
11. Vorburger SA, Hunt KK. Adenoviral gene therapy. *Oncologist* 7(1):46-59, 2002. PMID: 11854546.
12. Buchholz TA, Tucker SL, Katz A, McNeese MD, Strom EA, Perkins GH, Buzdar AU, Kuerer HM, Hunt KK, Singletary SE, Sahin AA, Thames HD, Meric F, Masullo L, Hortobagyi GN. Factors predictive for local-regional recurrence after neoadjuvant chemotherapy and mastectomy: Implications for radiation treatments. *Am J Oncol Review* 1(1):13-6, 2002.
13. Hunt KK, Ross MI. Sentinel lymph node dissection in early stage breast cancer. *Breast Cancer* 9(4):282-8, 2002. PMID: 12459707.
14. Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer patients receiving neoadjuvant chemotherapy. *Semin Breast Dis* 5(2):80-7, 2002.
15. Hwang RF, Hunt KK. Experimental approaches to treatment of soft tissue sarcoma. *Surg Oncol Clin N Am* 12(2):499-521, 4/2003. PMID: 12916466.
16. Buchholz TA, Strom EA, McNeese MD, Hunt KK. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. *Surg Clin North Am* 83(4):911-30, 8/2003. PMID: 12875602.
17. Meric-Bernstam F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Impact of positive surgical margins and ipsilateral breast tumor recurrence on disease-specific survival after breast-conserving therapy. *Am J Oncol Review* 2(8):428-33, 2003.
18. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Multidisciplinary considerations involved in using neoadjuvant chemotherapy for breast cancer. *Am J Oncol Rev* 3(3):156-64, 2004.
19. Chen AM, Meric-Bernstam F, Hunt KK, Buchholz TA. Neoadjuvant chemotherapy to permit breast conservation for patients with locally advanced breast cancer. *Am J Oncol Rev* 3:692-6, 2004.
20. Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. *Semin Cancer Biol* 15(4):319-26, 8/2005. PMID: 16043362.
21. Chen AM, Meric-Bernstam F, Hunt KK, Buchholz TA. Patient selection for breast conservation-after neoadjuvant chemotherapy: Developing a prognostic index. *Am J Oncol Rev* 4:398-404, 2005.
22. You YN, Hunt KK, Posner MC, Putnam JB, Nelson H, Ota DM, Pisters PW. Operative trials: the opportunity beckons-an update on the American College of Surgeons Oncology Group. *Surgery* 139(4):455-9, 4/2006. PMID: 16627052.
23. Boughey JC, Hunt KK. Expanding the indications for sentinel lymph node surgery in breast cancer. *Future Oncol* 3(1):9-14, 2/2007. PMID: 17280496.
24. Mittendorf EA, Hunt KK. Significance and management of micrometastases in patients with breast cancer. *Expert Rev Anticancer Ther* 7(10):1451-61, 10/2007. PMID: 17944569.
25. Boughey JC, Buzdar AU, Hunt KK. In brief. *Curr Probl Surg* 45(1):6-11, 1/2008. PMID: 18206435.
26. Boughey JC, Buzdar AU, Hunt KK. Recent advances in the hormonal treatment of breast cancer. *Curr Probl Surg* 45(1):13-55, 1/2008. PMID: 18206436.
27. Hunt KK. Invited Critique: Olsen MA et al. Hospital-associated costs due to surgical site infection after breast surgery. *Arch Surg* 2008;143:53-60. *Arch Surg* 143:61, 2008.
28. Modi S, Hunt KK, Hudis CA. Preoperative chemotherapy for breast cancer: pearls and pitfalls. *Medscape*, 3/2009.
29. Litton JK, Hunt KK. Management of the contralateral breast in women with newly diagnosed breast cancer CME. *Medscape*, 4/2009.

30. Fearmonti RM, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. *Cancer Treat Res* 147:1-36, 2009. PMID: 21461824.
31. Rourke LL, Hunt KK, Cormier JN. Breast cancer and lymphedema: a current overview for the healthcare provider. *Womens Health (Lond)* 6(3):399-406, 5/2010. PMID: 20426606.
32. Hunt KK. Axillary dissection in women in invasive breast cancer and sentinel node metastasis. *Curr Breast Cancer Reports* 3(2):75-8, 1/2011.
33. Caudle AS, Hunt KK. The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. *Curr Opin Obstet Gynecol* 23(1):31-6, 2/2011. PMID: 21124221.
34. Buchholz TA, Hunt KK. Breast conservation therapy in the 21st century. *Breast J* 17(5):445-7, Sep-Oct, 9/2011. PMID: 21899648.
35. Chawla A, Hunt KK, Mittendorf EA. Surgical considerations in patients receiving neoadjuvant systemic therapy. *Future Oncol* 8(3):239-250, 3/2012. PMID: 22409461.
36. Bednarski BK, Pisters PW, Hunt KK. The Role of Surgery in the Multidisciplinary Management of Patients with Localized Gastrointestinal Stromal Tumors. *Expert Rev Anticancer Ther* 12(8):1069-78, 8/2012. PMID: 23030225.
37. Black DM, Hunt KK, Mittendorf EA. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. *Gland Surg* 2(3):120-3, 8/2013. PMID: PMC4115749.
38. Hunt KK, Mittendorf EA. Review: Surgical considerations for breast cancer patients receiving neoadjuvant systemic therapy. *Breast Cancer Management* 2(5):385-395, 9/2013.
39. Hunt KK, Sahin AA. Too much, too little, or just right? Tumor margins in women undergoing breast-conserving surgery. *J Clin Oncol* 32(14):1401-6, 5/2014. e-Pub 3/2014. PMID: 24687821.
40. Teshome M, Hunt KK. Neoadjuvant Therapy in the Treatment of Breast Cancer. *Surg Oncol Clin N Am* 23(3):505-523, 7/2014. e-Pub 4/2014. PMID: PMC4044615.
41. Fornage BD, Hunt KK. Image-guided percutaneous ablation of small breast cancer: which technique is leading the pack? *Technol Cancer Res Treat* 14(2):209-11, 4/2015. e-Pub 11/2014. PMID: PMC4423750.
42. Boughey JC, Hunt KK. Spotlight on Neoadjuvant Therapy for Breast Cancer. *Ann Surg Oncol* 22(5):1406-7, 5/2015. e-Pub 3/2015. PMID: 25727559.
43. Buchholz TA, Mittendorf EA, Hunt KK. Surgical considerations after neoadjuvant chemotherapy: breast conservation therapy. *J Natl Cancer Inst Monogr* 2015(51):11-4, 5/2015. PMID: PMC6281279.
44. Roland CL, Hunt, KK. Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States. *Breast Diseases: A Year Book Quarterly* 26(2):125-126, 6/2015.
45. Martin LW, Veeramachaneni NK, Katz MH, You YN, Boughey JC, Nelson H, Hunt KK. New manual for cancer surgery issued: Operative Standards for Cancer Surgery. *Bull Am Coll Surg* 100(6):43-44, 6/2015. PMID: 26182523.
46. Mittendorf EA, Hunt, KK. Breast cancer immunotherapy: is it ready for prime time? *American Journal of Hematology /Oncology* 11(9), 9/2015.
47. Hunt KK. Axillary surgery after chemotherapy: challenges and opportunities. *Oncology (Williston Park)* 29(10):741-742, 10/2015. PMID: 26470897.
48. Leitch AM, Boughey JC, Hunt KK. Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options. *Bull Am Coll Surg* 100(11):43-5, 11/2015. PMID: 26677537.
49. Yi M, Hunt KK. Organizing a breast cancer database: data management. *Chin Clin Oncol* 5(3):45, 6/2016. e-Pub 4/2016. PMID: 27197511.
50. Menen RS, Hunt KK. Considerations for the Treatment of Young Patients with Breast Cancer. *Breast J* 22(6):667-672, 11/2016. e-Pub 8/2016. PMID: 27542172.
51. Hunt KK, Wingate HF. Satisfaction and Sustainability in a Surgical Career. *Ann Surg Oncol* 25(10):2785-2789, 10/2018. e-Pub 7/2018. PMID: PMC6193820.
52. Nurudeen S, Hunt KK. Contemporary management of the axilla in breast cancer. *Clin Adv Hematol Oncol* 16(12):823-831, 12/2018. PMID: 30843891.

53. Savard MF, Khan O, Hunt KK, Verma S. Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. *Am Soc Clin Oncol Educ Book* 39:e8-e21, 1/2019. e-Pub 5/2019. PMID: 31099662.
54. Fisher CS, Margenthaler JA, Hunt KK, Schwartz T. The Landmark Series: Axillary Management in Breast Cancer. *Ann Surg Oncol* 27(3):724-729, 3/2020. e-Pub 12/2019. PMID: 31863417.
55. Buchholz TA, Ali S, Hunt KK. Multidisciplinary Management of Locoregional Recurrent Breast Cancer. *J Clin Oncol* 38(20):2321-2328, 7/2020. e-Pub 5/2020. PMID: 32442059.
56. Francescatti AB, Roland CL, Hunt KK, Katz MH. 2020 Commission on Cancer (CoC) Operative Standards: Where are we now? *Bulletin of the American College of Surgeons* 106(1):109-112, 1/2021.
57. Li GZ, Raut CP, Hunt KK, Feng M, Chugh R. Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. *Am Soc Clin Oncol Educ Book* 41:390-404, 3/2021. PMID: 34010054.
58. Zheng L, Francescatti A, Deming S, Vreeland TJ, Boughey JC, Snyder RA, Hunt KK, Katz MH. Synoptic reporting for cancer surgery: Current requirements and future state. *ACS Cancer Research Program Bulletin*, 12/2021.
59. Tamirisa N, Hunt KK. Neoadjuvant Chemotherapy, Endocrine Therapy and Targeted Therapy for Breast Cancer: ASCO Guideline. *Ann Surg Oncol* 29(3):1489-1492, 3/2022. e-Pub 1/2022. PMID: 34989940.
60. Francescatti AB, Hunt KK, Katz MHG, Cancer Surgery Standards Program of the American College of Surgeons. ASO Author Reflections: Technical Standards for Cancer Surgery: From "How I Do It" to "How We Do It". *Ann Surg Oncol* 29(11):6559-6560, 10/2022. e-Pub 3/2022. PMID: 35288816.
61. Keung EZ, Hunt KK, Roland CL. ASO Author Reflections: A Call for Consensus, Collaboration and Data on the Role of Sentinel Lymph Node Biopsy for Soft Tissue Sarcoma. *Ann Surg Oncol* 30(2):968-969, 2/2023. e-Pub 11/2022. PMID: 36394686.
62. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. ASO Visual Abstract: Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. *Ann Surg Oncol* 30(2):941-942, 2/2023. e-Pub 9/2022. PMID: 36161369.
63. Murphy BL, Yi M, Barrera AG, Tripathy D, Hunt KK, Arun BK. ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. *Ann Surg Oncol* 30(3):1669-1670, 3/2023. e-Pub 10/2022. PMID: 36210399.

Editorials

1. McMasters KM, Hunt KK. Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life. *J Clin Oncol* 17(2):441-4, 2/1999. PMID: 10080583.
2. Hunt KK, Buchholz TA, Hortobagyi GN. Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy. *Ann Surg Oncol* 12(9):683-5, 9/2005. e-Pub 7/2005. PMID: 16041472.
3. Hunt KK, Buchholz TA, Hortobagyi GN. Now and later? The sticky question of lymph node management in patients receiving pre-operative chemotherapy. Editorial. *Ann Surg Oncol* 12(9):1-3, 2005.
4. Mittendorf EA, Hunt KK. Lymphatic interrupted: Do we really understand the risks and consequences? *Ann Surg Oncol* 16(7):1768-1770, 7/2009. e-Pub 4/2009. PMID: 19205875.
5. Hunt KK, Askew R, Cormier JN. Measuring lymphedema in patients with breast cancer: Go with the flow? *Breast Cancer Res Treat* 117(3):559-60, 10/2009. e-Pub 2/2009. PMID: 19205875.
6. Rourke LL, Hunt KK. Avoiding radiation after breast-conserving surgery for ductal carcinoma in situ of the breast: beyond the margin. *Ann Surg* 251(4):592-4, 4/2010. PMID: 20224366.
7. Hunt KK, Cormier JN. Risky business: Identifying risk factors associated with lymphedema after breast cancer: Comment on "Risk factors for lymphedema in a prospective breast cancer survivorship stud. *Arch Surg* 145(11):1063-4, 11/2010. PMID: 21121095.

8. Hunt KK, Woodward WA. Have we made progress in inflammatory breast cancer? Not so fast. *Oncology (Williston Park)* 25(3):276, 278, 3/2011. PMID: 21548471.
9. Haffty BG, Hunt KK, Harris JR, Buchholz TA. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. *J Clin Oncol* 29(34):4479-81, 12/2011. e-Pub 10/2011. PMID: 22042942.
10. Hunt KK, Smith BD, Mittendorf EA. The controversy regarding margin width in breast cancer: enough is enough. *Ann Surg Oncol* 21(3):701-3, 3/2014. e-Pub 1/2014. PMID: 24473644.
11. Mittendorf EA, Hunt KK. Following the data: past, present, and future management of the axilla in breast cancer patients. *Oncology (Williston Park)* 28(5):378, 380, 382, 5/2014. PMID: 25004649.
12. Dixon JM, Rutgers E, Hunt KK. Intraoperative assessment of axillary lymph nodes in patients with breast cancer. *BMJ* 349:g6803, 11/2014. e-Pub 11/2014. PMID: 25425017.
13. Yi M, Hunt KK. Optimizing Mammography Screening Intervals. *JAMA* 314(15):1635-6, 10/2015. PMID: 26501538.
14. Liao N, Hunt KK, Balch CM. Management of invasive and non invasive breast cancer in the United States and China. *Chin Clin Oncol* 5(3):30, 6/2016. PMID: 27265301.
15. Fayanju OM, Buchholz TA, Hunt KK. Postmastectomy radiation treatment rates as a quality measure: an opportunity for compliance through collaboration. *Ann Surg Oncol* 23(8):2377-2379, 8/2016. e-Pub 5/2016. PMID: 27160527.
16. Kuerer HM, Hunt KK. Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip? *Ann Surg Oncol* 23(11):3432-4, 10/2016. e-Pub 7/2016. PMID: 27469119.
17. Partain NS, Hunt KK. Imaging Surveillance After Definitive Treatment for Breast Cancer. *Ann Surg Oncol* 25(13):3790-3792, 12/2018. e-Pub 9/2018. PMID: PMC6234058.
18. Howe JR, Bartlett DL, Tyler DS, Wong SL, Hunt KK, DeMatteo RP, Society of Surgical Oncology. COVID-19 Guideline Modifications as CMS Announces "Opening Up America Again": Comments from the Society of Surgical Oncology. *Ann Surg Oncol*. e-Pub 5/2020. PMID: PMC7202680.
19. Hwang RF, Hunt KK. The Emergence of Robotic-assisted Breast Surgery: Proceed With Caution. *Ann Surg* 271(6):1013-1015, 6/2020. PMID: 32398613.
20. Nissen AP, Vreeland TJ, Teshome M, Archer MA, Francescatti AB, Katz MH, Hunt KK, Zheng L, Mullett TW. American College of Surgeons Commission on Cancer Standard for Curative-intent Pulmonary Resection. *The Annals of Thoracic Surgery*, 1/2022.
21. Hunt KK. Editorial on Toesca et al's "A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BRCA Mutation". *Ann Surg* 276(1):20-21, 7/2022. e-Pub 5/2022. PMID: 35703454.
22. Lillemoe HA, Williams JK, Teshome MK, Zheng L, Francescatti AB, Hieken TJ, Katz MH, Hunt KH, Vreeland TJ, Asare EA. Setting the Standard for Cutaneous Melanoma Wide Local Excision: An Overview of the American College of Surgeons Commission on Cancer Standard 5.5. *J Am Coll Surg* 236(2):424-428, 2/2023. e-Pub 11/2022. PMID: 36648270.
23. Zaveri S, Lillemoe HA, Teshome M, Reyna CR, Vreeland TJ, Francescatti AB, Zheng L, Hunt KK, Katz MHG, Kilgore LJ. Operative standards for sentinel lymph node biopsy and axillary lymphadenectomy for breast cancer: review of the American College of Surgeons commission on cancer standards 5.3 and 5.4. *Surgery*. e-Pub 5/2023. PMID: 37202308.

Other Articles

1. Hunt KK. Comment on Carlson GW. Skin sparing mastectomy: anatomic and technical considerations. *Am Surg*:62:151-5, 1996. *Breast Diseases: A Year Book Quarterly* 2:283, 1996.
2. Hunt KK. Comment on Bosek V, Cox CE. Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients. *Ann Surg Oncol* 1996;3:62-6. *Breast Diseases: A Year Book Quarterly* 8(1):52, 1997.
3. Hunt KK. Comment on Breant CM, Love SM. A hospital wide integrated database infrastructure to support a research program for a multidisciplinary breast center. *Breast J* 1997;2:289-298. *Breast Diseases: A Year Book Quarterly* 8(2):96, 1997.

4. Hunt KK. Comment on Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer: invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. *Arch Surg* 1996;131:301-8. *Breast Diseases: A Year Book Quarterly* 8(1):48-9, 1997.
5. Hunt KK. Comment on Curcio LD, Chu DZJ, Ahn C, et al. Local recurrence in breast cancer: implications for systemic disease. *Ann Surg Oncol* 1997;4:24-7. *Breast Diseases: A Year Book Quarterly* 8(3):242-3, 1997.
6. Hunt KK. Comment on Desai DC, Brennan EJ Jr, Carp NZ. Paget's disease of the male breast. *Am Surg* 1996;12:1068-72. *Breast Diseases: A Year Book Quarterly* 8(2):150-1, 1997.
7. Hunt KK. Comment on Frazee RC, Roberts JW, Symmonds RE, et al. Open versus stereotactic breast biopsy. *Am J Surg* 1996;172:491-5. *Breast Diseases: A Year Book Quarterly* 8(2):150, 1997.
8. Hunt KK. Comment on Liberman L, LaTrenta LR, Dershaw DD, et al. Impact of core biopsy on the surgical management of impalpable breast cancer. *AJR* 1997;168:495-9. *Breast Diseases: A Year Book Quarterly* 8(3):243-4, 1997.
9. Hunt KK. Comment on Love SM, Barsky SM. Breast-duct endoscopy to study stages of cancerous breast disease. *Lancet* 1996;348:997-9. *Breast Diseases: A Year Book Quarterly* 8(2):150, 1997.
10. Hunt KK. Comment on Salvat J, Knopf J-F, Ayoubi J-M, et al. Endoscopic exploration and lymph node sampling of the axilla: preliminary findings of a randomized pilot study comparing clinical and anatomic-pathologic results of endoscopic axillary lymph node sampling with traditional surgical treatment. *Eur J Obstet Gynecol Reprod Biol* 1996;70:165-73. *Breast Diseases: A Year Book Quarterly* 8(3):238-9, 1997.
11. Hunt KK. Comment on Schoenfeld A, Luqmani Y, Sinnott HD, et al. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. *Br J Cancer* 1996;74:1639-42. *Breast Diseases: A Year Book Quarterly* 8(3):244, 1997.
12. Hunt KK. Comment on Brain E, Garrino C, Misset J-L, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. *Br J Cancer* 1997;75:1360-7. *Breast Diseases: A Year Book Quarterly* 8(4):343-4, 1998.
13. Hunt KK. Comment on Fujii Y, Tanaka H, Toyooka H. Granisetron reduces incidence of nausea and vomiting after breast surgery. *Acta Anaesthesiol Scand* 1997;41:746-9. *Breast Diseases: A Year Book Quarterly* 9(1):78, 1998.
14. Hunt KK. Comment on Moore MM, Hargett CW III, Hanks JB, et al. Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. *Ann Surg* 1997;225:726-33. *Breast Diseases: A Year Book Quarterly* 9(1):77-8, 1998.
15. Hunt KK. Comment on Seltzer MH. Preoperative prediction of open breast biopsy results. *Cancer* 1997;79:1822-7. *Breast Diseases: A Year Book Quarterly* 8(4):365, 1998.
16. Hunt KK. Comment on Yim JH, Wick MR, Philpott GW, et al. Underlying pathology in mammary Paget's disease. *Ann Surg Oncol* 1997;4:287-92. *Breast Diseases: A Year Book Quarterly* 8(4):362-3, 1998.
17. Hunt KK. Comment on Berardo MD, Elledge RM, de Moor C, et al. Bcl-2 and apoptosis in lymph node positive breast carcinoma. *Cancer* 1998;82:1296-1302. *Breast Diseases: A Year Book Quarterly* 9(4):354-6, 1999.
18. Hunt KK. Comment on Bloomston M, D'Angelo P, Galliano D, et al. One hundred consecutive advanced breast biopsy instrumentation procedures: Complications, costs, and outcome. *Ann Surg Oncol* 1999;6:195-9. *Breast Diseases: A Year Book Quarterly* 10(3):316, 1999.
19. Hunt KK. Comment on Chan MTV, Chui PT, Ho WS, et al. Single-dose tropisetron for preventing postoperative nausea and vomiting after breast surgery. *Anesth Analg* 1998;87:931-5. *Breast Diseases: A Year Book Quarterly* 10(2):201-2, 1999.
20. Hunt KK. Comment on Winchester DJ, Fener S, Winchester DP, et al. Sentinel lymphadenectomy for breast cancer: Experience with 180 consecutive patients: Efficacy of filtered technetium 99m sulfur colloid with overnight migration time. *Breast Diseases: A Year Book Quarterly* 10(4):457-9, 2000.

21. Swisher SG, Pataer A, Fang B, Yu R, Nishizaki M, Fang B, Hunt KK, Roth JA. Enhancement of adenoviral mediated p53 (Adp53) tumor killing with amifostine induced CDC2 kinase activation. *Surg Forum* L1:312-3, 2000.
22. Hunt KK. Comment on Jokela RM, Kangas-Saarela TA, Valanne JVI, et al. Postoperative nausea and vomiting after sevoflurane with or without ondansetron compared with propofol in female patients undergoing breast surgery. *Breast Diseases. A Year Book Quarterly* 12(2):201, 2001.
23. Hunt KK. Spotlight on gastrointestinal tumors. (From the 32nd Annual Phoenix Surgical Symposium), jointly sponsored by the Maricopa Integrated Health System and the Phoenix Surgical Society) . *Audio-Digest General Surgery* 51(08), 4/2004.
24. Fang B, Hunt KK. Commentary for chapter, Gene Therapy and Virotherapy of Pancreatic Cancer. *Pancreatic Cancer*. Von Hoff DD, Evans D, Hruban RH (eds); Jones & Bartlett Publishers, Sudbury, MA, 2004.
25. Hunt KK. Spotlight on Breast Cancer. (From the 32nd Annual Phoenix Surgical Symposium, sponsored by the Maricopa Integrated Health System and the Phoenix Surgical Society) . *Audio-Digest General Surgery* 52(5), 3/2005.
26. Mittendorf EA, Hunt KK. Isolated tumor cells in sentinel lymph nodes and clinical implications for early breast cancer. *Ann Surg Oncol* 16(9):2661, 9/2009.
27. Ota DM, Nelson H, Ellis M, Hunt K. Measuring the impact of Z1031 on clinical practice. *Bulletin of the American College of Surgeons* 96(5), 5/2011.
28. Mittendorf EA, Hunt KK. Clinical Practice Implementation of findings from the American College of Surgeons Oncology Group Z0010 and Z0011 Trials. *Breast Diseases: A Year Book Quarterly* 22(2):115-118, 7/2011.
29. Mittendorf EA, Keyomarsi K, Hunt KK. Cyclin E amplication/overexpression is a mechanism of trastuzumab resistance in HER2 breast cancer patients. *Breast Diseases* 22(3):266-267, 10/2011.
30. Wagner JL, Hunt KK. Effect of Active Resistive Exercise on Breast Cancer - Related Lymphedema: A Randomized Controlled Trial. *Breast Diseases: A Year Book Quarterly* 22(3):255-256, 10/2011.
31. Hunt K, Kohman L, Nelson H. Announcing the Surgical Standards Manual Project: a call for volunteers. *Bull Am Coll Surg* 97(9):67-68, 9/2012. PMID: 23002684.
32. Yi M, Hunt KK. Nodal-Stage Classification in Invasive Lobular Breast Carcinoma: Influence of Different Interpretations of the pTNM Classification. *Breast Diseases: A Year Book Quarterly* 22(4):366-367, 2012.
33. Mittendorf EA, Hunt KK. Commentary on the Pilewskie/Morrow Article, Following the Data: Past, Present, and Future Management of the Axilla in Breast Cancer Patients. *Oncology* 28(5):378-382, 5/2014.
34. Mittendorf EA, Boughey JC, Hunt KK. SLN surgery for clinically node-positive breast cancer patients treated with neoadjuvant therapy. *Bull Am Coll Surg* 99(7):52-4, 7/2014. PMID: 25076741.
35. Liang DH, Black D, Yi M, Luo CK, Singh P, Sahin A, Scoggins ME, Moseley TW, Hunt KK. Correction to: Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions. *Ann Surg Oncol*. e-Pub 3/2022. PMID: 35298763.

Abstracts

1. Yoshida K, Feig B, Chiao PJ, Lu XL, Hunt KK. Adenovirus mediated overexpression of mutant IkbM gene enhances the effect of chemotherapeutic agents on the MCF-7 breast carcinoma cell line. . [Abstract] *Proceedings of the 91st Annual Meeting of the American Association for Cancer Research:350 (#2222)*, 3/2000.
2. Yoshida K, Liu T-J, Goodrich B, Feig B, Hunt K. Adenovirus mediated overexpression of truncated Rb gene enhances the effect of chemotherapeutic agents on breast carcinoma cell lines. [Abstract] *Proceedings of the 53rd Annual Cancer Symposium of the Society of Surgical Oncology:20 (#47)*, 3/2000.
3. Mirza N, Vlastos G, Singletary E, Ames F, Ross M, Feig B, Pollock R, Buchholz T, Hunt K. Ductal carcinoma in situ (DCIS): Long-term results of breast conserving therapy (BCT). .

- [Abstract] Proceedings of the 53rd Annual Cancer Symposium of the Society of Surgical Oncology:27 (#74), 3/2000.
4. Dackiw APB, Meric F, Chang DW, Colchin M, Porter GA, Ross MI, Hunt KK, Pollock RE, Ames FC, Feig BW, Newman LA, Robb GL, Singletary SE. Incidence and outcome of contralateral breast cancer (CBC) in patients status post unilateral mastectomy (MRM) with unilateral breast reconstruction (UBR). . Proceedings of the 53rd Annual Cancer Symposium of the Society of Surgical Oncology:42 (#P29), 3/2000.
 5. Bilimoria MM, Evans DB, Lee JE, Berman RS, Feig BW, Hunt KK, Mansfield PF, Pollock RE, Pisters PWT. Pancreatic closure after distal pancreatectomy: Relationship to postoperative pancreatic fistula. [Abstract] Proceedings of the 53rd Annual Cancer Symposium of the Society of Surgical Oncology:24 (#63), 3/2000.
 6. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Strom EA, Pollock RE, Newman LA, Feig BW, Fryer D, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of lymph node status after neoadjuvant chemotherapy (NCT) for operable T3N0 breast cancer. [Abstract] Proceedings of the 53rd Annual Cancer Symposium of the Society of Surgical Oncology:12 (#16), 3/2000.
 7. Yared MA, Middleton LP, Ross MI, Hunt KK, Sahin AA. Recommendations for sentinel lymph node processing in breast cancer. [Abstract] Accepted for presentation, US and Canadian Academy of Pathology Annual Meeting, 3/2000.
 8. Abujaiang P, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Adenoviral Bak overexpression mediates caspase dependent tumor killing. [Abstract] Proceedings of the 91st Annual Meeting of the American Association for Cancer Research:731 (#4644), 4/2000.
 9. Porter G, Ahmad S, Cantor S, Lenert J, Hunt K, Feig B, Patel S, Benjamin R, Pollock R, Pisters P. Cost-effectiveness of routine chest computed tomography in patients with T2 soft-tissue sarcoma. [Abstract] Proc Am Soc Clin Oncol:553 (#2180), 5/2000.
 10. Ahmad S, Patel S, Baker T, Feig B, Hunt K, Yasko A, Burgess M, Papadopoulos N, Plager C, Benjamin R, Pollock R, Pisters P. Extrasosseous osteosarcoma: Long-term results from a single institution experience. . [Abstract] Proc Am Soc Clin Oncol:560 (#2207), 5/2000.
 11. Meric F, Hess KR, Varma DGK, Hunt KK, Pisters PWT, Milas M, Patel SR, Benjamin, Plager C, Papadopoulos NEJ, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant therapy on local control of soft tissue sarcomas. [Abstract] Proc Am Soc Clin Oncol:558 (#2200), 5/2000.
 12. Pisters P, Patel S, Crane C, Feig B, Hunt K, Burgess M, Papadopoulos N, Plager C, Benjamin R, Pollock R, Janjan N. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and electron-beam intraoperative radiation therapy (IORT) for resectable retroperitoneal sarcomas. [Abstract] Proc Am Soc Clin Oncol:558 (#2199), 5/2000.
 13. Valero V, Esteva FJ, Rosales MF, Esparza-Guerra LT, Sahin AA, Strom EA, Ross MI, Booser DJ, Ibrahim NK, Cristofanilli M, Hunt KK, Hortobagyi GN. Phase II trial of primary chemotherapy with docetaxel and doxorubicin in locally advanced breast cancer: Clinical and pathological results. [Abstract] Proc Am Soc Clin Oncol:132 (#519), 5/2000.
 14. Berman RS, Feig BW, Porter GA, Laronga C, Kumparatana M, Leroux B, Hunt KK, Pisters PW, Mansfield PF, Pollock RE. Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancies. [Abstract] Proc Am Soc Clin Oncol:21 (#76), 5/2000.
 15. Wayne JD, Langstein HN, Pollack A, Hunt KK, Feig BW, Yasko AW, Smith LG, Zagars GK, Pollock RE, O'Sullivan B, Pisters PW. Preoperative radiotherapy for extremity soft tissue sarcoma (STS): Site-specific wound complication rates and the impact of reconstructive surgery. [Abstract] Proc Am Soc Clin Oncol:558 (#2198), 5/2000.
 16. Delpassand E, Hunt KK, Ross, MI. Early and delayed breast lymphoscintigraphy using TC-99m filtered sulfur colloid. EANM Paris 2000 Congress (#343), 9/2000.
 17. Pisters PWT, Patel SR, Crane C, Feig BW, Hunt KK, Burgess MA, Papadopoulos NE, Plager C, Benjamin RS, Pollock RE, Janjan NE. Combined modality management of retroperitoneal sarcomas (RPS): Phase I trial of preoperative doxorubicin-based concurrent chemoradiation, surgical resection, and intraoperative electron-beam radiation therapy (IORT). [Abstract] 6th Annual Scientific Meeting of the Connective Tissue Oncology Society, 11/2000.

18. Jhingran A, Kim JS, Buchholz TA, Katz A, Strom E, Hunt KK, Sneige N, McNeese MD. Excellent local control following breast conserving surgery and radiation for young women with ductal carcinoma in situ of the breast. [Abstract] RSNA Meeting, 11/2000.
19. Cormier JN, Patel SR, Herzog CE, Raney RB, Plager C, Papadopoulos NE, Burgess MA, Hunt KK, Feig BW, Ballo MT, Yasko AW, Pollock RE, Benjamin RS, Zagars G, Pisters PWT. Ifosfamide-based concurrent chemoradiation: analysis of treatment-related toxicity in 43 patients with sarcoma. [Abstract] 6th Annual Scientific Meeting of the Connective Tissue Oncology Society, 11/2000.
20. Yoshida K, Nishizaki M, Hunt K. Adenovirus mediated expression of E2F-1 in combination with Paclitaxel has a synergistic effect on breast cancer cell growth inhibition. *Breast Cancer Res Treat* 64(1):54 (#175), 2000.
21. Newman LA, Kuerer HM, Hunt KK, Vlastos G, Gurtner J, Ames FC, Ross MI, McNeese MD, Robb G, Singletary SE. Bilateral reduction mammoplasty (BRM) to improve breast conservation therapy (BCT) results in breast cancer patients with macromastia. *Breast Cancer Res Treat* 64(1):104 (#433), 2000.
22. Vlastos G, Mirza NQ, Meric F, Hunt KK, Newman LA, Kuerer HM, Ames FC, Ross MI, Pollock RE, Buchholz TZ, Hortobagyi GN, Singletary SE. Breast conserving therapy in the elderly: an appropriate treatment choice. *Breast Cancer Res Treat* 64(1):103 (#429), 2000.
23. Crane C, Snfilippo N, Taylor N, Skibber J, Feig B, Vauthey N, Hunt KK, Ellis L, Curley S, Dubrow R, Cleary K, Hamilton S, Allen P, Wolff R, Sinicrope F, Brown T, Hoff P, Janjan N. Comparison of patterns of failure between T3 and T4 rectal cancer after preoperative chemoradiation. Proceedings of the American Society for Therapeutic Radiology and Oncology, 42nd Annual Meeting, October 22-26, 2000, Boston, Massachusetts. *International Journal of Radiation Oncology Biology and Physics* 48(3 Supplement):304 (#2079), 2000.
24. Callister M, Janjan N, Brown T, Hoff P, Wolff R, Sinicrope F, Skibber J, Feig B, Ellis L, Hunt KK, Curley S, Bisanz A, Evetts P, Allen P, Wiatrek R, Mendoza T, Wang S, Cleeland C, Crane C, Sanfilippo N. Effective management of treatment-related enteritis during preoperative chemoradiation for locally advanced rectal cancer. Proceedings of the American Society for Therapeutic Radiology and Oncology, 42nd Annual Meeting, October 22-26, 2000, Boston, Massachusetts. *International Journal of Radiation Oncology Biology and Physics* 48(3 Supplement):225-226 (#228), 2000.
25. Buchholz TA, Tucker SL, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva F, Newman L, Singletary SE, Buzdar Au, Hunt KK. Impact of systemic treatment on local control for lymph-node negative breast cancer patients treated with breast conservation therapy. [Abstract] *Cancer J* 6:406, 2000.
26. Mirza NQ, Vlastos G, Meric F, Buchholz TA, Singletary SE, Ames FC, Newman LA, Kuerer HM, Feig BW, Ross MI, Pollock RE, Hortobagyi GN, Hunt KK. Incidence and survival impact of non-breast second primary malignancies (SPM) following breast-conserving therapy (BCT). *Breast Cancer Res Treat* 64(1):54 (#430), 2000.
27. Meric F, Buchholz TA, Mirza NQ, Vlastos G, Singletary SE, Ross MI, Ames FC, Pollock RE, Feig BW, Kuerer H, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast conservation surgery and radiation therapy. *Breast Cancer Res Treat* 64(1):54 (#428), 2000.
28. Wills DD, Meric F, Mirza NQ, Singletary SE, Ames FC, Kuerer H, Ross MI, Newman LA, Feig BW, Pollock RE, Hunt KK. Metastases to the Breast: Determinants of survival. *Breast Cancer Res Treat* 64(1) (#371), 2000.
29. Valero V, Esteva FJ, Sahin AA, Booser DJ, Strom EA, Esparza-Guerra LT, Ross MI, Rosales MF, Ibrahim NK, Cristofanilli M, Buchholz TA, Hunt KK, Hortobagyi GN. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- Tamoxifen in locally advanced breast cancer. *Breast Cancer Res Treat* 1(64):69 (#253), 2000.
30. Lee A, Hunt K, Kuerer H, Ross M, Ames F, Singletary S, Tucker S, Sahin A, Krishnamurthy S. Predictors of non-sentinel lymph node metastasis in breast carcinoma. [Abstract] USCAP Meeting, 2000.
31. Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, Ibrahim N, Smith T, Frye D, Manuel N, Kau S-W, McNeese M, Strom E, Hunt KK, Ames F, Hortobagyi G. Role of

- paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial. [Abstract] The American Society of Clinical Oncology, 2000.
32. Breslin, TM, Sahin, A, Kuerer, HM, Newman, LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate following neoadjuvant chemotherapy. . [Abstract] The Trainee Recognition Day Competition, The University of Texas M. D. Anderson Cancer Center, 2000.
 33. Krishnamurthy S, Tarco E, Hunt K, Kuerer H, Ross M, Ames F, Singletary E, Sneigt N. Utility of imprint cytology and rapid cytokeratin immunostaining for the intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. [Abstract] USCAP Meeting, 2000.
 34. Solorzano C, Hunt K, Mirza N, Meric F, Ames F, Kuerer H, Newman L, Singletary E, Delpassand E, Ross M. Utility of breast sentinel node biopsy using high dose technetium-99 sulfur colloid injection the day before surgery. 54th Annual Cancer Symposium of the Society of Surgical Oncology (#P38), 3/2001.
 35. Bilimoria MM, Feig B, Mansfield P, Pisters PWT, Pollock RE, Patel S, Plager A, Benjamin R, Burgess M, Chase J, Murphy A, Griffin J, Mirza N, Hunt K. A phase I trial of intraperitoneal hyperthermic chemotherapy for the treatment of sarcomatosis. [Abstract] Connective Tissue Oncology Society, *Sarcoma* 5(1):47-48, 11/2001.
 36. Newman L, Singletary S, Kuerer H, Buzdar A, Ames F, Ross M, Hunt K. A prospective trial of preoperative chemotherapy (CTX) in resectable breast cancer: Predictors of breast conservation therapy (BCT) feasibility. . 54th Annual Cancer Symposium of the Society of Surgical Oncology (#65), 2001.
 37. Albo D, Wayne JD, Hunt KK, Singletary SE, Ames FC, Ross MI, Kuerer HM. Anaphylactic reaction to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. [Abstract] American Society of Breast Surgeons Annual Meeting, 2001.
 38. Wayne JD, Albo D, Hunt KK, Lee J, Myers J, Gershenswald J, Mansfield P, Ames F, Singletary SE, Ross M, Kuerer H. Anaphylactic reaction to isosulfan blue dye during sentinel lymph node biopsy is more common in breast cancer than in melanoma. *Proc Am Soc Clin Oncol* 20:38a (#150), 2001.
 39. Kuerer H, Peoples G, Sahin A, Murray J, Singletary E, Castilleja A, Hunt K, Gershenson D, Ioannides C. Axillary lymph node (LN) cellular immune response to Her-2/Neu peptides in patients with carcinoma of the breast. The 54th Annual Cancer Symposium of the Society of Surgical Oncology (#P11), 2001.
 40. Meric F, Bernstam EV, Mirza NQ, Hunt KK, Ames FC, Ross MI, Kuerer HM, Pollock RE, Musen MA, Singletary SE. Breast Cancer on the World Wide Web: Determinants of Web Site Popularity. *Proceedings of the American Society of Clinical Oncology* 20:39b (#1904), 2001.
 41. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Puzstai L, Hortobagyi GN, Hunt KK. Breast conservation after neoadjuvant chemotherapy: Surgical planning in women with stage II and operable stage III breast carcinoma. [Abstract] Southwestern Surgical Congress, 2001.
 42. Verschraegen C, Le D, Kudelka A, Kavanagh J, Hunt KK. Cisplatin and Irinotecan (CPT-11) for peritoneal mesothelioma. *Proc Am Soc Clin Oncol* 20:90b (#2110), 2001.
 43. Yoshida K, Mishizaki M, Hunt KK. Combination therapy of adenovirus-mediated overexpression of E2F-1 transcription factor and chemotherapy enhances growth suppression in breast cancer cells. *Proc Am Assoc Cancer Res* 42:855 (#4586), 2001.
 44. Kuerer H, Gwyn K, Singletary E, Buchholz T, Hunt K, Ross M, Ames F, Theriault R. Conservative surgery and chemotherapy during pregnancy for breast carcinoma. 54th Annual Cancer Symposium of the Society of Surgical Oncology (#P10), 2001.
 45. Porter G, Cantor S, Patel S, Walsh G, Leung D, DeJesus Y, Hunt KK, Feig B, Pollock R, Benjamin R, Brennan M, Pisters P. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue. *Proc Am Soc Clin Oncol* 20:291b (#2916), 2001.
 46. Albo D, Ames FC, Hunt KK, Ross MI, Singletary SE, Kuerer HM. Lymphatic mapping for male breast cancer. *Breast Cancer Res Treat* 69(3):227 (#545), 2001.
 47. Pataer A, Nutt L, Yu R, Mhashilkar A, Bhada S, McConkey DJ, Hunt KK, Roth JASwisher SG. MDA-7 induces apoptosis by caspase activation through mitochondrial cytochrome C release. *Proc Am Assoc Cancer Res* 42:449 (#2414), 2001.

48. Vlastos G, Jean M, Mirza N, Kuerer H, Ames F, Hunt K, Ross M, Buchholz T, Buzdar A, Singletary E. Occult primary carcinoma presenting with axillary metastases: Is there a role for mastectomy? 54th Annual Cancer Symposium of the Society of Surgical Oncology (#69), 2001.
49. Mirza N, Vlastos G, Meric F, Singletary E, Ames F, Kuerer H, Ross M, Feig B, Pollock R, Buchholz, Hortobagyi G, Hunt K. Predictors of locoregional recurrence (LRR) among early stage breast cancer patients treated with breast conserving therapy (BCT). 54th Annual Cancer Symposium of the Society of Surgical Oncology (#18), 2001.
50. Mirza NQ, Vlastos G, Meric F, Ames FC, Feig BW, Kuerer HM, Pollock RE, Ross MI, Singletary E, Buchholz TA, Buzdar AU, Hortobagyi GN, Hunt KK. Predictors of systemic recurrences and impact of local failure among early stage breast cancer patients treated with breast conservation therapy. *Breast Cancer Res Treat* 69(3):227 (#141), 2001.
51. Hunt KK, Middleton L, Sahin A, Kuerer H, Ames F, Feig B, Newman L, Singletary E, Alderfer J, Ross M. Serial sectioning and immunohistochemical staining improve staging of sentinel lymph nodes. *Proceedings of the American Society of Clinical Oncology* 20:42b (#1914), 2001.
52. Wayne J, Hunt K, Ngo R, Esnaola N, Bisanz A, Pisters P, Ellis L, Vauthey J, Mansfield P, Curley S, Skibber J. The rate of venous thromboembolism (VTE) is low in patients undergoing surgery for colorectal cancer on clinical pathways. 54th Annual Cancer Symposium of the Society of Surgical Oncology (#P112), 2001.
53. Laronga C, Ross M, Alderfer J, Mirza N, Meric F, Kuerer H, Ames F, Delpassand E, Singletary E, Hunt KK. Tumor location and nodal drainage patterns on lymphoscintigraphy are predictors of axillary sentinel lymph node status. *Proceedings of the American Society of Clinical Oncology* 20:40a (#155), 2001.
54. Green MC, Buzdar AU, Singletary SE, Smith T, Carter C, Rosales M, Booser D, Puztai L, Cristofanilli M, Theriault R, Ibrahim N, Esteva FJ, Ames F, McNeese M, Strom E, Buchholz TA, Hunt KK, Kuerer H, Hortobagyi GN. Weekly Paclitaxel (P) Followed by FAC in the Neo-Adjuvant Setting Provides Improved Pathologic Complete Remission (PCR) Rates Compared to Standard Paclitaxel/FAC Therapy-Preliminary Results of an Ongoing Prospective Randomized Trial. *Proceedings of the American Society of Clinical Oncology* 20:33a (#129), 2001.
55. Vorburgen SA, Hetrakul N, Wilson-Heiner M, Liu TJ, Yu D, Pollock RE, Feig B, Pisters P, Hunt KK. Adenovirus mediated intratumoral E2F-1 gene therapy against leiomyosarcoma in vitro and in vivo. [Abstract] *The Predictive Oncology and Intervention Strategies Conference, Pasteur Institute, Paris, France, 2/2002.*
56. Solorzano CC, Hunt KK, Middleton LP, Mirza NQ, Ross MI, Kuerer HM, Ames FA, Feig BW, Meric F, Singletary SE, Babiera G. Treatment and outcome of intracystic papillary carcinoma of the breast: a contemporary series. *The American Society of Breast Surgeons Annual Meeting, 4/2002.*
57. Patten IC, Berger DH, Cleary KR, Curley SA, Hunt KK, Fagan SP, Lucci A, Feig BW. A prospective evaluation of radiocolloid and immunohistochemical staining in colon cancer lymphatic mapping. *Ann Surg Oncol* 9(1):S72 (#P107), 2002.
58. Vorburgen SA, Pataer A, Barber GN, Liu Y, Swisher SG, Hunt KK. Adenoviral gene transfer of E2F-1 induces apoptosis through upregulation of the DS-RNA activated protein kinase PKR. *Proc Am Assoc Cancer Res* 43:662 (#3285), 2002.
59. Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral MDA-7 induces apoptosis in lung cancer cells through mitochondrial permeability transition independent cytochrome C release. [Abstract] *AATS Annual Meeting, 2002.*
60. Liu Y, Nishikawa T, Vorburgen SA, Meyn RE, Swisher SG, Chada S, Mira N, Hunt KK. Adenoviral-mediated expression of the MDA-7 gene sensitizes breast carcinoma cells to ionizing radiation. *Proc Am Assoc Cancer Res* 43:646 (#3209), 2002.
61. Gilcrease MZ, Zhou X, Welch K, Jiang F, Katz R, Hunt KK, Price J, Hung MC. Alpha6BETA4 integrin-mediated signaling in breast cancer. *Era of Hope Meeting, 2002.*
62. Gilcrease MZ, Zhou X, Welch K, Hunt KK. Alpha6beta4-integrin-mediated phosphorylation of insulin receptor substrate 1 in fine-needle aspirates of breast cancer. *Breast Cancer Res Treat* 76(S1):S146 (#584), 2002.

63. Vlastos G, Mirza N, Meric F, Newman L, Hunt K, Kuerer H, Ames F, Ross M, Feig B, Babiera G, Babiera G, Buchholz T, Hortobagyi G, Singletary E. Breast conserving therapy among early stage breast cancer patients with a positive family history. *Ann Surg Oncol* 9(1):S51 (#P39), 2002.
64. Huang E, Buchholz TZ, Krishnamurthy S, Mirza NQ, Ames FC, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK. Classifying local recurrences after breast conservation therapy based on location and histology: New primary tumors have more favorable outcomes than true local recurrences. *Proceedings of the American Society of Clinical Oncology* 21(1):39a (#153), 2002.
65. Hwang R, Krishnamurthy S, Hunt KK, Mirza N, Ames F, Feig B, Kuerer H, Singletary E, Akins J, Neely J, Ross M. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. *Ann Surg Oncol* 9(1):S24 (#53), 2002.
66. Kuerer HM, Thompson P, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sniege N, Hunt KK. High expression of HER2/neu extracellular domain in bilateral ductal fluids from women with unilateral breast cancer. *Ann Surg Oncol* 9(1):S58 (#P60), 2002.
67. Bedrosian I, Bedi D, Kuerer H, Fornage B, Harker L, Ross M, Ames F, Krishnamurthy S, Edeiken-Monroe B, Singletary E, Mirza N, Hunt K. Impact of clinicopathologic factor on ultrasound detection of axillary nodal metastasis in patients with early stage breast cancer. *Ann Surg Oncol* 9(1):S63 (#P79), 2002.
68. Poindexter N, Hunt KK, Grimm EA, Sahin A. Increased numbers of mature CD83+ dendritic cells found in tumor-free sentinel lymph nodes from patients with breast cancer. *Proc Am Assoc Cancer Res* 43:679 (#3367), 2002.
69. Perkins GH, Middleton LP, Garcia SM, Strom EA, McNeese MD, Kuerer HM, Singletary SE, Hunt KK. Male breast carcinoma: outcomes and predictors of local-regional failure in patients treated without radiation therapy. *Breast Cancer Res Treat* 76(S1):S121 (#471), 2002.
70. Pataer A, Vorburgher SA, Barber GN, Chada S, Mhashikar AM, Yang HZ, Balachandran S, Roth JA, Hunt KK, Swisher SG. MDA-7 induces apoptosis via upregulation of the double stranded-RNA dependent protein kinase (PKR). *Proc Am Assoc Cancer Res* 43:1099 (#5445), 2002.
71. Frederick WA, Azzizadeh A, Harker LA, Mirza N, Hunt KK, Kuerer HM, Ames FC, Feig BW, Meric F, Ross MI, Singletary SE, Babiera GV. Metaplastic breast carcinoma: a single institution review. *Breast Cancer Res Treat* 76(S1):S50 (#151), 2002.
72. Lu X, Chen Z, Chiao PJ, Hunt KK, Feig BW. Metastasis-associated differences in gene expression in a human extra-osseous osteosarcoma cell line with spontaneous lung metastasis in mice. *Proc Am Assoc Cancer Res* 43:903 (#4478), 2002.
73. Cristofanilli M, Kau SW, Buzdar AU, Valero V, Booser D, Sniege N, Smith T, Fratarcangeli T, Singletary SE, Kuerer H, Hunt KK, McNeese M, Buchholz T, Hortobagyi GN. Paclitaxel significantly improves the prognosis in ER-negative inflammatory breast cancer (IBC): the M.D. Anderson Cancer Experience (1974-2000). *Breast Cancer Res Treat* 76(S1):S158 (#644), 2002.
74. Mirza N, Mirza A, Laronga C, Ross M, Ames F, Kuerer H, Newman L, Feig B, Singletary SE, Babiera G, Meric F, Delpassand E, Sahin A, Akins J, Neely J, Hunt KK. Predictors of failure to identify a sentinel lymph node among breast cancer patients undergoing lymphatic mapping. *Proceedings of the American Society of Clinical Oncology* 21(1):49a (#195), 2002.
75. Mirza AN, Fornage BD, Sniege N, Simmons R, Giuliano A, Hansen N, Ross MI, Kuerer HM, Newman LA, Ames FC, Babiera G, Meric F, Hunt KK, Edeiken BS, Singletary SE. Radiofrequency ablation of early-stage invasive breast tumors: results of a multicenter study. *Breast Cancer Res Treat* 76(S1):S116 (#450), 2002.
76. Lin T, Gu J, Zhang L, Huand X, Yu Y, Curley SA, Hunt KK, Fang B. Selective expression of the GFP-TRAIL fusion gene delivered by an adenoviral vector induces apoptosis in human breast cancer cells and hepatocarcinoma cells. *Proc Am Assoc Cancer Res* 43:801 (#3971), 2002.
77. Vorburgher SA, Liu Y, Swisher SG, Ellis LM, Hunt KK. The mitochondrial apoptosis-inducing factor plays an essential role in E2F-1 induced apoptosis human colon cancer. *Ann Surg Oncol* 9(1):S27 (#62), 2002.

78. Cabioglu N, Hunt KK, Singletary SE, Stephens TW, Marcy S, Meric F, Babiera GV, Ross MI, Ames FC, Kuerer HM. Utility of imaging techniques in surgical treatment and diagnosis of breast carcinoma in women presenting with nipple discharge. *Breast Cancer Res Treat* 76(S1):S94 (#349), 2002.
79. Green MC, Buzdar A, Smith T, Ibrahim NK, Valero V, Rosales M, Cristofanilli M, Booser DJ, Puzstai L, Rivera E, Theriault R, Carter C, Singletary SE, Kuerer HM, Hunt KK, Strom E, Hortobagyi G. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week P therapy followed by FAC- final results of a prospective phase III randomized trial. *Proc Am Society Clin Oncol* 21:35a (#135), 2002.
80. Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Coombes KR, Clarke C, Chen J, Xiao L, Sheta EA, Hunt MC, Hunt KK. Protein expression patterns in bilateral matched-pair breast ductal fluid specimens from women with unilateral invasive breast cancer. The 3rd Annual International Symposium on the Intraductal Approach to Breast Cancer March, 3/2003.
81. Chagpar A, Yen T, Sahin A, Hunt KK, Whitman G, Ames F, Ross M, Eric F, Babiera G, Singletary E, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in breast conservation surgery for ductal carcinoma in situ. The American Society of Breast Surgeons Annual Meeting 5:O-8, 5/2003.
82. Yen T, Hunt KK, Mirza N, Thomas E, Meric F, Babiera G, Buchholz T, Singletary E, Feig B, Ross M, Theriault R, Ames F, Kuerer H. Physician recommendations and patient utilization of Tamoxifen following surgery for ductal carcinoma in situ at a national comprehensive cancer center. The American Society of Breast Surgeons Meeting 4:P-34, 5/2003.
83. Chagpar AB, Mirza A, Buzdar A, Dempsey PJ, Ames F, Babiera G, Feig B, Hunt KK, Kuerer H, Meric-Bernstam F, Middleton L, Ross M, Sahin AA, Singletary S. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathological tumor size in patients treated with neoadjuvant chemotherapy. *Breast Cancer Res Treat* 82(Supp 1):S52 (#230), 2003.
84. Woodward WA, Huang E, McNeese MD, Perkins G, Tucker S, Strom E, Schechter NR, Middleton L, Hunt KK, Hortobagyi G, Gwyn K, Buchholz T. African-American patients with breast cancer have worse overall survival than Caucasian and Hispanic patients after mastectomy and doxorubicin-based chemotherapy: data from two independent data sets. *Breast Cancer Res Treat* 82(Supp 1):S145 (#613), 2003.
85. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary E, Ames FC, Feig BW, Hortobagyi GN, Sahin AA, Perkins GH, Schechter NR, Buchholz TA. Breast conserving therapy after neoadjuvant chemotherapy: the M.D. Anderson Cancer Center experience. *Breast Cancer Res Treat* 82(Supp 1):S7 (#6), 2003.
86. Chagpar A, Meric F, Hunt KK, Ross M, Cristofanilli M, Singletary SE, Buchholz T, Ames F, Mary S, Babiera G, Feig B, Hortobagyi G, Kuerer H. Chest wall recurrence following mastectomy does not always portend dismal prognosis. *Ann Surg Oncol* 10(1):S34 (#85), 2003.
87. Chagpar A, Middleton LP, Sahin A, Ross MI, Ames F, Feig B, Kuerer HM, Valero V, Hunt KK. Clinical outcome of node negative breast cancer patients with micrometastatic disease by immunohistochemistry. *Proc Am Society Clin Oncol* 22:14 (#52), 2003.
88. Garg A, Strom E, McNeese M, Buzdar A, Hortobagyi G, Kuerer H, Perkins G, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz T. Clinical stage T3 disease or pathologic involvement of four or more lymph nodes predict for local-regional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiation. *Breast Cancer Res Treat* 82(Supp 1):S182 (#1047), 2003.
89. Kronowitz SJ, Hunt KK, et al. Delayed-immediate breast reconstruction. The American Association of Plastic Surgeons 82nd Annual Meeting, 2003.
90. Lu X, Chiao PJ, Hunt KK, Vorburger SA, Ma J, Feig BW. Detection of differentially expressed genes in a series of extra-osseous osteosarcoma cell lines. . *Proc Am Assoc Cancer Res* 44:47, 2003.

91. Esnaola N, Feig BW, Hunt KK, Skibber JM, Rodriguez-Bigas MA. Disparities in care among patients with rectal cancer: patterns of care study using the national cancer data base. *Ann Surg Oncol* 10(1):S14 (#23), 2003.
92. Pawlik TM, Perry A, Hunt KK, Babiera G, Meric F, Ross M, Ames F, Feig B, Strom E, Kuerer H. Effect of surgical volume of resection on potential applicability of balloon intracavitary irradiation in breast conservation therapy. *Breast Cancer Res Treat* 82(Supp 1):S38 (#166), 2003.
93. Bonnen MD, Outlaw EF, McNeese MD, Thames HD, Strom EA, Perkins GH, Schechter NR, Romain ZD, Hortobagyi GN, Hunt KK, Theriault RL, Buchholz TA. Factors associated with breast recurrence in young females treated with breast conservation therapy: how young is young? *Int J Radiat Oncol Biol Phys* 57(2 Suppl):S356-7, 2003.
94. Shahar KH, Hunt KK, Thames H, Ross M, Perkins G, Kuerer H, Strom E, McNeese MD, Meric F, Schechter N, Sahin A, Middleton L, Buchholz T. Factors predictive of having four or more positive axillary lymph nodes in patients with involved sentinel lymph nodes: implications for selection of radiation treatment fields. *Breast Cancer Res Treat* 82(Supp 1):S182 (#1046), 2003.
95. Kawase K, DiMaio DJ, Tucker S, Ross , Feig B, Ames F, Kuerer H, Meric-Bernstam F, Singletary E, Babiera G, Buchholz T, Hunt KK. Paget's disease of the breast: a long-term followup study. *Breast Cancer Res Treat* 82(Supp 1):S108 (#449), 2003.
96. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi G, Buzdar A, Valero V, Perkins G, Schechter N, Hunt KK, Sahin A, Buchholz T. Predictors of local-regional recurrence in patients with locally-advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiation. *Breast Cancer Res Treat* 82(Supp 1):S182 (#1045), 2003.
97. Chagpar A, Eveleigh M, Fritche H, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel quantitative galactose oxidase-schiff reaction in nipple aspirate fluid from women with invasive breast carcinoma. *Proc Am Assoc Cancer Res* 44:1449 (#6327), 2003.
98. Huang EH, Tucker S, Strom E, McNeese M, Kuerer H, Hortobagyi G, Buzdar A, Valero V, Perkins G, Hunt KK, Sahin A, Buchholz T. Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. *Int J Radiat Oncol Biol Phys* 57(Suppl 2):S238, 2003.
99. Huang E, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins G, Hunt KK, Sahin A, Buchholz TA. Radiation treatment reduces local-regional recurrence and improves survival in selected breast cancer patients treated with neoadjuvant chemotherapy and mastectomy. The 2003 ASTRO meeting, 2003.
100. Vorburgen S, Gu J, Fang B, Pataer A, Yoshida K, Liu Y, Swisher SG, Hunt KK. Systemic treatment of established colon cancer metastases with tumor-specific E2F-1 gene overexpression from the human telomerase reverse transcriptase (hTERT) promoter. *Ann Surg Oncol* 10(1):S14 (#22), 2003.
101. Yen TW, Hunt KK, Thomas E, Mirza N, Meric F, Babiera G, Buchholz T, Singletary E, Feig B, Ross M, Theriault R, Ames F, Kuerer H. Tamoxifen following surgery for ductal carcinoma in situ: Physician perceptions and practices. *Ann Surg Oncol* 10(1):S58 (#P58), 2003.
102. Scaife CL, Hunt KK, Patel S, Benjamin RS, Burgess MA, Chen L, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. The natural history of cKIT + gastrointestinal stromal tumors. *Ann Surg Oncol* 10(1):S37 (#93), 2003.
103. Cabioglu N, Krishnamurthy S, Kuerer HM, Hunt KK, Singletary SE, Meric F, Feig BW, Ross MI, Ames FC, Babiera GV. The role of breast conserving surgery in women with breast cancer presenting with nipple discharge. *Proc Am Society Clin Oncol* 22:34 (#135), 2003.
104. Liu Y, Vorburgen SA, Swisher SG, Mhashilkar A, Chada S, Feig BW, Hunt KK. Tumor growth suppressor gene mda-7 induces apoptosis and affects the pathway of APC/ β -catenin in human breast cancer. *Proc Am Assoc Cancer Res* 44:497 (#2187), 2003.
105. Vorburgen SA, Gu G, Fang B, Pataer A, Liu Y, Feig BW, Swisher SG, Hunt KK. Tumor-specific E2F-1 overexpression from the human telomerase reverse transcriptase (hTERT) promoter allows systemic treatment of colon cancer metastases. *Proc Am Assoc Cancer Res* 44:1448 (#6496), 2003.

106. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-MDA7 and Trastuzumab increases cell death in Her2/neu-overexpressing breast cancer cells. The Society of University Surgeons Annual Meeting, 2/2004.
107. Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor S, Ross M, Babiera G, Kuerer H, Singletary SE, Hunt KK, Cormier JN. Cost-effectiveness of intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer. The Pharmaceutical Services and Outcomes Research Symposium, 3/2004.
108. Kronowitz SJ, Kuerer H, Hunt KK, Massey PR, Robb G. The impact of sentinel node biopsy on the evolution of autologous breast reconstruction. The American Association of Plastic Surgeons 83rd Annual Meeting, 5/2004.
109. Kronowitz SJ, Hunt KK, Kuerer H, Youssef A, Robb G. The importance of timing in reconstruction of partial mastectomy defects. The American Association of Plastic Surgeons 83rd Annual Meeting, 5/2004.
110. Swisher SG, Ajani JA, Chirieac L, Vaporciyan AA, Wu TT, Hunt KK, Correa AM, Komaki R, Rice DC, Walsh GL, Roth JA. Impact of pathologic response on pTNM esophageal cancer staging system following preoperative chemoradiation. The Southern Surgical Association Annual Meeting, 12/2004.
111. Feig B, Ross M, Hunt KK, Cormier J, Griffin J, Pisters R, Pollock R, Benjamin R. A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas. *Ann Surg Oncol* 11(2):S80 (#98), 2004.
112. Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral MDA-7 induces apoptosis in p53 resistant lung cancer cells through PKR induction. The Society of University Surgeons 2004 Annual Meeting, 2004.
113. Ding Y, Wang L, Su LK, Frey J, Shao R, Hunt KK, Yan DH. Anti-tumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer. *Proceedings of the American Association for Cancer Research* 45:258 (#3511), 2004.
114. Shen J, Valero V, Buchholz T, Singletary SE, Hunt KK, Ross M, Cristofanilli M, Babiera G, Meric-Bernstam F, Kuerer H. Breast conservation therapy in T4 locally advanced breast cancer: effective local control with long-term survival. *Ann Surg Oncol* 11(2):S75 (#85), 2004.
115. McKenzie T, Liu Y, Fanale M, Swisher S, Chada S, Hunt KK. Combination therapy of Ad-mda7 and herceptin inhibits tumor growth in nude mice and increases apoptosis in HER2/neu overexpressing breast cancer cells. *Proceedings of the American Association for Cancer Research* 45:346 (#5135), 2004.
116. McKenzie TS, Liu Y, Swisher S, Pataer A, Chada S, Fanale M, Hunt KK. Combination therapy of herceptin and Ad-mda7 inhibits growth of Her-2/neu overexpressing breast cancer in vivo. *Ann Surg Oncol* 11(2):S91 (#P27), 2004.
117. Goldflam K, Gershengwald JE, Hunt KK, Singletary SE, Mirza N, Arun B, Babiera G, Kuerer H, Ross MI, Ames FC, Feig BW, Sahin AA, Meric-Bernstam F. Contralateral prophylactic mastectomy: efficacy and determinants of significant histologic findings. *Ann Surg Oncol* 11(2):S94 (#P37), 2004.
118. Buchholz T, Woodward W, Tucker SL, Strom E, Hunt KK, Buzdar AU, Perkins GH, Schechter N, Hortobagyi G. Defining the competing risk of local-regional and distant recurrence in 1256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. *J Clin Oncol* 23:16S (#555), 2004.
119. Shen J, Mirza NQ, Gilcrease M, Babiera GV, Ross MI, Ames FC, Meric-Bernstam F, Feig BW, Singletary SE, Kuerer HM, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients with cytologically proven axillary metastases. *Breast Cancer Res Treat* 88(Suppl 1):S81 (#2013), 2004.
120. Cabioglu N, Mirza N, Hunt KK, Buchholz TA, Singletary SE, Kuerer HM, Babiera G, Ross MI, Ames FC, Feig BW, Sahin A, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single institution experience. *Breast Cancer Res Treat* 88(Suppl 1):S165 (#4058), 2004.
121. Liu Y, McKenzie T, Fanale M, Swisher S, Chada S, Hunt KK. Increased apoptosis in HER2/NEU overexpressing breast cancer cells by combination therapy of Ad-mda7 and herceptin. *Proceedings of the American Association for Cancer Research* 45:301 (#4402), 2004.

122. Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Babiera G. Intramammary lymph node metastases are an independent predictor in breast cancer outcomes. *J Clin Oncol* 23:31S (#615), 2004.
123. Cabioglu N, Hunt KK, Mirza N, Sahin AA, Singletary SE, Kuerer HM, Babiera GV, Ross MI, Ames FC, Feig BW, Meric-Bernstam F. Intraoperative margin assessment in breast-conserving surgery. *Breast Cancer Res Treat* 88(Suppl 1):S167 (#4057), 2004.
124. Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, Ross MI, Babiera G, Kuerer HM, Singletary SE, Hunt KK, Cormier JN. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost-effective? *Breast Cancer Res Treat* 88(Suppl 1):S82 (#2017), 2004.
125. Pataer A, Vorburger S, Balachandran S, Barber G, Chada S, Roth J, Hunt KK, Swisher SG. Melanoma differentiation associated gene-7 protein physically associates with the double-stranded RNA activated protein kinase PKR in vitro. *Proceedings of the American Association for Cancer Research* 45:269 (#3778), 2004.
126. Xing Y, Ding M, Cox D, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer. *J Clin Oncol* 23:17S (#561), 2004.
127. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas M, Feig B, Hunt KK, Ellis L, Curley S, Vauthey J, Skibber J. Outcome after curative resection for locally recurrent rectal cancer. *Ann Surg Oncol* 11(2):S108 (#P82), 2004.
128. Yen T, Mirza N, Hunt KK, Ross M, Babiera G, Singletary SE, Meric-Bernstam F, Feig B, Ames F, Kuerer H. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to the selective carcinoma in situ. *Ann Surg Oncol* 11(2):S93 (#P31), 2004.
129. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival following ipsilateral breast tumor recurrence. *Breast Cancer Res Treat* 88(Suppl 1):S54 (#1039), 2004.
130. Kawase K, Hunt KK, Kuerer H, Meric-Bernstam F, Mirza N, Feig B, Ames F, Babiera G, Singletary E, Ross M. Sentinel lymph node biopsy accurately reflects nodal status following preoperative chemotherapy for breast cancer. *Ann Surg Oncol* 11(2):S75 (#82), 2004.
131. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in ductal fluid protein expression in healthy women versus those with breast cancer identified by time-of-flight mass spectrometry. *Breast Cancer Res Treat* 88(Suppl 1):S189 (#5018), 2004.
132. Buzdar AU, Hunt KK, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi G. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with HER/2 positive disease. *J Clin Oncol* 23:7S (#520), 2004.
133. Andtbacka R, Babiera G, Singletary E, Hunt KK, Meric-Bernstam F, Feig B, Ames F, Ross M, DeJesus Y, Kuerer H. The incidence, prophylaxis and treatment of venous thromboembolism in patients undergoing breast cancer surgery. *J Clin Oncol* 23:31S (#616), 2004.
134. Tseng JF, Kronowitz SJ, Hunt KK, Sun CC, Babiera GV, Singletary E, Mirza N, Ames FC, Meric-Bernstam F, Ross MI, Feig B, Robb G, Kuerer H. The rate of immediate reconstruction following mastectomy for breast cancer varies by patient race. *Ann Surg Oncol* 11(2):S92 (#P30), 2004.
135. Fanale MA, Liu Y, Vorburger S, McKenzie T, Swisher S, Theriault R, Hunt KK. Utility of hTERT-driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells. *J Clin Oncol* 23:233S (#3158), 2004.
136. Fanale M, Liu Y, McKenzie T, Fokt I, Priebe W, Hunt KK. WP744, a novel anthracycline highly apoptotic in breast cancer cells. *Proceedings of the American Association for Cancer Research* 45:271 (#3843), 2004.
137. Suh Y, Chada S, McKenzie T, Liu Y, Swisher S, Lucci A, Hunt KK. Synergistic tumoricidal effect between celecoxib and melanoma differentiation-associated gene 7 on human breast cancer cells. *Society of University Surgeons Annual Meeting*, 2/2005.

138. Al-Refaie W, Kuerer HM, Khuwaja A, Perry AC, Xiao L, Hunt KK, Singletary SE, Meric-Bernstam F, Ross MI, Babiera GV. Determinants of mastectomy in breast conservation therapy candidates. The 6th Annual Meeting of the American Society of Breast Surgeons, Los Angeles, CA, 3/2005.
139. Khakpour N, Hunt KK, Ross MI, Kuerer HM, Yi M, Lucci A. Does negative sentinel lymph node dissection provide axillary control equal to complete axillary dissection in breast cancer patients with lobular histology? The 6th Annual Meeting of the American Society of Breast Surgeons, Los Angeles, CA, 3/2005.
140. Leitch AM, Beitsch PD, McCall LM, Posther KE, Newman LA, Herndon JE, Hunt KK, Giuliano AE. Patterns of participation and successful patient recruitment to ACOSOG Z0010, a phase II trial for patients with early stage breast cancer. The 6th Annual Meeting of the American Society of Breast Surgeons, Los Angeles, CA, 3/2005.
141. Khakpour N, Zager J, Yen T, Stephens T, Meric-Bernstam F, Kuerer HM, Singletary SE, Ross MI, Hunt KK, Babiera GV. The role of ultrasound in surgical management of patients diagnosed with ductal carcinoma in situ of the breast. The 6th Annual Meeting of the American Society of Breast Surgeons, Los Angeles, CA, 3/2005.
142. Liu Y, Keyomarsi K, Swisher SG, Hunt KK. Small interfering (siRNA) inhibits the expression of the elafin gene and induces the low molecular weight forms of cyclin E in breast epithelial cells. AACR Special Conference - Advances in Breast Cancer Research: Genetics, Biology and Clinical Applications, 9/2005.
143. Sun B, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced cell death in breast cancer cells. *Proc Amer Assoc Cancer Res* 46:3488, 2005.
144. McKenzie TS, Lui Y, Keyomarsi K, VonHolzen U, Suh YJ, Fanale M, Swisher S, Chada S, Hunt K. Adenoviral mediated delivery of the melanoma differentiation-associated gene-7 (Ad-mda7) regulates the Wnt signaling pathway in breast cancer cells. *Proc Amer Assoc Cancer Res* 46:3694, 2005.
145. Fanale MA, Vorburger SA, Liu Y, McKenzie TS, Swisher SG, Hunt KK. Adh TERT-E2F-1 can induce selective apoptosis of breast cancer cells through multiple mechanisms. *Proc Amer Assoc Cancer Res* 46:2834, 2005.
146. VonHolzen UW, Bocangel D, Pataer A, Takada Y, Liu Y, Aggarwal BB, Barber GN, Hunt KK, Swisher SG. Apoptosis of esophageal cancer cells following Ad-TNF α gene therapy: The role of the double-stranded RNA activated protein kinase (PKR) and the nuclear factor kappa B (NF-kB). *Proc Amer Assoc Cancer Res* 46:5364, 2005.
147. Trent JC, Choi H, Hunt K, Macapinlac H, McConkey D, Charnsangravej C, Abbruzzese J, Benjamin RS, Davis D. Apoptotic and anti-vascular activity of imatinib in GIST patients. *J Clin Oncol* 23:816s (#9001), 2005.
148. Zheng M, Bocangel D, Menander K, Hunt K, Chada S. Bystander activity of Ad-mda7: human MDA-7 protein kills breast cancer cells via an IL-20 receptor-dependent pathway. *Breast Cancer Res Treat* 94(Suppl 1):6105, 2005.
149. Rivers A, Griffith K, Hunt KK, Degnim A, Sabel M, Cimmino V, Lucas P, Chang A, Newman L. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. *Ann Surg Oncol* 12(2):S72 (#P105), 2005.
150. Bocangel D, Mhashilkar A, Zheng M, McKenzie T, Liu Y, Menander K, Hunt K, Chada S. Combination therapy of Ad-mda7 and herceptin synergistically increases apoptosis in Her2/neu over expressing breast cancer cells. *Breast Cancer Res Treat* 94((Suppl 1)):2087, 2005.
151. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. *Int J Rad Oncol Biol Phys* 63(2):s250, 2005.
152. Lambert LA, Hunt KK, Keyomarsi K. Deregulation of cyclin E in soft tissue sarcoma. *Proc Amer Assoc Cancer Res* 46:5407, 2005.
153. Suh YJ, Raju U, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A, Hunt KK. Enhanced radiosensitization of breast cancer cells in vitro by combining Adenovirus-mediated delivery

- of melanoma differentiation-associated gene-7 (Ad-mda7) and celecoxib. *Proc Amer Assoc Cancer Res* 46:2014, 2005.
154. Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of Adenoviral mda-7 mediated cell killing in human lung cancer cells by geldanamycin and its 17-allylamino-17-demethoxy analogue. *Proc Amer Assoc Cancer Res* 46:1349, 2005.
 155. Lambert LA, Hunt KK, Keyomarsi K. G1 cell cycle arrest associated with up-regulation of p16 and p21 in gastrointestinal stromal tumor cells treated with procain hydrochloride. *New England Surgical Society*, 2005.
 156. Liu Y, Keyomarsi K, Lu X, Swisher SG, Hunt KK. Induction of apoptosis in human breast cancer cells following adenovirus-mediated elafin gene expression in vitro. *Proc Amer Assoc Cancer Res* 46:5320, 2005.
 157. Shen J, Mirza NQ, Sahin A, Buchholz TA, Meric-Bernstam F, Kuerer H, Ross MI, Singletary SE, Babiera GV, Hunt KK. Invasive lobular carcinoma: clinicopathologic factors that impact extent of disease and margin status. *Ann Surg Oncol* 12(2):S71 (#100), 2005.
 158. Fanale MA, Liu Y, McKenzie TS, Fokt I, Priebe W, Hunt KK. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. *J Clin Oncol* 23:155s (#2082), 2005.
 159. Zager JS, Al-Refaie WB, Hunt KK, Khakpour N, Kuerer HM, Lin E, Yen T, Stephens T, Feig BW, Ames FC, Singletary SE, Ross MI, Babiera GV. Is ultrasound useful in the management of patients with ductal carcinoma in-situ? *Breast Cancer Res Treat* 94(Suppl 2):5013, 2005.
 160. von Holzen UW, Pataer A, Bocangel D, Raju U, Liu Y, Lu X, Barber GN, Aggarwal BB, Keyomarsi K, Hunt KK, Swisher SG. Lack of the double-stranded RNA activated protein kinase PKR sensitizes mouse embryo fibroblasts to ionizing radiation. *Clin Cancer Res* 11(24 Suppl):A178, 2005.
 161. Pawlik TM, Pisters PW, Feig BW, Hunt KK, Cormier JN, Mikula L, Catton CN, Jones JJ, Pollock RE, Swallow CJ. Long-term results of two prospective trials of preoperative external-beam radiation therapy for localized, intermediate-grade or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol* 12(2):S12 (#14), 2005.
 162. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Ames FC, Kuerer HM, Ross MI, Singletary SE, Babiera GV, Feig BW, Hunt KK. Low local-regional failure rates in selected breast cancer patients with tumor-positive sentinel nodes who do not undergo completion axillary dissection. *Breast Cancer Res Treat* 94(Supple 1):402, 2005.
 163. Kawase K, Gayed IW, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Singletary SE, Akins J, Yi M, Feig BW, Ames FC, Hunt KK. Lymphatic drainage patterns from breast cancer: a large cancer center experience. *Society of Nuclear Medicine*, 2005.
 164. Chada S, Mhashilkar A, Liu Y, Bocangel D, Zheng M, Ramesh R, Meyn R, Hunt K. mda-7: A remedy for oncogene addiction in breast cancer? *Breast Cancer Res Treat* 94(Suppl 1):4058, 2005.
 165. Oh JL, Strom EA, Perkins GH, Oswald M, Domain D, Hunt K, Giordano S, Buchholz TA. Optimal locoregional treatment after neoadjuvant chemotherapy for clinically multifocal or multicentric breast cancer at the time of diagnosis. *Int J Rad Oncol Biol Phys* 2005; 63(2):S52. 63(2):s52, 2005.
 166. Rao R, Feng L, Kuerer HM, Singletary SE, Hunt KK, Feig BW, Ross MI, Ames FC, Babiera G. Optimal timing of surgical intervention for the primary tumor in Stage IV breast cancer patients improves outcome. *Breast Cancer Res Treat* 94(Suppl 1):2082, 2005.
 167. Rao R, Kuerer H, Hunt KK, Hortobagyi G, Singletary SE, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Babiera GV. Progression-free survival after surgical extirpation of the intact primary in patients with stage IV breast cancer. *Ann Surg Oncol* 12(2):S16 (#28), 2005.
 168. Buzdar AU, Valero V, Ibrahim N, Francis D, Theriault RL, Green M, Hunt K, Sahin A, Buchholz T, Hortobagyi GN. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population. *Breast Cancer Res Treat* 94(Suppl 1):5049, 2005.
 169. McGuire SE, Gonzalez-Angulo AM, Tucker SL, Rouzier R, Strom EA, Perkins GH, Oh JL, Huang EH, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Radiation is an important component of therapy for patients with stage III breast cancer who achieve a pathological

- complete response after neoadjuvant chemotherapy. *Int J Rad Oncol Biol Phys* 63(2):S52, 2005.
170. von Holzen UW, Pataer A, Bocangel D, Lu X, Barber GN, Roth JA, Hunt KK, Swisher SG. Role of the double-stranded RNA activated protein kinase PKR in AD-TNFA gene therapy. Society of University Surgeons Annual Meeting, 2005.
 171. Khakpour N, Lucci A, Yi M, Meric-Bernstam E, Kuerer H, Babiera G, Feig B, Ross M, Singletary E, Ames F, Garg A, Buchholz T, Hunt KK. Sentinel node dissection provides similar local-regional control compared to axillary dissection in patients with node negative breast cancer. *J Clin Oncol* 23:25s (#588), 2005.
 172. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. *Ann Surg Oncol* 12(2):S35 (#89), 2005. PMID: 17072676.
 173. Suh Y, McKenzie T, Liu Y, Swisher SG, Lucci A, Hunt KK. Synergism between Ad-E2F1 and celecoxib results in increased rates of apoptotic cell death in breast cancer cells. *J Clin Oncol* 23:236s (#3181), 2005.
 174. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Sneige N, Buchholz TA, Hunt KK, Meric-Bernstam-F, Arun B, Kuerer HM. The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT). *J Clin Oncol* 23:36s (#632), 2005.
 175. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Zagars GK, Pollock RE, Pisters PW. The Effect of preoperative radiation therapy and reconstructive surgery on wound complications after resection of extremity soft tissue sarcomas. *Ann Surg Oncol* 12(2):S36 (#94), 2005.
 176. Bocangel DB, VonHolzen U, Chada S, Pataer A, Takada Y, Raju U, Aggarwal BB, Barber GN, Chiao P, Milas L, Hunt KK, Swisher SG. Threshold for radiation sensitization induced by adenoviral delivery of TNF-alpha: Role of the double stranded RNA activated protein kinase (PKR). *Proc Amer Assoc Cancer Res* 46:2016, 2005.
 177. Lambert L, Hunt KK, Hwang R, Ross MI, Kuerer H, Singletary SE, Babiera G, Ames FC, Feig B, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting additional nodal metastases after positive sentinel node biopsy. *Ann Surg Oncol* 12(2):S17 (#29), 2005.
 178. Gilcrease MZ, Zhou X, Hunt K, Meric-Bernstam F, Welch K. $\alpha 6\beta 4$ integrin-induced EGFR clustering in breast carcinoma. *Proc Amer Assoc Cancer Res* 46:3719, 2005.
 179. Rosenkranz K, Hartmann K, Ghonimi E, Kuerer H, Singletary SE, Hunt K, Meric-Bernstam F, Lucci A, Hwang R, Bedrosian I, Feig B, Ross M, Ames F, Babiera G. Breast cancer in the very elderly: treatment patterns in a comprehensive cancer center. *American Society of Breast Surgeons*, 4/2006.
 180. Sher T, Hennessy T, Valero V, Trent J, Broglio K, Woodward WA, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Angiosarcoma of the breast. *J Clin Oncol* 24(18S):533s (abstract 9554), 2006.
 181. Bedi DG, Krishnamurthy R, Krishnamurthy S, Edeiken B, Le-Petross H, Hunt K, Feig BW, Singletary SE, Ross MI, Ames FC, Bedrosian I, Meric F, Kuerer HM, Fornage BD. Cortical morphology of axillary lymph nodes as a predictor of metastatic disease in breast cancer: An in vitro ultrasound study. *Am J Roentgenol Supplement* 186:A79, 2006.
 182. Gong Y, Gonzalez-Angulo AM, Broglio K, Huo L, Sneige N, Cen P, Woodward W, Valero V, Hunt K, Buchholz T, Hortobagyi G, Cristofanilli M. Expression of Notch-1 and beta-catenin: defining the molecular portrait of inflammatory breast cancer. *Breast Cancer Res Treat* 100(Suppl 1):S299 (#6131), 2006.
 183. Leitch AM, McCall L, Beitsch P, Whitworth P, Reintgen D, Blumencranz P, Saha S, Bauer T, Hunt KK, Giuliano A. Factors influencing accrual to ACOSOG Z0011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer. *J Clin Oncol* 24(18S):28s (abstract 60), 2006.
 184. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? *Cancer* 100(Suppl 1):S84, 2006. PMID: 18457326.

185. Cristofanilli M, Valero V, Buzdar AU, Gonzalez-Angulo AM, Kau S-W, Broglio KR, Islam R, Sneige N, Krishnamurthy S, Ueno NT, Hunt KK, Kuerer HM, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC): patterns of recurrence and micrometastatic homing. *Breast Cancer Res Treat* 100(Suppl 1):S155 (#3093), 2006.
186. Al-Refaie WB, Cormier JN, Xing Y, Hunt KK, Fearmonti G, Ghandi R, Kuerer HM, Meric-Bernstam F, Bedrosian I, Lucci A. Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. *J Clin Oncol* 24(18S):27s (abstract 598), 2006.
187. Jeruss JS, Ayers GD, Cristofanilli M, Ross MI, Babiera G, Meric-Bernstam F, Kuerer HM, Feig BW, Yi M, Hunt KK. Positive sentinel nodes after neoadjuvant chemotherapy: What factors predict additional disease in the axilla? *J Clin Oncol* 24(18S):28s (abstract 602), 2006.
188. Tereffe W, Buchholz TA, Oh JL, Perkins GH, Strom EA, Woodward WA, Yu T-K, Hunt KK, Hwang RF. Radiotherapy targeting of regional nodes in sentinel lymph node-positive breast cancer patients who do not undergo axillary dissection. *Breast Cancer Res Treat* 100(Suppl 1):S200 (#4086), 2006.
189. Hird RB, Hunt KK, Cimmino VM, Sabel M, Diehl KM, Wong S, Lucas P, Degnim A, Chang AE, Newman LA. Risk of identifying metastatic nonsentinel nodes in patients with micrometastases in single versus multiple sentinel lymph nodes. *Ann Surg Oncol* 13(2):P111, 2006.
190. Boughey JC, Cormier JN, Xing Y, Meric-Bernstam F, Ross MI, Babiera GV, Ames FC, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: A decision analysis model. *J Clin Oncol*, 24(18S):29s (abstract 607, 2006.
191. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Hwang RF, Babiera GV, Lucci A, Kuerer HM, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in prophylactic mastectomy is not warranted. *Ann Surg Oncol* 13(2):P64, 2006.
192. Boughey JC, Hunt KK, Ames FC, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Singletary SE, Ross MI. Sentinel lymph node surgery in locally recurrent breast cancer. *Ann Surg Oncol* 13(2):P36, 2006.
193. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Hortobagyi GN, Hunt KK. Should pathologic response to neoadjuvant therapy be incorporated into the AJCC staging system for breast cancer? *Breast Cancer Res Treat* 100(Suppl):S259 (#6010), 2006.
194. Al-Refaie WB, Andtbacka RA, Ensor J, Pisters PW, Hunt KK, Cormier JN, Pollock RE, Feig BW. Should patients with isolated lymph node metastasis from extremity soft tissue sarcomas be considered to have Stage IV disease? *Ann Surg Oncol* 13(2):P28, 2006.
195. Lucci A, Mackie L, Beitsch P, Whitworth P, Reintgen D, Blumencranz, Leitch M, Saha S, Hunt KK, Giuliano AE. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection, versus SLND alone in the American College of Surgeons Oncology Group (ACOSOG) Trial Z0011. *Ann Surg Oncol* 13(2):9, 2006.
196. Yokota T, Liu Y, Hunt KK, Keyomarsi K. C/EBP β -elafin pathway is involved in generation of cyclin E low molecular weight isoforms in breast cancer. *Proc Amer Assoc Cancer Res* 48:101 (#421), 2007.
197. Kelten C, Mittendorf EA, Broglio K, Vo T, Middleton LP, Ueno N, Hunt KK, Sahin AA. Clinical significance of occult axillary lymph node metastases in breast cancer patients without adjuvant systemic therapy: A long-term retrospective study. *Breast Cancer Res Treat*(December 13-16), 2007.
198. Anaya DA, Xing Y, Cormier JN, Tuvin D, Lahat G, Pisters PW, Hunt KK, Feig BW, Lev DC, Pollock RE. Comparison of outcomes for patients with multifocal versus unifocal recurrent retroperitoneal sarcoma. 119th Annual Meeting, Southern Surgical Association, Hot Springs, VA December 2-5, 2007.
199. Hunt KK. Current status of sentinel lymph node biopsy for breast cancer. 2007 Congress of the World Society for Breast Disease, Tianjin, China, Oct 18-21, 2007.

200. Kronowitz SJ, Buchholz TA, Hunt KK, Kuerer HM, Robb GL, Ross MI, Strom EA. Delayed-immediate breast reconstruction: 4 years later. *American Association of Plastic Surgeons* May 20-23, 2007.
201. Roh V, Laemmle A, Dufour J-F, Stroka D, Hunt KK, Candinas D, Vorburger SA. Dual induction of PKR (dsRNA activated protein kinase) by E2F-1 overexpression and interferon alpha enhances efficacy of gene therapy for hepatocellular carcinoma in-vivo. *Proc Amer Assoc Cancer Res* 48:1139 (#4817), 2007.
202. Liu Y, Yokota T, Mittendorf EA, Keyomarsi K, Hunt KK. Elafin, serine protease inhibitor, is a novel tumor suppressor for breast cancer. *Proc Amer Assoc Cancer Res* 48:869 (#3653), 2007.
203. Mittendorf EA, McKenzie-Johnson T, Liu Y, Keyomarsi K, Hunt KK. HER2 and cyclin E: A novel interaction in breast cancer. *J Surg Res* 137(2):193 (#102), 2007.
204. Mittendorf EA, Liu Y, McKenzie T, Keyomarsi K, Hunt KK. HER2/neu gene silencing by small-interfering RNA leads to apoptotic cell death in HER2neu-overexpressing breast cancer cells. *Proc Amer Assoc Cancer Res* 48:1240 (#5244), 2007.
205. Olson J, McCall L, Beitsch P, Whitworth P, Reintgen D, Blumencranz P, Leitch M, Saha S, Hunt K, Guiliano A. Impact of immediate vs delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: Results from the American College of Surgeons Oncology Group (ACOSOG) Trials Z0010 and Z0011. *Ann Surg Oncol* 14(2):1, 2007.
206. Lang JE, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera GV. Impact on overall survival of primary tumor extirpation in breast cancer patients who present with stage IV disease. *J Clin Oncol* 25(18S):27s (#598), 2007.
207. Boughey JC, Goravanchi F, Parris RN, Kowalski AM, Kee S, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved post-operative pain management of breast oncologic surgeries with paravertebral block. *The American Society of Regional Anesthesia*, Boca Raton, FL November 14-18, 2007.
208. Fearmonti RM, Gayed IW, Kim E, Waraneke C, Bedrosian I, Hunt KK, Ghonimi E, Meric-Bernstam F, Babiera GV. In vivo comparison of lymphatic drainage patterns of subareolar and peritumoral isotope injection for breast cancer. *Ann Surg Oncol* 14(2):65, 2007.
209. Vo T, Xing Y, Meric-Bernstam F, Symmans F, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Long-term outcomes for mucinous, medullary, and tubular carcinomas treated with breast conservation therapy. *American Society of Breast Surgeons* May 2-6, 2007.
210. Mittendorf EA, Sahin A, Tucker SL, Meric-Bernstam F, Yi M, Ames FC, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are strong predictors of detecting isolated tumor cells in sentinel lymph nodes from early stage breast cancer patients. 2007 ASCO Breast Cancer Symposium, Sept 7-8, 2007.
211. Fearmonti RM, Batista LI, Meric-Bernstam F, Hunt KK, Bedrosian I, Kuerer HM, Singletary SE, Babiera GV. Margin width correlates with residual disease at re-excision for ductal carcinoma in situ (DCIS) of the breast. 2007 ASCO Breast Cancer Symposium, Sept 7-8, 2007.
212. Winiger IJ, Fanale M, Vorburger SA, Keyomarsi K, Hunt KK. Overexpression of E2F-1 using an hTERT promoter leads to selective cell cycle arrest and induces apoptosis in breast cancer cells. *Proc Amer Assoc Cancer Res* 48:783 (#3295), 2007.
213. Yi M, Hunt KK, Meric-Bernstam F, Bedrosian I, Hwang R, Kuerer HM, Lucci A, Ross MI, Akins J, Babiera GV. Sentinel lymph node biopsy in patients with multicentric invasive breast cancer. 2007 ASCO Breast Cancer Symposium Sept 7-8, 2007.
214. Lim SJ, Feig BW, Wang H, Hunt KK, Rodriguez-Bigas MA, Skibber JM, Ellis V, Cleary K, Chang GJ. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. *Ann Surg Oncol* 14(2):65, 2007. e-Pub 11/2007. PMID: 17985187.
215. Yi M, Hunt KK, Krishnamurthy S, Kuerer HM, Bedrosian I, Ames FC, Lucci A, Meric-Bernstam F, Ross MI. The significance of primary tumor characteristics in predicting positive sentinel lymph nodes in ductal carcinoma in situ or microinvasive breast cancer. *American Society of Breast Surgeons*, May 2-6, 2007.

216. Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin R, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK. Toxicity and outcomes associated with surgical cytoreduction and intraperitoneal hyperthermic peritoneal perfusion (IPHP) for patients with sarcomatosis. *Ann Surg Oncol* 14(2):4, 2007.
217. Boughey JC, Middleton L, Harker L, Garrett B, Fornage B, Hunt KK, Babiera GV, Dempsey PJ, Bedrosian I. Ultrasound and fine needle aspiration biopsy for preoperative nodal staging of patients with invasive lobular carcinoma of the breast. *American Society of Breast Surgeons*, May 2-6, 2007.
218. Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. *Ann Surg Oncol* 15(12):3369-3377, 9/2008. e-Pub 9/2008. PMID: 18815841.
219. Shaye A, Sahin A, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E overexpression in the progression of breast cancer. *Breast Cancer Res Treat*, 12/2008.
220. Boughey JC, Goravanchi F, Hunt KK, Paris RN, Kee SS, Frenzel JC, Kowalski AM, Kuerer HM, Ames FC, Lucci A. A prospective randomized controlled clinical trial of paravertebral block anesthesia for patients undergoing surgery for breast cancer. 2008 ASCO Breast Cancer Symposium, September 5-7, 2008.
221. Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Kowalski A, Hunt KK, Ames FC, Kuerer HM, Lucci A. A prospective randomized trial of paravertebral block for breast surgery. *American Society of Breast Surgeons*, New York, NY, April 30 - May 4, 2008.
222. Shinde SS, Forman MR, Kuerer HM, Hunt KK, Pusztai L, Symmans WF. Association of triple-negative breast cancer phenotype with parity and breastfeeding duration. 2008 ASCO Breast Cancer Symposium, September 5-7, 2008.
223. Bedrosian I, Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi. Cyclin E deregulation is an early event in the development of breast cancer. *Journal of Surgical Research* 151(2):295, 2008.
224. Mittendorf EA, Esteva FJ, Wu Y, Meric-Bernstam F, Hunt KK, Buzdar AU, Dawood S, Hortobagyi GN, Gonzalez-Angulo A. Determination of HER2 status in patients achieving less than a pathologic complete response following neoadjuvant therapy with combination chemotherapy plus trastuzumab. 2008 ASCO Breast Cancer Symposium, September 5-7, 2008.
225. Mittendorf EA, Wingate H, Liu Y, Keyomarsi K, Hunt KK. HER2 regulates expression of low molecular weight cyclin E isoforms in breast cancer. *J Surg Res* 144:380 (#QS287), 2008.
226. Shaye AN, Shen J, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK, Gilcrease MZ. Histologic predictors of false negative sentinel lymph nodes following preoperative chemotherapy. *US and Canadian Academy of Pathology Annual Meeting*, Denver, CO March 1-7, 2008.
227. Ching CD, Hunt KK, Mittendorf EA, Yi M, Feig B, Babiera GV. Impact of ultrasound and clinicopathologic factors on the accuracy of sentinel lymph node dissection in breast cancer patients following neoadjuvant chemotherapy. *American Society of Breast Surgeons*, New York, NY April 30 - May 4, 2008.
228. Ching CD, Mittendorf EA, Yi M, Naik B, Babiera GV, Feig BW, Ross MI, Hunt KK. Impact of ultrasound and clinicopathologic factors on the accuracy of sentinel lymph node dissection in breast cancer patients following neoadjuvant chemotherapy. *Ann Surg Oncol* 15(S2):P150, 2008.
229. Blazer III DG, Lazar AJ, Xing Y, Askew RL, Lev DC, Feig BW, Pisters PW, Pollock RE, Hunt KK, Cormier JN. Improved outcomes in patients with lymph node-only stage IV disease in clear cell sarcoma: Results from a large single-institution experience and SEER database analysis. *J Clin Oncol* 26(15S-1):10571, 2008.
230. Wang DM, Lazar A, Chelouche Lev D, Tuvin D, Feig BW, Cormier JN, Hunt KK, Patel S, Benjamin RS, Pollock RE, Pisters P. Intraabdominal visceral angiosarcoma (IAVA): Experience from a major referral center. *Ann Surg Oncol* 15(S2):P108, 2008.
231. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Feig BW, Lucci A, Hunt KK. Ipsilateral breast tumor relapse after breast conservation therapy. 2008 ASCO Breast Cancer Symposium, September 5-7, 2008.

232. Wagner JL, Boughey JC, Babiera GV, Kuerer HM, Meric-Bernstam F, Singletary SE, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. 2008 ASCO Breast Cancer Symposium September 5-7, 2008.
233. Fearmonti RM, Batista LI, Meric-Bernstam F, Hunt KK, Bedrosian I, Kuerer HM, Singletary SE, Babiera GV. Margin width correlates with residual disease at re-excision for ductal carcinoma in situ of the breast. *Ann Surg Oncol* 15(S2):P133, 2008.
234. Downs-Kelly E, Nayeemuddin KM, Wu Y, Albarracin C, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: Features associated with locoregional recurrence and survival. US and Canadian Academy of Pathology Annual Meeting, Denver, CO, March 1-7, 2008.
235. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 Antisense Oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. *Clin Cancer Res* 14(23):7909-7916, 2008. PMID: 19047121.
236. Hawes D, Patel M, Hunt KK, Guiliano AE, Cote RJ. Presence of putative breast cancer stem cells (BCSC) in lymph node occult metastases (LNOM) of patients with node negative (LN-) breast cancer (BC). *J Clin Oncol* 26(15S-I):1069, 2008.
237. Mittendorf EA, Tucker SL, Meric-Bernstam F, Gonzalez-Angulo A, Yu T, Yang W, Symmans W, Ross MI, Hortobagyi GN, Hunt KK. Relationship between extent of estrogen receptor (ER) expression and pathologic complete response rates after administration of neoadjuvant chemotherapy. 2008 ASCO Breast Cancer Symposium, September 5-7, 2008.
238. Kong A, Bedrosian I, Rao R, Meric-Bernstam F, Lee JE, Hunt KK, Ross MI. Surgical treatment for breast cancer metastasis to ipsilateral supraclavicular nodes. American Society of Breast Surgeons, New York, NY, April 30 - May 4, 2008.
239. Lewis CM, Bu D, Ashfaq R, Xie X-J, Miller A, Dooley W, O'Shaughnessy J, Arun B, Hunt K, Euhus DM. Tamoxifen modulates tumor suppressor gene methylation in breast cells and growth factors in plasma in women at increased risk for breast cancer. Proceedings AACR, San Diego, CA, April 12-16, 2008.
240. Moldrem AW, Ulissey MJ, Menendez CA, O'Shaughnessy JA, Hunt KK, Miller AR, Dooley WC, Euhus DM. The biology of mammographic density. *Ann Surg Oncol* 15(S2):8, 2008.
241. Kong AL, Hunt KK, Yi M, Weatherspoon K, Bedrosian I, Tereffe W, Hwang R, Ross MI, Buchholz TA, Meric-Bernstam F. The impact of IMC nodal drainage on primary breast cancer outcome. *J Clin Oncol* 26(15S):534, 2008.
242. Lang JE, Tereffe W, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi G, Babiera GV. Use of neoadjuvant chemotherapy (NC) prior to resection of the primary tumor in stage IV breast cancer may predict for improved survival. American Society of Breast Surgeons, New York, NY, April 30-May 4, 2008.
243. Yi M, Hunt KK, Meric-Bernstam F, Kronowitz SJ, Nayeemuddin K, Feig B, Hwang RF, Symmans WF, Lucci A, Ross MI, Ames FC, Bedrosian I, Singletary E, Kuerer HM. Local-regional and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. *Cancer Res* 69(292s), 1/2009.
244. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Journal of Surgical Research* 151(2):283, 2/2009. PMID: 18953611.
245. Lester TR, Nayeemuddin KM, Davis WG, Hunt KK, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast: Poor overall survival is independent of the amount of sarcomatoid component. 2009 United States and Canadian Academy of Pathology (USCAP), 3/2009.
246. Wagner JL, Warneke C, Bedrosian I, Mittendorf E, Babiera G, Kuerer H, Hunt K, Yang W, Sahin A, Meric-Bernstam F. Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. *J Clin Oncol* 27(15s):36s, 5/2009.
247. Yi M, Hunt KK, Arun BK, Bedrosian I, Gutierrez Barrera AM, Kuerer HM, Babiera G, Mittendorf EA, Meric-Bernstam. Factors leading to the decision for contralateral prophylactic mastectomy in patients with breast cancer. *J Clin Oncol* 27(15s):80s, 5/2009.
248. Buzdar AU, Green MC, Broglio KR, Carter CD, Valero V, Ibrahim NK, Hunt KK, Hortobagyi GN. Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in

- combination with capecitabine (DC) in operable breast cancer. *J Clin Oncol* 27(15S):16s, 5/2009.
249. Mittendorf EA, Tucker SL, Jeruss JS, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi, Hunt KK. Validation of a novel staging system for breast cancer patients treated with neoadjuvant chemotherapy. *J Clin Oncol* 27(15s):20s, 5/2009.
 250. Dawood S, Gonzalez-Angulo, Woodward W, Meric-Bernstam F, Hunt K, Buzdar A, Hortobagyi G, Buchholz T. Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. *J Clin Oncol* 27(15S):8s, 5/2009.
 251. Kronowitz S, Hunt K, Kuerer H, Strom E, Buchholz T, Ensor J, Koutz C, Robb G. Immediate versus delayed repair of partial mastectomy defects in breast conservation. *Cancer Res* 11 Suppl 1(S8), 6/2009. PMID: 20598180.
 252. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Pusztai L, Krishnamurthy S, Le-Petross HT, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt KK, Valero V, Kuerer HM. Eradication of axillary lymph node metastases occurs in 74% of patients receiving neoadjuvant chemotherapy with concurrent trastuzumab for HER2 positive breast cancer. *Cancer Res* 69(24):566s, 12/2009.
 253. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Kuerer HM, Pusztai L, KauS-WC, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. *Cancer Res* 69(24):567s, 12/2009.
 254. Yu TK, Tereffe W, Bedrosian I, Eskambi SH, Strom EA, Litton J, Gonzalez-Angulo AM, Buchholz TA, Hunt KK, Mittendorf EA. Local-Regional Control According to Surrogate Markers of Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast Conserving Therapy. *Cancer Res* 69(24):536s, 12/2009.
 255. Gainer SM, Lodhi AK, Krishnamurthy S, Jackson S, Hall CS, Andreopoulou E, Singh B, Bedrosian I, Meric-Bernstam F, Kuerer HM, Hunt KK, Critofanilli M, Lucci A. Predictors of persistent micrometastatic disease after neoadjuvant chemotherapy. *Cancer Res* 69(24):653s, 12/2009.
 256. Krishnamurthy S, Tang S, Wang X, Sahin AA, Pantoja LM, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of a One-Step Nucleic Acid Amplification (OSNA) Assay for Comprehensive Examination of Axillary Lymph Nodes in Breast Cancer. *Cancer Res* 69(24):541s, 12/2009.
 257. Wilke LG, McCall LM, Leitch AM, Ballman KV, Hunt KK, Giuliano AE. Adherence to the National Quality Forum (NQF) Measures in a Multi-Institutional Breast Cancer Clinical Trial. *Ann Surg Oncol* 16(S1):52, 2009.
 258. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC). *J Clin Oncol* 27(suppl; abstr e11528)), 2009.
 259. Nagar H, Mittendorf EA, Strom EA, Perkins G, Oh JL, Terrefe W, Woodward W, Gonzalez-Angulo A, Hunt K, Buchholz T, Yu TK. Local-regional recurrence with and without radiation after neoadjuvant chemotherapy and mastectomy for T3N0 breast cancer patients. *Cancer Res* 69(81s), 2009.
 260. Smith KD, Rice D, Blazer D, Wang X, Vaporicyan AA, Hunt K, Swisher S, Cormier J, Pisters PW, Pollock RE, Feig BW. Near-margin adventitial (NMA) vascular dissection is equivalent to en bloc vascular resection in soft tissue sarcomas (STS). *Ann Surg Oncol* 16(S1):120, 2009.
 261. Lahat G, Dukah A, Lahat S, Feig B, Cormier J, Hunt K, Pisters P, Lev D, Pollock R. Outcomes of soft tissue sarcoma surgery in the elderly. *Ann Surg Oncol* 16(S1):26, 2009.
 262. Nguyen CV, Hunt KK, Nayeemuddin KM, Lester TR, Falcon-Escobedo R, Gilcrease MZ. Pleomorphic carcinoma of the breast: Is severe pleomorphism associated with a worse clinical outcome? 2009 United States and Canadian Academy of Pathology (USCAP), 2009.
 263. Kong A, Hunt KK, Warneke CL, Hwang R, Meric-Bernstam F, Bedrosian I, Yi M, Ross MI, Babiera GV, Mittendorf EA. Sentinel Node Dissection (SLND) is Technically Feasible and Accurate in Older Breast Cancer Patients. *Ann Surg Oncol* 16(S1):60, 2009.
 264. Mittendorf EA, Tucker SL, Meric-Bernstam F, Gonzalez-Angulo AM, Yu TK, Yang W, Symmans WF, Hortobagyi GN, Ross MI, Hunt KK. Using extent of estrogen receptor

- positivity to predict pathologic complete response rates in breast cancer patients receiving neoadjuvant chemotherapy. *Ann Surg Oncol* 16(S1):54, 2009.
265. Lahat GJ, Tuvlin D, Torres K, Feig B, Cormier JN, Hunt KK, Pisters PW, Lev D, Pollock RE. Extremity high grade soft tissue sarcoma (STS): outcomes in patients with primarily negative vs. positive converted to negative microscopic margins following re-excision. *Ann Surg Oncol* 17(Suppl 1)(S7), 2/2010.
 266. Wagner J, Fearmonti R, Pantoja L, Beahm E, Crosby M, Bedrosian I, Hunt K, Kuerer H, Meric-Bernstam F, Ross M, Feig B, Lucci A, Hwang R, Krishnamurthy S, Feng L, Hernandez M, Babiera G. Nipple-areola complex sparing mastectomy is technically feasible for risk reduction and early-stage breast cancer. *Ann Surg Oncol* 17(Suppl 1)(S59), 2/2010.
 267. Sharma R, Lucci A, Hwang RF, Rourke LL, Buchholz TA, Qiao W, Meric-Bernstam F, Gonzalez-Angulo AM, Kronowitz SJ, Babiera GV, Mittendorf EA, Krishnamurthy S, Hunt KK, Kuerer HM. Present day local-regional recurrence rates (LRR) in patients with T1 and T2 breast cancer (BC) with 0 and 1 to 3 lymph node (LN) metastases following mastectomy without radiation. *Ann Surg Oncol* 17(Suppl 1)(S20), 2/2010.
 268. Liu Y, Palalon F, Keyomarsi K, Swisher SG, Hunt KK. Reduction of telomerase activity in human breast carcinoma cells by adenoviral-mediated overexpression of E2F-1. *Proc Amer Assoc Cancer Res:101 (#B27)*, 2/2010.
 269. Hayes-Jordan AA, Green JL, Anderson PM, Xiao L, Hunt K, Mansfield PF. A phase I trial of continuous hyperthermic peritoneal perfusion using cisplatin in pediatric patients with carcinomatosis. *Amer Soc Clin Onc* 28(15S) (#Poster Abstract 9544), 6/2010.
 270. Hunt K, Le-Petross HT, Suman V, Haffty BG, Leitch AM, Ollila D, Byrd DR, Buchholz TA, Symmans WF, Boughey JC. A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071. *Amer Soc Clin Onc* 28(15S) (#TPS118), 6/2010.
 271. Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. *Amer Soc Clin Onc* 28(15S) (#Oral Abstract CRA506), 6/2010.
 272. Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow M, Blumencranz PW, Leitch AM, Saha S, Hunt K, Ballman KV. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 NO MO breast cancer who have a positive sentinel node. *Amer Soc Clin Onc* 28(15S) (#Oral Abstract CRA506), 6/2010.
 273. Ellis MJ, Babiera G, Unzeitig GW, Marcom PK, Guenther JM, Deshryver FK, Allred DC, Suman V, Hunt K, Olson JA. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. *Amer Soc Clin Onc* 28(18) (#Poster - Abstract LBA513), 6/2010.
 274. Buzdar A, Suman V, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig GW, Ellis MJ, Ewer M, Hunt K. Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer. *Amer Soc Clin Onc* 28(15S) (#Poster Abstract 594), 6/2010.
 275. Symmans WF, Hatzis C, Valero V, Booser DJ, Esserman L, Martin M, Vidaurre T, Holmes F, Souchon EA, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Pusztai L. A genomic predictor of survival following taxane-anthracycline chemotherapy for breast cancer. *Cancer Res* 70(24):119s (#PD07-03), 12/2010.
 276. Ellis M, Suman V, Hoog J, Lin L, Snider J, Parker J, Deshryver K, Watson M, Allred C, Hunt K, Olson J. ACOSOG Z1031: A randomized neoadjuvant comparison between letrozole (LET), anastrozole (ANA) and exemestane (EXE) for postmenopausal women with ER rich stage 2/3 breast cancer: biomarker outcomes and the predictive value of the baseline pAM50 bBased intrinsic subtype. *Cancer Res* 70(24 Suppl):75s (#S1-2), 12/2010.

277. Yi M, Kuerer HM, Lucci A, Meric-Bernstam F, Babiera GV, Thomas CL, Ross MI, Hunt KK. Risk of ipsilateral breast events in patients with ductal carcinoma in situ after local excision. *Cancer Res* 70(24 Suppl):350s (#P4-10-14), 12/2010.
278. Mittendorf EA, Boughey JC, Degnim AC, Harrell R, Bassett R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Lucci A, Bedrosian I, Hunt KK, Hwang RF. Size Matters: Incorporation of sentinel lymph node (SLN) metastasis size into a nomogram predicting non SLN involvement in SLN positive breast cancer patients. *Cancer Res* 70(24 Suppl):117s (#PD06-08), 12/2010.
279. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar A, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in breast cancer patients treated with neoadjuvant chemotherapy. *Cancer Res* 70(24 Suppl):208s (#P2-09-02), 12/2010.
280. Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-individual comparison of lymphatic drainage patterns Using Subareolar and peritumoral isotope injection for breast cancer. *Ann Surg Oncol* 17(1):220-227, 2010.
281. Kronowitz SJ, Lam C, Terefe W, Hunt KK, Kuerer HM, Valero V, Lance S, Robb GL, Feng L, Buchholz TA. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. *J Clin Onc* 29(15S):110s, 5/2011.
282. Gao J, et al. Mechanism of early radiographic response to imatinib in GIST. *J Clin Onc* 29(15S):617s, 5/2011.
283. FitzSullivan E, Lari SA, Smith B, Caudle A, Krishnamurthy S, Lucci A, Mittendorf E, Barbier G, Black D, Wagner J, Bedrosian I, Woodward W, Gainer S, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HIM. Incidence and Consequence of Close Margins for Ductal Carcinoma In Situ Treated with Mastectomy. Oral Presentation at SSO's 66th Annual Cancer Symposium, March 6-9, 2013 in National Harbor, Maryland (#1517133), 11/2012.
284. Bednarski B, Araujo D, Yi M, Lev D, Lazar A, Cormier J, Pisters PW, Pollock R, Feig B, Hunt KK. KIT Mutation Status and Multi-Visceral Resection Impact Outcomes of Neoadjuvant Therapy for Gastrointestinal Stromal Tumors. Oral Presentation at SSO's 66th Annual Cancer Symposium, March 6-9, 2013 in National Harbor, Maryland (#1536510), 11/2012.
285. Francis AM, Grimes LM, Yi M, Mittendorf EA, Bedrosian I, Caudle A, Meric-Bernstam F, Barbier G, Krishnamurthy S, Kuerer HM, Hunt KK. Utility of Sentinel Lymph Node Dissection (SLND) in Ductal Carcinoma in Situ (DCIS). Poster Presentation at SSO's 66th Annual Cancer Symposium, March 6-9, 2013 in National Harbor, Maryland (#1519177), 11/2012.
286. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Symmans WF, Hortobagyi GN, Crow JR, Shah RR, Hunt KK. Estrogen Receptor Positivity: 10% or 1%? 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
287. Mittendorf EA, Ballman KV, McCall LM, Hansen N, Lucci A, Gabram S, Urist M, Crow J, Hurd T, Hunt KK, Giuliano AE. Evaluation of the Stage IB Designation of the 7th Edition of the AJCC Staging System: Biologic Factors are More Important. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
288. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wile LG, Taback B, Leitch AM, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Lepetross HT, Haffty BG, Buchholz TA, Hunt KK. The Role of Sentinel Lymph Node Surgery in Patients Presenting with Node Positive Breast Cancer (T0-T4, N1-2) who receive Neoadjuvant Chemotherapy - Results from the ACOSOG Z1071 Trial. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
289. Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RE, Caudle AS, Hunt KK, Graviss L, Chemaly RF, Tereffe W, Shaitelman SF, Babiera GV. Timing of Infectious Complications following Breast Conserving Therapy with Catheter-Based Accelerated Partial Breast Irradiation. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
290. Ellis MJ, Suman V, McCall L, Luo R, Hoog J, Brink A, Watson M, Ma C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Dayao Z, Leitch M, Ota D, Olson J, Hunt K. Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 Study of Triage to Chemotherapy Based

- on 2 To 4 Week Ki67 Level >10%. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
291. Ellis MJ, Suma V, McCall L, Luo R, Hoog J, Brink A, Watson M, Ma C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Dayao Z, Leitch M, Ota D, Olson J, Hunt K, Allred C. Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%. 2012 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2012.
 292. Gainer S, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. ACOSOG Z0011 Changing Behavior: results of a Survey of The American Society of Breast Surgeons. The American Society of Breast Surgeons Meeting (#0072), 2012.
 293. Caudle AS, Hunt KK, Lucci A, Tucker S, Kuerer HM, Meric-Bernstam F, Gainer S, Shah R, Babiera G, Sahin A. American College of Surgeons (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. The American Society of Breast Surgeons Meeting (#0055), 2012.
 294. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf E, Bedrosian I, Meric-Bernstam F, Hwang R, Caudle A, Akins J, Kuerer HM, Hunt KK. Is Sentinel Lymph Node Biopsy Accurate After Neoadjuvant Chemotherapy in Patients Who Present With Node-Positive Breast Cancer? The American Society of Breast Surgeons Meeting (#0183), 2012.
 295. Allen LR, Gadgil PV, Bassett Jr R, Hunt KK, Mittendorf EA, Yi M, Babiera G, Kuerer HM, Ross MI, Bedrosian I, Meric-Bernstam F, Hwang RF. Nomogram to Predict Sentinel Lymph Node Involvement in Patients with Clinically Node-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. ASCO Meeting (#103159), 2012.
 296. Caudle AS, Yi M, Mittendorf EA, Babiera G, Hwang R, Meric-Bernstam F, Sahin A, Hunt KK. The Identification of Internal Mammary Sentinel Lymph Node Metastasis Impacts Therapy in Breast Cancer. The American Society of Breast Surgeons Meeting (#0168), 2012.
 297. Bloom E, Gifford, Kirsner S, Nelson C, Mason B, Bejarano M, Hoover S, Hunt KK, Bedrosian I, Babiera G. The Importance of Multidisciplinary Collaboration between Surgeon and Radiation Oncologist for Optimal Choice and Placement of Single-entry Brachytherapy Catheters for Accelerated Partial Breast Irradiation. The American Society of Breast Surgeons Meeting (#0195), 2012.
 298. McBride A, Allen P, Woodward WW, Kim M, Kuerer H, Drinka K, Sahin A, Strom E, Buzdar A, Valero V, Hortobagyi G, Hunt K, Buchholz T. Locoregional Recurrence Risk for Patients With T1, 2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. American Radium Society Proceedings 2013, Oncology 27(Suppl 1):15, 4/2013.
 299. Shen MC, Bloom E, Shaitelman SF, Wei C, Haynes AB, Mittendorf EA, Kuerer HM, Bedrosian I, Hwang RF, Hunt KK, Tereffe W, Strom E, Babiera GV. Comparison of infectious complications between breast conserving therapy with catheter-based accelerated partial irradiation and whole breast irradiation. San Antonio Breast Cancer Symposium, 12/2013.
 300. Ikoma N, Tseng W, Torres K, Hunt K, Cormier J, Somaiah N, Feig B. Accuracy of Percutaneous Biopsy for Retroperitoneal Liposarcoma. Society of Surgical Oncology 2014 Annual Cancer Symposium, 3/2014.
 301. Teshome M, Ballman K, McCall L, Cormier J, Giuliano A, Hunt K. Long-term Incidence of Lymphedema after Sentinel Lymph Node Dissection for Early Stage Breast Cancer: ACOSOG Z0010 (Alliance). Society of Surgical Oncology 2014 Annual Meeting, 3/2014.
 302. Ikoma N, Chiang YJ, Cormier J, Torres K, Hunt K, You YN, Feig B. Spindle Cell Tumors of the Colon and Rectum. Society of Surgical Oncology 2014 Annual Meeting, 3/2014.
 303. Boughey JC, McCall L, Ballman K, Mittendorf EA, Ahrendt G, Wilke L, Taback B, Leitch AM, Flippo-Morton T, Hunt KK. Tumor Subtype Impacts Surgical Approach and Pathological Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients - Findings from a Prospective Multicenter Clinical Trial (ACOSOG Z1071 [Alliance]). American Surgical Association 134th Annual Meeting, 4/2014.
 304. Eberth JM, Xu Y, Smith GL, Jiang J, Buchholz T, Hunt KK, Black DS, Giordano SH, Whitman GH, Yang W, Shen C, Elting LS, Smith BD. Quality of breast cancer care in the US: a national analysis of Medicare beneficiaries, 2003-2007. Ann Epidemiol(9):683, 9/2014.
 305. Ma CX, Suman V, Leitch AM, Sanati S, DeSchryver K, Unzeitig GW, Haluska P, Watson M, Hahn O, Zujewski JA, Hunt K, Winer EP, Hudis CA, Ellis MJ. Alliance A011106: Alternate

- approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neoadjuvant Treatment (ALTERNATE) in postmenopausal women: A phase III study. Poster Presentation at 2014 San Antonio Breast Cancer Symposium, 12/2014.
306. Boughey JC, Ballman KV, Symmans WF, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Hunt KK. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy—results from a prospective trial—ACOSOG Z1071 (Alliance). 2014 San Antonio Breast Cancer Symposium, 12/2014.
 307. Dogan BE, Dryden MJ, Wei W, Fornage BD, Buchholz TA, Yang WT, Hunt KK. Value of US and US-guided needle biopsy of internal mammary (IM) nodal basin in baseline staging of breast cancer patients. 100th Radiological Society of North America Annual Meeting, 12/2014.
 308. Clemens MW, Collins MS, Butler CE, Hunt KK, Medeiros LJ, Fanale MA, Liu J, Miranda RN. Characteristics and treatment of patients with breast implant-associated anaplastic large cell lymphoma presenting with aggressive features. *Plast Reconstr Surg* 136(4S Suppl):119-120, 10/2015. PMID: 26397638.
 309. Haffty BG, Ballman KV, Hunt KK, McCall LM, Boughey JC. Impact of radiation on Local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND. *International Journal of Radiation Oncology*, 11/2015. PMID: PMCPMC4752720.
 310. Haffty BG, Mccall LM, Ballman KV, Mclaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC. Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071. *International Journal of Radiation Oncology*, 11/2015. PMID: PMCPMC4752720.
 311. Jose Vila, Roland L. Bassett, Elizabeth Ann Mittendorf, Isabelle Bedrosian, Simona Flora Shaitelman, Michael Charles Stauder, Mariana Chavez-Mac Gregor, Jennifer Keating Litton, Wei Tse Yang, Lei Huo, Henry Mark Kuerer, Kelly Hunt, Abigail Suzanne Caudle. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. , 12/2015.
 312. Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. *San Antonio Breast Cancer Symposium 2015*, 12/2015.
 313. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy. *Cancer Res* 76(4 Suppl) (#P5-08-04), 2/2016.
 314. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Ewer MS, Hunt KK. Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer. *Cancer Res* 76(4 Suppl) (#P1-14-02), 2/2016.
 315. Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters RS, Tripathy D, Hunt KK, Buchholz TA, Feeley TW, Kuerer HM. Implementing value-based cancer care: a multidisciplinary approach to defining breast cancer outcomes. 2016 ASCO Quality Care Symposium, 2/2016.
 316. Beitsch PD, Hunt KK, Bold RJ, Gittleman MA, Blair SL, Alvarado MD, Harmer QJ. Dallas Surgical Group, Dallas, TX; MD Anderson Cancer Center, Houston, TX; University of California at Davis Medical Center, Sacramento, CA; Coordinated Health Breast Care Specialists, Allentown, PA; University of California San Diego Moores Cancer Center, La Jolla, CA; University of California San Francisco, San Francisco, CA; Endomagnetics Inc, Austin, TX. Magnetic nano-device for identification of the breast sentinel nodes – A novel method. *Cancer Res* 76(4 Suppl) (#OT2-02-03), 2/2016.
 317. Lesurf R, Griffith O, Griffity M, Watson MA, Hoog J, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch M, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. The

- genomics of response to neoadjuvant trastuzumab in HER2-positive breast cancer—results from ACOSOG Z1041 (Alliance) trial. *Cancer Res* 76(4 Suppl) (#PD6-02), 2/2016.
318. Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. *Cancer Res* 76(8):2406-18, 4/2016. e-Pub 2/2016. PMID: PMC4873469.
 319. JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. *Cell Cycle*:1-12. e-Pub 4/2016. PMID: 27049344.
 320. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. *J Clin Oncol* 34(10):1072-8, 4/2016. e-Pub 1/2016. PMID: 26811528.
 321. Watson KL, Al Sanna GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, Cormier JN, Hunt KK, Feig BW, Ashleigh Guadagnolo B, Bishop AJ, Wang WL, Slopis JM, McCutcheon IE, Lazar AJ, Torres KE. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. *J Neurosurg*:1-11. e-Pub 4/2016. PMID: 27035165.
 322. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. *JAMA Oncol* 2(4):508-16, 4/2016. PMID: PMC4845895.
 323. Simmons RM, Ballman KV, Cox C, Carp N, Sabol J, Hwang RF, Attai D, Sabel M, Nathanson D, Kenler A, Gold L, Kaufman C, Han L, Bleznak A, Stanley Smith J, Holmes D, Fornage B, Le-Petross C, Hoda S, McCall L, Hunt KK, ACOSOG investigators. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. *Ann Surg Oncol*. e-Pub 5/2016. PMID: 27221361.
 324. Karakas C, Biernacka A, Bui T, Sahin A, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. *Am J Pathol*. e-Pub 5/2016. PMID: 27182644.
 325. Christina L. Roland MD1, Brian K. Bednarski MD1, Kelsey Watson BS 1, Keila E. Torres MD PhD1, Janice N. Cormier MD, MPH1, Gary Mann MD 1, Wei-Lien Wang MD2, Alexander Lazar MD PhD2, Neeta Somaiah MD3, Kelly K. Hunt MD1 and Barry W. Feig MD1. Surgical Management of Patients with Recurrent or Intra-abdominal Metastatic GIST Following Neoadjuvant Tyrosine Kinase Inhibitor Therapy: Who is Benefiting? , 6/2016.
 326. Roland CL, May CD, Watson KL, Al Sanna GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo BA, Feig B, Hunt KK, Cormier JN, Lazar AJ, Torres KE. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. *Ann Surg Oncol* 23(7):2220-8, 7/2016. e-Pub 2/2016. PMID: 26847678.
 327. Smith BD, Jiang J, Shih Y-CT, Giordano SH, Huo J, Jagsi R, Caudle AS, Hunt KK, Shaitelman SF, Buchholz TA, Shirvani SM. Complication and economic burden of local therapy options for early breast cancer. *Journal of the National Cancer Institute* 109(1):djw178 (#S3-07), 9/2016. PMID: 27678203.
 328. Brewster AM, Peterson SK, Bedrosian I, Thompson AM, Black DM, Nelson J, Cook R, DeSnyder SM, Hunt K, Cantor SB, Volk RJ, Dong W, and Parker PA. Prospective study of psychosocial outcomes of having contralateral prophylactic mastectomy among women with non-hereditary breast cancer. *Journal of Clinical Oncology*(15):6569-6569, 5/2017.
 329. Cheung KL, Green AR, Ellis IO, Keyomarsi K, Hunt KK, Syed BM. P011 Cyclin E in early operable primary breast cancer in older women – analysis of clinical outcome and relations with biomarkers. 2017: 17th Conference of the International Society of Geriatric Oncology, 11/2017.

330. Nurudeen S, Yi M, Bedrosian I, Caudle A, DeSnyder S, Kuerer HM, Mittendorf EA, Hunt KK. PT16: Factors Associated with Local-Regional Recurrence Following Sentinel Lymph Node Dissection (SLND) in Clinically Node Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. 2018 SSO's 71st Annual Cancer Symposium (#2837814), 11/2017.
331. Yi M, Hunt KK, Bedrosian I, Chavez-MacGregor M. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of the 8th Edition AJCC. 2018 SSO's 71st Annual Cancer Symposium (#2842498), 11/2017.
332. Singh P, Scoggins ME, Sahin A, Hwang RF, Kuerer HM, Caudle AS, Mittendorf E, Thompson A, Bedrosian I, Teshome M, DeSnyder S, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective Trial. Poster Presentation, Society of Surgical Oncology 2019 Annual Cancer Symposium, 3/2019.
333. Singh P, Scoggins ME, Sahin A, Hwang RF, Kuerer HM, Caudle AS, Mittendorf E, Thompson A, Bedrosian I, Teshome M, DeSnyder S, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective Trial. Podium Presentation, American College of Surgeons Quality and Safety Conference 2019, 7/2019.
334. Piotrowski MJ, Yi M, Bedrosian I, Caudle AS, Hunt KK, Le-Petross C, Miggins M, Teshome M, DeSnyder SM. Optimization of intraoperative lumpectomy specimen labeling. American College of Surgeons Quality and Safety Conference, 7/2019.
335. Rajkot N, Cormier JN, Torres KE, Somaiah N, Hunt KK, Feig BW, Ikoma N, Roland CL. The impact of surveillance interval following resection of primary well differentiated liposarcoma of the retroperitoneum. Oral Presentation, 2020 South Texas ACS Annual Meeting, 3/2020.
336. Piotrowski MJ, Yi M, Contreras A, Hunt KK, Hwang RF, Kuerer HM, Le-Petross HC, Teshome M, Underbrink A, DeSnyder SM. Optimization of intraoperative lumpectomy specimen labeling improves concordance between surgeon and pathology. The American Society of Breast Surgeons [ASBrS] Volume XXI, 5/2020.
337. Kuritzky A, Reyna C, McGuire KP, Sun W, DeSnyder SM, Aubry S, Nayyar A, Strassle P, Hunt KK, Zhou JM, Lee MC. Evaluation of 2014 margin guidelines on re-excision and recurrence rates after breast conserving surgery: A multi-institution retrospective study. *Breast* 51:29-33, 6/2020. e-Pub 3/2020. PMID: PMC7375557.
338. Hunt, KK, Liang DH. Effective localization of non-palpable breast lesions using Magseed. [Abstract] Accepted for presentation, 2020 ACS Quality and Safety Virtual Conference, 7/2020.
339. Ma CX, Suman VJ, Leitch AM, Sanati S, Vij KR, Unzeitig GW, Hoog J, Watson M, Hahn OM, Guenther JM, Caudle AS, Dockter T, Korde LA, Weiss A, Hunt KK, Hudis CA, Winer EP, Partridge AH, Carey LA, Ellis MJ. Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2-BC) in postmenopausal (PM) women: Alliance A011106. ASCO 2020 Virtual Scientific Program, 2020.
340. Erstad DJ, Chiang YJ, Witt RG, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Western Surgical Association 129th Scientific Session 2021 Annual Meeting, 11/2021.
341. Keung EZ, Nassif EF, Lin H, Lazar AJ, Wang WL, Parra ER, Lima CF, Wistuba I, G BA, Bishop AJ, Lewis V, Torres KE, Hunt KK, Feig BW, Scally CP, Rawi AN, Crosby S, Mathew G, Ingram D, Wani K, Wargo JA, Somaiah N, Roland CL. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB). Society for Immunotherapy of Cancer 36th Annual Meeting, 11/2021.
342. Witt RG, Chiang YJ, Erstad DJ, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel lymph node biopsy and formal lymphadenectomy for soft tissue sarcoma – a single center experience of 86 consecutive cases. Connective Tissue Oncology Society 2021 Virtual Annual Meeting, 11/2021.
343. Nassif EF, Roland CL, Thirasastr P, Scally CP, Zarzour A, Valenzuela R, Torres KE, Hunt KK, Feig BW, Wang WL, Lazar AJ, Somaiah N, Keung EZ. Surgical Outcomes of Patients

- With Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcomas Treated with Palbociclib. Connective Tissue Oncology Society 2021 Virtual Annual Meeting, 11/2021.
344. Alpard SK, Hunt KK, Bridges C, Jiang J, Tran J, Checka CM. Breast Surgical Oncology Innovation: Development of a Departmental Innovation Program in an Academic Institution. SSO 2022 International Conference on Surgical Cancer Care, 3/2022.
 345. Carlson KA, Wang Y, Singareeka A, Yi M, Durak M, Edgerton M, Keyomarsi K, Hunt KK. Margin Status is the Only Clinical or Treatment Related Factor Significantly Associated with Breast Cancer Recurrence in Patients Diagnosed with DCIS Over Long-term Clinical Follow-Up. SSO 2022 International Conference on Surgical Cancer Care, 3/2022.
 346. Alpard SK, Truskett V, Bartlett R, Boruta D, Jennings A, Price M, Romig K, Hunt KK, Lu K, Checka CM. Texas Biodesign: A Novel Cross Industry and University System Collaboration to Foster Convergent Healthcare Innovation. SSO 2022 International Conference on Surgical Cancer Care, 3/2022.
 347. Hwang S, Blumencranz P, Chagpar A, Smith B, Dodg D, Carr D, Hunt KK, Gold L, Clark L, Dekhne N, Karp S, Ferrer J, Smith K, Madden S, Cohen L. The clinical impact of intraoperative margin assessment in breast cancer surgery using a novel pegulicanine fluorescence guided surgery system: A Prospective Single Arm Study. SSO 2022 International Conference on Surgical Cancer Care, 3/2022.
 348. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. ASO Visual Abstract: Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. *Ann Surg Oncol*. e-Pub 9/2022. PMID: 36161369.
 349. Murphy BL, Yi M, Barrera AG, Tripathy D, Hunt KK, Arun BK. ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. *Ann Surg Oncol*. e-Pub 10/2022. PMID: 36210399.
 350. Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. ASO Visual Abstract: Practice Pattern Variability in the Management of Regional Lymph Node Metastasis in Extremity and Trunk Soft Tissue Sarcoma (ETSTS): A Survey of the Society of Surgical Oncology (SSO) and Musculoskeletal Tumor Society (MSTS) Membership. *Ann Surg Oncol* 30(6):3679-3680, 6/2023. e-Pub 2/2023. PMID: 36826618.
 351. Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. ASO Visual Abstract: Extremely Low Incidence of Local-Regional Recurrences Observed among T1-2N1 (one or two Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy without Completion Axillary Node Dissection. *Ann Surg Oncol*. e-Pub 8/2023. PMID: 37612547.
 352. Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt KK, Meric-Bernstam F, Barcenas C, Sun SX. Surgical Outcomes in Patients Receiving Pembrolizumab Containing Neoadjuvant Systemic Therapy Regimens for Triple Negative Breast Cancer. American Society of Breast Surgeons (ASBrS) 2023 Annual Meeting, 2023.
 353. Armer J, Ballamn, McCall L, Ostby P, Zagar E, Kuerer H, **Hunt KK**, Boughey J. A Prospective Clinical Trial in Women with Node-positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Dissection: Factors Associated with Lymphedema (ACOSOG Z1071: Alliance for Clinical Trials in Oncology [ALLIANCE]). 9th International Lymphoedema Framework Conference, ILF 2019. Submitted.
 354. Boughey JC, Ballman K, McCall L, Mittendorf EA, Julian T, Byrd D, Hunt KK. ACOSOG Z1071 (Alliance) Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Dissection: Long-Term Follow-Up. American Surgical Association's 137th Annual Meeting, Philadelphia, Pennsylvania. Submitted.
 355. Blair S, Zhao B, Tsai C, **Hunt KK**. Adherence to Surgical and Oncologic Standards Improves Survival in Breast Cancer Patients. . Submitted.
 356. Zhao B, Tsai C, **Hunt KK**, Blair SL. Adhering to Surgical and Oncologic Standards Improves Survival in Breast Cancer Cohorts. Academic Surgical Congress. Submitted (#ASC20190225).

357. Akli S, Lulla AR, Saenz FR, Low KH, Wang F, Fowlkes NW, Bui T, Wang Y, Mastoraki S, Ha MJ, Hunt KK, Keyomarsi K. Aurora Kinase is an actionable target in Low Molecular Weight Cyclin E induced mammary tumors. AACR 2022 Annual Meeting. Submitted.
358. Francis A, Alexander A, Carey JPW, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitor, PD-0332991 Synchronizes Sarcoma Cells for Synergistic Demise with WEE1 Inhibitor, MK-1775. 2014 CTOS Annual Meeting, October 15-18, 2014, Berlin, Germany. Submitted.
359. Lepetross C, McCall L, Hunt KK, Ballman K, Boughey J. Central versus Local Review of Axillary Ultrasound prior to and after Neoadjuvant Chemotherapy: Results from ACOSOG Z1071 Trial [Alliance]. . Submitted (#E2597).
360. Kettner NM, Bui T, Navarro-Yepes J, Eckols TK, Raghavendra AS, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Circulating IL-6, an early biomarker inof HR- positive, HER-2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors. AACR 2022 Annual Meeting. Submitted.
361. Kettner N, **Hunt KK**. Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer. AACR Annual Meeting 2019. Submitted.
362. Boughey JC, Ballman K, McCall L, **Hunt KK**. Development of a model to predict likelihood of additional positive axillary nodes in patients with a positive sentinel node after neoadjuvant chemotherapy using ACOSOG Z1071 clinical trial (Alliance). American Surgical Association. Submitted.
363. Navarro-Yepes J, Kettner NM, Bui T, Raghavendra AS, Rao X, Wang J, Sahin A, Damodaran S, Tripathy D, Hunt KK, Keyomarsi K. Differential mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib. AACR 2022 Annual Meeting. Submitted.
364. Nguyen TD, Pina M, Wang Y, Karakas C, Bui TN, Lazar A, Ingram DR, Houghton PJ, Hunt KK, Keyomarsi K. Early proliferative response via [18]FLT-PET/CT and serum TK1 activity are predictive biomarkers for synergistic effect of sequential cell cycle targeted therapy in sarcoma. AACR 2022 Annual Meeting. Submitted.
365. Kim MM, Dawood S, Allen P, Sahin A, Woodward W, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz T. Effect of Trastuzumab on Locoregional Recurrence of Breast Cancer According to HER2 and ER/PR Status. . Submitted.
366. Singh P, **Hunt KK**. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective Trial. 2019 ACS Quality and Safety Conference, Washington, DC. Submitted.
367. Singh P, Scoggins M, Sahin A, Hwang R, Kuerer HM, Caudle AS, Mittendorf EA, Thompson A, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, **Hunt KK**. Effectiveness and safety of Magseed-localization for excision of breast lesions: a prospective trial. ACS Quality and Safety Meeting. Submitted.
368. Singh P, Scoggins M, Sahin A, Hwang R, Kuerer HM, Caudle AS, Mittendorf EA, Thompson A, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, **Hunt KK**. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective Trial. SSO 2019. Submitted.
369. Lee M, Kuritzky A, Reyna C, McGuire K, Sun W, DeSnyder SM, Aubry S, Nayyar A, Strassle P, **Hunt KK**, Zhou JM. Evaluation of 2014 Margin Guidelines on Re-Excision and Recurrence Rates after Breast Conserving Surgery: A Multi-Institution Retrospective Study. Surgery. Submitted.
370. Ferrer JM, Hwang S, Hunt KK, Dodge D, Chagpar A, Grobmyer S, Karp S, Valente S, Wapnir I, Smith K, Ramirez E, Bischof T, Strasfeld D, Lee D, Smith B. Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. AACR Annual Meeting 2018. Submitted.
371. Simons JM, van Pelt M, Marinelli A, Straver ME, Zeillemaker AM, Arias-Bouda LM, van Nijnatten T, Koppert LB, **Hunt KK**, Smidt ML, Luiten E, van der Pol C. Experiences with axillary staging after neoadjuvant systemic therapy based on excision of both the pretreatment marked positive lymph node and sentinel lymph nodes. . Submitted.
372. Yi M, Mittendorf EA, Yang W, Arun BK, Babiera GV, Kuerer HM, Crow JR, Lange G, Shah RR, Hunt KK. Factors Associated with Increasing Mastectomy Rates in Early Stage Breast

- Cancer Patients: Report from a Single Institution and Population-Based Database. 126th Annual Meeting Southern Surgical Association. Submitted.
373. Armer JM, Ballman KV, McCall L, Ostby PL, Zagar E, Kuerer HM, **Hunt KK**, Boughey JC. Factors Associated with Lymphedema in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Dissection on a Prospective Clinical Trial (ACOSOG Z1071, Alliance. JAMA Surgery. Submitted.
 374. Kettner NM, Navarro-Yepes J, Bui T, Rao X, Wang J, Meric-Bernstam F, Hunt KK, Tripathy D, Keyomarsi K. Identifying therapeutic vulnerabilities in HR-positive, HER2-negative advanced breast cancer patient-derived xenograft models refractory to CDK4/6 inhibition. AACR 2022 Annual Meeting. Submitted.
 375. Boughey JC, Rosenkranz KM, Ballman K, McCall L, Haffty B, Cuttino L, Kubicky C, LePetross HC, Hunt KK, Carey LA, Partridge AH. Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from Alliance Z11102. San Antonio Breast Cancer Symposium (SABCS) 2022. Submitted.
 376. Caudle AS, Blair S, Dickson-Witmer D, Birken S, Kelly K, Lizarraga I, **Hunt KK**, Lowenstein LM. Leveraging community tumor boards for oncology trial dissemination. ACS Quality & Safety Conference. Submitted.
 377. Mastoraki S, Lulla AR, Schneider S, Clise-Dwyer K, Fowlkes NW, Hunt KK, Watowich SS, Keyomarsi K. LMW-E Induction and Crosstalk with Immune Cells Potentiates Local Immune Responses Leading to an Immunosuppressive Microenvironment at the Early Stages of Breast Tumorigenesis in Mouse Models. AACR 2022 Annual Meeting. Submitted.
 378. **Hunt KK**, Suman V, Meric-Bernstam F, Leitch M, Ellis M, Matthew J, Boughey JC, Unzeitig G, Royce M, Buzdar A. Local-regional recurrence (LRR) data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): a randomized neoadjuvant trial of sequential versus concurrent anthracycline with trastuzumab and paclitaxel plus trastuzumab in HER2-positive (HER2+) breast cancer (BC). Society of Surgical Oncology. Submitted.
 379. Simons JM, Nurudeen S, Yi M, Kuerer HM, Caudle AS, DeSnyder SM, Mittendorf EA, Bedrosian I, **Hunt KK**. Long-term survival following sentinel lymph node biopsy in clinically node negative breast cancer patients treated with primary surgery or neoadjuvant chemotherapy. American Society of Breast Surgeons. Submitted (#582052).
 380. Hronek J, Schwartz Gomez J, Stoner A, Hunt KK, Hurvitz S, Yardley D. Major Updates in the American Joint Committee on Cancer Eighth Edition Cancer. ONS 2018. Submitted.
 381. Lulla AR, Akli S, Warma LD, Fowlkes NW, Hunt KK, Rao X, Wang J, Watowich SS, Keyomarsi K. Neutrophil elastase (NE)- mediated remodeling of mammary tumors facilitates lung metastasis. AACR 2022 Annual Meeting. Submitted.
 382. Hwang R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, FitzSullivan E, **Hunt KK**, Kuerer HM, Lucci A, Meric-Bernstam F, Park KU, Teshome M, Thompson A, Mittendorf EA. OncotypeDX score and nodal burden. Annals of Surgical Oncology. Submitted.
 383. Park KU, Kyrish K, Terrell JA, Akay CL, Bedrosian I, Black DM, Caudle AS, Checka C, Feig BW, **Hunt KK**, Hwang RF, Kuerer HM, Lucci A, Meric-Bernstam F, Refinetti AP, Reyna C, Ross MI, Teshome M, Thompson AM, DeSnyder SM. Opioid prescriptions after breast cancer surgery: Perception and reality. Journal of Clinical Oncology. Submitted.
 384. Park KU, DeSnyder SM, Kyrish K, Min Y, Bedrosian I, Caudle AS, Kuerer HM, **Hunt KK**, Miggins MV, Carson CW. Opioid Use After Breast Conserving Surgery: Identifying Risk Factors For High Opioid Use. 20th Annual Meeting of the American Society of Breast Surgeons. Submitted.
 385. Sahin A, Keyomarsi K, **Hunt KK**, Barbara N, Ha MJ, Guray M, Bakarau K. Pathologic Discordance of African American and West African Breast Cancer Populations. United States and Canadian Academy of Pathology's 108th Annual Meeting in National Harbor, Maryland. Submitted (#1239).
 386. Smith B, **Hunt KK**, Hwang S, Wapnir I, Smith B. Preliminary results of a multi-center feasibility trial for real-time, intraoperative detection of residual breast cancer in lumpectomy surgical margins using the LUM Imaging System. American Society of Breast Surgical Oncology. Submitted.

387. Smith-Graziani D, Parker P, Peterson S, Bedrosian I, Shen Y, Black D, DeSnyder S, **Hunt KK**, Dong W, Brewster A. Prospective Study of Pain Outcomes Associated with Contralateral Prophylactic Mastectomy in Women with Nonhereditary Breast Cancer. Poster presented at: American Society of Clinical Oncology Annual Meeting; 2019 May 31 – Jun 4; Chicago, IL. Submitted.
388. Chapman BV, Lei X, Patil P, Tripathi S, Nicklaus, Fingeret MC, Shaitelman SF, **Hunt KK**, Buchholz TA, Merchant F, Markey MK, Smith BD, Reddy JP. Quantitative 3D Assessment of Breast Cosmesis after Conventional (CF-WBI) Versus Hypofractionated Whole Breast Radiation (HF-WBI): Results of a Randomized Clinical Trial. American Radium Society. Submitted.
389. Alvarado M, Mittendorf EA, Teshome M, Thompson A, Bold R, Gittleman M, Beitsch P, Blair S, Kivilaid K, Harmer Q, **Hunt KK**. SentimagiC: A non-inferiority trial comparing superparamagnetic iron oxide vs. Technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer. *Annals of Surgical Oncology*. Submitted.
390. Mastoraki S, Lin J, Rao X, Liu SR, Batra H, Raso MG, Cuentas EP, Raghavendra AS, Rasaputra KS, Yi M, Wang J, Sahin A, Tripathy D, Hunt KK, Navin NN, Keyomarsi K. Single-Cell Transcriptomic Analysis of HR+/HER2- Breast Cancer Identifies Gene Signatures That Predict Outcomes of Luminal A and B Subtypes. AACR 2022 Annual Meeting. Submitted.
391. Park KU, Kyrish K, Terrell JA, Yi M, Caudle AS, **Hunt KK**, Kuerer HM, Bedrosian I, Thompson AM. Surgeon Perception Versus Reality: Opioid Use After Breast Cancer Surgery. *Journal of Surgical Oncology*. Submitted.
392. Moran, MS, Zhao, Y, Ma S, Fourquet A, Chen P, Hoffman K, Hunt, KK, Wong J, Halasz L, Freedman G, Prosnitz Jr R, Yassa M, Nguyen D, Hijal T, Haffty B, Wai E, Truong P. The Benefit of Radiation Therapy Boost for Ductal Carcinoma In Situ (DCIS) after whole Breast radiation Therapy: Analysis of Outcomes from Ten Pooled Academic Institutions. . Submitted.
393. Hunt KK, Hwang. The clinical impact of intraoperative margin assessment in breast cancer surgery using a novel fluorescence guided surgery system: A Prospective Pilot Study. *JAMA Surgery*. Submitted.
394. Al-Refaie WB, Decker PA, Pisters PWT, Posner M, Hunt KK, Meyers B, Weinberg A, Nelson H, Newman L, Ballman KV. Variations in Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance). 2014 American Surgical Association. Submitted.
395. Blair S, Lopez N, Lee K, Bifolck KT, Y K, Dickson-Witmer D, Kelly K, **Hunt KK**. Chang C, Caudle AS, Francescatti A. What factors influence clinical trials implementation? Results from an NAPBC Survey. SSO's 72nd Annual Cancer Symposium. Submitted.

Book Chapters

1. Morton DL, Hunt KK, Bauer RL, Lee JD. Immunotherapy by active immunization of the host using nonspecific agents: Clinical applications using intralesional therapy. In: *Biologic Therapy of Cancer: Principles and Practice*. J.B. Lippincott Company, 627-42, 1991.
2. Hunt KK, Love S. Breast Disorders. In: *McGraw-Hill Encyclopedia of Science and Technology*. McGraw-Hill, Inc, 1996.
3. Hunt KK, Ross MI. Changing trends in the diagnosis and treatment of early breast cancer. In: *Surgical Oncology*. Kluwer Academic Publishers: Norwell, MA, 171-201, 1997.
4. Mansfield PF, Hunt KK. Classification, staging, and management of Non-Hodgkin's lymphomas. In: *Surgical Oncology*. Ed(s) RE Pollock. Springer, 203-212, 1997. PMID: 978-0792399001.
5. Love SM, Hunt KK. Diagnostic approaches to breast masses. In: *Mastery of Surgery*. Little Brown and Company, 563-9, 1997.
6. Hunt KK, Singletary SE, Smith TL, Ross MI, Strom EA, McNeese MD, Ames FC. Conservation surgery and radiation: The M. D. Anderson Cancer Center experience. In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*. W.B. Saunders Company, 1179-82, 1998.

7. Hunt KK, Bland KI, Ellis LM. General considerations for follow-up. In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*. W.B. Saunders Company, 1460-74, 1998.
8. Hunt KK, Kroll SS, Pollock RE. Surgical procedures for advanced local and regional malignancies of the breast. In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*,. W.B. Saunders Company, 1234-43, 1998.
9. Hunt KK, Buzdar AU. Breast conservation after tumor downstaging with induction chemotherapy. In: *Breast Cancer: The M.D. Anderson Solid Tumor Oncology Series*. Springer-Verlag, 196-207, 1999.
10. Robinson E, Hunt KK. Noninvasive breast cancer. In: *The M. D. Anderson Surgical Oncology Handbook*. Lippincott Williams and Wilkins, 1-2, 1999.
11. Hunt KK, Ross MI. Paget's disease of the nipple-areolar complex. In: *Breast Cancer: The M.D. Anderson Solid Tumor Oncology Series*. Springer-Verlag, 262-72, 1999.
12. Ross MI, Hunt KK. Role for lymphatic mapping and sentinel node biopsy in management of early-stage breast cancer. In: Singletary SE (ed), *Breast Cancer: The M.D. Anderson Solid Tumor Oncology Series*. Ed(s) Singletary SE. Springer-Verlag: New York, 171-83, 1999.
13. Hunt KK, Patel SR, Pollack A. Soft tissue sarcomas. In: *Integrated Cancer Management: Surgery, Medical Oncology and Radiation Therapy*. Marcel Dekker, Inc, 394-415, 1999.
14. Strom EA, Buzdar AU, Hunt KK. Multidisciplinary care of the breast cancer patient: Overview and implementation. In: *M.D. Anderson Cancer Care Series, Breast Cancer*. Springer, 1-19, 2001.
15. Meric F, Hunt KK. Surgical options for breast cancer. In: *M.D. Anderson Cancer Care Series, Breast Cancer*. Springer, 187-222, 2001.
16. Vorburger SA, Hunt KK. Experimental Approaches. In: *Soft Tissue Sarcoma*. BC Decker Inc, 375-90, 2002.
17. Bilimoria MM, Hunt KK. Stromal tumors of the stomach and small bowel. In: *The Practice of General Surgery*. W. B. Saunders Company, 405-8, 2002.
18. Hunt KK, Vorburger S, Cormier JN. Surgical approaches to extremity sarcoma. In: *Soft Tissue Sarcoma*. BC Decker Inc, 89-109, 2002.
19. Meric F, Robinson E, Hunt KK. Noninvasive breast cancer. In: *The M. D. Anderson Surgical Oncology Handbook*. Lippincott Williams and Wilkins, 1-13, 2003.
20. Bedrosian I, Bland K, Hunt KK. Follow-up care of the breast cancer patient. In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*. Saunders (Elsevier) and W.B. Saunders Company, 1513-32, 2004.
21. Beahm EK, Pollock R, Hunt KK. Surgical procedures for advanced local and regional malignancies of the breast. . In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*. Saunders (Elsevier) and W.B. Saunders Company, 1235-54, 2004.
22. Browne TS, Chagpar A, Hunt KK, Ramirez P. Perioperative care for breast and gynecological neoplasms. In: *Acute Care of the Cancer Patient*. Ed(s) Shaw AD, Riedel BJ, Burton AW, Fields AI, Feeley TW (eds),. Taylor & Francis Group: Florida, 433-53, 2005.
23. Andtbacka RHI, Meric-Bernstam F, Robinson EK, Hunt KK. Noninvasive breast cancer. In: *The M. D. Anderson Surgical Oncology Handbook*, 4th ed. Ed(s) Feig BW, Berger DH, Fuhrman GM. Lippincott Williams and Wilkins: Philadelphia, PA, 1-22, 2006.
24. Hunt KK. American College of Surgeons Oncology Group (ACOSOG). In: *BIG – An overview of recent & ongoing clinical trials for breast cancer*, 4th ed. Cambridge University Press: UK, 2007.
25. Chada S, Bocangel D, Pataer A, Mhashilkar AM, Inoue S, Miyahara R, Roth JA, Grimm EA, Swisher SG, Hunt KK, Ramesh R. MDA-7/IL-24 as a multi-modality therapy for cancer. In: *Gene Therapy for Cancer*. Ed(s) Hunt KK, Vorburger SA, Swisher, SG. Humana Press: Totowa, NJ, 413-34, 2007.
26. Hunt KK. Kelly K. Hunt. In: *Legends and Legacies: Personal Journeys of Women Physicians and Scientists at M. D. Anderson Cancer Center*, 1st, 52-60, 2008.
27. Strom EA, Buzdar AU, Hunt KK. Multidisciplinary care of breast cancer patients: Overview and implementation. In: *M. D. Anderson Cancer Care Series: Breast Cancer*, 2nd ed. Ed(s) Hunt KK, Robb GL, Strom EA, Ueno N. Springer: New York, NY, 197-234, 2008.

28. Boughey JC, Beahm EK, Hunt KK. Oncoplastic surgery for breast cancer. In: Textbook of Surgical Oncology. Ed(s) Poston GJ, Beauchamp D, Ruers T. Informa Healthcare: London & New York, 2008. PMID: 9781841845074.
29. McKenzie-Johnson T, Sahin A, Hunt KK. Sentinel lymph node dissection: Indications, technique and results. In: Advanced Therapy in Surgical Oncology. Ed(s) Pollock RE, Ross MI, Curley SA, Perrier ND. BC Decker Inc: Hamilton, Ontario, 511-22, 2008.
30. Ching CD, Hunt KK. Percutaneous Ablation: Minimally Invasive Techniques in Breast Cancer Therapy. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. 1, 4th. Ed(s) Bland KI, Copeland EM. Saunders (Elsevier), 1043-1050, 2009.
31. Fearmonti RM, Beahm EK, Pollock RE, Hunt KK. Surgical Procedures for Advanced Local and Regional Malignancies of the Breast. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. 1, 4th. Ed(s) Bland KI, Copeland EM. Saunders (Elsevier), 1147-1173, 2009.
32. Hunt KK, Newman LA, Copeland EM, Bland KI. The Breast. In: Schwartz's Principles of Surgery, 9th. Ed(s) Brunicaardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Pollock RE. McGraw-Hill, 2009.
33. Buchholz TA, Hunt KK. Breast-Conserving Therapy: Conventional Whole Breast Irradiation. In: Diseases of the Breast, 4th. Ed(s) Harris JR, Lippman ME, Morrow M, Osborne CK. Lippincott Williams & Wilkins: Philadelphia, PA, 507-528, 2010.
34. Torres, KE, Pollock RE and Hunt KK. Forequarter Amputation. In: Master Techniques in Breast Surgery, 2010.
35. Hunt KK and Boughey JC. The ACOSOG Experience. In: Kuerer's Breast Surgical Oncology. Ed(s) Kuerer H, 517-530, 2010.
36. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Breast Cancer - Axillary Management. In: Year Book of Oncology 2011, 2011. Elsevier, 29-30, 2011.
37. Hunt KK, Green MC, Buchholz TA. Diseases of the Breast. In: Sabiston Textbook of Surgery, 19th. Ed(s) CM Townsend, RD Beauchamp, BM Evers and KL Mattox. Elsevier: Canada, 824-869, 2012. PMID: 978-1-4377-1560-6.
38. McAuliffe PF, Andtbacka RHI, Robinson EK, Hunt KK. Noninvasive Breast Cancer. In: The M. D. Anderson Surgical Oncology Handbook, 5th. Ed(s) Feig BW, Berger DH, Fuhr GM. LWW: Philadelphia, 1-26, 2012.
39. Hunt KK, Litton JK. Systemic Treatment Strategies For Early Stage Breast Cancers. In: Surgery: Evidence-Based Medicine. People's Medical Publishing House - USA: Shelton CT, 604-611, 2012. PMID: 13978607951094.
40. Buzdar AU, Buchholz TA, Taylor SH, Horotobagyi GN, Hunt KK. Breast Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Ed(s) MA Rodriguez, RS Walters, TW Burke. Springer: United States, 19-34, 2013.
41. Buchholz TA, Hunt KK. Local-Regional Therapy following Systemic Treatment. In: Diseases of the Breast, 5th. Ed(s) Harris JR, Lippman ME, Morrow M, Osborne CK. Wolters Kluwer/Lippincott Williams & Wilkins Health: Philadelphia, 772-783, 2014.
42. Hunt KK, Robertson JFR, Bland KI. The Breast. In: Schwartz's Principles of Surgery, 10th. Ed(s) Brunicaardi FC, et al. McGraw Hill Professional, 565-604, 2014.
43. DeSnyder SM, Hunt KK. The Multidisciplinary Approach to Breast Cancer Management. In: Breast Cancer Screening and Diagnosis. Ed(s) Shetty MK. Springer Science + Business Media, 393-409, 2015.
44. Mathew J, Courtney CA, Hunt KK, Robertson JF. Surgical Management of Breast Cancer After Preoperative Systemic Treatment. In: Personalized Treatment of Breast Cancer. Springer, 263-293, 2016.
45. Hunt KK, Mittendorf EA. Diseases of the Breast. In: Sabiston Textbook of Surgery, The Biological Basis of Modern Surgical Practice, 20th. Elsevier, 820-879, 2017. PMID: 978-0-323-29987-9.
46. Bea VJ, Black D, Hunt KK. Percutaneous Ablation in the Treatment of Breast Cancer. In: Changing Paradigms in the Management of Breast Cancer, 1st. Ed(s) Marissa Howard-McNatt. Springer, 71-84, 2017. PMID: 978-3-319-60336-0.

47. Ravi V, Antonoff M, Wingate H, Wang W, Hunt KK. Primary Sarcoma of the Lung. In: Textbook of Uncommon Cancer, 5th. Ed(s) D Raghavan, MS Ahluwalia, CD Blanke, J Brown, ES Kim, GH Reaman, MA Sekeres. John Wiley & Sons Ltd., 248-265, 2017. PMID: 978-1119196204.
48. Fayanju OM, Garvey PB, Karuturi MS, Hunt KK, Bedrosian I. Surgical Procedures for Advanced Local and Regional Malignancies of the Breast. In: The Breast Comprehensive Management of Benign and Malignant Diseases, 5th. Elsevier, 778-801, 2017. PMID: 9780323511865.
49. Hunt KK, Kronowitz S. Technical Issues Related to Mastectomy for Breast Cancer. In: Textbook of Complex General Surgical Oncology, 1st. Ed(s) Morita SY, Balch CM, Klimberg VS, Posner MC, Schulick RD, Tanabe KK. McGraw Hill, 2017.
50. Keung E, Pollock RE, Hunt KK, Torres KE. Forequarter Amputation. In: Breast Surgery. Wolters Kluwer, 2018.
51. Torres KE, Hunt KK, Pollock RE. Forequarter Amputation. In: Master Techniques in Surgery: Breast Surgery. Ed(s) 2nd. Wolters Kluwer, 2018.
52. Weiss A, King TA, Hunt KK, Mittendorf EA. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System Review of the Supporting Evidence. In: Surg Clin North Am. 98, 4th, 687-702
https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=30005768, e-Book 2018. PMID: 30005768.
53. Hunt KK, Kronowitz SJ. Mastectomy and Breast Reconstruction. In: Textbook of Complex General Surgical Oncology. McGraw Hill Education, 809-816, 2018.
54. Bea VJ, Black DM, Hunt KK. Percutaneous Ablation in the Treatment of Breast Cancer. In: Changing Paradigms in the Management of Breast Cancer. Ed(s) Howard-McNatt M. Springer, 2018.
55. Hunt KK, Newman LA, Copeland III EM, Bland KI. The Breast. In: Schwartz's Principles of Surgery, 10th. Ed(s) Brunicaardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE. McGraw-Hill Education, 2018.
56. Antonescu C, Thway K, Hunt KK. Classification of Breast Tumors. In: WHO Classification of Tumours: Breast Tumours, 5th, 2019.
57. Simons JM, Teshome M, Hunt KK. Inflammatory Breast Cancer. In: Complex General Surgical Oncology. Decker, 2019.
58. Antonescu CR, Hunt KK, Rowe JJ, Thway K. Primary angiosarcoma of the breast. In: WHO Classification of Tumours: Breast Tumours, 5th. World Health Organization, 2019.
59. Parker CC, Damodaran S, Bland KI, Hunt KK. The Breast. In: Schwartz's Principles of Surgery. 1, 11th. McGraw Hill, 2019.
60. Hunt KK, Singh P, Shen Y. Trial Design: Overview of Study Designs. In: Success in Academic Surgery: Clinical Trials, 2nd. Ed(s) Pawlik TM, Sosa JA. Springer, 2020.
61. Klimberg VS, Hunt KK. Diseases of the Breast. In: Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 21st. Elsevier, 2021.
62. Murphy BL, Hunt KK, DeSnyder SM. The Multidisciplinary Approach to Breast Cancer Management. In: Breast and Gynecologic Diseases, 2nd. Springer, 2021. PMID: 978-3-030-69475-3.
63. Yoon E, Ding Q, Hunt K, Sahin A. High-Grade Spindle Cell Lesions of the Breast: Key Pathologic and Clinical Updates. In: Surg Pathol Clin. 15, 1st, 77-93
https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=35236635, e-Book 2022. PMID: 35236635.
64. Poli EC, Sahin AA, Hunt KK. Noninvasive Breast Cancer. In: The MD Anderson Surgical Oncology Manual, 7th. Lippincott Williams & Wilkins (LWW), 1-26, 2023. PMID: 978-1-97-519263-1.
65. Adesoye T, Ross K, Klimberg V.S, Hunt KK. General Principles of Mastectomy: From Halsted Radical Mastectomy and Modified Radical Mastectomy to Total (Simple) Mastectomy. In: The Breast. Elsevier. In Press.

66. Sun S, Hunt KK. Principles of Neoadjuvant Therapy for Locally Advanced Disease. In: A Practical Guide to Managing Breast Cancer for Low-Middle Income Countries. American College of Surgeons (ACS). Submitted.

Books (edited and written)

1. Hunt KK, Robb GL, Strom EA, Ueno NT, (eds). Breast Cancer. In: M.D. Anderson Cancer Care Series. Springer, 2001.
2. Hunt KK, Vorburger S, Swisher SG (editors). Gene Therapy for Cancer. Humana Press, 2007.
3. Hunt KK, Robb GL, Strom EA, Ueno NT (eds). Breast Cancer. In: M. D. Anderson Cancer Care Series, 2. Springer Science & Business Media, LLC: New York, New York, 2008.
4. Hunt KK, Nelson HD. Operative Standards for Cancer Surgery: Volume I: Breast, Lung, Pancreas, Colon. 1. Wolters Kluwer: China, 2015. PMID: 9781451194753.
5. Hunt KK. Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer. In: Surg Oncol Clin N Am. 27, 1, 1/2018. PMID: 29132570.
6. Morita SY, Balch CM, Klimberg VS, Pawlik TM, Posner MC, Tanabe KK. Ed(s) **Hunt KK**, Newman L. Textbook of Complex General Surgical Oncology. In: Breast 707. McGraw Hill Education, 2018.

Letters to the Editor

1. Buzdar AU, Hunt KK, Berry D, Hortobagyi GN. Reply to comment by Puglisi F, et al, on Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. [PMID: 15738535]. J Clin Oncol 23(27):6804-6805, 9/2005.
2. Hunt KK, Keyomarsi K. Reply to comment by Tez M on Chagpar A, et al. Clinical Outcome of patients with lymph node negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 104(8):1780, 10/2005.
3. Raut C, Hunt K, Kuerer HM. Blue dye of choice for lymphatic mapping. J Clin Oncol 15:3648-9, 2005.
4. Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins G, McNeese M, Strom E, Valero V, Hunt KK. Reply to comment by Evans R on Meric F, et al. Positive surgical margins and ipsilateral breast tumor recurrence predict systemic recurrence and disease-specific survival after breast-conserving therapy. Cancer, 2005.
5. Xing Y, Cormier JN, Hunt KK. Author's reply: meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer (Br J Surg 2006; 93: 539-546). Br J Surg 93(8):1026, 8/2006. PMID: 16845701.
6. Kronowitz SJ, Feledy JA, Hunt KK, Kuerer HM, Youssef A, Koutz CA, Robb GL. Determining the optimal approach to breast reconstruction after partial mastectomy: reply. Plast Reconstr Surg 118(3):814-5, 9/2006. PMID: 16932209.
7. Mittendorf EA, Hunt KK. Response to letter to the Editor: Isolated Tumor Cells in Sentinel Lymph Nodes and Clinical Implications for Early Breast Cancer. Ann Surg Oncol, 2009. e-Pub 4/2009.
8. Caudle AS, Hunt KK, Mittendorf EA. Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol 18 Suppl 3:S283, 12/2011. e-Pub 7/2011. PMID: 21725683.
9. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Hunt KK. Reply to comments by KJ Van Zee et al : Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30:600-607, 2012. J Clin Oncol 30(25):3144-3145, 7/2012.
10. Dixon JM, Rutgers E, Hunt KK. Authors' reply to Rayter. BMJ 350:h714, 2/2015. e-Pub 2/2015. PMID: PMC4707512.
11. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis

- but its residual expression predicts recurrence. *Breast Cancer Res* 17:87, 6/2015. e-Pub 6/2015. PMID: PMC4480452.
12. Mittendorf EA, Bedrosian I, Hunt KK. Reply to L. Antolini et al. *J Clin Oncol* 33(33):3978-9, 11/2015. e-Pub 8/2015. PMID: 26282647.
 13. Rosenkranz KM, Ballman K, McCall L, Kubicky CD, Cuttino L, Le-Petross H, **Hunt KK**, Giuliano A, Van Zee K, Haffty B, Boughey J. Reply to "Can Patients with Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? Response to the Preliminary Alliance 11102 Trial Report". *Ann Surg Oncol* 26(2):702, 2/2019. e-Pub 12/2018. PMID: 30542836.
 14. Boughey JC, Francescatti AB, Park KU, Hunt KK. ASO Author Reflections: Bridging the Gap between Clinical Trial Data and Real-World Cancer Care. *Ann Surg Oncol* 27(7):2276-2277, 7/2020. e-Pub 5/2020. PMID: PMC7360137.
 15. Buchholz TA, Ali S, Hunt KK. Reply to A. Thomsen et al. *J Clin Oncol* 38(30):3577, 10/2020. e-Pub 9/2020. PMID: 32897832.
 16. Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, Beitsch PD, Blair SL, Kivilaid K, Harmer QJ, Hunt KK. Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. *Ann Surg Oncol* 27(Suppl 3):979, 12/2020. e-Pub 6/2020. PMID: 32514803.

Manuals, Teaching Aids, Other Teaching Publications

1. Hunt KK. Regional node management in breast cancer. 2, 2nd. M.D.Anderson Breast Medical Oncology-Clinical Issues & Therapeutic Advances, Newsletter, 2-4, 2003.
2. Hunt KK. "Current status of sentinel lymph node biopsy" and "Neoadjuvant chemotherapy and breast conservation". 53(10). *Audio-Digest General Surgery*, 5/2006, May 21, 2006.

Other Publications

1. Web-Based Publication.

Comment on Ringash J, with the Canadian Task Force on Preventive Health Care, and a joint collaboration of Canadian Association of General Surgeons & American College of Surgeons. "Screening Mammography for Women 40-49 years" *Clinical Review. Evidenced Based Reviews in Surgery (EBRS) Website*, December 2004.

2. Web-Based Publication.

Expert Reviewer, *Chemotherapy for Locally Recurrent Advanced Breast Cancer; Reporting Source: Additional Chemotherapy Relieves Symptoms of Locally Recurrent Advanced Breast Cancer*". Editorial. *BreastLink.org*, December 2001 Issue.

3. Web-Based Publication.

Cormier JN, Hunt KK, Feig B. Sarcoma. In: Pappas TP, Percell GP (eds) *Unbound Surgery*, Unbound Medicine, Inc., Charlottesville, VA., 2003

4. Videos/CD ROM.

Posterior Proctectomy Approach to Early Rectal Cancers, Skibber J, Hunt KK, Curley S.; Presented at the American College of Surgeons Annual Meeting, 1995.

5. Videos/CD ROM.

Sentinel Lymph Node Dissection in Early Stage Breast Cancer, Ross M, Hunt KK, Ames F.; Presented at the Society of Surgical Oncology Annual Meeting, 2000.

6. Videos/CD ROM.

Latin American Virtual Expert Panel in Breast Cancer, Buzdar AU, Hunt KK, Woodward WE. CME videoconference satellite transmission from M.D. Anderson, Houston, TX, July 27, 2006.

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editor, Basic Sciences Survival Guide, University of Tennessee Center for Health Sciences, 1984-1986

Guest Editor and Ad hoc Reviewer, Breast Diseases, A Yearbook Quarterly, 1996-present

Editorial Board Member in the Breast Oncology Section, Annals of Surgical Oncology, 2000-2005

Section Editor, Local-regional therapy for breast cancer in Current Breast Cancer Reports, Local-regional therapy for breast cancer in Current Breast Cancer Reports, 2009-2011

Editor, MD Anderson Cancer Care Series, 2010-present

Section Editor for the Local-Regional Evaluation and Therapy Section, Current Breast Cancer Reports, 2012-2015

Breast Section Editor, Annals of Surgical Oncology, 2013-2018

Editorial Board Member, Journal of Clinical Oncology, 2014-2019

Editor-in-Chief, Current Breast Cancer Reports, Springer, 2015-present

Member of Editorial Review Board

Member, Annals of Surgical Oncology, 2000-2006

Member, Molecular Cancer, 2001-present

Member, Cancer Therapy, 2003-present

Member, Chinese Journal of Clinical Oncology, 2005-present

Member, Annals of Surgical Oncology, 2009-2015

Member, Clinical Oncology & Cancer Research, 2011-present

Member, American Journal of Translational Research, 2012-present

Member, Journal of Clinical Oncology, 2015

Journal Reviewer

Manuscript Reviewer, American Journal of Surgery

Editorial Board Member in the Breast Oncology Section, Annals of Surgery

Manuscript Reviewer, Annals of Surgery

Manuscript Reviewer, Cancer

Manuscript Reviewer, Cancer Detection and Prevention

Manuscript Reviewer, Cancer Gene Therapy

Manuscript Reviewer, Cancer Research

Manuscript Reviewer, Clinical Cancer Research

Manuscript Reviewer, International Journal of Radiation Oncology, Biology & Physics

Manuscript Reviewer, Journal of American College of Surgeons

Manuscript Reviewer, Journal of Clinical Oncology

Manuscript Reviewer, New England Journal of Medicine

Manuscript Reviewer, Oncogene

Manuscript Reviewer, Surgery

Manuscript Reviewer, The Lancet

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

Director of Surgical Oncology Training Module, The Susan G. Komen Multidisciplinary Breast Cancer Fellowship Training Program

7/2001-2009

Other Formal Teaching

Lecturer, Breast Lymphatic Mapping, Minimally Invasive Nodal Staging for Early Stage Melanoma and Breast Cancer Course

9/1998

Lecturer, Breast Lymphatic Mapping, Minimally Invasive Nodal Staging for Early Stage Melanoma and Breast Cancer Course

10/1998

Lecturer, Breast Lymphatic Mapping, Minimally Invasive Nodal Staging for Early Stage Melanoma and Breast Cancer Course

11/1998

Lecturer, Breast Lymphatic Mapping, Breast Lymphatic Mapping, Minimally Invasive Nodal Staging for Early Stage Melanoma and Breast Cancer Course

12/1998

Lecturer, Breast Center Clinical Research Meeting, Lymphatic Mapping After Neoadjuvant Chemotherapy

11/1999

Lecturer, Breast Lymphatic Mapping, Minimally Invasive Nodal Staging for Early Stage Melanoma and Breast Cancer Course

1/2000

Course Director, The M D Anderson Breast Lymphatic Mapping Course

9/2002

Lecturer, Screening & Local Management of Breast C, Annual Medical Oncology Board Review Course, The University of Texas MD Anderson Cancer Center & Baylor College of Medicine

10/2002

Lecturer, Screening & Local Management of Breast C, Comprehensive Board Review in Hematology & Medical Oncology, The University of Texas MD Anderson Cancer Center & Baylor College of Medicine

10/2003

Lecturer, Neoadjuvant Chemotherapy for Operable Br, 45th Annual Clinical Conference on Multidisciplinary Care: The Present and Future

3/2004

Lecturer, Advanced Topics in Multidisciplinary Care Program, Surgical Management of Breast Cancer

7/2004

Lecturer, Screening & Local Management of Breast C, Comprehensive Board Review in Hematology & Medical Oncology, The University of Texas MD Anderson Cancer Center & Baylor College of Medicine
9/2004

Lecturer, Screening & Local Management, Comprehensive Board Review in Hematology & Medical Oncology, The University of Texas MD Anderson Cancer Center & Baylor College of Medicine
9/2007

Lecturer, Comprehensive Board Review in Hematology & Medical Oncology, Screening & Local Management, The University of Texas MD Anderson Cancer Center and Baylor College of Medicine
9/2008

Lecturer, Screening/Local Management of Breast Can, Comprehensive Review in Hematology and Medical Oncology and Baylor College of Medicine
9/2009

Lecturer, Screening/Local Management of Breast Can, Comprehensive Review in Hematology and Medical Oncology and Baylor College of Medicine
9/2011

Supervisory Teaching Committees

Advisory Committees

- Member, Doctoral Examinee Committee, Eun Lee, 1998-1999
- Member, Doctoral Examinee Committee, John J. Davis, 2002-2003
- Member, Doctoral Examinee Committee, Hannah Wingate, 2002
- Member, Doctoral Examinee Committee, Ying Cao, 2002
- Member, Doctoral Examinee Committee, Jennifer Frey, 2003-2004
- Member, Doctoral Examinee Committee, John McAuliffe, 2004-2006
- Member, Doctoral Examinee Committee, Benjamin Mull, 2004-2010
- Member, Angela Webb, PhD, 2006-2007
- Member, GSBS, Kai-Lieh Huang, PhD, 2010-2011

Supervisory Committees

- Member, Supervisory Committee, John J. Davis, 2005-2006
- Member, Kari J. Brewer, 2009-2010

Examining Committees

- Member, Bahareh Tavana, 2006-2007
- MyLinh Duong, 2008-2011
- MD Anderson Cancer Center, Kari J Brewer, 2009-2012
- MD Anderson Cancer Center, Kate Lynn Bill, 2011

Direct Supervision

Undergraduate and Allied Health Students

- Ashleigh Francis, 2003-2005
- Catherine Luo, 2020

Medical Students

- Daniel Holtz, 1997
- Eugene Huang, 2002

Gregory Lakin, 2002
Karen Shahar, 2004-2005
Ashleigh Francis, 2009-2010
Vicente Valero III, 2009-2010
Christine Haugen, 2013-2014

Graduate Students

N/A

Postdoctoral Research Fellows

Nophadol Hetrakul, M.D, 1997-1998
Kazumi Yoshida, M.D., Ph.D., 1998-2001
Jeffrey Wayne, M.D, 1999-2000
Stephan Vorburger, M.D, 2001-2003
Michelle Fanale, M.D, 2003-2005
Tamra McKenzie, M.D, 2003-2005
Young-Jin Suh, M.D, 2004-2005
Baohua Sun, M.D., Ph.D., 2004-2006
Urs VonHolzen, M.D, 2004-2006
Ivo Winiger-Candolfi, M.D., 2006-2007
Hannah Wingate, Ph.D., 2007-2012
UTMDACC, Chun-Hui Su, 2011-2015
Ashleigh Francis, MD, 2012-2014
Nicole Kettner, PhD, 2017-present
Amriti R. Lulla, PhD, 2018-present
Juliana Navarro-Yepes, PhD, 2018-present
Sofia Mastoraki, PhD, 2019-present
Tuyen Nguyen, PhD, 2019-present
Chen Braun, PhD, 2020-present

Clinical Residents and Fellows

Research Elective, Jeffrey Gershenwald, M.D., Surgical Oncology Fellow, 1995-1998
Research Elective, Keith Heaton, M.D., Surgical Oncology Fellow, 1996-1998
Research Elective, Henry Kuerer, M.D., Ph.D., Surgical Oncology Fellow, 1997-1998
Research Elective, Christine Laronga, M.D., Surgical Oncology Fellow, 1997-2000
Research Elective, Tara Breslin, M.D., Surgical Oncology fellow, 1997-2000
Research Elective, Malcolm Bilimoria, M.D., Surgical Oncology Fellow, 1998-2000
Research Elective, Funda Meric, M.D., Surgical Oncology Fellow, 1998-2001
Research Elective, Carmen Solorzano, M.D., Surgical Oncology Fellow, 2000-2002
Research Elective, Rosa Hwang, M.D., Surgical Oncology Fellow, 2000-2003
Research Elective, Emily Robinson, M.D., Resident, 2000
Research Elective, Isabelle Bedrosian, M.D., Surgical Oncology Fellow, 2001-2004

Research Elective, Anees Chagpar, M.D., Surgical Oncology Breast Fellow, 2002-2003
Research Elective, Jeannie Shen, M.D., Surgical Breast Oncology Fellow, 2003-2004
Research Elective, Kazumi Kawase, M.D., Surgical Breast Oncology Fellow, 2003-2004
Research Elective, Jacqueline Jeruss, M.D., Surgical Breast Oncology Fellow, 2006-2007
Research Elective, Judy Boughey, M.D., Surgical Breast Oncology Fellow, 2006-2007
Research Elective, Elizabeth Mittendorf, M.D., Surgical Oncology Fellow, 2006-2008
Research Elective, Eric Silberfein, M.D., Resident, 2007
UTMDACC, Amanda Kong, MD, 2007-2008
UTMDACC, Jonathan Nelson, MD, 2007-2008
UTMDACC, April Spencer, MD, 2008-2009
UTMDACC, Laura Dominici, MD, 2008-2009
UTMDACC, Viviana Negron Gonzalez, MD, 2008-2009
UTMDACC, Abigail Caudle, MD, 2009-2010
UTMDACC, Jamie Wagner, DO, 2009-2010
UTMDACC, Catherine Akay, MD, 2010-2011
UTMDACC, Jessica Colen Suarez, MD, 2010-2011
UTMDACC, Lisa Allen, MD, 2011-2012
UTMDACC, Rosalinda Alvarado, MD, 2011-2012
UTMDACC, Sarah Gainer, MD, 2011-2012
UTMDACC, Brian Bednarski, MD, 2011-2013
UTMDACC, Elizabeth Fitzsullivan, MD, 2012-2013
UTMDACC, Michelle Shen, MD, 2012-2013
Catherine Parker, MD, 2013-2014
Julie Cupp, MD, 2013-2014
Mediget Teshome, MD, 2013-2014
Meeghan Lautner, MD, 2013-2014
Alfred J. Colfry, III, MD, 2014-2015
Candice A. Sauder, MD, 2014-2015
Catherine Loveland-Jones, MD, 2014-2015
Makesha V. Miggins, MD, 2014-2015
Katrina Blackburn Mitchell, MD, 2015-2016
Oluwadamilola M. Fayanju, MD, 2015-2016
Rhiana S. Menen, MD, 2015-2016
Stacey A. Carter, MD, 2015-2016
Anna C. Weiss, MD, 2016-2017
Audree B. Tadros, MD, 2016-2017
Kelly J. Rosso, MD, 2016-2017

Vivian J. Bea, MD, 2016-2017
Sarah Tevis, 2017-2018
Alicia A. Heelan, MD, MS, 2020-2021
Leisha C. Elmore, MD, MPHS, 2020-2021
Solange Cox, MD, 2020-2021
Taiwo Adesyoe, MD, 2020-2021
Adrienne N. Cobb, MD, 2021-2022
Clara R. Farley, MD, 2021-2022
Elizabeth Poli, MD, MS, 2021-2022
Kjirsten Carlson, MD, 2021-2022
Ashley A. Woodfin, MD, 2022-2023
Helen M. Johnson, MD, 2022-2023
Shlermine Everidge, MD, 2022-2023
Shruti Zaveri, MD, MPH, 2022-2023
Alexa Glencer, MD, 2023-2024
Alexandra Moore, MD, 2023-2024
Alycia So, MD, 2023-2024
Kerollos Wanis, MD, PhD, 2023-2024

Other Supervisory Teaching

Mentor, Abdulkader Almosa, Direct Supervision - MDA Summer Experience, 6/2022-8/2022

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Society of Surgical Oncology, Chicago, IL, Moderator, 3/1997

American Radium Society, American Radium Society 80th Annual Meeting, Monte Carlo, Monaco, Moderator, 5/1998

Society of Surgical Oncology, CME Satellite Symposium: Society of Surgical Oncology Annual Meeting, Los Angeles, CA, Moderator, 3/2003

American Radium Society, Houston, TX, Scientific Program Committee, 4/2003

The American Society of Clinical Oncology, Scientific Program Committee, 1/2004

Society of Surgical Oncology, Scientific Program Committee, 1/2005

The Society of Surgical Oncology, San Diego, CA, Moderator, 3/2006

MDACC, 8th Annual Oncology Update, Park City, UT, Moderator, 1/2008

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, Boston, MA, Moderator, 8/2008

Society of Surgical Oncology, Phoenix, AZ, Moderator, 3/2009

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, Boston, MA, Moderator, 7/2009

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, New York, NY, Moderator, 8/2010

Western Surgical Association, Chicago, IL, Panel Discussion, 11/2010

CTRC-San Antonio Breast Cancer Symposium, San Antonio, TX, Case Discussion Panelist, 12/2010

ASBS, Washington, DC, Panelist, 5/2011

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, San Francisco, CA, Moderator, 7/2011

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, San Francisco, CA, Moderator, 7/2011

American Society of Breast Surgeons, Phoenix, AZ, Moderator, 5/2012

MD Anderson Physicians Network Symposium, Chicago, IL, Program Co-Chair and Moderator, 7/2012

MD Anderson Cancer Center, 11th Oncology Update: Advances and Controversies, Steamboat Springs, CO, Moderator, 1/2013

American Association for Cancer Research, AACR Annual Meeting 2013, Washington, DC, Panelist, The Promise and Challenges of Pathological Complete Response (pCR) as a Novel Endpoint for Drug Approval in high-Risk Early-Stage Breast Cancer, 4/2013

2013 Breast Cancer Research Program Spring Annual Retreat, UT MD Anderson Cancer Center, Houston, TX, Chair, 5/2013

MD Anderson Physicians Network Symposium, Orlando, FL, Chair, 7/2013

American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, CA, Co-Chair, 2014

MD Anderson Cancer Center, 12th Oncology Update: Advances and Controversies, Steamboat Springs, CO, Session Chair and Moderator, 1/2014

Breast Cancer Coordinated Care 2014 Conference, Washington, DC, Moderator, 2/2014

Breast Cancer Coordinated Care 2014 Conference, Washington, DC, Panelist, Nipple-Sparing Mastectomy, 2/2014

Society of Surgical Oncology, 67th Annual Meeting, Phoenix, AZ, Co-moderator: Breast Parallel Session, 3/2014

2014 Breast Cancer Research Program Spring Annual Retreat, UT MD Anderson Cancer Center, Houston, TX, Chair, 5/2014

MD Anderson Physicians Network Symposium, UT MD Anderson Cancer Center, Boston, MA, Co-Chair, 7/2014

American College of Surgeons Clinical Congress, San Francisco, CA, Co-Moderator, Human Genomics and Personalized Medicine in Surgical Practice, 10/2014

Senologic International Society & American Society of Breast Disease, 18th SIS World Congress on Breast Healthcare, Orlando, FL, Panelist, Tumor Board: Multidisciplinary Approach to Rare Breast Lesions, 10/2014

American Society of Clinical Oncology, Chicago, IL, Co-Chair, 2015

American Society of Clinical Oncology, 2015 Breast Cancer Symposium, San Francisco, CA, Co-Chair Elect, 2015

15th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, Moderator, 1/2017

MD Anderson Cancer Center & MD Anderson Physicians Network Symposium, Houston, TX, Co-Chair, 5/2017

2018 American Society of Breast Surgeons, Orlando, FL, Keynote Speaker, 5/2018

Presentations at National or International Conferences

Invited

Clarifying the Role of Fine Needle Aspiration Cytology and Frozen Section Examination in the Operative Management of Thyroid Cancer, The Pacific Coast Surgical Association, Vancouver, 2/1/1989

Complement Dependent Cytotoxicity against Tumor Cell Lines by a Purified Baboon IgM Antibody to a Tumor Associated Antigen, American Association for Cancer Research, San Francisco, CA, 5/1/1989

The Pathology of Nonpalpable Breast Cancer, Southern California Chapter of the American College of Surgeons, Santa Barbara, CA, 1/1/1990

Identification and Cloning of Somatic DNA Alterations in Soft Tissue Sarcomas, The University of California at Los Angeles Symposia on the Biology of Sarcomas, Lake Tahoe, CA, 2/1/1990

Diurnal Variation in the Excretion of a Tumor Associated Antigen into the Urine of Cancer Patients, American Association for Cancer Research, Washington, DC, 5/1/1990

DNA Fingerprint Analysis of Sarcomas of Soft Tissue and Bone, The University of California at Los Angeles Dept of Surgery Grand Rounds, Los Angeles, CA, 5/1/1990

Identification of Alterations in Genomic DNA of Sarcomas of Soft Tissue and Bone Using 'DNA Fingerprint' Analysis, American Association for Cancer Research, Washington, DC, 5/1990

In Vivo Gene Transfer into Tumors Using a Recombinant Adenovirus Vector, Society of Surgical Oncology, Houston, TX, 3/1/1994

- Gene Therapy and Adenovirus Vectors, The University of California at Los Angeles Gene Therapy Conference, Los Angeles, CA, 5/1/1994
- Post-Operative Radiotherapy Does Not Interfere with TRAM Flap Viability or Cosmetic Results in Patients with High Risk Breast Cancer, Society of Surgical Oncology, Boston, MA, 3/1/1995
- Breast Conservation Surgery for Locally Advanced Breast Cancer, 6th Annual Cancer Update: Controversies in Endocrine and Breast Diseases, Houston, TX, 3/1/1996
- Recent Experience with 100 Desmoid Tumors: Analysis of Prognostic Factors Influencing Outcome, Society of Surgical Oncology, Atlanta, GA, 3/1/1996
- Recurrence After Breast Conservation: Most Patients Can Be Salvaged, Society of Surgical Oncology, Atlanta, GA, 3/1/1996
- Lymphatic Mapping for Melanoma, Multispecialty Conference on Skin Malignancies: Melanoma, Grand Rapids, MI, 5/1/1996
- Diagnosis and Treatment of Breast Cancer, Plastic Surgery Nurses Association, Houston, TX, 7/1/1996
- Overexpression of the Transcription Factor E2F-1 Leads to Apoptosis in Human Breast and Ovarian Cancer Cell Lines, AACR Special Conference on Programmed Cell Death, Bolton Landing, NY, 10/1/1996
- Skin-Sparing Mastectomy with Immediate Breast Reconstruction, Australasian College of Surgeons, Townsville, Australia, 10/1/1996
- Adenovirus-Mediated Gene Transfer of an N-Terminal Truncated Form of the Retinoblastoma Tumor Suppressor Gene Inhibits the Malignant Phenotype of Human Breast Carcinoma Cell Lines, International Conference on Gene Therapy of Cancer, San Diego, CA, 11/1/1996
- Surgical Treatment of Breast Cancer Based on Mammographic Findings, Imaging Perspective III Mammography in the Diagnosis & Treatment of Breast Diseases, Houston, TX, 11/1/1996
- Adenovirus-Mediated Gene Transfer of the Transcription Factor E2F-1 Induces Apoptosis in Human Breast Cancer, Society of Surgical Oncology, Chicago, IL, 3/1/1997
- Apoptosis Induced by Overexpression of E2F-1 in Breast Cancer Cells Cannot be Blocked by Pretreatment with a Recombinant Adenovirus Overexpressing pRb, American Association for Cancer Research, San Diego, CA, 4/1/1997
- Treatment Options for Intraductal Carcinoma and Lobular Carcinoma In Situ of the Breast, American College of Surgeons Spring Meeting, San Diego, CA, 4/1/1997
- Management of the Locoregional Recurrence after Treatment for Breast Cancer, Brazilian College of Surgeons, Rio de Janeiro, Brazil, 5/1/1997
- Induction of Apoptosis in a Leiomyosarcoma Cell Line by Adenoviral-Mediated Overexpression of the Transcription Factor E2F-1, Connective Tissue Oncology Society, Milan, Italy, 11/6/1997
- Adenoviral Mediated E2F-1 Overexpression Induces Apoptosis in Human Breast Cancer with Paradoxical Upregulation of BCL-2, 20th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1/1997
- A Double-Blind, Randomized, Placebo-Controlled Trial of Oral Ondansetron to Reduce Nausea and Vomiting after Outpatient Surgery for Breast Cancer, The Society of Surgical Oncology, San Diego, CA, 3/1/1998
- Diagnosis and Treatment of Breast Cancer, UICC Breast Cancer Conference on the Psychosocial Aspects of Breast Cancer, Luzern, Switzerland, 4/1/1998
- Survival Rates are High and Complication Rates are Low Following Breast Conservation Therapy for Early Stage Breast Cancer, The American Radium Society, Monte Carlo, Monaco, 5/2/1998

Laparoscopic Approaches in the Treatment of Colorectal Cancer, State of the Art in the Multidisciplinary Management of Gastrointestinal Cancer, Lima, Peru, 10/1998

Surgery in the Multidisciplinary Approach to Colorectal Cancer, State of the Art in the Multidisciplinary Management of Gastrointestinal Cancer, Lima, Peru, 10/1/1998

Breast Cancer Surgery and Neoadjuvant Treatment, 1st International Congress on Early Breast Cancer Detection, Cadiz, Spain, 12/1/1998

Surgical Treatment for In Situ Carcinoma, 1st International Congress on Early Breast Cancer Detection, Cadiz, Spain, 12/1/1998

Meet the Professor: Ductal Carcinoma In Situ, 52nd Annual Cancer Symposium of the Society of Surgical Oncology, Orlando, FL, 3/1/1999

Evaluation of the Abnormal Mammogram, 1st Annual Primary Care Oncology Screening and Prevention Conference, Orlando, FL, 4/1/1999

Newest Information Available on Detection and Treatment of Breast Cancer, 1st Annual Primary Care Oncology Screening and Prevention Conference, Orlando, FL, 4/1/1999

Surgical Approaches to Breast Cancer Treatment, Japan / U.S. Cancer Therapy Symposium, Hiroshima, Japan, 4/1/1999

Surgical Treatment Options for Early Stage Breast Cancer, 1st Annual Primary Care Oncology Screening and Prevention Conference, Orlando, FL, 4/1/1999

Minimally Invasive Surgery in the Management of Breast Cancer, Oncology 2000, The University of Texas MD Anderson Cancer Center Symposium at Albert Einstein Hospital, Sao Paulo, Brazil, 8/1/1999

Conservation Therapy after Induction Chemotherapy, Commission on Cancer Postgraduate Course #8, 85th Annual Clinical Congress of the American College of Surgeons, San Francisco, CA, 10/1/1999

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Historical Perspective and Surgical Techniques, Imaging Perspective VI: Mammography in the Diagnosis and Treatment of Breast Diseases - III. Baylor College of Medicine Department of Radiology and Houston Radiological Society, Houston, TX, 10/1/1999

Lymph Node Mapping, Refresher Course, 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, 11/1/1999

Controversies in Breast Cancer: Irradiation of Augmented or Reconstructed Breasts—What is the Expected Cosmetic Outcome and Complication Rate?, Panel Discussion, Radiation Oncology 2000, Houston, TX, 2/16/2000

Induction of Apoptosis in Human Breast Cancer by Adenoviral-Mediated Gene Transfer of the Transcription Factor E2F-1, Breast Cancer Research Program Meeting: Era of Hope Conference, Department of Defense, Atlanta, GA, 6/1/2000

M.D. Anderson's Surgical Approach to Patients with Breast Cancer, M.D. Anderson International España Inauguration Program, Madrid, Spain, 6/1/2000

Breast Cancer: Advances of Diagnosis and Treatment, RSNA 86th Scientific Assembly and Annual Meeting, Chicago, IL, 11/1/2000

Lymphatic Mapping for Breast Cancer, The 29th Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/21/2001

Adjuvant Therapy for Breast Cancer, The 29th Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/31/2001

Skin Sparing Mastectomy, The 29th Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/31/2001

Surgical Treatment Options for Breast Cancer, The 29th Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/31/2001

Breast Conservation - Expanding the Indications, 1st Annual Oncology Update: Advances and Controversies, Steamboat Springs, CO, 2/1/2001

Can Sentinel Lymph Node Biopsy Replace Axillary Dissection?, 1st Annual Oncology Update: Advances and Controversies, Steamboat Springs, CO, 2/1/2001

Sentinel Lymph Node Biopsy for Breast Cancer: Impact on Locoregional and Systemic Therapy, Japan/U.S. Cancer Therapy Symposium, La Jolla, CA, 4/24/2001

Sentinel Lymph Node Surgery: Defining the Possibilities and Limitations, American Radium Society, San Diego, CA, 4/27/2001

Soft Tissue Sarcoma, Meet the Professor, American Society of Clinical Oncology Annual Meeting, San Francisco, CA, 5/12/2001

Induction Chemotherapy for Breast Cancer, 1st Annual Karmanos Cancer Institute Breast Cancer Symposium, Detroit, MI, 9/29/2001

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer, 1st Annual Karmanos Cancer Institute Breast Cancer Symposium, Detroit, MI, 9/29/2001

Surgical Management of Breast Cancer, The 23rd Annual Pharmacy Symposium, Houston, TX, 10/2/2001

Decision Making for Cancer Treatment: Who and How?, Japanese Society of Clinical Oncology, Hiroshima, Japan, 11/1/2001

DCIS: Surgery Plus Radiotherapy vs. Surgery Alone, 2nd Annual Oncology Update, Steamboat Springs, CO, 1/19/2002

Sentinel Lymph Node Biopsy in Breast Cancer, Korean Breast Cancer Society Annual Meeting, Seoul, Korea, Republic of, 6/1/2002

Surgical Aspects of Breast Cancer Therapy, 10th Annual Meeting of the Japanese Breast Cancer Society, Nagoya, Japan, 7/1/2002

The Clinical Significance of the Sentinel Node Biopsy, 10th Annual Meeting of the Japanese Breast Cancer Symposium, Nagoya, Japan, 7/5/2002

The Role of Neoadjuvant Therapy in Breast Cancer and Controversies in the Surgical Management of Breast Cancer, 5th Annual West Hawaii Cancer Symposium, Kailua-Koa, HI, 9/5/2002

Lymphatic Mapping and Sentinel Lymph Node Biopsy, 2nd Annual Karmanos Cancer Institute Breast Cancer Symposium, Dearborn, MI, 9/14/2002

Treatment of Locally Recurrent Breast Cancer, 3rd Annual Oncology Update: Advances & Controversies, Steamboat Springs, CO, 1/18/2003

Debate of Current Issues in Breast Cancer, American Radium Society, Houston, TX, 4/26/2003

Controversies in the Management of Locally Advanced Breast Cancer, The American Society of Breast Surgeons, Atlanta, GA, 5/2/2003

Breast Conservation Therapy with Sentinel Lymph Node Dissection, 2003 Breast Cancer Symposium, Paradigms of Breast Cancer in the New Millennium, Mexico City, Mexico, 6/12/2003

Skin Sparing Mastectomy for Early-Stage Breast Cancer, 2003 Breast Cancer Symposium, Paradigms of Breast Cancer in the New Millennium, Mexico City, Mexico, 6/12/2003

Sentinel Lymph Node Biopsy and Micrometastases, 1st Annual University of Michigan Conference on Contemporary Issues in Multidisciplinary Breast Cancer Management, Dearborn, MI, 6/21/2003

Oncologic Surgery for Breast Cancer and Preventive or Prophylactic Mastectomy, Argentine Congress of Senology and Mercosur, Buenos Aires, Argentina, 8/24/2003

Surgical Aspects of Management of Breast Cancer, Greater Cincinnati 7th Annual Breast Cancer Conference, Cincinnati, OH, 10/18/2003

Participant Refresher Course, Lymphatic Mapping for Breast Cancer RSNA Scientific Assembly and Annual Meeting, Chicago, IL, 12/1/2003

Breast Conservation Therapy after Neoadjuvant Chemotherapy, 32nd Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/1/2004

Gastrointestinal Stromal Tumors, 32nd Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/1/2004

Sentinel Lymph Node Surgery for Breast Cancer, 32nd Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/1/2004

Skin-Sparing Mastectomy for Breast Cancer, 32nd Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/1/2004

Treatment of Recurrent Breast Cancer, 32nd Annual Phoenix Surgical Symposium, Scottsdale, AZ, 1/1/2004

Expanding Indications for Sentinel Lymph Node Biopsy, 4th Annual Oncology Update: Advances & Controversies, Steamboat Springs, CO, 1/17/2004

Panel Discussant, Surgical Forum, American College of Surgeons Annual Meeting, New Orleans, LA, 10/10/2004

When do We Treat Micrometastatic Disease?, 5th Annual Oncology Update: Advances & Controversies, Park City, UT, 1/12/2005

Breast Cancer Trials, Society of Surgical Oncology 58th Annual Cancer Symposium, Atlanta, GA, 3/3/2005

The Surgeon's Role: What the Surgeon Needs to Know When the Patient Asks for an Opinion about Adjuvant Therapy, Primary Hormonal Update and Specialists Education Program, Houston, TX, 5/9/2005

Breast Cancer II: Breast Cancer Disease-Specific Tracks, Oral Presentation Discussant, 2005 ASCO Annual Meeting, Orlando, FL, 5/13/2005

Current Status of Sentinel Node Surgery for Early Stage Breast Cancer Patients, Breast and Prostate Cancer Update, UT M.D. Anderson Cancer Center, Physicians Network, Princeville, HI, 5/31/2005

Local Therapy Considerations Following Pre-Operative Chemotherapy for Breast Cancer, Breast and Prostate Cancer Update, UT M.D. Anderson Cancer Center, Physician Network, Princeville, HI, 5/31/2005

Antivascular and Apoptotic Effects of Imatinib in GI Stromal Tumors, 2005 International Symposium on Bone and Soft Tissue Tumors, Tianjin Medical University, Tianjin, China, 9/23/2005

Controversies in Breast Reconstruction after Mastectomy, American College of Surgeons 91st Annual Congress, San Francisco, CA, 10/16/2005

Correlative Clinic: Case #1 Reconstructive Breast Surgery, American College of Surgeons 91st Annual Congress, San Francisco, CA, 10/16/2005

Genetic Determinants of Disease and Outcomes, American College of Surgeons 91st Annual Congress, San Francisco, CA, 10/16/2005

Multidisciplinary Management of Breast Cancer, XXIV National Congress of Oncology, Sociedad Mexicana de Oncologia, A.C., Acapulco, Mexico, 10/19/2005

Post Mastectomy Radiation Therapy—Who, When, Why, 6th Annual Oncology Update: Advances and Controversies, The University of Texas MD Anderson Cancer Center, Park City, UT, 1/4/2006

Regional Management of the Axilla, 6th Annual Oncology Update: Advances and Controversies, The University of Texas MD Anderson Cancer Center, Park City, UT, 1/14/2006

Co-Moderator, Oral Poster Session II: Oncology V - Therapeutics, Diagnostics and Clinical Outcomes 2, 1st Annual Academic Surgical Congress (AAS/SUS), San Diego, CA, 2/7/2006

Breast Conservation after Pre-Operative Chemotherapy: Selection Criteria and Results, 2nd International Symposium on Breast Cancer, Albert Einstein Hospital and M. D. Anderson Cancer Center, Sao Paulo, Brazil, 3/10/2006

Contralateral and Prophylactic Mastectomy – when are they indicated?, 2nd International Symposium on Breast Cancer, Albert Einstein Hospital & M. D. Anderson Cancer Center, Sao Paulo, Brazil, 3/10/2006

Surgery of Sentinel Lymph Nodes: State of the Art, 2nd International Symposium on Breast Cancer, Albert Einstein Hospital and M. D. Anderson Cancer Center, Sao Paulo, Brazil, 3/10/2006

Neoadjuvant Therapy for Operable Breast Cancer: Pitfalls and Possibilities, The Society of Surgical Oncology, San Diego, CA, 3/23/2006

Open Trials & New Concepts in Breast Cancer Trials, The Society of Surgical Oncology, San Diego, CA, 3/23/2006

Conservacion de mama en cancer localmenta avanzado, Peruvian Society of Mastology Sixth International Meeting, Lima, Peru, 4/6/2006

Controversias en ganglio centinela, Peruvian Society of Mastology Sixth International Meeting, Lima, Peru, 4/6/2006

Mastectomia preservadora de piel, Peruvian Society of Mastology Sixth International Meeting, Lima, Peru, 4/6/2006

Breast Conserving Surgery Following Preoperative Chemotherapy for Breast Cancer, IV Mastology Conference of CECLINES, Caracas, Venezuela, 4/20/2006

Current Management of Ductal Carcinoma in situ, IV Mastology Conference of CECLINES, Caracas, Venezuela, 4/20/2006

Sentinel Lymph Node Biopsy in the Management of Breast Cancer, IV Mastology Conference of CECLINES, Caracas, Venezuela, 4/20/2006

Current Controversies in Sentinel Lymph Node Surgery for Breast Cancer, Taipei International Breast Cancer Symposium, Taipei, Taiwan, 9/2/2006

Ganglio centinela en cáncer de mama, Semana de Investigacion e Innovacion en Salud 2006, Hospital San Jose de Monterrey, Monterrey, Mexico, 9/26/2006

Breast Cancer Update: What Every Surgeon Needs to Know about ACOSOG Z1031, American College of Surgeons Annual Clinical Congress, Chicago, IL, 10/9/2006

Update on Multimodality Management of GIST, 7th Annual Oncology Update: Advances and Controversies, Steamboat Springs, CO, 1/13/2007

Meet the Professor: Management of Breast Micrometastases and Extra-Axillary Sentinel Nodes, The Society of Surgical Oncology, Washington DC, 3/15/2007

Controversias y consensus en cáncer de mama, XVIII Curso Internacional de Cirugía General / XXX Reunión Intercapital del Colegio Americano de Cirujanos, Monterrey, Mexico, 3/22/2007

Procedimientos quirúrgicos actuales en cirugía de mama, XVIII Curso Internacional de Cirugía General / XXX Reunión Intercapitular del Colegio Americano de Cirujanos, Monterrey, Mexico, 3/22/2007

Nodal Mapping for Breast Cancer, 5th Japan-US Cancer Therapy Symposium, Sendai, Japan, 9/7/2007

Sequencing of Sentinel Node Procedure with Neoadjuvant Chemotherapy: After Preoperative Chemotherapy, American College of Surgeons 93rd Annual Clinical Congress, New Orleans, LA, 10/7/2007

Adjuvant Therapy for Breast Cancer: Is Sentinel Node Biopsy Necessary?, First International Sentinel Node Congress in Mexico, Mexico City, Mexico, 11/14/2007

Management of Sentinel Node Biopsy Results in Breast Cancer, First International Sentinel Node Congress in Mexico, Mexico City, Mexico, 11/14/2007

State of the Art and Evolution of the Sentinel Lymph Node Biopsy in Breast Cancer, First International Sentinel Node Congress in Mexico, Mexico City, Mexico, 11/14/2007

Clinical Trials Updates, American Society of Breast Diseases 32nd Annual Symposium, San Diego, CA, 4/11/2008

Preoperative Systemic Therapy in Breast Cancer, American Society of Breast Diseases 32nd Annual Symposium, San Diego, CA, 4/11/2008

Breast Cancer Prevention, AAPA's 36th Annual Physician Assistant Conference, San Antonio, TX, 5/24/2008

Optimal Management of the Axilla for Invasive Breast Cancer, The University of Texas M. D. Anderson Cancer Center and M. D. Anderson Physicians Network Fourth Annual Symposium, Boston, MA, 8/23/2008

Local-Regional Treatment Decisions in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy - Panel Participant, American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting, Boston, MA, 9/21/2008

Breast Cancer, Annual BCRF Symposium & Awards Luncheon, BCRF, New York, NY, 10/1/2008

Partial Mastectomy Without Reconstruction, American College of Surgeons 94th Clinical Congress, San Francisco, CA, 10/13/2008

Z1041: Randomized Phase III Trial Comparing Neoadjuvant Chemotherapy and Trastuzumab for Patients with Operable Breast Cancer, American College of Surgeons 94th Clinical Congress, San Francisco, CA, 10/13/2008

New surgical options, skin-sparing, and areolar-nipple complex sparing mastectomy. Sentinel node biopsy, new techniques. Who needs a complete axillary nodal dissection?, MDA Breast Cancer Symposium, MD Anderson International, Madrid, Spain, 11/12/2008

Targeted Therapies in Breast Cancer Treatment, Taiwan, China Medical University Hospital (CMUH), Taipei, Taiwan, 11/15/2008

Breast Cancer, 31st SABCS, SABCS, San Antonio, TX, 12/1/2008

Expanding Role of Aromatase Inhibitors, 9th Annual Oncology Update: Advances and Controversies, MDACC, Park City, UT, 1/17/2009

Evidence-Based Follow-up of the Breast Cancer Patient, 9th Annual Society of Surgical Oncology, SSO, Phoenix, AZ, 3/4/2009

Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer, 129th Annual Meeting, American Surgical Association, Indian Wells, CA, 4/23/2009

The Current Status of Neoadjuvant Therapy in Operable Breast Cancer, 12th Annual West Hawaii Cancer Symposium, HI, 9/4/2009

The Current Status of Neoadjuvant Therapy in Operable Breast Cancer, 12th Annual West Hawaii Cancer Symposium, Kona, HI, 9/5/2009

Breast Conservation after Neoadjuvant Therapy, When and Who? Sentinel Node Mapping, Prior or After Neoadjuvant Therapy?, Multidisciplinary Management of Breast Cancer Meeting, Panama City, Panama, 9/26/2009

New surgical options, skin sparing, and areolar-nipple complex sparing mastectomy. Sentinel node biopsy, new techniques, and who needs a complete Axillary nodal dissection?, Multidisciplinary Management of Breast Cancer Meeting, Panama City, Panama, 9/26/2009

The MDA approach to neoadjuvant therapies, Australasian Society for Breast Disease Seventh Scientific Meeting, ASBD, Gold Coast, Queensland, Australia, 10/1/2009

The use of cryoblation in both benign and malignant disease, Australasian Society for Breast Disease Seventh Scientific Meeting, ASBD, Gold Coast, Queensland, Australia, 10/1/2009

Surgical options for early stage breast cancer, MDACC Banner Health - A Day of Science, Phoenix, AZ, 10/19/2009

New surgical options: Skin sparing and nipples sparing mastectomy, Latino-American Society of Radiation Therapy, Cancun, Mexico, 11/15/2009

Sentinel node biopsy new techniques: who needs a complete axillary lymphadenectomy? Sentinel node mapping before or after neoadjuvant therapy? Surgical options for early stage breast cancer, Latino-American Society of Radiation Therapy, Cancun, Mexico, 11/15/2009

Personalizing surgical therapy and best clinical practices for breast cancer patients, Symposium on Personalized Therapies for Breast Cancer, LaJolla, CA, 2/5/2010

Session 2 Case Study, Personalized Therapies for Breast Cancer, LaJolla, CA, 2/5/2010

Meet the Professor - Extremity Sarcoma: Principles of Management, SSO 63rd Annual Cancer Symposium, St Louis, MO, 3/3/2010

Update on Current ACOSOG Clinical Trials in Breast Cancer, SSO 63rd Annual Cancer Symposium, St Louis, MO, 3/3/2010

Clinical Trial Update: ACOSOG, ASBS 11th Annual Meeting, Las Vegas, NV, 4/28/2010

Clinical Program Building, Academic Surgical Congress, San Antonio, TX, 5/5/2010

ACOSOG Z0010, ASCO 2010, Chicago, IL, 6/7/2010

Surgeon-Pathologist Interaction in Management of Breast Cancer: Case Discussion, 1st Joint Symposium of Pathology & Clinical Medicine of Xi'an, Fourth Military Medical University, Xi'an, China, 6/12/2010

Update in Breast Surgery, 1st Joint Symposium of Pathology & Clinical Medicine of Xi'an, Fourth Military Medical University, Xi'an, China, 6/12/2010

Micrometastases and Breast Cancer, American College of Surgeons 96th Annual Clinical Congress, Washington, DC, 10/4/2010

Advances in Surgical Oncology: What All Surgeons Should Know, Western Surgical Association 2010, Chicago, IL, 11/7/2010

ACOSOG Z10 & ACOSOG Z11, Trials & Audit Meetings, Dundee, Scotland, 11/18/2010

Scottish Breast Cancer Network Audit of QIS Standards 2009, Trials and Audit Meetings, Dundee, Scotland, 11/19/2010

Overutilization of Axillary Dissection for Clinically Node Negative Node Breast Cancer, Report from the American College of Surgeon's National Cancer Database, 2003-2007, American Surgical Association, Boca Raton, FL, 4/14/2011

ACOSOG Update, American Society of Breast Surgeons 12th Annual Meeting, Washington, DC, 5/1/2011

Chemo and Surgical Management of Advanced Breast Cancer, MDACC - Fudan University, Shanghai, China, 5/14/2011

Surgical Management of DCIS, MDACC-Fudan University, Shanghai, China, 5/14/2011

Breast Cancer Update, AAPA, Las Vegas, NV, 6/1/2011

Axillary Management After A Positive Sentinel Node, 2011 Breast Cancer Academic Conference in Taiwan, Taipei, Taiwan, 9/3/2011

Current State-of-the Art and Future Directions of Breast Cancer Surgery, Minnesota Society of Clinical Oncology, Minneapolis, MN, 9/22/2011

Findings from the American College of Surgeons Z0011 Study, 23rd Annual Breast Cancer Symposium, Dallas, TX, 9/24/2011

Panelist: Clinical Case Discussion 1. Surgical Challenges, Modena International Breast Cancer Conference, Modena, Italy, 10/5/2011

Sentinel node biopsy and axillary node dissection: what is new?, Modena International Breast Cancer Conference, Modena, Italy, 10/5/2011

Neohormonal Therapy for Breast Cancer: Who Is a Candidate?, American College of Surgeons, San Francisco, CA, 10/23/2011

Neohormonal Therapy for Breast Cancer: Who Is a Candidate?, American College of Surgeons, San Francisco, CA, 10/23/2011

Axillary dissection in the sentinel node era, 12th Portuguese Congress of Oncology, Argave, Portugal, 11/12/2011

The Expanding Role of Aromatase Inhibitors, 10th Annual Oncology Update: Advances & Controversies, Steamboat Springs, CA, 1/14/2012

Practice Changing Trials that Personalize Locoregional Management of Breast Cancer, Miami Breast Cancer Conference, Miami, FL, 3/15/2012

Management of Central Breast Tumors, Miami Breast Cancer Conference, Miami, FL, 3/16/2012

ASA Women in Surgery Breakfast, American Surgical Association, San Francisco, CA, 4/27/2012

New Surgical Techniques - Skin conserving surgery, Nipple- Areola conserving surgery, Oncoplastic surgery, DCIS & Early Breast Cancer Symposium, Nevsehir, Cappadocia, Turkey, 6/16/2012

Surgery in DCIS – Breast conserving surgery or mastectomy, DCIS & Early Breast Cancer Symposium, Nevsehir, Cappadocia, Turkey, 6/16/2012

Z0011 Study Results, DCIS & Early Breast Cancer Symposium, Nevsehir, Cappadocia, Turkey, 6/17/2012

Local-regional therapy issues after neo-adjuvant chemotherapy, 7th Edition Breast Cancer Conference, Brazil, 8/24/2012

Management of high risk patients, 7th Edition Breast Cancer Conference, Brazil, 8/24/2012

Surgical management of early breast cancer, 7th Edition Breast Cancer Conference, Brazil, 8/24/2012

The role of axillary node dissection in patients with positive sentinel lymph nodes, 7th Edition Breast Cancer Conference, Brazil, 8/24/2012

Ongoing Controversies in the Local Regional Management of Breast Carcinoma, 15th Annual West Hawaii Cancer Symposium, HI, 9/8/2012

- Multidisciplinary Approach in Locally Advanced Breast Cancer, Philippine Society of Medical Oncology in collaboration with Philippine Breast Cancer Society, Mandaluyong, Philippines, 10/18/2012
- Sentinel Node Dissection, Philippine Society of Medical Oncology in collaboration with Philippine Breast Cancer Society, Mandaluyong, Philippines, 10/18/2012
- Neoadjuvant Therapy in Breast Cancer, Philippine Society of Medical Oncology in collaboration with Philippine Breast Cancer Society, Mandaluyong, Philippines, 10/19/2012
- Hunt KK. Mastectomy and Metastasectomy in Stage IV Breast Cancer, GBECAM, 7th Brazilian Breast Cancer Conference, Sao Paulo, Brazil, 3/2013
- Hunt KK. Can a complete axillary dissection be avoided in breast conservative surgery with more than 3 positive nodes?, Plenarium Organization of Congresses-Brazil, 8th Breast Cancer Symposium, Gramado, Brazil, 8/2013
- Hunt KK. DCIS: How to manage the possibility of overdiagnosis, Plenarium Organization of Congresses-Brazil, 8th Breast Cancer Symposium, Gramado, Brazil, 8/2013
- Hunt KK. Should the molecular profile interfere with the indication of the surgical procedure?, Plenarium Organization of Congresses-Brazil, 8th Breast Cancer Symposium, Gramado, Brazil, 8/2013
- Hunt KK. Mock Oncoplastic Tumor Board Panel, Breast Cancer Coordinated Care 2014 Conference, Washington, DC, 2/20/2014
- Hunt KK. Is it necessary an axillary dissection for the patient with positive sentinel lymph node biopsy, IX Santiago Breast Cancer International Symposium, Santiago, Chile, 4/2014
- Hunt KK. Local-regional therapy in the setting of neoadjuvant chemotherapy, Association of Breast Surgery Conference & AGM, Liverpool, United Kingdom, 5/2014
- Hunt KK. Risk reducing surgery, Association of Breast Surgery Conference & AGM, Liverpool, United Kingdom, 5/2014
- Hunt KK. Over-treatment of DCIS and Margin Controversies, 18th SIS World Congress on Breast Healthcare, Senologic International Society and American Society of Breast Disease, Orlando, FL, 10/17/2014
- Hunt KK. New Paradigms of Breast Cancer Surgery, Radiological Society of North America 100th Scientific Assembly and Annual Meeting, Chicago, IL, 11/30/2014
- Hunt KK. Surgical Management in Treatment of Breast Cancer, Nebraska Oncology Society, 5th Annual Midwest Regional San Antonio Breast Cancer Symposium Review, Omaha, NE, 1/24/2015
- Hunt KK. Stage vs Biology: What Drives Adjuvant Treatment Decisions?, ASCO-RUSSCO Joint Session, American Society of Clinical Oncology, Moscow, Russian Federation, 2/5/2015
- Hunt KK. Tumor Biologic Subtypes and Breast Conservation Therapy, 32nd Annual Miami Breast Cancer Conference, Miami Beach, FL, 2/26/2015
- Hunt KK. Incorporating Tumor Biology Into an Improved Staging System for Breast Cancer, 32nd Annual Miami Breast Cancer Conference, Miami Beach, FL, 2/27/2015
- Hunt KK. Late-Breaking News from the Breast Cancer Research Front, 32nd Annual Miami Breast Cancer Conference, Miami Beach, FL, 2/28/2015
- Hunt KK. Management of the Axilla After Neoadjuvant Chemotherapy, 32nd Annual Miami Breast Cancer Conference, Miami Beach, FL, 2/28/2015
- Fourth International Breast Cancer Meeting, Antonio Emirio de Moraes Cancer Centre, Brazil, 6/2015
- 2016 Palm Beach Making Cancer History Seminar, MD Anderson Cancer Center, West Palm, FL, 2/20/2016

Incorporating Tumor Biology Into Staging of Breast Cancer, The American Society of Breast Surgeons, Dallas, TX, 4/16/2016

Operative Standards in Cancer Surgery, San Francisco, CA, 4/29/2016

Prognostic and Predictive Factors in Breast Cancer, University of Chicago Hospital, Chicago, IL, 5/17/2016

Prognostic and Predictive Factors in Breast Cancer, Henry Ford Health Systems, Detroit, MI, 6/1/2016

Women in Surgery: Advocating from Coast to Coast, Festschrift Honoring Michael J. Zinner, Brigham and Women's Hospital, Boston, MD, 6/25/2016

The Future of Breast Surgeons, IV Annual Meeting of Spanish Association of Breast Surgeons, Madrid, Spain, 5/6/2017

Advances in the Surgical Management of Breast Cancer, UTMB Health - The University of Texas Medical Branch at Galveston, Houston, TX, 4/4/2018

Hunt, K. Can we avoid breast surgery after complete response in neoadjuvant chemotherapy, Brazilian Breast Cancer Conference, Belem, Brazil, 7/13/2018

Hunt, K. Changes to the AJCC staging system for breast cancer, Brazilian Breast Cancer Conference, Belem, Brazil, 7/13/2018

Hunt, K. Personalizing breast cancer surgery based on biologic subtypes, The 3rd Asian Breast Cancer Conference, 2018 ASCO Joint Session, Tianjin, China, 8/17/2018

Hunt KK. Case Discussion, Cancer De Mama, Sao Paulo, Brazil, 9/28/2018

Hunt KK. Surgical approach of the axilla in 2018: State of the Art, Cancer De mama, Sao Paulo, Brazil, 9/28/2018

Hunt KK. Risk reducing surgery: indications and results, Cancer De Mama, Sao Paulo, Brazil, 9/29/2018

Surgical Update, Idaho Society of Clinical Oncology, Boise, ID, 10/6/2018

Breast Surgery Updates, CME River Cruises, Budapest, Hungary, 10/30/2018

Novel Approaches to the Axilla in Node Positive Breast Cancer after Neo-Adjuvant Therapy, 17th Oncology Update: Advances and Controversies, The University of Texas MD Anderson Cancer Center, Breckenridge, CO, 1/19/2019

The Changing Landscape of Prognostic and Predictive Factors In Breast Cancer Treatment, John Wayne Cancer Institute, Santa Monica, CA, 1/24/2019

AASC Table Talk - Lessons Learned from NCI Cooperative Group Trials, Annual Academic Surgical Congress, Houston, TX, 2/5/2019

Evolution in the Surgical Management of Breast Cancer, Georgetown University Hospital, Washington, DC, 2/19/2019

Hunt KK. The Evolving Role of Surgery in the Management of Patients Receiving Neoadjuvant Therapy, The 119th Annual Congress of Japan Surgical Society, Japan Surgical Society, Osaka, Japan, 4/19/2019

Hunt KK. Sustainability in Breast Surgery: Combating Physician Burnout, The ASBrS 20th Annual Meeting, The American Society of Breast Surgeons, Dallas, TX, 5/3/2019

Hunt KK. Updates in Breast Cancer Care, 2019 OhioHealth Cancer Conference, OhioHealth, Columbus, OH, 9/21/2019

Hunt KK. Clinical Congress Special Session: Cancer Surgery and Quality of Care Standards, Co-Moderator, ACS Clinical Congress 2019, American College of Surgeons (ACS), San Francisco, CA, 10/30/2019

Hunt KK. Breast Cancer and Melanoma (Workshop), Chairperson, EGSSO 19th Annual Conference - Best of SSO, Egyptian Society of Surgical Oncology (EGSSO), Cairo, Egypt, 11/6/2019

Hunt KK. Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer., EGSSO 19th Annual Conference - Best of SSO, Egyptian Society of Surgical Oncology (EGSSO), Cairo, Egypt, 11/6/2019

Hunt KK. Anaplastic Large Cell Lymphoma: A Risk in Textured Implant Based Breast Reconstruction, EGSSO 19th Annual Conference - Best of SSO, Egyptian Society of Surgical Oncology (EGSSO), Cairo, Egypt, 11/7/2019

Hunt KK. Breast Cancer Management: Systemic Therapy (Workshop), Chairperson, EGSSO 19th Annual Conference - Best of SSO, Egyptian Society of Surgical Oncology (EGSSO), Cairo, Egypt, 11/7/2019

Hunt KK. Clinical Case Breakout – Diagnosis, Staging, and Initial Treatment for Metastatic Breast Cancer, Speaker, ASCO Advantage Breast Cancer Course, American Society of Clinical Oncology (ASCO), Alexandria, VA, 11/18/2019

Hunt KK. Etiology, Risk Factors, and Screening, Speaker, ASCO Advantage Breast Cancer Course, American Society of Clinical Oncology (ASCO), Alexandria, VA, 11/18/2019

Hunt KK. Clinical Case Breakouts – Ongoing Treatment Options for Recurrent and Metastatic Breast Cancer, Speaker, ASCO Advantage Breast Cancer Course, American Society of Clinical Oncology (ASCO), Alexandria, VA, 11/19/2019

Hunt KK. Tumor Board – Recurrent and Metastatic Breast Cancer, Speaker, ASCO Advantage Breast Cancer Course, American Society of Clinical Oncology (ASCO), Alexandria, VA, 11/19/2019

Hunt KK. Results from the expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with Breast Cancer Clinical Trial, Poster Presentation, 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, 12/11/2019

Hunt KK. Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer (Lumicell), Poster Presentation, 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, 12/31/2019

Hunt KK. Breast and Gynecological Cancer - Session, Moderator, The 18th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, 1/18/2020

Hunt KK. Methods for Intraoperative Detection of Positive Margins in Breast Conserving Surgery, 4th Annual TARGIT Collaborative Group Conference, TARGIT Collaborative Group (TCG), New Orleans, LA, 2/8/2020

Hunt KK. Axillary Node Dissection or Axillary Radiation? How do We Decide?, The 25th Annual Multidisciplinary Symposium on Breast Disease, University of Florida, Amelia Island, FL, 2/13/2020

Hunt KK. Surgical Management of the Axilla Following Neoadjuvant Chemotherapy, The 25th Annual Multidisciplinary Symposium on Breast Disease, University of Florida, Amelia Island, FL, 2/15/2020

Hunt KK. The Role for Neoadjuvant Endocrine Therapy in Hormone Receptor Positive Breast Cancer, The 25th Annual Multidisciplinary Symposium on Breast Disease, University of Florida, Amelia Island, FL, 2/15/2020

Hunt KK. Cancer Care Delays: Town Hall Answering Your Questions on What it Means to You and Your Patients (Webinar), American College of Surgeons (ACS) Cancer Programs, 4/15/2020

Hunt KK. COVID-19 Cancer Management Challenges – Using Virtual Tumor Boards, Cancer Programs Commission on Cancer (CoC), American College of Surgeons (ACS), 4/23/2020

Hunt KK. COVID-19 Pandemic Breast Cancer Consortium's Consideration for Re-Entry (Podcast), Society of Surgical Oncology, 5/28/2020

Hunt KK. PER Live Webcast: COVID-19 and Cancer Care: What Oncologists Need to Know Today, Focus on Managing Patients with Breast Cancer, Physician Education Resource, LLC, 6/29/2020

Hunt KK. Operative Standards for Cancer Surgery: Standards (Webinar), Session Moderator, American College of Surgeons (ACS) Cancer Programs, 7/8/2020

Hunt KK. Local-regional Recurrence (LRR) Following Neoadjuvant Endocrine Therapy (NET): Data from ACOSOG Z1031 (Alliance) - Abstract Presenter, SSO 2020 Virtual Meeting, Society of Surgical Oncology, Virtual Conference, 8/17/2020

Hunt KK. Quality of Care Through the Operative Standards for Cancer Surgery, NCRA 2020 Virtual Education Conference, National Cancer Registrars Association, 9/23/2020

Hunt KK. Technical Standards for Cancer Surgery: Bringing Evidence into Practice, ACS Clinical Congress 2020, American College of Surgeons, Virtual Conference, 10/4/2020

Hunt KK. What is the role of clipping nodes prior to neoadjuvant therapy?, Internacional Multidisciplinary Symposium on Breast Cancer, Albert Einstein Israelite Hospital Oncology Center, Virtual Conference, Brazil, 11/20/2020

Hunt KK. Operative Standards in Cancer Surgery – Defining the Critical Elements for Surgical Success, Michigan Surgery Quality Collaborative Meeting, University of Michigan, Virtual Conference, 12/4/2020

Hunt KK. Combatting Endocrine Resistance Panel, Virtual 2021 Best of Breast Conference, Total Health, Virtual Conference, 1/16/2021

Hunt KK. Operative Standards in Cancer Surgery – Defining the Critical Elements for Surgical Success - Keynote Address, ISQIC Virtual Conference, Illinois Surgical Quality Improvement Collaborative, Virtual Conference, 1/29/2021

Hunt KK. Clinical Decision Making: Early and Locally Advanced Breast Cancer, Virtual ASCO Advantage Breast Cancer Course, American Society of Clinical Oncology, Virtual Course, 2/17/2021

Hunt KK. Axillary Reverse Mapping and Impact on Lymphedema Outcomes, 38th Annual Miami Breast Cancer Conference, MJH Life Sciences, Virtual Meeting, 3/5/2021

Hunt KK. Neoadjuvant Endocrine Therapy: Optimal Strategies and Impact on Surgical Outcomes, 38th Annual Miami Breast Cancer Conference, MJH Life Sciences, Virtual Meeting, 3/5/2021

Hunt KK. Medical Crossfire®: Neoadjuvant Chemotherapy for T1c HR-Negative/HER2-Positive Breast Cancer?, 38th Annual Miami Breast Cancer Conference, MJH Life Sciences, Virtual Meeting, 3/6/2021

Hunt KK. Axillary Surgery and Radiation in cN+ Patients Treated with Neoadjuvant Chemotherapy with Good Clinical Response, SSO 2021 International Conference on Surgical Cancer Care, Society of Surgical Oncology, Virtual Meeting, 3/18/2021

Hunt KK. Translating Cell Cycle Checkpoint Defects into Cancer Therapy, MSKCC Department of Surgery Grand Rounds, Memorial Sloan Kettering Cancer Center, Virtual Conference, 4/5/2021

- Hunt KK. Management of Luminal Breast Cancer, Brazilian Breast Conference, Virtual Meeting, 4/9/2021
- Hunt KK. Management of Neoadjuvant Treatment, Brazilian Breast Conference, Virtual Meeting, 4/9/2021
- Hunt KK. De-escalation of local treatment breast cancer, Brazilian Breast Conference, Virtual Meeting, 4/10/2021
- Hunt KK. Emerging Concepts in the Surgical management of Early Stage Breast Cancer, MSCO Virtual Meeting, Minnesota Society of Clinical Oncology, Virtual Meeting, 4/15/2021
- Hunt KK, Weiser R. De-escalation Of Endocrine Therapy In Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? - Primary Discussant, ASA 141st Annual Meeting, American Surgical Association, Virtual Meeting, 4/16/2021
- Hunt KK. ACS Cancer Programs Conference - Ask the Experts - Moderator, 2021 ACS Cancer Programs Conference: Quality Cancer Care in Motion, American College of Surgeons, Virtual Meeting, 4/28/2021
- Hunt KK. Can Genomic Tests Serve as Surrogates for Sentinel Node Biopsy?, ASBrS 22nd Annual Meeting, American Society of Breast Surgeons, Virtual Meeting, 4/29/2021
- Hunt KK. ACS Cancer Programs Innovation Hour – What else do we need to be doing? - Moderator, ACS Cancer Program Meeting, American College of Surgeons, Virtual Meeting, 5/21/2021
- Hunt KK. From Desmoid and Phyllodes to UPS: A One-Size-Does-Not-Fit-All Approach to Surgery, 2021 ASCO Annual Meeting, American Society of Clinical Oncology, Virtual Meeting, 6/4/2021
- Hunt KK. Neoadjuvant Endocrine Therapy in HR+ Breast Cancer, 4 Cali Breast Meeting - Virtual Meeting, Hemato Oncologos, Santiago de Cali, Colombia, 6/24/2021
- Hunt KK. CCSP Webinar on 2022 CoC Site Review Preparation - Panelist, Cancer Surgery Standards Program, American College of Surgeons, Webinar, 8/30/2021
- Hunt KK. Axillary Management After Neoadjuvant Chemotherapy - Panelist, Breastics24h - Breast Oncoplastics 2021, The American Society of Breast Surgeons, Virtual Conference, 9/25/2021
- Hunt KK. Selection Session: Genitourinary Cancer / Breast Cancer, 103rd ARS Annual Meeting, American Radium Society, Virtual Meeting, 9/30/2021
- Hunt KK. Beyond Guidelines: Surgical Management of Advanced BIA-ALCL, 3rd World Consensus Conference on BIA-ALCL, Sapienza University of Rome and MD Anderson Cancer Center, Rome, Italy, 10/9/2021
- Hunt KK, Suman VJ, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Olson J, Ellis MJ. Local-regional recurrence (LRR) following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), Annual NCI-EGSSO-SSO-ESSO Joint Meeting, Society of Surgical Oncology, Cairo, Egypt, 11/3/2021
- Hunt KK. Neoadjuvant Systemic Treatment for Breast Cancer: The Surgeon's Views, Annual NCI-EGSSO-SSO-ESSO Joint Meeting, Society of Surgical Oncology, Cairo, Egypt, 11/3/2021
- Hunt KK. Targeted axillary dissection: Who, why and how?, Annual NCI-EGSSO-SSO-ESSO Joint Meeting, Society of Surgical Oncology, Cairo, Egypt, 11/3/2021
- Hunt KK. CSSP Webinar on CoC Standards 5.3 & 5.4 for Breast Cancer, Cancer Surgery Standards Program, American College of Surgeons, Webinar, 11/17/2021
- Hunt KK. To Look or Not to Look—Does Every Woman with Newly Diagnosed Breast Cancer Need Axillary Imaging?, RSNA 2021 Annual Meeting, Radiological Society of North America, Chicago, IL, 12/1/2021

Hunt KK. Clinical Case Discussion: Trends in Axillary Surgery, Florianopolis Meeting, Brazillian Breast Society, Virtual Meeting, Brazil, 2/7/2022

Hunt KK. David B. Kaner Distinguished Lecture, Dartmouth Cancer Center, Cancer Center Grand Rounds, Boston, MA, 5/10/2022

Hunt KK. Axillary Surgery in Breast Cancer, XII Breast Cancer Weekend, Brazilian Society of Mastology, Hybrid Meeting - Virtual Participation, Brazil, 6/24/2022

Hunt KK. Screening and Diagnosis - Lecture, ASCO Advantage: Breast Cancer Course, American Society of Clinical Oncology, Alexandria, VA, 8/23/2022

Hunt KK. Challenges of Advanced BIA-ALCL, 8th International Breast Surgery Workshop & 4th World Consensus Conference on BIA-ALCL, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/1/2022

Hunt KK. Breast Cancer Masterclass - Speaker, AZ/MSD The OlympiA Journey: Breast Cancer Speaker Masterclass, AstraZeneca, Amsterdam, Netherlands, 10/3/2022

Hunt KK. Synoptic Reporting Requirements in the ACS Cancer Programs: Past, Present and Future - Panel Session, ACS Clinical Congress 2022, American College of Surgeons, San Diego, CA, 10/17/2022

Hunt KK. Ten Hot Topics in Surgical Oncology - Panel Session/Co-Moderator, ACS Clinical Congress 2022, American College of Surgeons, San Diego, CA, 10/20/2022

Hunt KK. Evaluation of the Axillary Node After Neoadjuvant Chemotherapy, ACM 2022 National Congress of Mastology, Colombian Society of Mastology, Cartagena, Bogota, Colombia, 11/11/2022

Hunt KK. Neoadjuvant Hormone Therapy in Breast Cancer, ACM 2022 National Congress of Mastology, Colombian Society of Mastology, Cartagena, Bogota, Colombia, 11/12/2022

Hunt KK. Master Class - Overview on How We are Going to Treat Breast Cancer in the Next Decade, The Brazilian Women's Cancer Congress, Brazilian Society of Surgical Oncology (BSSO), Hybrid Meeting - Virtual Participation, Brasilia, Brazil, 11/25/2022

Hunt KK. Her2 Breast Cancer - State of the Art Management in 2022, The Brazilian Women's Cancer Congress, Brazilian Society of Surgical Oncology (BSSO), Hybrid Meeting - Virtual Participation, Brasilia, Brazil, 11/26/2022

Hunt KK. Breast Cancer - Session, Moderator, 19th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, 1/14/2023

Hunt KK. Breast-Implant Associated Anaplastic Large Cell Lymphoma: What Have We Learned?, 40th Annual Miami Breast Cancer Conference, MJH Life Sciences, Miami, FL, 3/4/2023

Hunt KK. Technical Considerations for Axillary Reverse Mapping in Lymphedema Prevention, 40th Annual Miami Breast Cancer Conference, MJH Life Sciences, Miami, FL, 3/4/2023

Hunt KK. Management of Multiple Ipsilateral Primary Breast Cancers, 22nd Annual International Congress on the Future of Breast Cancer (East), MJH Life Sciences, New York, NY, 7/15/2023

Hunt KK. Management of Multiple Ipsilateral Primary Breast Cancers, 22nd Annual International Congress on the Future of Breast Cancer (West), MJH Life Sciences, San Diego, CA, 7/29/2023

Other, Including Scientific Exhibitions

Breast Cancer, Southern Surgical Association, SSO, W. Palm Beach, FL, 11/1/2008

Evidence-Based Advances in Selecting Breast Surgery Options, 9th Annual Society of Surgical Oncology, SSO, Phoenix, AZ, 3/4/2009

Breast surgery in the context of metastatic disease, Australasian Society for Breast Disease Seventh Scientific Meeting, ASBD, Gold Coast, Queensland, Australia, 10/1/2009

Resection of the primary tumor in patients with stage IV breast cancer, MDACC Physician Relations, United Arab Emirates, 11/4/2009

ACOSOG Z1071 - Poster Session, ASCO 2010, Chicago, IL, 6/7/2010

Hunt KK. Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Biopsy: Results of the ACOSOG Z0010 Trial, American Surgical Association, San Francisco, CA, 4/26/2012

Whole Genome Sequencing to Characterize Luminal-type breast Cancer, American Society of Clinical Oncology, Chicago, IL, 6/3/2012

Hunt KK. Are We Over-Treating Ductal Carcinoma in Situ?, 11th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, 1/2013

Hunt KK. Ductal Carcinoma in Situ: Current Approach, GBECAM, 7th Brazilian Breast Cancer Conference, Sao Paulo, Brazil, 3/2013

Hunt KK. Neoadjuvant Treatment of Breast Cancer: Role of the Surgeon, GBECAM, 7th Brazilian Breast Cancer Conference, Sao Paulo, Brazil, 3/2013

Hunt KK, Sahin A, Tripathy D. Panelist, Multidisciplinary President's Course: Breast Cancer with Interesting Case Discussion, American Radium Society 95th Annual Meeting, Scottsdale, AZ, 4/27/2013

Hunt KK. Survivorship Issues: Guidelines for Surveillance (ASCO and NCCN), 14th Annual Meeting, The American Society of Breast Surgeons, Chicago, IL, 5/2013

Hunt KK. Breast Conservation and Oncoplastic Techniques, The University of Texas MD Anderson Cancer Center and MD Anderson Physicians Network Symposium, Orlando, FL, 7/2013

Hunt KK. Neoadjuvant treatment: Just to avoid mastectomy or whenever systemic adjuvant therapy is indicated?, Plenarium Organization of Congresses-Brazil, 8th Breast Cancer Symposium, Gramado, Brazil, 8/2013

Hunt KK. Recent Advances in Local/Regional Therapies for Early-Stage Breast Cancer, 12th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, 1/18/2014

Hunt KK. The Evidence on the Oncologic Safety of Prophylactic NSM, Breast Cancer Coordinated Care 2014 Conference, Washington, DE, 2/21/2014

Francis A, Carey JP, Alexander A, Keyomarsi K, Hunt KK. Poster Presentation, Targeting the RB-Pathway in Sarcoma: Utility of CDK 4/6 Inhibitors, American Association for Cancer Research Annual Meeting 2014, San Diego, CA, 4/2014

Hunt KK. What type of surgery after neoadjuvant systemic treatment, IX Santiago Breast Cancer International Symposium, Santiago, Chile, 4/2014

Hunt KK. Z0011 and the impact on the management of early stage breast cancer, Association of Breast Surgery Conference & AGM, Liverpool, United Kingdom, 5/2014

Hunt KK. Challenging Breast Cancer Case Presentations with Interactive Audience Participation, UT MD Anderson Cancer Center, MD Anderson Physicians Network, Boston, MA, 7/28/2014

Hunt KK. What is the Appropriate Margin in Breast Conserving Surgery, UT MD Anderson Cancer Center, MD Anderson Physicians Network Symposium, Boston, MA, 7/28/2014

Hunt KK. Early Disease Tumor Board, American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, CA, 10/4/2014

Hunt KK. New Paradigms in the Surgical Management of the Regional Lymph Nodes in Breast Cancer, 13th Oncology Update: Advances and Controversies, MD Anderson Cancer Center, Steamboat Springs, CO, 1/16/2015

Caudle AS, Fleming JB, Garcia BM, Lozano M, Rigby D, Manuel-Byrd R, McMillian L, Avalos C, Hodge R, Butler CE, Hunt KK, Baumann D. Optimizing Surgical Instrument Sets for Cases Involving Breast and Plastic Surgeons, 2016 ASCO Quality Care Symposium, American Society of Clinical Oncology, 2016

Panel Session: Marking the axilla. Surgical approach following neoadjuvant therapies, IV Annual Meeting of Spanish Association of Breast Surgeons, Madrid, Spain, 5/6/2017

Hunt KK, Katz MH. SurgOnc Today Podcast: Operative Standards for Cancer Surgery and the ACS Cancer Surgery Standards Program, Society of Surgical Oncology, 12/7/2020

Hunt KK. Plenary Session 2, Moderator, SSO 2023 International Conference on Surgical Cancer Care, Society of Surgical Oncology (SSO), Boston, MA, 3/24/2023

Hunt KK. Breast Imaging Update - Does Everyone Over 20% Risk Need an MRI?, ASBrS 24th Annual Meeting, American Society of Breast Surgeons (ASBrS), Boston, MA, 4/28/2023

Seminar Invitations from Other Institutions

Complement Dependent Lysis of Tumor Cells by a Baboon IgM Antibody to a Tumor Associated Antigen, Department of Surgery Grand Rounds, The University of California at Los Angeles, Surgery, Los Angeles, CA, 5/1/1990

Atypical Ductal Hyperplasia, The University of California at Los Angeles Breast, Los Angeles, CA, 10/1/1993

Methods of In Vivo Gene Transfer, The University of California at Los Angeles Breast, Los Angeles, CA, 5/1/1994

Breast Cancer: Controversies for the 1990's, Methodist Hospital, Knipling Education/Conference Center, Lubbock, TX, 8/1/1994

What is the Role for Axillary Dissection in the Treatment of Breast Cancer?, Department of Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 3/1/1995

Difficult Cases in Breast Cancer, UniMed Medical Center, Minot, ND, 6/1/1995

Surgical Management of Breast Cancer: Where We are Now and What's in the Future, UniMed Medical Center, Minot, ND, 6/1/1995

Current Strategies in the Treatment of Locally Advanced Breast Cancer, The University of Texas at Houston Medical School, Department of Surgery Grand Rounds, Houston, TX, 3/1996

Multimodality Treatment of Locally Advanced Breast Cancer, Department of Surgery Grand Rounds, Butterworth Hospital, Grand Rapids, MI, 5/1/1996

Breast Cancer Update: Treatment and Control, Physician Oncology Education Program on Breast and Colorectal Cancer, Texas Medical Association, St. Elizabeth Hospital, Beaumont, TX, 6/1/1996

Breast Conservation Surgery Following Tumor Downstaging with Neoadjuvant Chemotherapy, Princess Alexandra Hospital, Brisbane, Australia, 9/1/1996

Breast Conservation Surgery Following Tumor Downstaging with Neoadjuvant Chemotherapy, Prince of Wales Hospital, Sydney, Australia, 9/1/1996

Breast Conservation Surgery Following Tumor Downstaging with Neoadjuvant Chemotherapy, New South Wales Breast Cancer Institute, New South Wales, Australia, 9/1/1996

Breast Conservation Surgery Following Tumor Downstaging with Neoadjuvant Chemotherapy, University of Hong Kong, Hong Kong, China, 11/1/1996

Role of Lymphatic Mapping in the Management of Breast Cancer, University of Cincinnati Medical Center, Cincinnati, OH, 12/1/1996

Surgical Treatment of Early Breast Cancer, Candler Hospital, Savannah, GA, 12/1/1996

Surgical Treatment of Early Breast Cancer, Hilton Head, SC, 12/1/1996

Diagnosis, Staging and Surgical Treatment of Carcinoma of the Breast, Citizens Medical Center, Victoria, TX, 1/1/1997

Advanced Breast Cancer, Citizens Medical Center, Victoria, TX, 2/1/1998

The Role for Axillary Node Dissection in Early Stage Breast Cancer, Julie and Ben Rogers Cancer Institute, Beaumont, TX, 2/1/1998

Management of Locally Advanced Breast Cancer, Department of Surgery Grand Rounds, University of Louisville, Louisville, KY, 6/1/1998

Sentinel Node Biopsy for Breast Cancer, College Station Medical Center, College Station, TX, 1/1/1999

Breast Conservation Therapy for Early Stage and Locally Advanced Breast Cancer, Department of Medicine and Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 2/1999

Reducing the Incidence of Breast Cancer with Nolvadex (tamoxifen) in Women with High Risk, Northeast Regional Medical Center, Humble, TX, 5/1/1999

Reducing the Incidence of Breast Cancer with Nolvadex (tamoxifen) in Women with High Risk, Beaumont, TX, 5/1/1999

Reducing the Incidence of Breast Cancer in Women with High Risk, Gulf Coast Medical Center, Wharton, TX, 6/1/1999

Induction of Apoptosis in Human Breast Carcinoma by Overexpression of a Truncated and Mutated Retinoblastoma Gene Product: Implications for Clinical Gene Therapy Trials, The Molecular Surgeon Symposium, Michael E. DeBakey Department of Surgery, Michael E. DeBakey Department of Surgery, Houston, TX, 8/1/1999

Feasibility of Breast Conservation after Tumor Downstaging with Induction Chemotherapy, Bristol-Myers Squibb Oncology Visiting Faculty Program, Bayshore Medical Center, Pasadena, TX, 4/2000

Advances in the Surgical Management of Breast Cancer, Bristol-Myers Squibb Oncology Visiting Faculty Program, Worcester Centrum, Worcester, MA, 10/1/2000

Multidisciplinary Care of the Breast Cancer Patient, The Jikei University School of Medicine, Tokyo, Japan, 11/1/2001

Advances in the Treatment of Locally Advanced Breast Cancer, Citizens Medical Center, Victoria, TX, 10/15/2003

Neoadjuvant Chemotherapy for Breast Cancer and Sentinel Lymph Node Biopsy, Houston Northwest Medical Center, Houston, TX, 10/28/2003

New Approaches in the Surgical Management of Breast Cancer, Grand Rounds, Baylor College of Medicine, Houston, TX, 9/22/2004

Sentinel Node Surgery for Breast Cancer: Patient Selection, Technical Details and Results of Clinical Trials, Department of Surgery Grand Rounds, The Methodist Hospital, Houston, TX, 5/8/2008

Local-regional control: Evaluating the surgical, radiological and chemotherapeutic treatment strategies for local-regional control of breast cancer, Priorities in Breast Cancer Clinical Research: A Stakeholder Discussion with the Scientific Leadership Council and the Breast Cancer Community, Coalition of Cancer Cooperative Groups, Dallas, TX, 9/13/2008

Clinical Trials of the ACOSOG, Grand Rounds, University of Michigan, Ann Arbor, MI, 10/17/2008

Prognostic and Predictive Factors in Breast Cancer, University of Nebraska Medical Center, Department of Surgery, Omaha, NE, 2/11/2009

Evaluation and Treatment of Women at High Risk for Breast Cancer – BRCA1&2, Breast MRI and Prophylactic Mastectomies, The ProMedica Cancer Institute 2009 Fall Symposium, ProMedica Health System, Toledo, OH, 10/9/2009

Prognostic and Predictive Factors in Breast Cancer, Dartmouth Medical School, Department of Surgery Grand Rounds, Dartmouth, NH, 4/14/2010

American College of Surgeons Oncology Group Clinical Trials, 8th Annual Contemporary Issues in Multidisciplinary Breast Cancer Management 2010, University of Michigan, Plymouth, MI, 10/30/2010

Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy, Hackensack University Medical Center, Surgery, Hackensack, NJ, 2/1/2011

The Case Against Nipple-sparing Prophylactic Mastectomy, Georgetown University Hospital, Breast Cancer Coordinated Care Conference (BC3), Plastic & Reconstructive Surgery and Breast Surgery, Washington, DC, 2/1/2011

MD Anderson Cancer Center, Georgetown University Hospital, Breast Cancer Coordinated Care Conference (BC3), Plastic & Reconstructive Surgery and Breast Surgery, Washington, DC, 2/3/2011

Cancer Treatment in the Previously-Augmented Patient: A Surgeon's Perspective, Georgetown University Hospital, Breast Cancer Coordinated Care Conference (BC3), Plastic & Reconstructive Surgery and Breast Surgery, Washington, DC, 2/4/2011

The Changing Role for Axillary Surgery in Breast Cancer Treatment, Banner M. D. Anderson Cancer Center Oncology Grand Rounds, Oncology, Gilbert, AZ, 2/28/2012

Surgical Considerations for Stage IV Breast Cancer, Medstar Washington Hospital Center - Advances in Breast Cancer 2012, Washington, DC, 3/24/2012

Surgical Management After Preoperative Therapy, Breast Cancer: New Horizons, Current Controversies, Harvard Medical School Department of Continuing Medical Education, Boston, MA, 7/2013

Prognostic and Predictive Factors in Breast Cancer, Beth Israel Cancer Center, New York, NY, 9/18/2013

Surgical Management of Breast Cancer after Neoadjuvant Therapy, University of Illinois, The Ninth Annual Breast Cancer Symposium, Peoria, IL, 9/29/2016

Management of the Node Positive Axilla, The 25th Annual Meeting of the Japanese Breast Cancer Society, Fukuoka, Japan, 7/14/2017

How your dollars are advancing cancer care, Third Party Appreciation Luncheon, MD Anderson Cancer Center, 7/19/2017

Advances in Breast Cancer Surgery, 20th Annual West Hawaii Cancer Symposium, HI, 9/9/2017

Lectureships and Visiting Professorships

TITLE, Australasian College of Surgeons, Australia, 9/1996

Breast Cancer Care 2000: Where We Are Now and the Challenges Ahead, The Jan Moore Memorial Lecture on Breast Cancer, Lufkin, TX, 10/2000

Post-Mastectomy Reconstruction, Surgical Oncology Week, Clinica Oncologica, Oporto, Spain, 5/21/2001

Sentinel Lymph Node Biopsy, Surgical Oncology Week, Clinica Oncologica, Oporto, Spain, 5/21/2001

Surgical Oncology Week, Clinica Oncologica, Oporto, Portugal, 5/21/2001

Surgical Treatment of Invasive Breast Cancer, Clinica Oncologica, Oporto, Spain, 5/21/2001

Breast Cancer, Pachtman Memorial Lecture on Medical and Surgical Management of Breast Cancer, Mesa, AZ, 10/24/2001

Induction of Apoptosis via Gene Therapy: The Story of Ad-mda7, Department of Surgery Grand Rounds, University of California at Los Angeles Medical School, Los Angeles, CA, 2/5/2003

Targeted Therapies for Breast Cancer, Women in Surgery Lecture, Brigham and Women's Hospital, Boston, MA, 2/20/2006

Prognostic and Predictive Factors in Breast Cancer, Department of Surgery Grand Rounds, University of Massachusetts Medical School, Worcester, MA, 5/15/2007

New Targets in Breast Cancer Therapy, Station Biologique, Centre National de la Recherche Scientifique, Roscoff, France, 7/21/2008

Prognostic and Predictive Factors in Breast Cancer, The Inaugural Morris Deutsch Memorial Lectureship in Breast Cancer, Johns Hopkins, Department of Surgery Grand Rounds, Baltimore, MD, 10/14/2010

The Changing Role for Axillary Surgery in the Management of Breast Cancer, The Annual Harold Cheek Breast Lectureship, Baylor University Medical Center of Dallas, Surgery, Dallas, TX, 4/11/2012

Prognostic and Predictive Factors in Breast Cancer, UCLA Department of Surgery Grand Rounds, UCLA, Surgery, Los Angeles, CA, 5/2/2012

Current management of the axilla in breast cancer, Canadian Surgery Forum, Canadian Society of Surgical Oncology, Calgary, Alberta, Canada, 9/15/2012

Management of the axilla in invasive breast cancer, Canadian Society of Surgical Oncology, Canadian Surgery Forum, Calgary, Alberta, Canada, 9/15/2012

Prognostic and predictive markers in breast cancer treatment, Canadian Surgery Forum, Canadian Society of Surgical Oncology, Calgary, Alberta, Canada, 9/15/2012

The Changing Role for Axillary Surgery in Breast Cancer Management, General Surgery Grand Rounds, MD Anderson Cancer Center - Orlando Health, Orlando, FL, 11/2/2012

New Paradigms in the Management of Regional Nodes in Breast Cancer, J.C. Thoroughman Lecture, Emory University School of Medicine, Surgical Oncology, Atlanta, GA, 2/12/2015

Prognostic and Predictive Factors in Breast Cancer, The Oliver H. Beahrs Visiting Professorship, Mayo Clinic and Mayo Foundation, Surgery, Rochester, MN, 3/20/2015

Gross Lectureship 2018, Samuel Gross Lectureship, University of Louisville, Louisville, KY, 5/11/2018

Focus on New Frontiers in Cancer Treatment, Local-regional management following neoadjuvant, Sapienza Medical School, Rome, Italy, 5/18/2018

Logistics of Clinical Trials, Division of Surgery Clinical Trials Course, MD Anderson Cancer Center, Houston, TX, 9/23/2022

Targeting the Cell Cycle in Breast Cancer Treatment, Department of Surgery/Cancer Center Visiting Professor, Massachusetts General Hospital Cancer Center, Surgery, Boston, MA, 3/2/2023

Cell Cycle Checkpoint Defects as Targets for Breast Cancer Therapy: From Bench to Bedside, William D. Seybold Distinguished Lectureship, Baylor College of Medicine, Surgery, Houston, TX, 3/29/2023

Other Presentations at State and Local Conferences

Breast Cancer in the 1990's, Woman to Woman: A Breast Health Seminar, American Cancer Society, Santa Maria, CA, 10/1993

Parenting and Medicine, American Medical Women's Association, The University of California at Los Angeles Chapter, Los Angeles, CA, 1/1994

Options for Treatment of Breast Cancer, Women Taking Charge: Health and Leadership, California Women in Legal Services, Torrance, CA, 11/1994

Current Issues in Women's Breast Health, 4th Annual Breast Health Symposium, The Doris Kupferle Breast Center, Fort Worth, TX, 4/1995

Taking the Right Road to Cancer Conference, Surgical Treatment of Breast Cancer, MD Anderson Cancer Center, Houston, TX, 4/1995

Breast Cancer: Indications for Surgical Treatment, Department of Anesthesiology, MD Anderson Cancer Center, Department of Anesthesiology, Houston, TX, 4/1997

Surgical Options for the Treatment of Breast Cancer, Fifth Annual Oncology Conference, Spohn Health System, Corpus Christi, TX, 4/1997

Diagnosis and Management of Noninvasive Breast Cancer, Surgical Oncology Fellows Conference, MD Anderson Cancer Center, Surgical Oncology, Houston, TX, 7/1997

Panel Discussion on Breast Cancer, American Cancer Society League of Fort Bend County, Houston, TX, 9/1997

Surgical Management of Breast Cancer, Preceptorship Clinical Exchange Program, Rhone-Poulenc Rorer, Houston, TX, 10/1997

Surgical Options for Treatment of Breast Cancer, Texas Academy of Family Physicians, Houston, TX, 10/1997

Breast Cancer and Lymphatic Mapping, Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Department of Pathology and Laboratory Medicine, Houston, TX, 11/1997

Sentinel Node Biopsy and Breast Cancer, Surgical Oncology Fellows Conference, MD Anderson Cancer Center, Surgical Oncology, Houston, TX, 1/1998

Breast Cancer Update, Annual Meeting, South Texas Chapter American College of Surgeons, San Antonio, TX, 2/1998

Gene Therapy, Preceptorship Clinical Exchange Program, Rhone-Poulenc Rorer, Houston, TX, 4/1998

Surgical Management of Breast Cancer, USA Preceptorship Program, Roche Laboratories, Houston, TX, 4/1998

Surgical Management of Colorectal Cancer, USA Preceptorship Program, Roche Laboratories, Houston, TX, 4/1998

Breast Conservation Therapy After Downstaging with Chemotherapy, Institutional Grand Rounds, MD Anderson Cancer, Houston, TX, 6/1998

Gene Directed Therapy, Clinical Exchange Program, Rhone-Poulenc Rorer, Houston, TX, 6/1998

Sentinel Node Biopsy Update, Innovations in Breast Cancer Therapy, Houston, TX, 10/1998

E2F-1 and Its Potential for Cancer Gene, Cancer Metastasis Research Program Seminar Series, MD Anderson Cancer Center, Houston, TX, 11/1998

Lymph Node Mapping: Applications in Breast Cancer, Seminars in Nuclear Medicine Program, MD Anderson Cancer Center, Houston, TX, 11/1999

Lymphatic Mapping After Neoadjuvant Chemotherapy, Breast Center Clinical Research Meeting, MD Anderson Cancer Center, Houston, TX, 11/1999

Tumor Downstaging After Neoadjuvant Therapy, Institutional Grand Rounds, MD Anderson Cancer Center, Houston, TX, 11/1999

Lymphatic Mapping and Sentinel Node Biopsy, Clinical Exchange Program, Aventis Pharmaceuticals, Houston, TX, 3/10/2000

Breast Cancer: Clinical Perspectives of Malignant Disease, MD Anderson Cancer Center, Houston, TX, 4/2000

Hyperthermic Peritoneal Perfusion & Systemic Therapy for Sarcoma, Surgical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 5/2000

Lymphatic Mapping and Sentinel Node Biopsy, Preceptorship Program, Genentech, Houston, TX, 5/2000

Surgical Management of Breast Cancer, Genentech, Inc., Preceptorship Program, Houston, TX, 5/2000

The Role of Tamoxifen in the Treatment of Breast Cancer, Discovery International, Memphis, TN, 8/2000

Current Surgical Treatment of Breast Cancer, Memorial Health System Medical Staff, Lufkin, TX, 10/2000

Lymph Node Mapping: Clinical & Nuclear Medicine Perspective, MD Anderson Cancer Center, Houston, TX, 10/2000

Use of Animal Models to Develop Adenoviral Gene Therapy, Institutional Grand Rounds, MD Anderson Cancer Center, Houston, TX, 10/2000

Lymph Node Mapping: Clinical & Nuclear Medicine Perspective, MD Anderson Cancer Center, Houston, TX, 11/2000

Adenovirus Vectors in Gene Therapy Research, Pancreatic Cancer Working Group Seminar Series, MD Anderson Cancer Center, Houston, TX, 1/2001

Breast Lymphatic Mapping, South Texas Chapter of the American College of Surgeons, San Antonio, TX, 3/2/2001

Sentinel Lymph Node Biopsy & Surgical Management of Breast Cancer, Breast Center Clinical Research Meeting, MD Anderson Cancer Center, Houston, TX, 4/2001

Lymphatic Mapping, Surgical Oncology Fellows Conference, MD Anderson Cancer Center, Houston, TX, 8/2001

Current Management of Ductal Carcinoma In Situ, Surgical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 10/2001

Current Treatment of Breast Cancer, Aventis Oncology Speakers' Bureau, Enid, OK, 10/25/2001

Sentinel Lymph Node Mapping: Clinical & Nuclear Medicine Perspective, Seminars in Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, 11/2001

Sentinel Lymph Node Mapping: Clinical & Nuclear Medicine Perspective, Seminars in Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, 11/2001

Local Therapy Issues After Neoadjuvant Chemotherapy, Surgical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 1/2002

Surgical Considerations Before & After Neoadjuvant Chemotherapy, Breast Center Clinical Research Meeting, MD Anderson Cancer Center, Houston, TX, 1/2002

Regional & Intraperitoneal Therapy for Sarcoma, Surgical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 3/2002

What's New in Cancer Research?, New Directions in Cancer Research, UT M D Anderson Cancer Center, Indian Wells, CA, 3/7/2002

FNA Biopsy in the Diagnosis and Management of Breast Cancer Patients, Pathology Conference, Baylor College of Medicine, Houston, TX, 4/2002

Breast Cancer Fund Raiser, Shooting Down Cancer, Houston, TX, 5/3/2002

Ask the Experts - Breast Cancer Breakout, Bush Endowment National Finance Advisory Council Meeting, MD Anderson Cancer Center, Houston, TX, 11/2002

Surgical Considerations Before and After Neoadjuvant Chemotherapy, Greater Cincinnati Breast Cancer Forum, Cincinnati, OH, 2/1/2003

Plastic Surgery Curriculum Conference, Baylor College of Medicine, Houston, TX, 4/10/2003

Meet the Experts, Panel, Day of Science, Breast Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2003

The Many Faces of Research: Meet the Experts - Breast, Day of Science, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 5/22/2003

Panel Discussion Member, Before Time Runs Out Program on Breast Cancer, M D Anderson Cancer Center, US Food and Drug Administration Office of Women's Health, Mt Ararat Baptist Church, Houston, TX, 10/25/2003

Controversies in Breast Cancer, Institutional Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2004

Panel Discussion: Elements of Peer Review, Faculty Development Brown Bag Lunch Series, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2004

Plastic Surgery Residents Curriculum Conferences, Baylor College of Medicine, Houston, TX, 4/1/2004

Surgical Management of Breast Cancer, Advanced Topics in Multidisciplinary Care Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2004

What's New in Breast Cancer?, Aspen Cancer Conference, The University of Texas MD Anderson Cancer Center, Aspen, CO, 7/29/2004

Sentinel Lymph Node Dissection in Breast, Advanced Topics in Multidisciplinary Cancer Care Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2004

Current Treatment of Locally Advanced Breast Cancer, American College of Surgeons Oregon Chapter, Bend, OR, 9/17/2004

Evolving Indications for Sentinel Lymph Node Mapping, American College of Surgeons Oregon Chapter, Bend, OR, 9/17/2004

Ask the Experts Breakout Session on Breast Cancer, 2004 Board of Visitors Annual Meeting, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2004

Sentinel Lymph Node Surgery for Breast Cancer, Radiation Oncology Resident Lecture Series, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2004

The role of Cyclin E in Breast Cancer, Surgical Oncology Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2004

What's New in Breast Cancer?, MD Anderson Cancer Prevention Seminar, Colorado Springs, CO, 7/29/2005

Management of Breast Cancer, General Surgery 2005: 27th Annual Postgraduate Course, Davis Health System, University of California-Davis, Napa, CA, 9/16/2005

Trials of the ACOSOG and Neoadjuvant Endocrine Therapy for Breast Cancer, 3rd Annual Contemporary Issues in Multidisciplinary Breast Cancer Management, University of Michigan Medical School, Dearborn, MI, 10/29/2005

The Role of Axillary Lymph Node Dissection, Breast Cancer Update: 2005 and Beyond, Western Ohio Breast Cancer Conference, Miami Valley Hospital, Dayton, OH, 11/16/2005

Ad-mda7 Sensitizes Breast Cancer Cells to Chemotherapy, Advances in Oncology Institutional Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2006

Local Regional Therapy Advances, 3rd Annual Best of San Antonio Breast Cancer Symposium: Bench to Bedside, Loyola University, Chicago, IL, 1/28/2006

Breast Conservation Therapy, Department of Plastic and Reconstructive Surgery Fellows Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2006

Sentinel Node Biopsy Skills Verification, Interdisciplinary Breast Cancer Journal Club, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2006

Practical Approach to Multidisciplinary Care in Oncology, Current Topics in Cancer Medicine and Research: A Community Outreach Series, Alumni and Faculty Association of the M. D. Anderson Cancer Center, Houston, TX, 5/20/2006

New Trends in the Diagnosis and Treatment of Breast Cancer, Texas Club of Internists, Texas Medical Association, Houston, TX, 2/23/2007

Local-Regional Therapy for Breast Cancer, Update in the Management of Breast Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/19/2007

Targeting LMW Isoforms for Prognosis and Treatment of Breast Cancer, Guideposts Reception and Morning of Science, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2/2007

Elastase, A Novel Target for Breast Cancer, Advances in Oncology Institutional Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2007

What a Successful Career Looks Like at M. D. Anderson, Junior Faculty Development Program Retreat, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/3/2008

Combined Clinical & Pathologic Staging for Breast Cancer Patients, Interdisciplinary Breast Cancer Journal Club, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2008

Targeted Therapies in Breast Cancer, 2008 Board of Visitors Annual Meeting, The University of Texas M.D. Anderson Cancer Center/2008 Board of Visitors, Houston, TX, 11/6/2008

N/A, Pearland Volleyball Classic, Pearland, TX, 8/25/2011

Findings from the American College of Surgeons Z0011 Study, 23rd Annual Breast Cancer Symposium, Dallas, TX, 9/24/2011

Surgical Perspective, Breast Cancer Clinical Research Seminar, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/17/2012

Hunt KK. Update on Local Regional Therapy of Breast Cancer, GAP Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2013

Hunt KK. Update on Local-regional Therapy, Moon Shots: Connect for Global Networking, Global Academic Programs 2013, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2013

Hunt KK. Advances in GIST Surgery, GIST Summit 2013, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2013

Hunt KK. Surgical Management of the Axilla in Breast Cancer Patients: Lessons Learned from Clinical Trials: Management of the clinically node negative axilla, Institutional Grand Rounds, Advances in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/13/2014

Hunt KK. Latest Developments in Breast Cancer Therapies, Palm Beach Educational Seminar, The University of Texas MD Anderson Cancer Center, Palm Beach, FL, 3/1/2015

Hunt KK. Latest Developments in Breast Cancer Therapies, Sarasota Educational Seminar, The University of Texas MD Anderson Cancer Center, Sarasota, FL, 3/7/2015

Updates in Breast Cancer Treatment, The University of Texas MD Anderson Cancer Center, Aspen, CO, 7/2015

Dr. Vinod Ravi, Dr. Andrew Futreal, Dr. Kelly Hunt & Dr. Khandan Keyomarsi. Panel Discussion: The cutting edge of LMS research at MD Anderson, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2/2016

Treatment of Breast Cancer at the Extremes of Age, Meet the Professor Session, SSO 2017 Annual Cancer Symposium, Seattle, WA, 3/18/2017

Panel Discussion on Novel treatment strategies for ER+HER2-breast cancer: Practice changing approaches on the horizon, The 25th Annual Meeting of the Japanese Breast Cancer Society, Fukuoka, Japan, 7/13/2017

Hunt KK. Panel Discussion: Case Studies, Meet the Experts: A Focus on Breast Cancer, ISCO 2018 Fall Meeting, Idaho Society of Clinical Oncology, Boise, ID, 10/6/2018

Hunt KK. Evolution in the Surgical Management of Breast Cancer, Grand Rounds at Georgetown University Hospital, MedStar Georgetown University Hospital, Washington, DC, 2/19/2019

Hunt KK. Predictive Biomarkers in Breast Cancer, Emory University Grand Rounds, Emory Winship Cancer Institute, Atlanta, GA, 10/2/2019

Kelly K. Hunt, MD. Division of Surgery Surgical Fellows Clinical Trials Course Fall 2020, Logistics of Clinical Trials, The University of Texas MD Anderson Cancer Center, Division of Surgery, Houston, TX, 8/14/2020

Hunt KK. Logistics of Clinical Trials, The Clinical Trials Design Course for the DoS Fellows, Division of Surgery, The University of Texas MD Anderson Cancer Center, Virtual Course, 8/14/2020

Hunt KK, Tripathy D, Woodward W, Kalambo M. The Latest in Individualizing Breast Cancer Screening and Treatment, MD Anderson Physician Advisory Board Educational Series, The University of Texas MD Anderson Cancer Center, Virtual Lecture, 10/28/2020

Sorotos M, Miranda R, Hunt K, Hollrah R. 2nd World Consensus Conference on BIA-ALCL - Scientific Committee, The University of Texas MD Anderson Cancer Center, Virtual Course, 11/6/2020

Hunt KK. Local-Regional Management of Breast Cancer Patients, Academic Tuesday, The University of Texas MD Anderson Cancer Center, Cancer Medicine - Fellowship Program, Virtual Lecture, 3/9/2021

Hunt KK. Toolbox to Becoming a Compassionate Physician, Summer Experience Career Conversations, MD Anderson Cancer Center, Breast Medical Oncology, Virtual Conference, 7/26/2021

Hunt KK. A Survivor's Story: Breast Cancer Awareness, Virtual Breast Cancer Presentation, Junior League of Houston, Virtual Lecture, 10/12/2021

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

Alpha Omega Alpha Medical Honor Society
Member, 1985-present

American Association for Cancer Research
Member, 1989-present

Association of Women Surgeons
Member, 1990-present

Longmire Surgical Society
Member, 1993-present

American Radium Society
Member, 1995-present

American Society of Clinical Oncology
Member, 1995-present
Breast Cancer Guideline Advisory Group Member, 9/2017-present

Society of Surgical Oncology
Member, 1995-present
Chair, Breast Diseases Task Force, 2012-2013

Executive Council Representative-SSO Nominating Committee, 2017-2018
Executive Council, 2017-2020
Executive Council Representative-Breast Training Program Directors Subcommittee,
2017-2020

Connective Tissue Oncology Society
Member, 1998-present

American College of Surgeons
Fellow, 2000-present

Society of University Surgeons
Member, 2001-present

Southern Surgical Association
Member, 2001-present

Western Surgical Association
Member, 2002-present

American Society of Breast Surgeons
Member, 2003-present

American Surgical Association
Member, 2004-present

1in8 Foundation
Member, Medical Advisory Board, 2008-present

Cancer Information & Support Network
Member, Medical Advisory Board, 2008-present

The University of Texas at MD Anderson Cancer Center K12 Advisory Committee, Houston,
TX
Member, 1/2009-present

U.S. Food and Drug Administration-
Consultant, General and Plastic Surgery Devices Panel of the Medical Devices Advisory
Committee, 12/2011-12/2015

American Society of Clinical Oncology, Breast Cancer Guideline Advisory Group
Member, 5/2014-5/2019

American Radium Society, Mount Royal, NJ
Member - Executive Committee, 1/2019-present

Bone Marrow & Cancer Foundation, New York, NY
Member, Medical Advisory Board, 2019-present

Society of Surgical Oncology
Chair - Membership Committee, 2019-2022

Society of Surgical Oncology
Member - SSO Education Council, 2019-2022

Society of Surgical Oncology
Member - Finance Committee, 2019-2022

ACS Cancer Programs Leadership Committee, Chicago, IL
Member, 3/2019-present

Society of Surgical Oncology
Executive Council Liaison to the FSSO Work Group, 4/2019-present

Society of Surgical Oncology
Executive Council Liaison to the Membership Committee, 4/2019-present

Society of Surgical Oncology

Executive Council Liaison to the Training - Breast Program Directors Subcommittee,
4/2019-present

American College of Radiology, Philadelphia, PA
TMIST Scientific Advisory Board, Member, 2020

Local/State

Harris County Medical Society, Houston, TX
Member, 1994-present

Texas Medical Association, Houston, TX
Member, 1994-present

The University of Texas MD Anderson Associates, Houston, TX
Member, 1994-present

UNIQUE ACTIVITIES

1. Online Lecture

Breast Cancer: Surgical Treatment Approaches for Professional Oncology Education (POE),
www.mdanderson.org/poe 2012

Magazine Interviews

Amy Robach's Breast Cancer Battle 'I Have a Lot to Fight For'. People Magazine, 12/16/2013.

Jonathan D. Rockoff and Ron Winslow. Two Drugs Show Promise in Slowing Breast Cancer. Wall Street Journal. April 6, 2014.

Lori Baker. Our passion: doing more for patients, Conducting clinical trials is at the heart of helping patients. Messenger Magazine, July-Aug 2014.

Searching for understanding and meaning in medicine and life. Association for Women in Science Magazine, October 2018.

Claudia Feldman. Where the best outcomes begin. Conquest, November 2018.

\$30 million awarded to MD Anderson scientists for various research investigations. ASCO Post, January 2019.

A randomized Neoadjuvant Trial of Sequential versus concurrent anthracycline with trastuzumab and paclitaxel plus trastuzumab in HER2+ breast cancer. ASCO Post, 2019

Julie Mazziotta. 'What You Need to Know: COVID-19 & Breast Cancer'. People Magazine, October 2020, pp. 114

Andrea Wurzburger. "Age What to Know About Breast Cancer at Every Stage of Your Life, According to Experts". People Magazine. October 1, 2021

News Interviews

Health News Interview: Why more women are choosing double mastectomies. CNN Health, 3/13/2013.

http://www.cnn.com/2013/03/13/health/double-mastectomy-rates-up/index.html?hpt=he_c1

Television Interviews

TV Interview: Prophylactic Mastectomy. Fox 26 Houston, 1/11/2013.

Web Interviews

Consensus Guidelines Recommend No Ink on Tumor as Optimal Margin for Breast-Conserving Therapy. Breast Cancer Symposium Daily News, 6/2014.

Dr. Hunt Talks Neoadjuvant Endocrine Therapy for Breast Cancer. Insights from the Miami Breast Cancer Conference. Oncology Learning Network, 3/2021

Media Coverage

Needle biopsy underused in patients with breast cancer. 2014 June 9. Health Day News. Available at: <http://www.doctorslounge.com/index.php/news/pb/47335>

Surgeon characteristics explain less-than-ideal rates of needle biopsy. 2014 June 9. ASCO Connection. Available at: <http://connection.asco.org/Magazine/Article/id/3902/Surgeon-Characteristics-Explain-Less-than-Ideal-Rates-of-Needle-Biopsy.aspx>

Needle biopsies may be underused for breast cancer patients. 2014 June 13. Reuters. Available at: <http://www.reuters.com/article/2014/06/13/us-breast-cancer-diagnosis-surgery-idUSKBN0EO1Z020140613>

What is the Role of Surgery in Metastatic Breast Cancer? MedPage Today. Available at: <https://www.medpagetoday.com/meetingcoverage/ascovideopearls/81526>

Doctors Debate: Is Neoadjuvant Chemotherapy Appropriate for T1c HR-, HER2+ Breast Cancer? 2021 May 20. Targeted Oncology. Available at: <https://www.targetedonc.com/view/doctors-debate-is-neoadjuvant-chemotherapy-appropriate-for-t1c-hr--her2-breast-cancer->

How to Prep Your Home for After Breast Surgery. 2022 July 28. Everyday Health. Available at: <https://www.everydayhealth.com/breast-cancer/how-to-prep-your-home-for-after-breast-surgery/>

DATE OF LAST CV UPDATE

2/28/2024